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ABSTRACT
Discovery of Novel Molecular and Biochemical Predictors
of Response and Outcome in Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the commonest form of non-Hodgkin 
lymphoma and responds to treatment with a 5-year overall survival (OS) of 40-50%.  
Predicting outcome using the best available method, the International Prognostic Index 
(IPI), is inaccurate and unsatisfactory.  This thesis describes research undertaken to 
discover, explore and validate new molecular and biochemical predictors of response 
and long-term outcome with the aims of improving on the inaccurate IPI and of 
suggesting novel therapeutic approaches.  Two strategies were adopted: a rational and 
an empirical approach. The rational strategy used gene expression profiling to identify 
transcriptional signatures that correlated with outcome to treatment and from which a 
model of 13-genes accurately predict long-term OS. Two components of the 13-gene 
model, PKC and PDE4B, were studied using inhibitors in lymphoma cell-lines and 
primary cell cultures.  PKC inhibition using SC-236 proved to be cytostatic and 
cytotoxic in the cell-lines examined and to a lesser extent in primary tumours.  PDE4 
inhibition using piclamilast and rolipram had no effect either alone or in combination 
with chemotherapy.  The empirical approach investigated the trace element selenium in 
presentation serum and found that it was a biochemical predictor of response and 
outcome to treatment.  In an attempt to provide evidence of a causal relationship as an 
explanation for the associations between presentation serum selenium, response and 
outcome, two selenium compounds, methylseleninic acid (MSA) and 
selenodiglutathione (SDG) were studied in vitro in the same lymphoma cell-lines and 
primary cell cultures.  Both MSA and SDG exhibited cytostatic and cytotoxic activity 
and caspase-8 and caspase-9 driven apoptosis.  For SDG reactive oxygen species 
generation was important for its activity in three of the four cell-lines.  In conclusion, 
molecular and biochemical predictors of response and survival were discovered in 
DLBCL that led to viable targets for drug intervention being validated in vitro.
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variant of Bcl-x gene)
BCR B-cell receptor
Bik bcl-2 interacting killer – BH3 only pro-apoptotic Bcl-2
family memberprotein
Bim Bcl-2-interacting protein
BL Burkitt lymphoma
bp base pairs
 pol polymerase, DNA, beta
BSA body surface area
BUB1B budding uninhibited by benzimidazoles 1
c-JUN v-JUN avian sarcoma virus 17 oncogene homologue
CASPASE-8 cysteine-aspartic acid protease-8
CASPASE-9 cysteine-aspartic acid protease-9
CD4 cluster of differentiation 4
CD8 cluster of differentiation 8
CD19 cluster of differentiation 19
CD20 cluster of differentiation 20
CD22 cluster of differentiation 22
CD34 cluster of differentiation 34
CD79a cluster of differentiation 79a
CDC6 cell cycle controller CDC6
CDC20 cell division cycle 20 homologue
CDC25A cell division cycle 25 homologue A
CDK1 cyclin-dependent kinase 1
CDK2 cyclin-dependent kinase 2
CDK4 cyclin-dependent kinase 4
CDK6 cyclin-dependent kinase 6
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CDKN2A cyclin-dependent kinase inhibitor 2A gene
cDNA complementary deoxyribonucleic acid
CDP cytidine 5 -diphosphate
Cdw32Fc Fc fragment of IgG, low affinity IIa, receptor (CD32)
CEM human T-cell ALL cell-line
CGH comparative genomic hybridisation
c-GMP cyclic guanosine 3’-, 5’- monophosphate
CH3SeH methylselenol
(CH3)2Se dimethylselenide
(CH3)3Se+ trimethylselenide
CHK-1 checkpoint kinase 1
CHK-2 checkpoint kinase 2
CHO Chinese Hamster Ovary cell-line
CHOEP-14 CHOP plus etoposide given every 14 days
CHOEP-21 CHOP plus etoposide given every 21 days
CHOP cyclophosphamide, doxorubicin, vincristine
prednisone
CHOP 14 CHOP chemotherapy given every 14 days
CHOP 21 CHOP chemotherapy given every 21 days
CHOP-R CHOP chemotherapy plus rituximab
CI confidence interval
CIBMTR Center for International Blood and Marrow Transplant
Research
CLL chronic lymphocytic leukaemia
CNS central nervous system
COPD chronic obstructive airways disease
COX-1 cyclo-oxygenase-1
COX-2 cyclo-oxygenase-2
CpG cytosine base followed immediately by a guanine base
CR complete response
CRu complete response undefined
GPR good partial response
CRL-2261 DLBCL cell-line
CRL shortened version of CRL-2261
cRNA complementary ribonucleic acid
CRu complete response unconfirmed
CR-UK Cancer Research United Kingdom
CsCl caesium chloride
CTP cytidine triphosphate
c-MYC cellular homologue of a transforming gene encoded by the
avian myelocytomatosis virus, MC29
DAB 3’3’diaminobenzidine
DCDP deoxycytidine 5-diphosphate
DCF-DA 2’7’-dichlorodihydrodifluoroscein diacetate
DFCI Dana Farber Cancer Institute
DHAP cisplatin-cytarabine-dexamethasone chemotherapy
DHL4 DLBCL cell-line
DHL6 DLBCL cell-line
DLBCL diffuse large B-cell lymphoma
DMBA 7,12-dimethylbenz(a)anthracene
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DMSO dimethyl sulphoxide
DNA deoxyribonucleic acid
DoHH2 transformed FL cell-line
DRP2 dystrophin related protein 2
DU145 human prostate cancer cell-line
E etoposide
E2F-1 E2F transcription factor 1
E2F-2 E2F transcription factor 2
EBV Epstein-Barr virus
EGFR epidermal growth factor receptor
ECOG Eastern Co-operative Oncology Group
EC50 effective concentration to achieve 50% response
E coli Escherichia coli bacteria
EDTA ethylenediaminetetraacetic acid
EGTA ethylene glycol tetraacetic acid
ERK extracellular signal-regulated kinase
cFLIP long cellular FADD-like interleukin 1 converting enzyme
inhibitory protein
FAS a death receptor; aliases include CD95 and Apo-1
FL follicular lymphoma
Fors forskolin
G0 phase of the cell cycle where cells exist in a quiescent state
G1 first phase of interphase within the cell cycle
G1/S transition between G1 and S phase in the cell cycle
G2/M second checkpoint of the cell cycle
G2 third and final phase of interphase within the cell cycle
GADD45 growth arrest- and DNA damage-inducible gene 45
GADD153 growth arrest- and DNA damage-inducible gene 153
GAPDH glyceraldehyde-3-phosphate dehydrogenase
GATA-1 GATA binding protein 1 (globin transcription factor1)
GC germinal centre
GCB germinal centre B-cell
GCB- germinal centre B-cell-like
GELA Groupe d’Etude des Lymphomes de l’Adulte
GPR good partial response
GPx glutathione peroxidase
G-CSF granulocyte-colony stimulating factor
HAART highly active antiretroviral therapy
HCL hydrochloric acid
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid
HIF-1 hypoxia-inducible factor 1
HG-U133 human genome U133 Affymetrix gene chip
HG-U95A human genome U95A Affymetrix gene chip
HIV human immunodeficiency virus
HR hazard ratio
HU6800 human genome 6800 Affymetrix microarray chip;
alternative name HuGeneFl microarray chip
IC50 Inhibitor Concentration needed to achieve 50% enzyme
inhibition
IgG immunoglobulin G
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IgG1 immunoglobulin G-1
Ig/BCL-6 chromosomal translocation involving an immunoglobulin
chain locus and the Bcl-6 gene locus
IgH immunoglobulin heavy chain
IHC immunohistochemistry
I lambda immunoglobulin lambda light chain
I kappa immunoglobulin kappa light chain 
IB inhibitor of kappa light chain gene enhancer in B-cells
IB IB
IL-4 interleukin-4
IMDM Iscove's modified Dulbecco's medium
IPI international prognostic index
JNK Jun N-terminal Kinase
JNK-1 Jun N-terminal Kinase-1
JNK-2 Jun N-terminal Kinase-2
kb kilo base pair
kDa kilo Dalton
KH2PO4 potassium diphosphate
Ki the dissociation constant for the enzyme-inhibitor complex
K-ras Kirsten rat sarcoma viral oncogene homologue
LDH lactate dehydrogenase
LNCaP human prostate cancer cell-line
Ly379196 PKC inhibitor
M mitotic phase of the cell cycle
MACOP anthracycline-based combination chemotherapy regimen
MALT extranodal marginal zone B-cell lymphoma of
mucosa associated lymphoid tissue
MAPK1 mitogen-activated protein kinase 1 (ERK2)
MAPK3 mitogen-activated protein kinase 3 (ERK1)
MBP methylated DNA binding proteins
MBR major breakpoint region
MCF10AT1 human premalignant mammary epithelial cell-line
MCF10AT3B human premalignant mammary epithelial cell-line
MCL mantle cell lymphoma
MCL-1/Mcl-1 myeloid cell differentiation 1 gene/protein
MCM2 minichromosome maintenance 2
MCM3 minichromosome maintenance 3
MCM5 minichromosome maintenance 5
MCM6 minichromosome maintenance 6
MCM7 minichromosome maintenance 7
Mcr minor cluster region
MDM2 mouse double minute 2 homologue
MEL mouse erythroleukaemia cell-line
mer oligomer
MES 2-[N-morpholino]ethansulphonic acid
MHC major histocompatibility complex
MinT MabThera International Trial
MINOR mitogen induced nuclear orphan receptor
MOD mouse mammary cancer cell-line
mRNA messenger ribonucleic acid
Abbreviations
23
MSA methylseleninic acid
MSC Se-methylselenocysteine
MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)
2 (4-sulphophenyl)-2H-tetrazolium
NAC N-acetyl cysteine
NaCl sodium chloride
NADPH Nicotinamide adenine dinucleotide phosphate
NaOH sodium hydroxide
NCI national cancer institute of the United States of America
NFB nuclear factor-kappaB
NHL non-Hodgkin lymphoma
nm23-H1 non-metastatic protein 23, homologue 1
NPM-ALK nucleophosmin-anaplastic lymphoma kinase fusion protein
NSAID non-steroidal anti-inflammatory drug
OCI-Ly3 human DLBCL cell-line
OCI-Ly10 human DLBCL cell-line
OD optical density
oligo-Dt short strings of thymidylate
OxPhos oxidative phosphorylation 
PI3-kinase phosphatidylinositol 3-kinase
p14ARF 14 kDa protein (alternative reading frame); beta transcript
of CDKN2A gene
p16INK4a 16 kDa protein (inhibitor of kinase CDK4); alpha transcript
of CDKN2A gene
p19INK4d 19 kDa protein (inhibitor of kinase CDK4); alternative
name cyclin-dependent kinase inhibitor 2D (CDKN2D)
p21WAF1 21 kDa protein (wild type p53-activated fragment 1)
alternative name CDK-interacting protein 1 (CIP1)
P27kip1 cyclin-dependent kinase inhibitor 1B
p38 MAP kinase p38 mitogen-activated protein kinase;
alternative name MAPK14
p53 tumour protein of 53 kDa
p63 tumour protein of 63 kDa
p73 tumour protein of 73 kDa
p90RSK 90 kDa ribosomal protein S6 kinase
P450 pigment at 450 nm
PARP poly(ADP-ribose) polymerase
PAX5 paired domain gene 5
PBS phosphate buffered saline
PC3 prostate cancer 3 cell-line
PCNA proliferating cell nuclear antigen
PCR polymerase chain reaction
PDE phosphodiesterase
Pic piclamilast
PFS progression free survival
PIM1 serine/threonine protein kinase PIM1
PKA c-AMP-dependent protein kinase A protein 
PKC      protein kinase C beta
PKC      protein kinase C beta-1
PKC2 protein kinase C beta-2
Abbreviations
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PLK polo-like kinase
PMA phorbol-12-myristate-13-acetate
PMBCL primary mediastinal B-cell lymphoma
PPR poor partial response
PR partial response
pRb phosphorylated retinoblastoma protein
PTLPDs post-transplant lymphoproliferative disorders
P values probability values
PI propidium iodide
PMSF phenylmethanesulphonyl fluoride
PTEN phosphatase and tensin homologue deleted on chromosome
ten
Puma p53-upregulated modulator of apoptosis
p48XPE DNA damage-binding protein 2 p48 subunit
p-XSC 1,4-phenylenebis(methylene)selenocyanate
R rituximab
RAD9 radiation gene 9
Rad-51 radiation gene 51
Rad-54 radiation gene 54
RAG recombination-activating gene
RB1 retinoblastoma-1 gene
REAL revised European and American lymphoma classification
REL avian reticuloendotheliosis viral oncogene homologue
RhoH/TTF RAS homolog gene family, member H/
translocation three four
RNA ribonucleic acid
RQ-PCR quantitative real-time polymerase chain reaction
Rol rolipram
ROS reactive oxygen species
RPMI Roswell Park Memorial Institute
RRM1 ribonucleotide reductase, M1 subunit
RRM2 ribonucleotide reductase, M2 subunit
S S or synthesis phase of the cell cycle during which DNA
synthesis or replication occurs
Se Selenium
Sepp1 selenoprotein P
SAPE streptavidin-phycoerythrin
SBH St Bartholomew’s Hospital
SDG selenodiglutathione
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel
electrophoresis
SEER surveillance, epidemiology and end results
SLL small lymphocytic lymphoma
SNP single nucleotide polymorphism
SNU-1 gastric adenocarcinoma cell-line
SOM self-organising map
SPIB spleen focus forming virus proviral integration oncogene B
STK15 serine/threonine protein kinase 15
Sub-G1 apoptotic cell fraction
SUD4 human DLBCL
Abbreviations
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SV40 simian virus 40
TGF- transforming growth factor 
TGF-R1 transforming growth factor  receptor 1
TGF-R2 transforming growth factor  receptor 2
Th2 T-helper cell type 2
TM12 mouse mammary epithelial cell-line
TM2H mouse mammary epithelial cell-line
TNF tumour necrosis factor
TP53 tumour protein 53 gene
TOP2A topoisomerase II alpha
TR thioredoxin reductase
TRAIL tumour necrosis factor related apoptosis inducing ligand
Trx thioredoxin
TYMS thymidylate synthetase gene (TS)
tRNA transfer ribonucleic acid
Tris-Cl tris base and hydrochloric acid solution
UACC-903 melanoma cell-line
UK United Kingdom
ULN upper limit of normal
UTP uridine triphosphate
US United States
USA United States of America
V(D)J variable, diversity and joining genes
VEGF vascular endothelial growth factor
VEGFR1 vascular endothelial growth factor receptor
VIM etoposide-ifosfamide-methotrexate chemotherapy
w/ with
w/o without
WHO World Health Organisation
Thesis Aims
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THESIS AIMS
 To discover, explore and validate new molecular and biochemical predictors of 
response and long-term outcome in diffuse large B-cell lymphoma (DLBCL).
 To improve on the International Prognostic Index in DLBCL.
 To discover novel therapeutic targets in DLBCL.
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CHAPTER 1: INTRODUCTION
1.1 Pathogenesis of Lymphoma and Cancer
1.1.1 The Process of Carcinogenesis
The process of carcinogenesis involves the acquisition of at least six functional changes: 
resistance to growth inhibition, evasion of apoptosis, independence of mitogenic 
stimulation, angiogenesis, metastasis and invasion (Hahn and Weinberg, 2002b). It is 
hoped that the disruption of a limited number of regulatory pathways will underlie 
carcinogenesis and bring meaning to the ever-burgeoning number and complexity of 
described genetic and epigenetic alterations in tumours. The genetic and biochemical 
rules governing the transformation of human cells into malignant clones are the subject 
of intense worldwide research. The discovery and validation of such rules will redefine 
not only the diagnosis of tumours such as DLBCL but also prognostic accuracy and 
ultimately therapy development and deployment.
Strong, direct evidence supporting a genetic basis for carcinogenesis began to emerge in 
the 1980’s with the demonstration of the malignant transformation of immortalised cells 
through the introduction of genetic material containing oncogenes and the identification 
of such dominantly acting, growth-controlling oncogenes in tumour derived cell-lines. 
In immortalised rodent cells the collaboration of just two oncogenes was sufficient to 
produce neoplastic cells, whilst in human cells more hurdles have to be overcome to 
achieve malignant transformation suggesting a more complex carcinogenic pathway. In 
lymphomas, the collaborative effect of oncogenes is illustrated by the presence in a 
minority of follicular lymphoma (FL) and DLBCL of both a BCL-2 and a c-Myc
translocation, an occurrence associated with aggressive, progressive disease (Yano et 
al., 1992, Karsan et al., 1993).
Each cancer develops through the clonal expansion of a single founder cell, which has 
acquired a survival advantage. In DLBCL, and other B-cell non-Hodgkin lymphomas 
(NHLs), the clonal nature of each tumour is readily proven by confirmation of a single 
idiotype common to each of the neoplastic cells.
Tumour development is considered to follow a multi-step pathway involving the 
disruption of critical genes involved in genome integrity, cell proliferation, 
differentiation and survival (Hahn and Weinberg, 2002a, Hahn and Weinberg, 2002b). 
The multi-stage progression from early to late, from pre- to metastatic cancer is 
conditional upon the acquisition of modifications in particular oncogenes and tumour 
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suppressor genes (Kinzler and Vogelstein, 1996b, Brat et al., 1998). The acquisition of 
the critical genetic and epigenetic abnormalities for neoplastic transformation occurs as 
the clone undergoes many stochastic cycles of clonal selection. Many ‘bystander’ 
events are produced prior to a tumour’s clinical presentation, with the consequence of 
wide-ranging alterations in gene and protein expression and also considerable diversity 
within each tumour, as different daughter cells of the original clone randomly acquire 
different lesions. Critical to carcinogenesis is the rate at which genetic aberrations are 
acquired. Under normal conditions, the rate of base-pair mutations is only 0.16 per 
genome per cell division and the occurrence of chromosomal abnormalities also 
develop infrequently and almost always result in the cell’s elimination through 
programmed cell death (Drake et al., 1998). Lymphomagenesis is expected to follow 
such a multi-step pathway, however, the absence of a pre-malignant forerunner of 
DLBCL and other NHLs in the immunocompetent has prevented detailed identification 
of early molecular events as has been possible in bowel, breast, lung and pancreatic 
cancer. Indeed, possibly most of the critical genetic, epigenetic and biochemical events 
in lymphomagenesis, beyond putative cell of origin and hallmark translocations, still 
await discovery. It is however already apparent that acquisition of critical carcinogenic 
properties occurs in DLBCL and other high-growth fraction lymphomas, including 
subversion of the cell cycle, resistance to apoptosis and independence of mitogenic 
stimulation. The normal cell cycle has three checkpoints built into it to prevent 
replication of a defective genome or division of misaligned daughter chromosomes as 
illustrated in Figure 1.1.
The acquisition of resistance to growth inhibition and the evasion of apoptosis are 
achieved by inactivation, through mutation, epigenetic silencing or deletion of 
recessive, tumour suppressor genes causing loss of their proteins and the failure of their 
regulatory pathways. In order to maintain homeostasis in normal tissues the balance 
between cell death and cell growth is tightly controlled. During carcinogenesis, this 
sensitive and dynamic process, controlled by the cell cycle regulators and checkpoints 
controls, is disrupted and lost (Hartwell and Kastan, 1994, Hanahan and Weinberg, 
2000). Oncogenes, in contrast to tumour suppressor genes, positively promote cell 
proliferation by overcoming cell cycle checkpoints, by resisting apoptosis and 
preventing differentiation. Oncogenes become constitutively active through gain of 
function mutations or through excessive transcription, as produced through 
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chromosomal translocation. Chromosomal translocation of c-Myc and CCND1 (the gene 
for cyclin-D1, originally named BCL-1) are examples of proto-oncogene deregulation in 
NHLs (Magrath, 1990, Kuroda et al., 1995). The protein products of both these 
oncogenes and a third, Cyclin-D3, are overexpressed in a significant proportion of 
DLBCL.
Figure 1.1 Phases and Checkpoints of the Cell Cycle The relative lengths of the phases of 
the cell cycle are typical of rapidly dividing human cells. If sufficient growth factors are available the cell 
can pass through the G1 restriction point to move towards S phase. Otherwise the cell is forced to enter 
G0. The cell grows during the three phases of interphase with DNA replication occurring during S phase. 
Chromosome separation and cell division occur during M phase. The three checkpoints prevent cell 
proliferation if DNA damage, faulty or incomplete replication has occurred or the chromosomes are not 
correctly aligned on the mitotic spindle. M = mitosis phase; G1 = 1st growth phase of interphase; S = 
DNA synthesis phase; G2 = 2nd growth phase of interphase; G0 = quiescent/senescent phase. Adapted 
from (Cooper, 2002).
1.1.2 Impaired Apoptosis in NHL and Cancer
Two independent but convergent pathways, referred to as the ‘intrinsic’ and ‘extrinsic’ 
pathways, initiate programmed cell death, or apoptosis. The intrinsic pathway is centred 
on the cell’s mitochondria where translocation of Bcl-2 family members into the 
mitochondria promotes changes in the mitochondrial membrane permeability, with the 
consequent release of cytochrome c. The association of cytochrome c with APAF-1 
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(apoptotic protease-activating factor-1) allows activation of the initiator caspase 
(cysteine-aspartic acid protease), caspase-9, which in turn triggers the effector caspase 
apoptotic cascade. The binding of ligands to cell surface death receptors, e.g. Fas ligand 
binding to Fas and tumour necrosis factor- (TNF binding to TNF receptor-1, 
activates the extrinsic apoptotic pathway. Once a death receptor complex is formed, the 
initiator caspase, caspase-8 is recruited and activated, leading to ignition of the effector 
caspase apoptotic cascade. The apoptotic cell shows cell surface membrane blebbing, 
chromatin condensation and internucleosomal DNA fragmentation (Kerr et al., 1972, 
Savill and Fadok, 2000). These changes are accompanied by the cell surface exposure 
of certain ligands, which indicate that the cell is marked for phagocytosis. The 
impairment of programmed cell death not only allows tumourigenesis to begin, but 
facilitates the accumulation of other lesions critical to the development of an overt 
tumour as proliferation and cell accumulation become uncontrolled. Apoptosis is 
subdued in DLBCL and other tumour cells by the combination of overexpression of 
anti-apoptotic, pro-survival genes such as BCL-2, the inhibitors of apoptosis proteins 
(IAPs) and NFB; decreased expression and response to cell surface death receptors 
and their ligands, for example, Fas and Fas ligand; and inactivation of TP53 and its 
pathways (Wickremasinghe and Hoffbrand, 1999, Schimmer et al., 2001, Johnstone et 
al., 2002, Evan and Vousden, 2001, Igney and Krammer, 2002, Salvesen and Duckett, 
2002, Baldwin, 2001).
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Figure 1.2 The Intrinsic Apoptotic Pathway. The pro- and anti-apoptotic Bcl-2 family 
members vie to cause and prevent release of cytochrome C from the mitochrondria. When cyctochrome C 
release occurs, it binds to the adaptor protein APAF-1 (apoptotic protease-activating factor-1) facilitating 
the activation of the initiator caspase-9 by autocleavage. Activated caspase-9 then cascades its signal via 
other caspases to produce programmed cell death – apoptosis. Adapted from (Cooper, 2002).
Inhibits cytochrome C release. Promotes cytochrome C release.
1.1.3 Impairment of the Intrinsic Apoptotic Pathway: Alterations in The Bcl-2 
Family of Proteins
The Bcl-2 family of nearly twenty proteins are divisible into three subgroups, the Bcl-2-
like subgroup of anti-apoptotic proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, Boo and A1), and 
two subgroups of pro-apoptotic proteins, the Bax/Bak-like proteins (Bax, Bak, Bok, 
Bcl-xS and Bcl-GL) and the BH-3-only subgroup (Bmf, Bad, Hrk, Noxa, Puma, Bik, 
Bim and Bid) (Coultas and Strasser, 2003, Strasser et al., 2000). As the Bcl-2 family 
has grown and its members roles explored, it has become clear that considerable 
functional overlap exists amongst them; that interaction of the pro- and anti-apoptotic 
Bcl-2 family proteins is integral to their regulation of cell death and that their relative 
levels determine the pro- or anti- apoptotic inclination of cells (Yi et al., 2003, Huang 
and Strasser, 2000, Cheng et al., 2001) – see Figure 1.2.
The Bcl-2 family of proteins are critical for normal embryonic development and, once 
born, tissue homeostasis, including regulation of the death of lymphocytes and other 
blood cells as a counterbalance to haematopoiesis (Jacobson et al., 1997, Newton and 
Strasser, 2000). This protein family is involved in the intrinsic apoptotic pathways 
initiated by cytokine withdrawal and cytotoxic stress conditions but are not required for 
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death receptor initiated cascades mediated by the TNF-receptor family (Strasser et al., 
2000, Strasser et al., 1995, Ashkenazi and Dixit, 1998). The Bax/Bak-like subclass and 
the Bcl-2 subgroup are involved in controlling the integrity of the mitochondrial 
membrane, breach of which is essential if the intrinsic caspase pathway is to bring about 
apoptosis. The Bax/Bak-like subclass promotes cytochrome c release from the 
mitochondria, whilst the Bcl-2 subgroup prevents cytochrome c escape from the 
mitochondrial inter-membrane space, so by disabling cell death signal promotion (Gross
et al., 1999, Wang, 2001). The BH-3 only subgroup function upstream of the Bax/Bak-
like proteins promoting cell death signal initiation (Huang and Strasser, 2000, Zong et 
al., 2001, Cheng et al., 2001, Bouillet et al., 2002). In DLBCL, inactivating mutations 
in pro-apoptotic Bcl-2 family members have only been described in Bik, being seen in 
18% of DLBCLs (Arena et al., 2003). Whether epigenetic silencing of the Bax/Bak-like 
and BH-3 proteins occurs, as part of lymphomagenesis, is unknown at present.
BCL-2 was the first proto-oncogene to be described that exerted its transforming action 
by preventing cell death instead of promoting cell proliferation (Tsujimoto et al., 1984). 
Transgenic overexpression of Bcl-2 subgroup members BCL-2, MCL-1 and Bcl-xL in 
mice results in B-cell lymphomas and plasma cell lesions (McDonnell and Korsmeyer, 
1991, Strasser et al., 1993, Zhou et al., 2001, Linden et al., 2003, Naik et al., 1996). A 
synergistic interaction, in terms of tumourigenesis, has been observed in transgenic 
experiments between pro-survival BCL-2 and the pro-cell growth and cell cycling 
genes, Pim-1 and v-abl and Bcl-xL and c-Myc (Strasser et al., 1990, Acton et al., 1992, 
Jaiswal et al., 2003, Harris et al., 1997, Naik et al., 1996). Although transgenic mice 
overexpressing Bcl-2 display a preneoplastic, polyclonal lymphoproliferative condition 
that foretells the appearance of tumours (McDonnell et al., 1989), frustratingly an 
analogous phenomenon has not been described in humans despite Bcl-2’s evident 
function as a proto-oncogene. In DLBCL, overexpression of Bcl-2 is seen due to the 
presence of a t(14;18)(q32;q21) translocation or gene amplification in a minority of 
cases, with mRNA levels of BCL-2 correlating with Bcl-2 protein levels (Shen et al., 
2004, Iqbal et al., 2004).
1.1.4 Impairment of the Extrinsic Apoptotic Pathway: Fas and TRAIL Death 
Receptor Signalling in NHL
Fas (APO-1/CD95) is a cell surface death receptor belonging to the TNF-receptor 
family, which functions as a tumour suppressor gene in NHL (Straus et al., 2001). 
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Stimulation of Fas by its natural ligand (FasL) results in receptor trimerisation and 
recruitment of procaspase-8 and FADD (Fas associated death domain) to form the 
death-inducing signalling complex  (DISC) (Walczak and Krammer, 2000, Krammer, 
2000). The resultant activation of caspase-8 triggers cell death through the extrinsic 
apoptotic pathway (illustrated in Figure 1.3). Fas signalling is the principle means of 
activated T-cell elimination and appears important for B-cell removal and malignant 
lymphocyte cell death (Rathmell and Goodnow, 1998, Krammer, 2000, Dhein et al., 
1994). Fas is encoded by nine exons found at 10q23 (Behrmann et al., 1994). The 
inherited, usually autosomal dominant, ‘autoimmune lymphoproliferative syndrome’ is 
caused by mutations in the ligand binding and death domain exons of Fas, which result 
in benign lymphadenopathy, hepatosplenomegaly, an increased incidence of 
lymphomas and failure of T-cells to undergo apoptosis in response to FasL stimulation 
(van den Berg et al., 2002, Martin et al., 1999). Escape from apoptotic cell death 
through inactivation of Fas appears important in NHLs. Sporadic mutations of Fas 
occur in 20-30% of NHLs and Hodgkin lymphoma cases (Gronbaek et al., 1998, 
Muschen et al., 2000). Other NHLs inactivate the extrinsic Fas death pathway through 
silencing of Fas expression (Clodi et al., 1998, Laytragoon-Lewin et al., 1998). Hueber
et al demonstrated that c-Myc-induced apoptosis requires interaction on the cell surface 
between Fas and its ligand. His findings linked two apoptotic pathways previously 
thought to be independent and established the dependence of c-Myc on Fas signalling 
for its killing activity (Hueber et al., 1997). Recent Fas mutation analysis in a series of 
117 DLBCL samples found eight cases (7%) with death domain mutations that resulted 
in loss of the death domain (Takahashi et al., 2006). The frequency of Fas death domain 
mutations was highest, 15%, in DLBCL with an ‘oxidative phosphorylation (OxPhos)’ 
expression profile (see page Chapter 5). In the same series, overexpression of cFLIP 
long (cellular FADD-like interleukin 1 converting enzyme inhibitory protein) the 
competitive antagonist of FADD was seen in the ‘host response’ transcriptional 
signature subtype of DLBCL, suggesting that suppression of the extrinsic apoptotic 
pathway by Fas signalling silencing is important in these DLBCL.
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Figure 1.3 The Extrinsic Apoptotic Pathway. Activated caspase-8 then cascades its signal via 
caspases-3-7 to produce apoptosis. Caspase-8 can also activate the intrinsic apoptotic pathway via 
activation of Bid, which then binds to mitochondria, promoting cytochrome C release. FasL = Fas-ligand; 
DR3 ligand = death receptor 3 ligand; TRAIL = TNF-related apoptosis-inducing ligand; DR3 = death 
receptor 3; TRAIL-R1 & R2 = ; TNF = tumour necrosis factor alpha; TNFR1 = tumour necrosis factor 
receptor-1; DD = death domain; TRADD = tumour necrosis factor receptor-1-associated death domain; 
FADD = Fas-associated death domain; DISC = death-inducing signalling complex; Bid = BH3-
interacting domain death agonist; Apaf-1 = apoptotic protease activating factor-1; caspase = cyteine 
aspartate-specific proteinase.
Adapted from (Zimmermann et al., 2001, Cooper, 2002). Promotes cytochrome C release. 
Study of the frequently deleted chromosome 8p21.3 in 45 B-cell NHL cell-lines defined 
a minimal deleted region of 600 kb that contains the TRAIL-R1 and –R2 genes. Further 
investigation, including FISH analysis of >100 primary NHL samples suggest that 
deletion-induced haploinsufficiency of TRAIL-R1/R2 can impair TRAIL-induced 
extrinsic pathway apoptosis in NHL and may therefore contribute to lymphomagenesis 
in B-cells through a gene dosage effect (Rubio-Moscardo et al., 2005). Mutations in the 
death domain of TRAIL-R1/R2 have been found in 7% of NHL (Lee et al., 2001).
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1.1.5 Cell Cycle Deregulation in Cancer and Lymphoma
Tumour suppressor genes prevent unrestrained cell growth, cycling, and survival. 
Tumour suppressor genes were divided into two classes: ‘caretaker’ genes and 
‘gatekeeper’ genes by Kinzler and Vogelstein, based on their observations of genetic 
abnormalities in colorectal cancer (Kinzler and Vogelstein, 1996a). ‘Caretaker’ genes 
are critical for maintaining genetic stability. Mutations in ‘caretaker’ genes make 
mutation in other genes much more likely so by creating a state of genetic instability. 
Examples of ‘caretaker’ genes include the DNA mismatch repair genes MLH1 and 
MSH2, alteration of which predisposes to colorectal cancer; the breast and ovarian 
cancer susceptibility genes BRCA-1 and –2 and ATM (ataxia telangiectasia mutated) in 
MCL (mantle cell lymphoma) and other NHLs. ‘Gatekeeper’ genes and their proteins 
control aspects of cell proliferation, with the consequence of uncontrolled cell 
proliferation on their mutation. ‘Gatekeeper’ genes include RB1 (retinoblastoma gene) 
in retinoblastoma, APC and b-catenin genes in colorectal cancer and VHL gene in renal 
cell cancer. Kinzler and Vogelstein proposed that only one additional somatic mutation 
would be necessary if a ‘gatekeeper’ gene was disrupted as opposed to three or more 
additional somatic mutations if a ‘caretaker’ gene was mutated (Kinzler and Vogelstein, 
1997, Michor et al., 2003, Frank, 2003).
Two pathways dominate the control of the cell cycle: the pRb protein pathway 
(p16INK4a-Cyclin D-cdk4-pRb) and the p53 pathway (p14ARF-mdm2-p53-p21WAF1). Both 
pRb and p53 are ‘gatekeeper’ tumour suppressor proteins. p53 also functions as a 
‘caretaker’ tumour suppressor. Members of these two pathways and a third, the p27KIP1-
cyclin E-cdk2, are found mutated or silenced in virtually every human cancer including 
DLBCL, with particular genetic and epigenetic alterations being seen in different 
tumour types (Giaccia and Kastan, 1998, Sherr and McCormick, 2002, Dyson, 1998). 
The pRb and p53 pathways interact at both the genetic and protein level (Stewart et al., 
2001, Yamasaki, 2003). The transforming potential of defective pRb and p53 is 
illustrated by the results of mouse embryo fibroblast knockout research, where the 
addition of just a Ras oncogene to either TP53-/-,p19-/- (the mouse homologue of 
p14ARF) or RB1/p107/p130-/- cells was sufficient to induce transformation. Clinical 
consequences appear to stem from the concurrent disruption of p16INK4a and p14ARF-
TP53 with a significantly worse 5-year OS of only 7% compared to 38% in those 
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DLBCL patients with retention of one or both pathways (P = 0.005) (Gronbaek et al., 
2000).
1.1.6 Resistance to Cell Cycle Arrest
Disruption of the pRb Pathway in DLBCL
pRb regulates the G1/S checkpoint according to its phosphorylation status. 
Unphosphorylated Rb blocks G1/S progression by sequestration of the transcription 
factor E2F. Conversely, the phosphorylation of different sites on the pRb protein by the 
different cyclins/cdks removes pRb’s inhibition of the G1/S checkpoint, releasing E2F 
and allowing irreversible progression into S phase and consequent cell division, even in 
the absence of growth signals. Normally pRb protein levels rise and fall in relation to 
the proliferative activity of the haematological cells concerned (Martinez et al., 1993). 
This relationship is preserved in many NHLs where low growth fraction tumours 
express little pRb, whilst high growth fraction tumours display higher levels (Kiviniemi
et al., 2000). Rb is itself mutated in various solid tumours and inactivated in a third of 
lymphoid malignancies (Hangaishi et al., 1996). Three members of the pRb pathway, 
p16INK4a, cyclin-D1 and D3, are frequently disrupted in lymphomas and other cancers 
(Tsutsui et al., 2002, Steeg and Zhou, 1998, Tetsu and McCormick, 1999, Ruas and 
Peters, 1998, Beasley et al., 2003, Bai et al., 2003). Overexpression of cyclin-D1 or D3 
and suppression of p16INK4a cause sustained hyperphosphorylation and therefore 
inactivity of pRb. p16INK4a and p15INK4b suppress cell cycling by binding cdk-4 and -6, 
so by displacing bound Cyclin-D and preventing Cyclin-D rebinding (Sandhu et al., 
1997). The p15INK4b gene CDKN2B is located adjacent to the p16INK4a/p14ARF gene locus 
CDKN2A at 9p21 (Hannon and Beach, 1994). 9p21 deletion, small homozygous 
deletions and hypermethylation all result in the silencing of p16INK4a (Nakahara et al., 
2001, Cairns et al., 1995). The importance of the pRb pathway in DLBCL is illustrated 
by the high frequency of its disruption, with 53% of cases displaying p16INK4a
inactivation, Cyclin-D3 overexpression or aberrant pRb expression and E2F-1 low 
expression being a poor prognostic factor for OS on multivariate analysis (relative risk 
= 6.9; P = 0.0037) (Moller et al., 2000).
Resistance to Cell Cycle Arrest, Apoptosis and Induction of Genetic Instability: 
Disruption of the p53 Pathway in DLBCL
p53 functions as both a ‘gatekeeper’ and a ‘caretaker’ gene through its ability to induce 
cell cycle arrest and apoptosis and as a preserver of genomic integrity respectively 
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(Giaccia and Kastan, 1998, Morris, 2002). The key role p53 plays at the intersection of 
multiple pathways regulating cell fate, in response to internal and external stresses is 
illustrated in Figure 1.4 and is borne out by it being the most frequently mutated gene 
yet discovered in human cancer. Indeed TP53 mutations, usually in the DNA binding 
domain, are seen in >50% of human solid tumours, 20% of DLBCLs (16/84) and 22% 
(22/102) of aggressive NHLs (DLBCL and Burkitt lymphoma (BL)) (Ichikawa et al., 
1997, Koduru et al., 1997). Wild-type TP53 serves as a ‘guardian of the genome’ 
preventing proliferation of genetically damaged cells. After DNA damage, p53 activates 
transcription of genes to mediate its biologic role as a tumour suppressor, including 
transcription of p21WAF1 to induce a G2 cell cycle arrest (Bunz et al., 1998). 
Surprisingly, the cdk inhibitor p21WAF1 is rarely mutated in human malignancies 
(Kawamata et al., 1995). In tumour cells with inactive p53 cell cycle progression cannot 
be blocked permitting upregulated growth. The half-life of p53 is short, due to binding 
of its antagonist the oncoprotein mdm2. Binding by mdm2 allows p53’s efficient 
removal by ubiquitination, followed by proteosomal degradation (Haupt et al., 1997). 
The phenotype of wild-type TP53 cases revealed by IHC is therefore p53-/p21+. This 
changes to p53+/p21- in mutated TP53 cases (Villuendas et al., 1997). Where wild-type 
TP53 persists, mdm2 overexpression frequently occurs in NHLs (22-28%) and serves as 
a means of p53 pathway deregulation (Moller et al., 1999c, Watanabe et al., 1994).
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Figure 1.4 The Role of p53 at the Crossroads of Cellular Stress Response Pathways
The upregulation of p53 in response to different types of cellular stress can result in apoptosis, cell cycle 
arrest, DNA repair or senescence according to the cellular stress, the availability of partners and modifiers 
of p53 and its isoforms. TGF- = transforming growth factor beta; p14ARF = 14 kDa protein (alternative 
reading frame); p16INK4a = 16 kDa protein (inhibitor of kinase CDK4); Puma = p53-upregulated 
modulator of apoptosis; Bax = Bcl-2-associated x protein; Bim = Bcl-2-interacting protein; Bak = Bcl-2 
antagonist killer; Bid = BH3 Interacting domain Death agonist; p21 = 21 kDa protein (wild-type p53-
activated fragment 1); cdc25A = cell division cycle 25 homologue A;  pol = polymerase, DNA, beta; 
Gadd45 = growth arrest- and DNA damage-inducible gene 45; p48XPE = DNA damage-binding protein 
2 p48 subunit; TFIIH = transcription factor IIH, 62-kDa subunit; Rad-51 and -54 = radiation genes 51 and 
54; mdm2 = mouse double minute 2 homologue; ATM = ataxia telangiectasia mutated; p38 MAP kinase 
= p38 mitogen-activated protein kinase; CHK-1 and -2 = checkpoint kinase 1 and 2; p63 = tumour protein 
of 63 kDa; p73 = tumour protein of 73 kDa. Adapted from (Braithwaite et al., 2005, Smith and Seo, 
2002).
p53 has been proposed to induce apoptosis through a three step process: transcriptional 
induction of redox-related genes; formation of reactive oxygen species; and oxidative 
degradation of mitochondrial components. Multiple interactions between p53 and 
members of the Bcl-2 family to effect apoptosis have been described. p53 translocates 
to mitochondria following DNA damage and directly induces permeability of the outer 
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mitochondrial membrane by forming complexes with the anti-apoptotic Bcl-xL and Bcl-
2 proteins, resulting in cytochrome c release (Mihara et al., 2003). Cytosolic p53 can 
induce apoptosis by directly activating pro-apoptotic Bax, and releasing pro-apoptotic 
BH3-only proteins sequestered by Bcl-xL (Chipuk et al., 2004). Following cellular 
stress, p53 can interact with pro-apoptotic Bak, causing Bak oligomerisation and 
cytochrome c release from mitochondria (Leu et al., 2004). Coincident with formation 
of p53-Bak complexes, loss of Bak sequestration by the anti-apoptotic Mcl-1 protein is 
seen. The Bcl-2 family member Bid is also induced by p53 and mediates p53-induced 
apoptosis (Sax et al., 2002).
Interaction between p53 and another protein important in lymphomagenesis, c-Myc, has 
also been described. c-Myc can determine the choice between p53 induced cell cycle 
arrest or p53 induced apoptotic cell death, by blocking p21WAF1 induction by p53, so by 
switching the response to DNA damage from cytostatic to apoptotic (Seoane et al., 
2002). Such an effect is seen in the majority of BL, which are exquisitely sensitive to 
chemotherapy-induced DNA damage and constitutionally overexpress c-Myc.
The importance of disruption of the p53 pathway in DLBCL is illustrated by the 
discovery of homozygous deletion of CDKN2A, the p14ARF locus, in 19%, TP53
mutations in 22% and mdm2 overexpression in 43% of DLBCL examined, resulting in 
62% of tumours having alterations of one or more p53 pathway components (TP53, 
p14ARF and mdm2) (Moller et al., 1999b). Overall, 82% of DLBCLs displayed pRb 
and/or p53 pathway disruption (Moller et al., 2000).
1.2 Diffuse Large B-cell Lymphoma
1.2.1 Pathology
Thomas Hodgkin made the first description of tumours arising within the lymphoid 
system in 1832 (Hodgkin, 1832). In 1864 and 1871 Virchow and Bilroth respectively 
referred to these illnesses as ‘lymphosarcomas’ and ‘malignant lymphomas’. Since that 
time it has become apparent the lymphomas are divisible into Hodgkin lymphoma and 
the NHLs, which together constitute the fifth commonest form of cancer in developed 
countries (Baris and Zahm, 2000). Several classifications of the lymphomas were 
developed and used in Europe and North America through the twentieth century. The 
World Health Organisation (WHO) classification of neoplastic diseases of the 
haemopoetic and lymphoid tissues is the most recent (Harris et al., 1999). The lymphoid 
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neoplasms are divided into distinct disease entities in the WHO classification and its 
forerunner the REAL classification (Armitage and Weisenburger, 1998, Harris et al., 
1994) according to a combination of morphology, immunophenotype, genetic features 
and clinical syndromes. Numerous NHL subtypes are now recognised of both B-cell 
and T-cell origin. The B-cell NHLs constitute the major group, with diffuse large B-cell 
lymphoma (DLBCL) being the commonest, representing 30-40% of all NHLs, followed 
by FL, which constitutes 20-30% of NHLs, as illustrated in Figure 1.5. The B-cell 
NHLs can be segregated into low and high-growth fraction tumours. The low-growth 
fraction NHLs display a relatively low proliferation index due to deregulated apoptosis 
rather than subversion of cell cycle control genes. The consequence is cell accumulation 
due to the failure of cells to die. Thus the low-growth fraction NHLs tend to present 
with advanced stage disease, which follow an indolent treatable but incurable course. 
The high growth-fraction NHLs, which include DLBCL, exhibit a raised proliferative 
index due to alterations in cell cycle regulators in combination with apoptotic pathway 
defects. Clinically such tumours follow a more aggressive course, yet often present with 
more localised disease. A proportion is curable with radical treatment.
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Figure 1.5 Frequency of Non-Hodgkin Lymphoma Subtypes Revised European 
American Lymphoma Classification Project Clinical Validation Data. More than 2000 cases of NHL 
from eight centres were reviewed and reclassified as the above subtypes resulting in the percentage 
frequencies in the Figure (Armitage and Weisenburger, 1998).
For the conclusive diagnosis of a lymphoma and assignment of a particular subtype, 
biopsy for histology with immunohistochemistry (IHC) is required. DLBCL supplants 
the normal architecture of invaded lymph nodes and extranodal sites with a diffuse 
pattern of large transformed lymphoid cells with various cytological appearances (Jaffe
et al., 2001). Despite clearly discernable variations in the microscopic appearance of 
DLBCL, highly reproducible histological subcategories of DLBCL have not been 
defined to date (Dick et al., 1987). The sub-typing of DLBCL into immunoblastic and 
centroblastic in the Kiel classification (Lennert and Feller, 1992) was problematic in 
terms of reproducibility between pathologists (Harris et al., 1994) and added little in the 
way of clinical relevance, as response to treatment and survival were usually the same 
for the two subtypes (Melnyk et al., 1997, Salar et al., 1998). The lack of clinical utility 
and inconsistent sub-classification in both the Kiel and Working Formulation systems 
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(the European and North American predecessors of the REAL classification) led to the 
optional, rather than compulsory, cytological subdivision of DLBCL in the REAL 
classification of 1994 (Harris et al., 1994) and the later WHO classification, launched in 
1999 (Harris et al., 1999). Immunohistochemically, the malignant cells in DLBCL 
express some if not all of the pan-B-cell markers such as CD19, CD20, CD22 and 
CD79a and are negative for T-cell markers, such as CD4, CD8 and T-cell receptors. 
Surface and/or cytoplasmic immunoglobulin is displayed by half to three quarters of 
DLBCL cases. Staining for Ki-67 demonstrates the proliferative index of DLBCL to be 
>40% in the vast majority, and >90% in a minority (Miller et al., 1994).
1.2.2 Clinical Presentation and Natural History
DLBCL can masquerade as numerous other illnesses and affect any part of the body. In 
the majority of patients DLBCL presents with the appearance of a swollen mass of 
lymph nodes in the neck, axilla or groin. Night sweats; fevers and/or weight loss - the 
constitutional (B) symptoms of the lymphomas - are described by a third of patients at 
the time of diagnosis (Armitage and Weisenburger, 1998). Three quarters of patients 
have at least one extranodal site involved at presentation. Left untreated, DLBCL 
proves fatal within months of diagnosis in the majority of patients. The more advanced 
the disease at diagnosis, the shorter the time until death.
The Importance of Staging
Accurate assessment of the sites and extent of disease in DLBCL is important, as the 
more widespread the illness, the lower the probability is of long-term survival following 
treatment. From the REAL classification clinical validation project, at presentation, half 
of patients with DLBCL have limited stage disease (stage I or II) just 13% have disease 
above and below the diaphragm without major organ involvement (stage III), leaving a 
third of patients with disseminated disease involving at least one extranodal site (stage 
IV disease) (Armitage and Weisenburger, 1998). Bone marrow involvement is seen in 
20% at presentation in contrast to 42% of patients presenting with FL (Armitage and 
Weisenburger, 1998). In the 687 DLBCL cases treated within the Medical Oncology 
Unit, St Bartholomew’s Hospital (SBH) between February 1970 and November 2003, 
23% had stage I, 24% stage II, 12% stage III and 40% stage IV disease at presentation 
(see Table 1.1).
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Response CR/CRu PR OR Fail N/A Total
Stage I 123 (76%) 13 (8%) 126 (84%) 19 (12%) 6 (4%) 161 (23%)
Stage II 109 (66%) 21 (13%) 130 (79%) 28 (17%) 6 (4%) 164 (24%)
Stage III 52 (62%) 13 (15%) 65 (77%) 15 (18%) 4 (5%) 84 (12%)
Stage IV 114 (41%) 42 (15%) 156 (56%) 104 (37%) 18 (6%) 278 (40%)
All 398 (58%) 89 (13%) 487 (71%) 166 (24%) 34 (5%) 687 (100%)
Table 1.1 Response According To Stage For The 687 DLBCL Patients Treated At 
St Bartholomew’s Hospital CR/CRu= Complete Response/Complete Response unconfirmed PR= 
Partial Response; OR=CR/CRu + PR= Overall Response; Fail= Stable or Progressive Disease; N/A = Not 
available/ Not Applicable
1.2.3 Treatment
‘CHOP’: the Gold Standard of Care from the 1980’s to 2002
A combination of four drugs, given the acronym ‘CHOP’ (cyclophosphamide, 
hydroxydaunomycin (now referred to as doxorubicin), Oncovin (more commonly 
referred to as vincristine), and prednisolone) was the best available treatment for 
DLBCL for 25 years. A standard course of CHOP therapy involves six to eight cycles 
administered every three weeks, side-effects permitting. The overall response (OR) rate 
to CHOP has been consistently in the order of 65%, with a complete response (CR) rate 
of ~50% for advanced (stage III and IV) disease and up to 99% CR rate in limited stage 
(I or II) disease (Gottlieb et al., 1990, Armitage et al., 1984, Jones et al., 1989). The 
response according to stage and for all 687 patients with DLBCL treated at SBH is 
illustrated in Table 1.1. In the 154 patients with DLBCL treated with CHOP at SBH the 
OR and CR/CRu (Complete Response unconfirmed) rates were 77 and 59% 
respectively (see Table 1.2). Through the late 1980’s and 1990’s numerous empirical 
variants of CHOP were investigated. Disappointingly, in randomised, controlled trials 
no novel combination or schedule produced clinically important, superior results 
compared to standard 3-weekly CHOP (Fisher et al., 1994). At SBH a phase II study 
investigated a weekly multi-drug regimen called VAPEC-B in 154 newly diagnosed 
DLBCL patients (Radford et al., 1994). The resulting CR/CRu and OR rates of 55 and 
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76% were identical to the 59 and 77% CR/CRu and OR rates in the 154 DLBCL SBH 
patients treated with CHOP (See Table 1.2).
Regimen CR/CRu PR OR Fail N/A Total
CHOP 91 (59%) 27 18%) 118 (77%) 33 (21%) 3 (2%) 154 (100%)
VAPEC-B 84 (55%) 33 (21%) 117 (76%) 34 (22%) 3 (2%) 154 (100%)
Table 1.2 Response According Regimen For The 154 DLBCL Patients Treated 
with CHOP and VAPEC-B At St Bartholomew’s Hospital CR/CRu= Complete 
Response/Complete Response unconfirmed PR= Partial Response; OR=CR/CRu + PR= Overall 
Response; Fail= Stable or Progressive Disease; N/A = Not available/ Not Applicable
Despite being unbeaten in terms of percentage of long-term survivors produced, 
CHOP and variants resulted in only 40-50% of patients being cured of their lymphoma, 
as illustrated by the overall survival (OS) curves for the 687 SBH DLBCL patients and 
this group’s CHOP and VAPEC-B subsets (Figures 1.6, 1.7 and 1.8).
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Figure 1.6 Overall Survival of SBH 
DLBCL Patients 30 year follow-up 
illustrates the clinical problem of treatment 
failure and early relapse as the cause of the 
steep decline in survival in the first three years 
post treatment followed by a steady decline due 
to deaths from other causes.
Figure 1.7 Overall Survival of SBH 
DLBCL Patients treated with CHOP
15-year follow-up illustrates the clinical 
problem of treatment failure and early relapse as 
the cause of the steep decline in survival in the 
first three years post treatment followed by a 
steady decline due to deaths from other causes.
Figure 1.8 Overall Survival of SBH 
DLBCL Patients treated with 
VAPEC-B 15-year follow-up illustrates the 
clinical problem of treatment failure and early 
relapse as the cause of the steep decline in 
survival in the first three years post treatment 
followed by a steady decline due to deaths from 
other causes.
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Improved Outcome with Newer Regimens
In the last six years six randomised controlled trials have advanced the treatment of 
DLBCL, four in the elderly (>60) (Coiffier et al., 2002, Tilly et al., 2003, Pfreundschuh
et al., 2004b, Pfreundschuh et al., 2008) and two in the <60 years old (Pfreundschuh et 
al., 2006, Pfreundschuh et al., 2004a), have reported treatments superior to CHOP in 
terms of response rates, event-free survival (EFS) and OS. These trials investigated 
CHOP combined with another agent (rituximab (R) four of the trials or etoposide (E) 
two of the trials) and/or increased dose-intensity achieved by use of G-CSF 
(granulocyte colony stimulating factor) to decrease the frequency and duration of 
neutropenia (four of the trials).
In the first of these randomised controlled trials run by the GELA (Groupe d’Etude des 
Lymphomes de l’Adulte) group, CHOP plus the humanised anti-CD20 monoclonal 
antibody rituximab vs. CHOP alone was investigated in the elderly (Coiffier et al., 
2002).  CD20 is a phosphoprotein present on the cell surface of nearly all B-cells. It 
plays a role in many cellular signalling events including activation, differentiation, 
proliferation and apoptosis upon cross-linking. As CD20 is not shed, internalised or 
present as a soluble factor in serum it became an attractive target for immunotherapy in 
the late 1980’s and early 1990’s (Stashenko et al., 1980). Preclinical work confirmed 
that antibody blockade of CD20 produced b-cell death in malignant and benign cells 
(Reff et al., 1994, Liu et al., 1987). Phase I human studies confirmed the humanised 
anti-CD20 antibody rituximab as safe (Maloney et al., 1997). The following Phase II 
trials in aggressive NHL demonstrated rituximab to have single agent activity of <30% 
(OR rate) (Coiffier et al., 1998) and an OR rate when added to CHOP of 94% (CR rate 
of 61%) (Vose et al., 2001). In the GELA phase III study of six cycles of CHOP ± R, 
‘CHOP-R’, produced a higher CR rate of 76% vs. 63% for CHOP alone (p = 0.005) and 
significantly better 2-year EFS of 57% vs. 38% (P <0.001) and 2-year OS of 70% vs. 
57% (p = 0.007) for CHOP-R vs. CHOP alone (Coiffier et al., 2002). Unlike many trials 
where data is released early, the significance of the OS results has increased with time. 
Furthermore, CHOP-R overcame the resistance to chemotherapy associated with Bcl-2 
protein overexpression, improving OR rate from 60 to 78% (P = 0.01) and 2-year OS 
from 48 to 67% (P = 0.004) in those with Bcl-2 positive tumours (>50% tumour cells 
expressing Bcl-2) (Mounier et al., 2003). Multivariate analysis confirmed the 
significant benefit for survival and EFS of CHOP-R in Bcl-2+ patients. Rituximab 
Chapter 1
47
appears to overcome Bcl-2 overexpression through inhibition of the NFB and ERK 
1/2 pathways and by causing increased expression of the pro-apoptotic proteins Bax and 
Bak and down regulation of the anti-apoptotic factors Bcl-xL, Mcl-1 and Apaf-1 in 
addition to Bcl-2 itself (Olejniczak et al., 2008, Jazirehi et al., 2005, Jazirehi et al., 
2004, Jazirehi et al., 2003). Rituximab has been confirmed to overcome the negative 
prognostic effect of Bcl-2 overexpression in several other patient series/trials (Wilson et 
al., 2008, Wilson et al., 2007, Shivakumar and Armitage, 2006).
The subsequent MinT (MabThera International Trial) study confirmed the better 
efficacy of six cycles of CHOP-R like treatment over CHOP-like chemotherapy in those 
<60 years old with good prognosis DLBCL (Pfreundschuh et al., 2006).
In the first positive study of dose intensification, an aggressive chemotherapy induction 
regimen (ACVBP 3-weekly with G-CSF support (doxorubicin, cyclophosphamide, 
vindesine, bleomycin, prednisone including CNS prophylaxis)) followed by sequential 
consolidation (2 courses high-dose methotrexate plus leucovorin rescue, four courses of 
etoposide and ifosfamide and two courses of cytosine-arabinoside – all fortnightly with 
G-CSF support) was compared to eight cycles of standard CHOP. The trial was 
conducted in 708 poor-risk, elderly patients (age-adjusted IPI >1; see page 65) with 
aggressive NHL (80% DLBCL) (Tilly et al., 2003). Despite treatment-related mortality 
being 13% vs. 7% (P = 0.1) and the CR rates being similar (58% vs. 56%) in the 
ACVBP and CHOP groups respectively, both 5-year EFS (39% vs. 29%, P = 0.005) and 
OS (46% vs. 38%, P = 0.036) were significantly longer for the ACVBP patients 
compared to the CHOP patients. CNS recurrence was significantly more frequent in the 
CHOP group (8% overall, 9% in DLBCL patients) compared to the ACVBP group (3% 
overall, 3% in DLBCL patients), P = 0.004. Recent results of a phase II GELA 
investigation of four cycles of fortnightly R-ACVBP with pegfilgrastim support 
followed by BEAM autograft have been published in abstract form (Belhadj et al., 
2007).  The CR/CRu rate post R-ACVBP induction was 63% and the PR rate 25% with 
3% (2 patients) dying during the induction phase. Seventy three% experienced febrile 
neutropenia. After a median follow-up of two years, 2-year PFS was 71% (95% 
confidence interval (CI)=61–84), and OS was 91% (95% CI=74–97). A longer follow-
up is needed to see whether the addition of rituximab definitely decreases the relapse 
rate cf. ACVBP alone.
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The other two studies of dose intensification of chemotherapy compared CHOP with 
CHOEP (CHOP plus etoposide, the long-established topoisomerase II inhibitor) ± the 
haemopoietic growth factor G-CSF in a ‘2 x 2’ multifactorial design (Pfreundschuh et 
al., 2004b). The use of G-CSF lessened the frequency and duration of neutropenia, 
allowing the treatment interval to be shortened to 14 days from the standard 21 days. 
Thus the 689 patients aged 61-75 years old in the NHL-B2 trial were randomised to 
receive six cycles of CHOP-21, CHOP-14, CHOEP-21 or CHOEP-14. The CR rates 
were CHOP-14 (76.1%), CHOP-21 (60.1%), CHOEP-14 (71.6%) and CHOEP-21 
(76.1%). The toxicity of CHOP-14 was similar to that of CHOP-21, whilst CHOEP-21 
and particularly CHOEP-14 were more toxic. CHOP-14 produced significant 5-year 
event-free survival (EFS) and OS advantages compared to standard CHOP-21: EFS 
43.8% vs. 32.5% respectively (relative risk reduction = 0.66, P = 0.003) and OS 53.3% 
vs. 40.6% respectively (relative risk reduction = 0.58, P <0.001). CHOEP-21 produced 
a non-significant improvement in OS compared to CHOP-21 whilst CHOEP-14 was 
poorly tolerated and had similar OS to CHOP-21. The German High-Grade Non-
Hodgkin Lymphoma Study Group therefore recommended CHOP-14 as the new 
standard of care in the elderly (>60 years old).
As in their elderly patient study, the German High-Grade Non-Hodgkin Lymphoma 
Study Group’s NHL-B1 trial in 710 patients aged 18-60 years old with good prognosis 
DLBCL (normal LDH) saw patients randomised to receive six cycles of CHOP or 
CHOEP given every 21 or 14 days with G-CSF support (Pfreundschuh et al., 2004a). 
CHOEP achieved a better CR rate (87.6% vs. 79.4%; P = 0.003) and 5-year EFS rate 
(69.2% vs. 57.6%; P = 0.004, the primary endpoint) than CHOP. Interval reduction 
from 21 to 14 days improved OS (P = 0.05; P = 0.044 in the multivariate analysis). All 
regimens were well tolerated, although the CHOEP regimens induced more 
myelosuppression. The German High-Grade Non-Hodgkin Lymphoma Study Group 
therefore recommended CHOEP as the new standard of care in the good prognostic 
under-60’s.
The outstanding question following the demonstration of superior survival through dose 
intensification and addition of rituximab was would the combination of these two 
strategies bring a further incremental improvement in survival? The answer to this 
question has started to emerge and from the single published study of this approach is 
positive.
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The German High-Grade Non-Hodgkin Lymphoma Study Group RICOVER-60 trial 
randomly assigned 1,222 elderly patients (>60 years old) to six or eight cycles of 
CHOP-14 with or without rituximab (Pfreundschuh et al., 2008). Using multivariate 
analysis (after adjusting for known prognostic factors) and six cycles of CHOP-14 
without rituximab as the reference, all three intensified regimens improved 3-year EFS, 
both R-CHOP-14 regimens improved PFS but only six cycles of R-CHOP-14 improved 
OS. The 3-year EFS were 47.2% after six cycles of CHOP-14 (95% CI 41.2-53.3) and 
66.5% (95% CI 60.9-72.0) after six cycles of R-CHOP-14, a 19.3% increase (relative 
risk reduction 0.51; 95% CI 0.40-0.65, P <0.0001). The 3-year OS was 67.7% (95% CI 
62.0-73.5) for six cycles of CHOP-14 and 78.1% (95% CI 73.2-83.0) for six cycles of 
R-CHOP-14, a 10.4% advantage (relative risk reduction 0.63; 95% CI 0.46-0.85, P = 
0.0031). In patients with a partial response after four cycles of chemotherapy, eight 
cycles were not better than six cycles. The German High-Grade Non-Hodgkin 
Lymphoma Study Group has therefore reasonably concluded that six cycles of R-
CHOP-14 is the new standard of care for elderly patients with DLBCL. The UK R-
CHOP 14 vs. 21 has addressed the same question and its results are awaited.
Not only have these studies resulted in improvements in responses and survival in 
DLBCL but they also suggest that the long recognised clinical and biological 
heterogeneity of DLBCL may respond to, and require different, scheduling of treatment 
to allow optimisation of response. Still to be clarified is which patients don’t 
need/benefit from rituximab and which if any need a dose intensified schedule akin to 
ACVBP as first-line treatment?
Retreatment of DLBCL
The introduction of high-dose chemotherapy treatment with autologous stem cell rescue 
to retreatment strategies has improved outcome, producing durable long-term 
remissions in half of responders to retreatment (Philip et al., 1995). However, only half 
of patients respond to standard-dose retreatment and many patients are not fit enough to 
safely undergo high-dose treatment. Consequently, less than half of all relapsing 
patients undergo high-dose consolidation, resulting in less than 25% of patients 
becoming long-term survivors after retreatment at first relapse. Therefore the majority 
of patients who relapse or fail to achieve remission from their DLBCL will die of their 
lymphoma (or its treatment). This sequence of events explains the 5-year overall and 
failure-free survival figures of 46% and 41% respectively derived from the ~400 
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DLBCL patients surveyed by the REAL classification clinical validation project (Non-
Hodgkin's-Lymphoma-Classification-Project, 1997). What is clear is that CR/CRu 
patients are more likely than PR patients and especially stable/progressive disease 
patients to achieve long-term remission from their DLBCL when consolidated with 
high-dose treatment. Addition of rituximab to combination second-line chemotherapies 
appears to improve response rates and critically CR rates from single-arm phase II 
studies (Joyce et al., 2003). In a subsequent randomised phase III trial those randomised 
to rituximab plus chemotherapy (2 cycles of DHAP (cisplatin-cytarabine-
dexamethasone)-VIM (etoposide-ifosfamide-methotrexate)-DHAP) achieved a higher 
ORR of 75% vs. 54% in the chemotherapy alone arm (P = 0.01). After two 
chemotherapy courses responding patients were eligible for autologous stem-cell 
transplantation. At 24 months median follow-up there was a significant difference in 
progression-free survival (PFS) of 52% vs. 31% P < 0.002) for those in the rituximab 
chemotherapy vs. chemotherapy alone arm (Vellenga et al., 2008). 
Further confirmation of the superior outcome produced by adding rituximab to pre-
autologous transplant chemotherapy in relapsed/refractory DLBCL comes from a 
review of the Center for International Blood and Marrow Transplant Research 
(CIBMTR) database (Fenske et al., 2007). Between 1996 and 2003 1,006 such patients 
were reported to the CIBMTR, of which 188 received R-chemotherapy and 818 
chemotherapy alone, prior to their autologous transplant. PFS at one and three years 
was superior in the R-chemotherapy group (62% vs. 49% at 1 year, P = 0.002; 49% vs. 
38% at three years, P = 0.010). OS was also superior in the R-chemotherapy group 
(68% vs. 60% at 1 year, P = 0.032; 57% vs. 45% at three years, P = 0.003). In 
multivariate analysis, pre-transplant R, age <55, and fewer than three lines of 
chemotherapy were associated with improved PFS and OS. 
Treatment Conclusions 
DLBCL is highly responsive to chemotherapy, however just less than half of patients 
became long-term survivors pre-rituximab and dose intensification of CHOP/CHOEP. 
In those that experience relapse of their DLBCL, long-term EFS in response to 
retreatment is unlikely without high-dose consolidation of a CR/CRu. The 
heterogeneous clinical presentation of DLBCL is thus also apparent in terms of the 
response DLBCL to treatment and curability. There is therefore a pressing need for 
means of dividing DLBCL into robust and biologically meaningful homogeneous 
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subtypes for which considerably more accurate prognostic factors and predictors of 
response can be discovered and novel treatments pioneered.
1.2.4 Epidemiology of DLBCL and NHL
NHL, without Hodgkin lymphoma, is now the sixth commonest cancer (excluding non-
melanomatous skin cancers, which account for half of all tumours) in the UK and the 
rest of the developed world, constituting 3% of the total non-skin cancer incidence and 
mortality in the UK in 1999 and 2001 respectively (CR-UK, 2003, Ferlay et al., 2001). 
This amounts to 9,000 new cases and 4,600 deaths per annum (CR-UK, 2003). Diffuse 
large B-cell lymphoma (DLBCL) is the most frequently seen subtype of NHL in the 
developed world, accounting for up to 40% of NHL diagnoses (Anderson et al., 1998, 
Armitage and Weisenburger, 1998). The incidence of DLBCL is currently 5/100,000 
adults per annum and has been rising at 4% per annum since the 1950’s (Weisenburger, 
1994). More males than females develop NHL and DLBCL (Ferlay et al., 2001, Ferlay
et al., 1998). The predominance of male patients with DLBCL at 55% is less than seen 
for NHL overall (62%) (Armitage and Weisenburger, 1998). of the 687 DLBCL 
patients treated at SBH 379 (55%) were male.
In the retrospective clinical validation of the REAL classification (conducted in nine 
lymphoma centres on four continents), the median age of those affected by DLBCL 
(422) was 64 years (range 14 – 83) (Armitage and Weisenburger, 1998). Globally, 
DLBCL makes up a similar proportion of NHL cases from one continent to the next, 
despite the fluctuation in FL incidence (Anderson et al., 1998). In terms of racial 
distribution, DLBCL is seen more frequently in white Americans than black, or 
Hispanic Americans (SEER and Surveillance, 2002).
1.2.5 Clinical Aetiolology of DLBCL
Inherited Risk Factors for Lymphoma: Familial Lymphoma
Familial lymphoma can be seen as part of the Li-Fraumeni syndrome, caused by germ-
line mutations in TP53, the gene encoding the p53 protein. However, in the majority of
familial cases of lymphoma the relative risk for a first-degree relative of an affected 
case is raised only 2-3 fold compared to that of the general population (cf. 25-fold in Li-
Fraumeni families (Evans and Lozano, 1997)) and mutations in multiple rather than 
single genes would appear to underlie the predisposition with no descriptions of TP53
germline mutations (Last et al., 2000, Weintraub et al., 1996, Potzsch et al., 1999).
DLBCL and Oncogenic Infections
Chapter 1
52
The causes of DLBCL in the general population remain unknown. Despite repeated 
screens for oncogenic viruses - spurred on by the consistent observation of Epstein-Barr 
virus (EBV) in virtually all cases of endemic BL (Xue et al., 2002) – no infectious agent 
has been found in the majority of DLBCLs. EBV infection of normal B-lymphocytes 
results in their polyclonal activation in vivo (Thorley-Lawson and Gross, 2004). This 
manifests itself clinically as infectious mononucleosis or glandular fever. In vitro, EBV 
infection causes B-cell immortalisation. Where T-lymphocytes are concurrently 
immunosuppressed, as is the case in many West African children due to coincident 
malarial infection, polyclonal B-cell proliferation proceeds unchecked. This increases 
the probability of t(8;14)(q24;q32) translocation development, which in turn heralds the 
evolution of BL. EBV is found in the malignant cells of 33% of Hodgkin lymphoma, 
where late first exposure to EBV is a significant risk factor for EBV+ Hodgkin 
lymphoma (Alexander et al., 2003). In DLBCLs, EBV is aetiologically related but only 
in the context of immunosuppression as detailed below. Two other viruses have been 
linked with DLBCL outside of the context of HIV infection: SV40 and hepatitis C.
The polyomavirus simian virus 40 (SV40) is a potent oncovirus in laboratory animals, 
where tumours of the brain, mesothelium, bone and lymphoid system develop following 
inoculation with SV40 (Vilchez and Butel, 2003). Collation of data from the more 
‘stringent’ studies investigating the presence of SV40 DNA in human cancers has 
revealed the presence of SV40 more frequently in human NHLs, mesotheliomas, brain 
and primary bone tumours than in corresponding tissue from controls (odds ratios and 
95% CI of 5.4 [3.1 – 9.3], 17 [10 –28], 3.9 [2.6 – 5.8], 25 [6.8 – 88] respectively) 
(Vilchez et al., 2003). In contrast to the 40% incidence of SV40 in US NHL, not one of 
the 152 UK NHL samples examined carried SV40 DNA nor was exposure to SV40-
contaminated poliovirus vaccine in childhood associated with an increased cancer or 
NHL incidence in Denmark (Engels et al., 2003, Vilchez et al., 2002, MacKenzie et al., 
2003). A possible explanation for this major discrepancy comes from a recent study of 
mesotheliomas where the 60% incidence of SV40 in the samples was due entirely 
erroneous. False-positive results accounted for the findings due to contamination by 
common laboratory plasmids containing SV40 sequences (Lopez-Rios et al., 2004).
A recent meta-analysis of 48 case-control studies, comprising 5,542 patients, found the 
prevalence of hepatitis C in patients with B-cell NHL to be ~15%. This is higher than 
that reported in both the general population (1.5%) and in patients with other 
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haematological malignancies (2.9%) (Gisbert et al., 2003). Hepatitis C may therefore 
play a role in the aetiology of B-cell NHL whilst SV40 probably does not.
DLBCL and Chemical Exposures
Pesticides and hair dyes have been implicated in the aetiology of DLBCL but far from
conclusively so,  as the associations, when present, have been weak (McDuffie et al., 
2001, De Roos et al., 2003, Cantor et al., 2003, Altekruse et al., 1999). The most recent 
population-based case-control study was conducted in Connecticut between 1996 and 
2002 (Zhang et al., 2004b). A small increased risk of NHL was observed among women 
who began use of hair dyes before 1980, but not afterwards (odds ratio (OR) = 1.3, 95% 
CI = 1.0 - 1.8).
DLBCL and Chronic Immunosuppression
Chronic immunosuppression and/or immune stimulation are risk factors for DLBCL 
development for reasons still to be fully elucidated. The lymphoproliferative disorders 
that develop in the immunosuppressed tend to be of B-cell origin and diffuse large cell 
histology, to present with extranodal site involvement and to be associated with EBV. 
The dysfunctional T-cell activity seen in immunodeficiency states appears crucial for 
EBV+ B-cells to proliferate and transform.
Congenital Immunodeficiency Syndromes and Autoimmune Disease
In those with congenital immunodeficiencies the incidence of NHL ranges from 0.7% in 
those with X-linked agammaglobulinaemia to 12-15% in patients with ataxia 
telangiectasia (Oertel and Riess, 2002). The relative risk of DLBCL is increased 2-fold 
in patients with the autoimmune disease rheumatoid arthritis rising to an OR of 26-fold 
in those with high levels of inflammatory activity compared to those with low 
inflammatory activity (OR = 1) (Beauparlant et al., 1999, Baecklund et al., 1998). 67% 
of the NHLs seen in rheumatoid arthritis are of the DLBCL subtype, with only 2% 
being EBV+ outside the setting of methotrexate immunosuppression where up to 30% 
are EBV+ and can be considered to be post-transplant lymphoproliferative disorders 
(Kamel et al., 1999, Dawson et al., 2001, Baecklund et al., 2003).
DLBCL in the Context of HIV Infection
In HIV positive individuals the incidence of aggressive lymphoma is much higher than 
in the general population, with a prevalence of 5.4% in European AIDS sufferers in 
2000 (Dal Maso and Franceschi, 2003). The relative risk of developing aggressive NHL 
(principally DLBCL of immunoblastic subtype, Burkitt and Burkitt-like NHL) in the 
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HIV+ has been up to 400-fold that seen in the general population (Dal Maso and 
Franceschi, 2003). The relative risk has dramatically reduced since the introduction of 
effective antiretroviral drug combinations in the mid 1990’s, the so-called HAART 
(highly active antiretroviral therapy) era. In Denmark the incidence of NHL has fallen 
from 1.99 cases/100 person years of prospective follow-up before September 1995 to 
just 0.3 cases/100 person years of prospective follow-up after March 1999 (Kirk et al., 
2001). Not surprisingly, after starting HAART, poor response, in terms of failure of 
CD4+ count to rise and HIV viral load to fall, predicts for those most at risk of NHL 
development (Kirk et al., 2001). Although the survival of AIDS-related NHL patients 
has improved from 6 to 20 months, AIDS-related NHL still remains incurable in all but 
a few (Besson et al., 2001).
DLBCL in the Context of Allogeneic Transplantation
In those immunosuppressed to prevent allogeneic transplant rejection and graft versus 
host disease, DLBCL is seen at the aggressive end of a spectrum of EBV driven 
lymphoproliferative disorders collectively termed post-transplant lymphoproliferative 
disorders (PTLPDs) (Jaffe et al., 2001, Nalesnik, 2002). The cumulative incidence of 
PTLPDs rises from 1.0% +/- 0.3% at 10 years following allogeneic bone marrow 
transplantation to 8% in recipients of allogeneic lung transplants (Curtis et al., 1999, 
Armitage et al., 1991). The WHO classification splits the PTLPD spectrum into four 
categories of increasing severity: plasmacytic hyperplasia; polymorphic PTLPDs; the 
uncommon Hodgkin lymphomas and Hodgkin lymphoma-like PTLPDs; and 
monomorphic PTLPDs, the majority of which are DLBCLs (Jaffe et al., 2001). The 
progression from polyclonal, plasmacytic hyperplasia to monoclonal DLBCL 
graphically illustrates the multi-step nature of lymphomagenesis in the EBV+ 
immunosuppressed, and like the similar progressive spectrum of lymphoproliferations 
seen in mice overexpressing Bcl-2, illustrates that EBV alone is insufficient to render a 
normal B-cell lymphomatous (Strasser et al., 1990). The oncogenic drive provided by 
EBV is confirmed by the finding that 30-50% of EBV-naïve patients who seroconvert 
after lung transplantation develop a PTLPD; a calamity preventable in most by 
continuous anti-viral prophylaxis (Malouf et al., 2002).
Potential Protective Factors Against NHL Development
A recent study found plant or animal allergies, previous mononucleosis and receipt of 
>5 vaccinations to be protective against DLBCL development (Holly and Bracci, 2003). 
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Prescription medications associated with a protective effect against NHL include 
benzodiazepines (OR 0.34; 95% CI 0.18, 0.64), and H(2) blockers (OR 0.29; 95% CI 
0.12, 0.69) and, in women, non-steroidal anti-inflammatory drugs (NSAIDs) (OR 0.40; 
95% CI 0.22, 0.71) (Beiderbeck et al., 2003b, Beiderbeck et al., 2003a). Calcium 
channel blocker use was inversely associated with DLBCL incidence (OR = 0.35) and 
NSAIDs use was inversely associated with FL risk (OR = 0.67) (Holly and Bracci, 
2003). Results from the recent European EPILYMPH Case-Control Study involved 
included 2,362 cases of incident B- and T-cell lymphoma and 2,206 hospital or 
population controls from six European countries suggest that regular statin use 
decreases the risk of lymphoma (Fortuny et al., 2006). Information was collected via 
face-to-face interviews on drug use, diagnosis at admission (for hospital controls), and 
putative risk factors for lymphoma. The odds ratio for regular statin use was 0.61 (95% 
CI, 0.45-0.84), with all major lymphoma subtypes showed similarly decreased risks. 
Duration of statin use was not associated with a greater reduction in the risk of 
lymphoma and decreased risk of developing lymphoma was observed in all centres. 
Replication of these findings is desirable.
Transformation of an Indolent Lymphoma
Transformation of follicular and other indolent lymphomas to DLBCL was thought to 
account for up to a third of all cases of DLBCL. This was suggested by the presence of 
the hallmark translocations of follicular (17-30%), and lymphoplasmacytoid (LPCL) 
(1.6%) lymphomas in 20-30% of DLBCLs (Weiss et al., 1987, Dalla-Favera et al., 
1994, Cigudosa et al., 1999). In BCL-2/IgH+ FL, disruption of cell cycle regulators 
such as TP53, c-Myc and p16INK4A appear to be important transformation events. Recent 
data however suggest that transformation of FL to DLBCL occurs by two distinct 
processes: direct evolution in about half of cases and FL and DLBCL arising from a 
common precursor cell in the other half of cases (Carlotti et al., 2007). The aetiology of 
indolent lymphomas (beyond Helicobacter pylori, Chlamydia psittaci, Borrelia 
burgdorferi and Campylobacter jejuni as the causative pathogen of gastric extranodal 
marginal zone lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) type, 
ocular adnexal lymphomas, skin MALT-type NHLs, and small intestine MALT-type 
NHLs respectively (Cerroni et al., 1997, Lecuit et al., 2004, Ferreri et al., 2004, 
Lehours et al., 2004)) remains obscure, as do the processes that engender 
transformation itself.
Chapter 1
56
In summary, rare germ-line mutations predispose to DLBCL directly or by causing 
congenital immunosuppression; acquired immunosuppression, often driven by EBV, 
predisposes to DLBCL but such cases account for <5% of the total DLBCL incidence; 
hepatitis C virus infection may predispose to DLBCL; no chemical exposure has been 
strongly linked to DLBCL development and transformation of an indolent NHL into 
DLBCL may account for a third of DLBCLs. The aetiology of DLBCL therefore 
remains poorly understood in all but a small minority of cases.
1.2.6 Prognostic Factors in DLBCL and other Lymphomas
Definition of Prognostic And Predictive Factors
Prognostic factors estimate the risk of relapse or death, allowing the stratification of 
patients according to the outcome measures chosen, be they response to therapy, 
duration of remission or OS. Prognostic factors are associated with the metastatic 
potential and/or the growth rate of the tumour. Predictive factors are able to foretell the 
response to a particular treatment due to the existence of a clearly-defined relationship 
between the factor and the mechanisms underlying response to the intervention. 
Predictive factors are associated with relative sensitivity and/or resistance to specific 
therapeutic agents. A factor can be both prognostic and predictive. A poor prognostic 
factor separates poor from favourable groups independent of treatment. The outcome of 
the groups is equally separated regardless of whether the patient receives no therapy or 
is treated with a systemic treatment, as is illustrated in Figure 1.9. For a purely 
predictive factor, in the absence of the specific treatment the factor is predictive for, 
patient outcome is the same for those patients positive and negative for the marker in 
question. When the specific treatment is used for which the factor predicts sensitivity or 
resistance, the group that score highly for the predictive factor fare better than those that 
score low, as depicted in Figure 1.10 for a visual depiction of a pure predictive factor. 
Truly predictive factors are rare. In the lymphomas, CD20 expression has no prognostic 
significance but is a predictive factor for rituximab efficacy (as CD20 can not bind to 
the CD20 negative B-cell lymphomas and so by can have no possibility of activity 
against them). Beyond NHLs, K-Ras and epidermal growth factor receptor (EGFR) 
gene mutation status have proven to be positive predictive factors for cetuximab in 
colorectal cancer (as single agent or in combination with chemotherapy (Van Cutsem et 
al., 2008)) and gefitinib therapy as single agent treatment in non-small cell lung cancer 
(Paez et al., 2004, Lynch et al., 2004). A mixed prognostic and predictive factor 
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separates groups in the absence of the specific treatment it is predictive for (its 
prognostic ability) and goes on to separate the low and high expressing/scored groups 
much more in the presence of the relevant therapy. In Figure 1.11 the factor is both a 
favourable prognostic and predictive factor. A factor can be a poor prognostic factor 
and a favourable predictive factor. The best example of such a predictive and prognostic 
factor in routine use in oncology is of Her2/neu protein overexpression (as determined 
by IHC) or Her2/neu gene amplification (as detected by FISH), which is a poor 
prognostic factor and accurately predicts for response to trastuzumab, a humanised anti-
Her2/neu monoclonal antibody (Ross et al., 2003)
Description of Individual Prognostic Factors in DLBCL
The prognostic factors discovered in DLBCL can be grouped into the following 
categories: patient characteristics independent of their lymphoma diagnosis, 
macroscopic disease characteristics, parameters related to the patient-lymphoma 
interaction, parameters related to the patient’s doctor, biological disease characteristics 
and molecular disease characteristics. Each type will be reviewed in turn. The number 
of potential prognostic factors in DLBCL has increased rapidly over the last two 
decades. However, most still await further investigation to enter standard clinical care.
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Figure 1.9 Graphical 
Illustration of a Pure 
Prognostic Factor Presence of the 
poor prognostic factor reduces 
prognosis equally in the untreated and 
treated
Figure 1.10 Graphical 
Illustration of a Pure 
Predictive Factor Presence of the 
positive predictive factor has no effect 
on the prognosis of the untreated but 
its presence significantly improves 
prognosis upon treatment
Figure 1.11 Graphical 
Illustration of a Mixed 
Prognostic and Predictive 
Factor Presence of the good 
prognostic and predictive factor 
improves prognosis in the untreated 
(its prognostic effect) and results in a 
further improvement in prognosis 
upon treatment for those that express 
the factor compared to those without it 
(its predictive effect).
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Patient characteristics independent of their DLBCL
Age has been repeatedly demonstrated to be a poor prognostic risk factor in DLBCL 
with older patients (>60 or >65 years old) responding less well to treatment and 
relapsing more often, due to reduced dose-delivery and being more likely to die during 
the first cycles of treatment than younger patients (Vose et al., 1988). Of the 687 
DLBCL patients treated at SBH, 370 were < 60 years old at diagnosis and 317 were >
60 years old. The OR and CR/CRu rates were 76 and 64% and 66 and 51% for the <60 
and >60 years old respectively. Their OS according to age < or > 60 years old is 
illustrated for all 687 patients in Figure 1.12 and Figures 1.13 and 1.14 for the subsets 
of CHOP and VAPEC-B treated patients respectively. HIV infection is the other 
profound negative prognostic factor in patients with DLBCL, changing the disease from 
potentially curable to a fatal diagnosis even with HAART and better-tolerated 
chemotherapy regimens (Besson et al., 2001).
Patient-Lymphoma Related Prognostic Factors
Presence of B symptoms (night sweats, fevers >380C, weight loss >10% of body weight 
in preceding 6 months) has been linked to adverse outcome in DLBCL compared to 
their absence. A more reliable prognostic factor subsequently discovered is performance 
status, whether assessed by the Eastern Co-operative Oncology Group (ECOG) or 
Karnovsky indices (Shipp et al., 1990). The two other well-recognised prognostic 
factors in this category are haemoglobin and serum albumin level (Conlan et al., 1991, 
Dhaliwal et al., 1993).
Treatment-Related Prognostic Factors
Although easily overlooked in such an introduction of prognostic factors, the effect 
treatment choice has on outcome can be profound e.g. the choice of CHOP-R or CHOP 
in those less than 60 years old and the elderly patients suffering from DLBCL 
(Pfreundschuh et al., 2008, Coiffier et al., 2002, Pfreundschuh et al., 2006); or the 
decision of physician and patient to dose-reduce therapy, as dose-intensity of 
chemotherapy has been shown to have prognostic significance for adriamycin-based 
treatment, with delivery of >75% of the adriamycin dose being the single most 
important predictor of survival (Kwak et al., 1990). The latter example has recently 
been borne out by the improved outcome following treatment with day-14 vs. day-21 
CHOP and CHOEP in the NHL-B1 study and 14-day CHOP vs. 21-day CHOP in the 
NHL-B2 study (Pfreundschuh et al., 2004a, Pfreundschuh et al., 2004b).
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Figure 1.12 Overall Survival of SBH 
DLBCL Patients According to Age 
Patients >60 years old have a significantly 
worse overall survival compared to patients <60 
years old both before and following five years 
of follow-up.
Figure 1.13 Overall Survival of SBH 
DLBCL Patients treated with CHOP 
According to Age. Patients >60 years old 
have a significantly worse overall survival 
compared to patients <60 years old following 
CHOP chemotherapy.
Figure 1.14 Overall Survival of SBH 
DLBCL Patients treated with 
VAPEC-B, According to Age Patients 
>60 years old have a significantly worse overall 
survival compared to patients <60 years old 
following VAPEC-B chemotherapy.
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Disease-Related Serum Prognostic Factors
Lactate dehydrogenase (LDH) is measurable in serum by virtue of its release from the 
cytoplasm of lysed cells. In lymphomas and certain other tumours, LDH is a surrogate 
marker of cell turnover and tumour mass. Elevated serum LDH has been consistently 
demonstrated to be an adverse prognostic factor in DLBCL (Coiffier and Lepage, 
1989). Similarly elevated serum -2 microglobulin >3 mg/ml is associated with reduced 
OS in patients with large cell lymphomas (Swan et al., 1989). Subsequently, elevated 
serum levels of nm23-H1 have been demonstrated to be a poor prognostic factor in both 
indolent and aggressive (majority DLBCL) lymphomas (Niitsu et al., 2001a, Niitsu et 
al., 2001b). nm23-H1 is an inhibitor of differentiation and is normally expressed in 
lymphoid tissue.
Prognostic Macroscopic Disease Characteristics
Increasing stage has proven to be an adverse prognostic factor in almost all large studies 
of DLBCL e.g. (Coiffier et al., 1991). In the SBH DLBCL patients, response and OS 
according to stage are illustrated in Table 1.1 and Figure 1.15 respectively. It can be 
seen that increasing stage is associated with falling CR/CRu and OR rates: stage I-III 
vs. stage IV OR rates of 81% vs. 56%. The two other macroscopic disease 
characteristics with adverse prognostic significance in DLBCL are presence of 
extranodal disease and presence of tumour bulk. Increasing number of extranodal sites 
is a strong negative prognostic factor and is considered to reflect greater metastatic 
ability of certain DLBCL (Coiffier and Lepage, 1989). Bulky tumour mass (>10 cm) 
was an adverse prognostic factor in a series of 94 de novo DLBCL, in addition to the IPI 
(see page 65) and Bax protein expression (Sohn et al., 2003).
Cytogenetic Prognostic Factors
In a multivariate analysis of 104 cases of presentation diffuse large cell lymphoma, 
breaks at 1q21-23 and presence of more than four marker chromosomes were found to 
be significant, independent estimators of reduced OS (Offit et al., 1991). Breaks at 
6q21-25 predicted for a decreased probability of achieving remission, whilst patients 
with breaks at 1q21-23 or 1p32-36 had a shorter duration of complete remission. The 
presence (or absence) of BCL-2 or c-Myc translocations in DLBCL has not been found 
to have prognostic significance (Kramer et al., 1998). BCL -6 translocations have been 
variably associated with better, worse and no different OS: BCL -6 translocation, found 
in 25% of cases was an adverse prognostic factor in the series examined by Barrans et 
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al (Barrans et al., 2002b); presence of a 3q27 translocation was a positive prognostic 
factor in the group of patients investigated by Offit et al (Offit et al., 1995); whilst 
Kramer et al found no prognostic power attached to the presence of a 3q27 translocation 
vs. germline DLBCL (Kramer et al., 1998).
Figure 1.15 Overall Survival of SBH DLBCL Patients According to Stage
Molecular Prognostic Factors: Gene Mutations
Mutation of TP53 appears to be a poor prognostic factor in DLBCL. In the 61 patients 
with a low/low-intermediate IPI (see page 65) reviewed by Leroy et al, TP53 mutated
DLBCL was associated with a significantly reduced OS on multivariate analysis, as it 
was in the NHL series examined by Moller et al (Moller et al., 1999a, Leroy et al., 
2002). Similarly, mutated TP53 was revealed as a poor predictive factor in terms of 
response (33% CR rate vs. 91% in TP53 mutated and wild-type cases respectfully, P < 
0.001) and OS (27% vs. 81% alive at five years in TP53 mutated and wild-type cases 
respectfully, P < 0.001) in DLBCL patients with low/low-intermediate IPI (see page 65) 
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(Ichikawa et al., 1997). However, a fourth series of 177 presentation DLBCL examined 
by Barrans et al, TP53 mutation status was not a prognostic factor (Barrans et al., 
2002a). Recently 24 mutations in 113 DLBCL cases (21%) were found to be associated 
with poorer prognosis, confirmed on multivariate analysis and to be linked to low 
TRAIL receptor-2 expression (Young et al., 2007). This year mutated TP53 has been 
shown to have prognostic significance in a series of nearly 200 FL patients, where it 
was mutated in 6% of cases (O'Shea et al., 2008).
Polymerase chain reaction (PCR) determined mutation status of TP53, p16INK4a and 
p14ARF was found to be abnormal in 40% of 87 aggressive NHL investigated by 
Gronbaek et al. Concurrent disruption of p16INK4a and p14ARF-TP53 was associated with 
a significantly worse outcome with only 7% of patients alive at five years compared to 
38% in those with retention of one or both pathways (P = 0.005) (Gronbaek et al., 
2000).
Molecular Prognostic Factors: Protein Expression as Detected by 
Immunohistochemistry
Immunohistochemical (IHC) assessment of proteins involved in the tumourigenesis has 
been undertaken in various retrospective NHL and DLBCL series. As the techniques 
involved in IHC and formalin-fixed material are both readily available as part of the 
diagnostic service for NHLs, production of IHC prognostic and predictive factors is 
both practical and affordable and can be expected to increase in importance and 
number.
Good Prognostic Protein Factors
High Bax protein expression was seen in 38% of 94 de novo DLBCL and was 
significantly associated with a better disease-free and OS (Sohn et al., 2003), although 
Bax protein expression was inconsequential in the other series to date (Gascoyne et al., 
1997). No prognostic significance has been identified for other Bax family members to 
date. E2F-1 expression has been linked with a favourable outcome on multivariate 
analysis in one DLBCL series to date (Moller et al., 2000) and high pRb and low mdm2 
(mouse double minute-2 homologue) expression with OS in another DLBCL cohort 
(Sanchez et al., 1998). High expression of VEGFR1 (vascular endothelial growth factor 
receptor 1) by DLBCL cells was associated with improved OS (P = 0.044) in the series 
examined by Gratzinger and colleagues only for the opposite result to be found by 
Ganjoo et al who (Gratzinger et al., 2008, Ganjoo et al., 2008). Co-expression of Bcl-6 
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and CD10 were found to predict for better outcome and is now considered indicative of 
a germinal centre-like phenotype (Hans et al., 2004). Bcl-6 protein expression was also 
shown to be a positive predictor of disease-free survival in two other series of DLBCL 
patients (Barrans et al., 2002a, Zhang et al., 1999).
Poor Prognostic Protein Factors
Elevated Bcl-2 protein expression is a poor prognostic factor for disease-free survival 
and OS in three series where it was expressed in 26% of 177 de novo DLBCL cases, 
24% of 116 diffuse aggressive NHL and 24% of 73 DLBCL patients with a low/low-
intermediate IPI (see page 65) score (Gascoyne et al., 1997, Barrans et al., 2002a, Sohn
et al., 2003). In the cohorts of 141 DLBCL examined by Sanchez et al and 165 cases 
scrutinised by Kramer et al, Bcl-2 expression exhibited an inverse association with 
disease-free survival, substantiated on multivariate analysis (Sanchez et al., 1998, 
Kramer et al., 1996).
The consequence of mutated TP53 is usually a p53 protein with an abnormal 
conformation, which poorly binds DNA and has a prolonged half-life due to disrupted 
binding of its antagonist mdm2. Immunohistochemically detected nuclear expression of 
p53 is therefore indicative of TP53 mutation and is seen in ~20% of de novo DLBCL 
(Ichikawa, 2000). p53 protein expression appears to be an adverse prognostic factor in 
DLBCL as its expression was associated with curtailed OS on multivariate analysis by 
Zhang et al in a cohort of 158 DLBCL patients, in the 61 low/low-intermediate IPI (see 
page 65) risk DLBCL patients studied by Leroy et al in association with concurrent 
absence of p21WAF1 expression (15/61) (47% vs. 74% 6-year OS, P = 0.05) and in 50 
aggressive NHL patients examined by Navaratnam et al (Navaratnam et al., 1998, 
Leroy et al., 2002, Zhang et al., 1999). Despite two other series failing to find 
prognostic significance for positive p53 staining (Sohn et al., 2003, Barrans et al., 
2002a), simultaneous expression of p53 and Bcl-2 was noted to be associated with a 
worse prognosis than p53 expression alone by Piris et al in their examination of 119 
patients with high-grade B-cell lymphomas (Piris et al., 1994).
Cyclin-D2 and Cyclin-D3 overexpression were confirmed to be poor prognostic factors 
on multivariate analysis in 152 and 81 DLBCL respectively (Filipits et al., 2002, Hans
et al., 2004). Cyclin-D3 overexpression was associated with a reduced CR rate (17% vs. 
74%, P < 0.001) and 3-year OS (18% vs. 74%, P <0.001) (Filipits et al., 2002). Cyclin-
D1 overexpression has not been shown to influence outcome in DLBCL. To date c-Myc 
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protein expression has only been found to be a poor prognostic factor in a single series 
of 61 aggressive NHLs (Pagnano et al., 2001). A single study has identified p27kip1
paradoxical overexpression on multivariate analysis in 133 DLBCL to be a negative 
predictive factor (Saez et al., 1999). Additionally, high cell surface expression of nm23-
H1 was found to be a poor prognostic factor in aggressive NHL, in agreement with the 
prognostic status of high serum nm23-H1 (Niitsu et al., 2003). A high proliferation rate 
assessed by Ki-67 staining of >60% of malignant cells (19/105 diffuse large cell 
lymphomas) was associated with a median OS of 8 months compared to 39 months in 
those with <60% Ki-67 positive cells (P = 0.003) (Grogan et al., 1988). Multivariate 
analysis confirmed Ki-67+ >60% as a predictor of poor outcome in the 63 cases with 
DLBCL (P = 0.002).
Combined Prognostic Factor Models – the International Prognostic Index
During the early 1990’s an international collaboration of 16 co-operative groups and 
single centres investigated the available prognostic factors in a combined cohort of 
~2000 patients to see if a combination of the best of them would result in a more useful 
prognostic model that could be used to risk-stratify patients. The result, the International 
Prognostic Index (IPI), remains the best available model to date (The-International-
Non-Hodgkin's-Lymphoma-Prognostic-Factors-Project, 1993). The IPI comprises the 
patient characteristics of age and performance status with the disease characteristics of 
LDH, stage of disease and number of extranodal sites. Each factor is scored as 0 or 1. 
The higher the aggregate score, the less likely a patient will achieve a meaningful 
response to treatment and the less likely they will become a long-term survivor. Four 
risk groups: low, low-intermediate, high-intermediate and high were created based upon 
the total scores of the five prognostic factors  (total scores: low = 0 or 1, low-
intermediate = 2, high-intermediate = 3 and high risk = 4 or 5). The predicted 5-year OS 
rates for the four groups were significantly different: low = 73%, low-intermediate = 
51%, high-intermediate = 43% and high = 26% (The-International-Non-Hodgkin's-
Lymphoma-Prognostic-Factors-Project, 1993). For the 1274 patients 60 years old or 
younger, an age-adjusted model (age-adjusted IPI) based on tumour stage, lactate 
dehydrogenase level, and performance status identified four risk groups with predicted 
5-year OS rates of 83%, 69%, 46%, and 32%.
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Failure of The IPI To Resolve The Heterogeneity of DLBCL
Despite the ability to stratify patients according to the IPI, it is a crude tool upon which 
to base treatment decisions. Clearly, for those with low IPI risk (0-1) CHOP is an 
effective treatment and for those with high risk (IP 4-5) it is an ineffective treatment in 
most cases (Armitage and Weisenburger, 1998). Yet, half of patients do not fall into the 
low or high-risk categories but into the intermediate categories where 5-year OS is 
~40% with CHOP chemotherapy i.e. equivalent to that of the DLBCL population 
considered as a whole (Armitage and Weisenburger, 1998). As such the IPI-determined 
prognosis for intermediate risk patients remains uncertain at the point of treatment. 
Furthermore, although the IPI can provide a gauge of a patient’s likelihood to achieve a 
meaningful response, it is not a direct measure of chemosensitivity. In short the IPI is 
not a predictive factor model.
There is, therefore, an urgent need to improve on the IPI with more accurate dissection 
of the heterogeneity of response and outcome to treatment contained within the 
intermediate categories of the IPI in particular. Studies of large numbers of patients 
treated uniformly to evaluate the place of IHC prognostic factors will hopefully allow a 
tissue based prognostic index to be developed and validated that may supersede or at 
least be combined with the IPI. In the first such report using tissue microarrays, the 
expression of 52 selected proteins was investigated in a series of 152 DLBCLs (Saez et 
al., 2004). A biological predictor, which used eight proteins, was built and validated and 
identified the probability of failure for a given patient with 78% accuracy. Combining 
this biological score and the International Prognostic Index (IPI) indeed improved the 
capacity for predicting failure and survival.
The discovery of predictive factors in DLBCL should help comprehension of treatment 
failure, allow patient stratification before clinical trial entry to aid response and other 
outcome measure interpretation and aid treatment decision making. An important caveat 
to consider when reviewing predictive and prognostic factors is that they are, by their 
nature, retrospective and, as such, may no longer be valid following introduction of a 
new therapy, schedule or strategy. This caveat has recently been illustrated in DLBCL 
where the poor prognostic status of Bcl-2 protein expression in DLBCL was 
lost/overcome on addition of rituximab to CHOP chemotherapy (Mounier et al., 2003).
Chapter 1
67
1.3 Genetic Events in Lymphoma and DLBCL
1.3.1 Genetic Instability: an Integral Part of Tumourigenesis
Integral to the process of neoplasia is genetic instability, whereby genetic lesions are 
acquired and sustained at an increased rate compared to normal cells. Genetic instability 
occurs early on in carcinogenesis at both the chromosomal and nucleotide levels 
(Lengauer et al., 1998). The occurrence of genetic instability at the chromosomal level 
is seen in virtually all human tumours, including lymphomas and DLBCL, and in a 
minority of solid cancers at the nucleotide level. Genetic instability fuels the 
development and progression of tumours and their intra- and inter- heterogeneity. At the 
chromosomal level, genetic instability manifests as variations in chromosomal numbers 
(aneuploidy), chromosomal translocations, gene amplifications and gene deletions. At 
the cellular level genetic instability is clinically relevant because it causes tumour 
heterogeneity, which is one of the causes of mixed responses to treatment and of 
relapses despite excellent responses. It is hoped that specifically attacking the molecular 
causes of chromosomal and nucleotide instabilities will yield new, rational approaches 
to tumour treatment. DLBCL is chromosomally unstable and cytogenetically 
heterogeneous, with rife aneuploidy, several recurrent as well as many non-recurrent 
translocations, amplifications and chromosomal deletions (Mitelman et al., 1994, 
Johansson et al., 1995). This cytogenetic and genetic heterogeneity is presumed to 
contribute to the clinical heterogeneity of DLBCL. These chromosomal and genetic 
abnormalities are described in the sections below.
Nucleotide Instability
Nucleotide instability is produced in cancers by defects in two DNA repair pathways: 
the nucleotide excision and the mismatch repair systems. The genetic lesions produced 
by nucleotide instability take the form of deletions, insertions and base substitutions.
Nucleotide excision repair defects are seen principally in suffers of xeroderma 
pigmentosum, who are supersensitive to ultraviolet light DNA damage and 
consequently have a very high incidence of skin cancers (Cleaver, 1968). Surprisingly, 
despite nucleotide excision repair correcting DNA damage caused by many types of 
mutagens in addition to UV light, the incidence of non-skin cancers in xeroderma 
pigmentosum is raised (compared to the general population) to a much lower extent 
than the incidence of skin cancers in these patients. The most likely explanation for this 
discrepancy is that environmental agent exposure is not the rate-limiting step in the 
Chapter 1
68
development of most common cancers, with the exception of skin cancers (Ames and 
Gold, 1991).
Mismatch repair defects are responsible for microsatellite instability, which is usually 
caused by inactivating mutations of one of the six human homologues of the mutS and 
mutL genes (Peltomaki and de la Chapelle, 1997). The consequence of mismatch repair 
deficiency is the failure of DNA error correction during DNA replication. The DNA 
mutation rate is therefore dramatically increased in mismatch repair deficient 
neoplasms. Microsatellite instability, a consequence of mismatch repair defects, is seen 
in 13% of colorectal (mostly in hereditary non-polyposis coli suffers), and a minority of 
gastric and endometrial cancers, but is uncommon in NHL (Aaltonen et al., 1993, Ionov
et al., 1993, Perucho, 1996).
1.3.2 Chromosomal Instability: Gains and Losses
Chromosomal gains and losses affect parts, or entire chromosomes and also the 
chromosome copy number present per cell (aneuploidy). These cytogenetic 
abnormalities are present in almost all malignancies, including the majority of NHLs 
(Mitelman et al., 1994). Loss of heterozygosity affects about 25% of all alleles in the 
common solid cancers and the majority of DLBCL (Cigudosa et al., 1999, Seymour et 
al., 1994, Vogelstein et al., 1989). Gains, losses and loss of heterozygosity have been 
found to occur in malignant cells at >10 times more often than in normal cell 
equivalents (Phear et al., 1996, Lengauer et al., 1997). The molecular basis of 
chromosomal instability includes the silencing of ‘caretaker’ tumour suppressor genes, 
which allows cytogenetic disruption to begin; and defective mitotic and spindle 
checkpoints, with the consequence of re-entry into S phase without cell death or repair 
of the gains, losses or translocations produced during previous defective cell cycles 
(Paulovich et al., 1997, Jin et al., 1998). The two ‘caretaker’ tumour suppressor genes 
shown to be frequently inactivated in DLBCL are TP53 and ATM. p53 may cause 
genetic instability by affecting centrosome duplication. Absence of p53 results in 
multiple copies of functionally competent centrosomes being generated during a single 
cell cycle (Fukasawa et al., 1996). The abnormally amplified centrosomes profoundly 
affected mitotic fidelity, resulting in unequal segregation of chromosomes. ATM plays a 
central role in the cellular response to DNA double-strand breaks, modulating 
numerous signalling pathways (Shiloh, 2003). ATM expression is down-regulated at 
those stages of lymphoid development where physiological DNA double-strand breaks 
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occur (Starczynski et al., 2003). Patients with ataxia telangiectasia have bi-allelic 
inactivation of ATM and develop lymphomas and leukaemias at a higher rate than the 
general population (Gumy-Pause et al., 2004). Mutations of ATM are seen in 10-20 % 
of DLBCLs and up to 45% of MCLs (Gronbaek et al., 2002, Fang et al., 2003), whilst 
deletion of the gene due to loss of 11q is seen frequently in MCL and CLL (Boultwood, 
2001, Monni and Knuutila, 2001). At the protein level most follicular and DLBC 
lymphomas are negative for, or weakly express, ATM (Starczynski et al., 2003).
Recurrent genetic changes, such as the hallmark translocations of FL, MCL and BL are 
considered to be primary events, essential for the development and phenotype of an 
NHL subtype. The many non-recurrent genetic changes seen in NHLs are considered to 
be secondary to, rather than a cause of, the inherent genetic instability that develops 
during the oncogenic process
Gains and Losses in DLBCL due to Chromosomal Instability
In the largest series of DLBCL subjected to cytogenetic examination only 13% of 
tumours displayed a normal karyotype (Cigudosa et al., 1999). The majority of cases 
(63%) were hyperdiploid (>46 chromosomes/cell), 16% were pseudodiploid 
(approximately 46 chromosomes/cell but with gains and losses of individual 
chromosomes) and 8% were hypodiploid (<46 chromosomes/cell). The modal 
chromosomal number ranged from 38 to 107. The identification of 11 regions of 
common cytogenetic deletions on chromosomes 1, 3, 6 and 7 in DLBCL suggests that 
several tumour-suppressor genes involved in lymphomagenesis still await identification 
(Cigudosa et al., 1999). Rearrangements at 1q25, 6p23, 7p36 and 19q13 occur more 
often in treated (52%) than untreated cases (7%, P <0.01) suggesting such 
rearrangements could contribute to treatment resistance frequently encountered at 
relapse (Cigudosa et al., 1999).  An example of a frequent homozygous deletion where 
the genetic consequences have been identified is that of CDKN2A and CDKN2B at 
9p21, which code for the cdk-4 and –6 inhibitors p15INK4b and p16INK4a as well as 
p14ARF. These cell cycle inhibitors are co-deleted in 15% of DLBCLs (Elenitoba-
Johnson et al., 1998, Koduru et al., 1995). Array formatted, genome-wide comparative 
genomic hybridisation (CGH), single nucleotide polymorphism (SNP) analyses and 
systematic application of 24 colour fluorescent in-situ hybridisation to large series of 
DLBCL will undoubtedly reveal yet more changes. For example, array-based CGH and 
gene-expression microarray analysis of ~50 B-cell NHL cell-lines found 20 
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homozygous deletions at seven chromosome areas, all of which contained putative 
tumour suppressor genes including BIM, NOXA and p18INK4c (Mestre-Escorihuela et al., 
2007). Very recently examination of 203 DLBCL samples by high-resolution, genome-
wide copy number analysis coupled with gene-expression profiling found 30 recurrent 
chromosomal aberrations that were differentially associated with the ‘cell-of-origin’
DLBCL subtypes (Lenz et al., 2008). Of these, an amplicon on chromosome 19 
containing the overexpressed SPIB gene was detected in 26% of ABC-DLBCLs but in 
only 3% of GCB-DLBCLs, with in vitro experiments suggesting SPIB is an oncogene 
in ABC-DLBCL. Deletion of the p16INK4a/p14ARF tumour suppressor locus and trisomy 
3 also occurred almost exclusively in the ABC-DLBCL subgroup and was associated 
with inferior outcome within this subtype. In GCB-DLBCL, amplification of the 
oncogenic mir-17–92 microRNA cluster and deletion of the tumour suppressor PTEN 
were recurrent. In conclusion recurrent patterns of chromosomal aberrations and orders 
of changes and predispositions to DLBCL are being discerned that suggest different 
oncogenic pathways lead to different subtypes of DLBCL arising.
1.3.3 Chromosomal Instability: Translocations in the NHLs
The leukaemias, myeloma and lymphomas are distinct from most other adult cancers by 
virtue of the presence of recurrent, simple, reciprocal chromosomal translocations, 
where sections of DNA not normally adjacent to each other become juxtaposed. In solid 
cancers the translocations seen are complex, involving multiple chromosomes in non-
recurrent rearrangements (Johansson et al., 1996). In most simple, recurrent 
translocations the breakpoints occur within the same small sections of DNA. The 
occurrence of such translocations as the sole karyotypic aberration, in a proportion of 
cases, supports the hypothesis that simple, recurrent translocations play an early 
aetiological role in lymphomagenesis and are critical for the development of particular 
NHL subtypes.
The molecular causes of translocations so far discovered include failure of double-
strand DNA break repair before cells undergo mitosis; dysfunctional somatic 
hypermutation; and abnormal recombination of the immunoglobulin genes in B-cells 
and T-cell receptor genes in T-cells (e.g. through deregulated recombinase-activating 
gene (RAG) enzyme activity) (Tsujimoto et al., 1985, Jager et al., 2000, Hiom et al., 
1998, Tycko et al., 1989). The formation of specific translocations in human 
lymphomas is probably determined, in part, by the higher-order spatial organisation of 
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the genome. Evidence for this theory comes from the discovery that the c-Myc, BCL and 
immunoglobulin loci exist in close spatial proximity relative to each other, towards the 
nuclear interior of normal B-cells and that such locus proximity is caused by higher-
order genome structure rather than the properties of the individual genes (Roix et al., 
2003). The consequence of simple translocations is either the activation of an oncogene 
by its juxtaposition to a strong promoter or creation of an oncogene by deregulated 
expression of a fusion protein. In B-cell NHL, the immunoglobulin genes 
(immunoglobulin heavy chain gene (IgH) at 14q32 and the  (22q11) and  (2p12) 
light-chain genes) are the predominant translocation partners and the source of such 
powerful promoters. Overexpression of Bcl-2 results from the juxtaposition of the BCL-
2 gene to the IGH gene in the t(14;18) translocation, with transcription of BCL-2 being 
driven by IGH’s powerful E promoter. Indeed in the WHO classification of 
haematological malignancies the presence of a c-Myc-IgH/I/I t(8;14)(q24;q32) is now 
required for the diagnosis of BL and a CCND1-IgH/I/I t(11;14)(q13;q32) for the 
diagnosis of MCL (Jaffe et al., 2001).
c-Myc, the first oncogene to be discovered, was cloned and sequenced by virtue of its 
involvement in the t(8;14)(q24;q32) translocation (Taub et al., 1982, Dalla-Favera et 
al., 1982, Zech et al., 1976). The consequence of a t(8;14) or a t(8;22) translocation in 
lymphoma cell-lines and primary BL tissue is indeed transcriptional overexpression, as 
such cells expressed 2- to 5-fold more c-Myc RNA than normal B-cells or B-cell-lines 
without a t(8;14) translocation (Maguire et al., 1983, Saez et al., 2003).
Recurrent translocations that create a fusion protein have been described in anaplastic 
large cell lymphoma (ALCL) and MALT lymphoma but have not been discovered in 
DLBCL. In ALCL, its hallmark t(2;5)(p23;q35) creates an oncogenic fusion protein: the 
nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) (Drexler et al., 2000). NPM-
ALK binds to, and activates, signal transducer and activator of transcription 3 (STAT3), 
resulting in constitutional STAT3 activity, which in turn results in deregulated 
expression of multiple target proteins that are involved in the control of apoptosis and 
cell cycle progression (Amin et al., 2004). The importance of the NPM-ALK gene 
fusion in ALCL is borne out by studies of NPM-ALK transgenic mice, which 
spontaneously develop B-cell lymphomas with marked overexpression of Jun and ERK 
kinases (Turner et al., 2003). The frequency and NHL subtypes in which the 
commonest translocations in NHL occur are illustrated in Table 1.3.
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Translocation Disease Frequency Genes Involved Function References
t(14;18)(q32;q21) DLBCL 20% BCL-2 Anti-apoptosis (Weiss et al., 1987)
t(8;14)(q24;q32) DLBCL 10% c-Myc Proliferative factor (Kawasaki et al., 2001)
t(3;x)(q27;x)
(Several partners) DLBCL 20-40% BCL-6 Transcription repressor (Barrans et al., 2002b)
t(11;14)(q13;q32) DLBCL 15% CCND1 Cell cycle promoter (Kawasaki et al., 2001)
t(14;18)(q32;q21) Follicular Lymphoma 80-85% BCL-2 Anti-apoptosis (Weiss et al., 1987)
t(8;14)(q24;q32) and 
light chain variants Burkitt Lymphoma 100% c-Myc Proliferative factor (Magrath, 1990)
t(11;14)(q13;q32) Mantle Cell Lymphoma >85% CCND1 Cell cycle promoter (Li et al., 1999)
t(9;14)(p13; q32) LymphoplasmacytoidLymphoma 50% PAX5 Transcription factor (Offit et al., 1992)
t(1;14)(p22;q32) Extranodal Marginal Zone Lymphoma <5% BCL-10 NFkB activation (Wotherspoon et al., 1992)
t(14;18)(;q21) Extranodal Marginal Zone Lymphoma 20% MALT1 Unknown (Streubel et al., 2003)
t(11;18)(q21;q21) Extranodal Marginal Zone Lymphoma 20-35% MALT1 and API2 Inhibition of apoptosisand NFkB activation
(Ott et al., 1997)
(Remstein et al., 2000)
t(2;5)(p23;q35) Anaplastic Large Cell Lymphoma 30-50% ALK and NPM Anti-apoptotic tyrosine kinaseActivation of STAT3 (Drexler et al., 2000)
Table 1.3 Chromosomal translocations in non-Hodgkin lymphomas
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Recurrent Translocations in DLBCL
DLBCL is distinguished from most other subtypes of NHL by the lack of a dominant, 
hallmark translocation. Indeed, only 46% of DLBCLs carry a translocation involving 
the IgH gene at 14q32, in stark contrast to nearly all FL, MCL and BL (Cigudosa et al., 
1999). The DLBCL carrying a 14q32 translocation are more likely to harbour additional 
rearrangements (P <0.001) (Cigudosa et al., 1999). Translocations involving the cyclin-
D1 gene CCND1 of MCL and c-Myc gene of BL are seen in 15% and 10% of DLBCLs 
respectively (Kawasaki et al., 2001). The hallmark translocations of FL, 
t(14;18)(q32;q21), and LPCL, t(9;14)(p13; q32), are seen in 17-30% and 1.6% of 
DLBCLs in keeping with the origin of up to a third of DLBCLs being a low-growth 
fraction NHL that has undergone transformation (Weiss et al., 1987, Dalla-Favera et al., 
1994, Cigudosa et al., 1999). The chromosomal breakpoints occur primarily in the 3’-
non-coding regions of BCL-2 and cluster in three sections, the major breakpoint region 
(MBR) (50-70% of translocations), the intermediate cluster region (icr), the minor 
cluster region (mcr) and ~10% in the 5’ end of the gene (Cleary et al., 1986, Albinger-
Hegyi et al., 2002).
3q27 translocations are seen in ~30% of DLBCLs and are the only recurrent 
rearrangement seen more often in DLBCL than in other NHL subtypes (Otsuki et al., 
1995). Unlike other common translocations in NHL, breakpoint partners of 3q27 are 
heterogeneous, involving non-immunoglobulin loci in half of cases (Cigudosa et al., 
1999). The BCL-6 gene was cloned from the 3q27 breakpoint by three groups in the 
early 1990’s (Ye et al., 1993, Miki et al., 1994, Kerckaert et al., 1993). The 3q27 region 
is also subject to amplifications in 5% of cases and to BCL-6 somatic mutation events as 
will be discussed below (Martinez-Climent et al., 2003). The section of BCL-6 involved 
in most translocations is the major breakpoint region, which contains the regulatory 
sequences for the gene’s expression and is restricted to 4 kb that span the first non-
coding exon and the 5’ portion of the first intron. In 2002, an alternative breakpoint 
cluster region 5’ to BCL-6 was described that proved to be involved in many of the 
cytogenetically detected 3q27 translocations in which BCL-6 remains intact (Butler et 
al., 2002). The presence of a BCL-6 translocation in a minority of DLBCLs suggests 
that although BCL-6 is likely to be a proto-oncogene, a 3q27 translocation is not 
essential for DLBCL development. The effect of the translocation in terms of patient 
outcome has become clearer since the discovery that the partner in the translocation 
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affects the expression of Bcl-6. In Ig/BCL-6 translocation tumours, the expression of 
Bcl-6 is higher than in non-Ig/BCL-6 translocation-bearing tumours, with the former 
being associated with a better clinical outcome (Ueda et al., 2002). In keeping with this 
finding, somatic mutations in the mutation ‘hotspot’ between 423 and 443 are 
associated with higher expression of Bcl-6 and a better clinical outcome (Artiga et al., 
2002).
Bcl-6 is a zinc-finger/POZ protein that acts as a sequence-specific transcriptional 
repressor, a function elicited in part through recruitment of class II histone deacetylases 
(Lemercier et al., 2002). Normally, expression of Bcl-6 is seen in cells with a high 
proliferation index. In FL Bcl-6 expression is therefore restricted to the proliferating 
cells and is down-regulated in the interfollicular compartment. It is expressed in 
germinal centre B-cells and CD4+ T-cells, where it controls germinal centre formation, 
Th2-type (T-helper cell) immune response/T-cell-dependent antigen response and B-
cell differentiation (Ye et al., 1997, Reljic et al., 2000). Bcl-6 can down-regulate the 
expression of the cell cycle kinase inhibitor p27kip1 (Shaffer et al., 2000). 
Overexpression of Bcl-6 in cell-lines has been found to inhibit cell growth and induced 
apoptotic cell death, suggesting that preceding abnormalities need to occur in B-cells 
for Bcl-6 to function as an oncogene (Yamochi et al., 1999, Albagli et al., 1999). In the 
last five years, Bcl-6 overexpression was found to inhibit apoptosis in response to 
etoposide by preventing the generation of reactive oxygen species (Kurosu et al., 2003).
After 14q32 and 3q27, the third commonest site of recurrent breakpoints and 
translocations in DLBCL is 1q21 (Cigudosa et al., 1999). This observation, taken 
together with the occurrence of a 1q21 translocation as the sole chromosomal 
abnormality in several DLBCLs, raises the possibility of a novel oncogene important in 
lymphomagenesis existing at 1q21. The presence of chromosomal instability in DLBCL 
is well illustrated by the high incidence of non-recurrent translocations (65% of the 
total) in DLBCL.
Gene Amplification in DLBCL 
Gene amplifications or ‘Amplicons’ contain extra copies of particular sections of DNA 
between 0.5 and ten megabases in size. Amplicons usually contain a growth-promoting 
gene and exist as double minutes or inserts into different chromosomes. In DLBCL 
amplicons have been described involving BCL-2 (18q21) (11% of cases), a small region 
of chromosome 2 containing the REL gene (2p12-16) (23%), c-Myc (8q24) (16%) and 
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the cdk -4 (CDK-4) gene (11%) (Rao et al., 1998). In the series quoted, no overlap 
between DLBCLs exhibiting translocations and amplifications of REL, c-Myc and BCL-
2 was seen, indicative of translocation and amplification being potentially independent 
pathways to overexpression of these oncogenes. The importance of REL and BCL-2 to 
lymphomagenesis is further suggested by the frequent development of amplification 
these oncogenes on transformation of FL to DLBCL (Martinez-Climent et al., 2003).
Somatic Mutation in DLBCL
The occurrence of individual base substitutions or the insertion or deletion of several 
nucleotides in certain genes can have dramatic consequences and be critical 
determinants of the progression of carcinogenesis. Inactivating mutations of tumour 
suppressor genes alter the gene product structure rendering it ineffective or inefficient at 
its cancer-inhibiting process. Less commonly, mutations can change a gene into an 
oncogene through constitutive activation or change of function. TP53 is the most 
frequently mutated tumour suppressor gene in solid cancers (50%) and in DLBCL, 
where mutations are seen in 20% of cases (Ichikawa, 2000). Eighty % of TP53
mutations are dominant negative missense mutations. The most frequently mutated 
genes in DLBCL are listed in Table 1.4 below.
Gene 
Name
Mutation 
frequency 
in DLBCL
Mutation 
frequency in 
other Cancers
Gene Function References
Bik 18% Pro-apoptotic Bcl-2 family member
(Arena et al., 
2003)
Fas 20-30%
20-30% 
Hodgkin 
lymphoma
Cell surface death 
receptor
(Gronbaek et al., 
1998, Muschen et 
al., 2000)
Rb 33% Regulates G1/S checkpoint
(Hangaishi et al., 
1996)
TP53 20% >50% solid tumours
Cell cycle arrest and 
apoptosis; guardian of 
genomic integrity
(Ichikawa et al., 
1997, Koduru et 
al., 1997).
ATM 10-20 % 45% Mantle Cell Lymphoma
Cellular response to 
DNA double-strand 
breaks
(Gronbaek et al., 
2002, Fang et al., 
2003)
Table 1.4 Frequency of Somatic Gene Mutations in DLBCL
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Somatic Hypermutation In DLBCL
The term ‘somatic hypermutation’ refers to the process first noted in the 
immunoglobulin heavy chain gene where, post-V(D)J rearrangement, point mutations 
are actively created, resulting in further refinement of the antibody to its target antigen. 
The process of somatic hypermutation is RAG and activation-induced cytidine 
deaminase (AID) enzyme dependent and occurs in B-cells within the germinal centres 
of lymph node follicles. Recent animal work has shown the critical need for AID for the 
development of Bcl-6 but not c-Myc driven NHLs (Pasqualucci et al., 2008).
Due to the high fidelity with which the genome is maintained and replicated in normal 
cells, the mutation rate is only 0.16 nucleotide per genome each time a cell divides. The 
rate of somatic mutation in the immunoglobulin gene sections favoured by somatic 
hypermutation occurs at a frequency of more than a million times greater than the 
spontaneous mutation rate in other genes i.e. 1 in 103 base pairs (bp) per cell division. 
The discovery of somatic hypermutations in ~70% of DLBCLs within a confined area 
of the regulatory region of BCL-6 was the first description of this process occurring 
outside of the immunoglobulin genes (Migliazza et al., 1995). The somatic 
hypermutation region of BCL-6 covers 700 bp and overlaps with the major breakpoint 
region, however, the presence and number of somatic hypermutations is unaffected by 
the presence or absence of a translocation involving BCL-6 (Migliazza et al., 1995). 
Several mutations caused by hypermutation result in deregulated BCL-6 expression, in 
part through preventing Bcl-6 protein binding to its own gene promoter region, thereby 
disrupting its auto-regulatory negative feedback system (Capello et al., 2000, 
Pasqualucci et al., 2003). Subsequent to the discovery of BCL-6 somatic hypermutation 
in DLBCL and other B-cell NHLs, examination of 18 genes revealed aberrant 
hypermutation in PIM1, c-Myc, RhoH/TTF and PAX5 in >50% of DLBCLs examined 
(Pasqualucci et al., 2001). It is not yet known if somatic hypermutation significantly 
affects the expression profile, phenotype or clinical course of DLBCL.
1.3.4 Epigenetic Changes in Lymphoma
Epigenetic alterations affect the heritable state of gene expression and chromatin 
organisation without changes to the DNA sequence itself. Methylation of the DNA base 
cytosine to form 5-methylcytosine was the first epigenetic silencing mechanism 
described. Approximately 45,000 small genomic regions (200 bp to 5 kb), termed CpG 
islands, that are rich in cytosine-guanosine dinucleotides (>60%) exist throughout the 
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genome ~100 kb apart (Bird, 1986, Cross and Bird, 1995). The DNA methyltransferase 
enzymes control the heritable phenomenon of cytosine methylation in CpG 
dinucleotides. CpG islands are found commonly in the promoter regions of genes and in 
repetitive DNA regions of the genome such as Alu repeats (Graff et al., 1997, Bird, 
1986). The consequence of DNA methylation is chromatin structure modification, 
which prevents gene transcription (Baylin et al., 1998). Through the association of 
methylated DNA binding proteins (MBPs) at methylated CpG islands, a complex of co-
repressors is assembled. A critical group of co-repressors are the histone deacetylases 
(Kim et al., 2003a). The silencing produced by cytosine methylation and histone 
deacetylation is thus brought together in what is probably a synergistic manner (Jones et 
al., 1998, Cameron et al., 1999). A further mechanism of epigenetic silencing has been 
demonstrated in the last five years: methylation of histones, catalysed by the histone 
methyltransferases (Jaenisch and Bird, 2003, Kouzarides, 2002). Hypermethylation of 
the CpG islands in a gene’s promoter region is now recognised as a means of creating a 
‘hit’ critical to Knudson’s hypothesis of recessive tumour suppressor gene inactivation 
(Chim et al., 2002). The other ‘hit’ being met by deletion, mutation or epigenetic 
silencing of the other allele.
The methylation status of a number of genes has been investigated in haematological 
malignancies - see (Claus and Lubbert, 2003). p15INK4B, the cdk-4 and -6 inhibitor, is 
unmethylated in normal CD34+ cells but is methylated in 10-88% of NHL cases, 30-
90% of acute myeloid leukaemia (AML) cases and <10% of CLL cases. The related 
p16INK4A tumour suppressor gene is methylated in 20-40% of DLBCL, in 15-73% of 
NHL cases, in 17-50% % of AML cases and <10% CLL cases (Drexler, 1998, Chim et 
al., 2002, Sanchez-Beato et al., 2001, Guo et al., 2000). Hypermethylation of p16INK4A
has been shown to translate into absent expression of the p16INK4A protein (Klangby et 
al., 1998). A detailed, genome-wide investigation of the frequency and genes affected 
by cytosine methylation in DLBCL and other NHLs is eagerly awaited.
1.4 Application of Empirical and Rational Research Strategies to Discover 
and Validate Novel Factors Predictive of Response and Outcome in 
DLBCL
There is a clear need for more accurate prognostic factors in DLBCL and for predictive 
factors that would allow a move away from generic, homogeneous treatment to more 
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individualised, heterogeneous therapeutic strategies. The discovery and validation of 
such novel predictors of response and outcome in DLBCL is the subject of this thesis.
Two strategies were used in the hope of discovering and validating novel prognostic 
and predictive factors in DLBCL: the traditional empirical approach of scientific 
research and a modern rational strategy. The empirical method of scientific enquiry uses 
evidence derived from experiment and observation (empiric evidence) to construct new 
scientific theories. To prove or discount a scientific theory, testable hypotheses with 
explicit, observable predictions are generated. This approach, called the hypothetico-
deductive method is at the heart of the scientific method. ‘Trial and error’ is implicit to 
empiric drug discovery in oncology, as expounded by the testing of thousands of 
potential drugs in panels of cell-lines considered representative of a broad spectrum of 
cancers. The majority of existing drugs have been discovered empirically, either by 
their isolation as the active ingredients in traditional remedies (e.g. the vinca alkaloids 
derived from the Madagascar periwinkle Catharanthus roseus, which has been used in 
Chinese traditional medicine to treat malaria, skin diseases, diarrhoea, hypertension, and 
diabetes (Gidding et al., 1999)), by serendipity (e.g. the anthracyclines were originally 
discovered as antibiotic fermentation products of Streptomyces peucetius var. caesius in 
the late 1960’s (Arcamone et al., 1969) and the serendipitous discovery of cisplatin was 
made following the observation of bacterial growth inhibition during experiments on 
the effects of electric current on bacterial growth using a platinum electrode. Several 
platinum compounds were isolated from the media, of which cisplatin was the most 
active (Rosenberg et al., 1969).) or by active screening of natural sources for anticancer 
drugs (e.g. paclitaxel (Taxol) isolated in 1971 following the discovery in the 1963 that 
the bark extract from the Pacific yew Taxus brevifolia had cytotoxic properties (Wani et 
al., 1971)).
Rational scientific research involves the reasoned generation of theory and hypothesis, 
where their creation depends more on the logical application of ideas than on 
experimentally acquired data. The application of the rational approach to scientific 
research has been well illustrated in the field of cancer drug discovery in the last 
decade, where understanding of the disease at the molecular and physiological levels 
has been used to target specific pathways and molecules. Examples of rational drug 
developments include imatinib, the tyrosine kinase inhibitor, which targets the 
molecular cause of chronic myeloid leukaemia, the oncogenic fusion protein bcr-abl, 
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rituximab the chimeric monoclonal antibody which targets the CD20 surface antigen of 
malignant and benign B-cells and bevacizumab a humanised anti-VEGF (vascular 
endothelial growth factor) antibody (Hoff et al., 2004, Druker, 2004, Grillo-Lopez, 
2003).
1.4.1 The Empirical Research Strategy: To Investigate Serum Selenium for 
Associations with Response and Outcome in DLBCL
The empirical hypothesis I chose to test was “If selenium influences the short-term 
toxicity and the short- and long-term efficacy of treatment in patients with DLBCL and 
other aggressive lymphomas, then presentation serum selenium should be inversely 
associated with measures of treatment delivery, response and OS.” This hypothesis was 
based on in vitro data, generated using non-haematological tumour cell-lines, that 
supported the empirical theories ‘selenium is a chemosensitiser; selenium can prevent 
chemoresistance; and selenium can reduce chemotherapy associated toxicity’. These 
laboratory data will be discussed in detail in section 1.4.2 through 1.4.8 below.
If my hypothesis proved to be true in part or whole, then the investigation of selenium 
compounds, as novel therapeutics in DLBCL, would be pursued. Such an attempt at 
drug discovery would be empirical, as it would be based on laboratory data generated 
using non-haematological tumour cells, where the targets and actions of cytotoxic 
selenium compounds remain far from clear. A summary of the clinical, epidemiological 
and laboratory data linking selenium deficiency with carcinogenesis is given in sections 
1.4.1 through 1.4.8 below and the results of this empirical research in Chapter 3 and 4.
1.4.2 The Physiological Role of Selenium
Selenium (Se) is an essential trace element in humans, best known for its function as an 
antioxidant (Stadtman, 1996). Se is the defining component of selenocysteine, the 21st
amino acid (Leinfelder et al., 1988, Soll, 1988). For selenocysteine to be incorporated 
into the protein, selenocysteine insertion sequences (SECIS) within the 3’ untranslated 
region require a UGA codon to be alternatively read thanks to binding of several 
proteins including Se binding protein 2, nuclease sensitive binding protein 1, SECp43 
and soluble liver antigen (Xu et al., 2005, Shen et al., 2006). The function of proteins is 
also affected by the non-specific incorporation of selenomethionine during protein 
translation. Se is increasingly considered to be of importance to human physiology, and 
conversely its deficiency to the pathophysiology of conditions ranging from depression 
to atherosclerosis to cancer (Rayman, 2000).
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The Selenoproteome
Selenocysteine is critical to the function of nearly 40 enzymes, collectively termed the 
selenoproteome (Moghadaszadeh and Beggs, 2006). The best-described selenoproteins 
are the four glutathione peroxidases (GPx) (Arthur, 2000), the three thioredoxin 
reductases (TR) (Gladyshev and Hatfield, 1999) and the three iodothyronine 
deiodinases, which are involved in the production of triiodothyronine from thyroxine
(Kohrle, 2000). Others include selenoprotein P (Sepp1), selenoprotein K, selenoprotein 
W and selenophosphate synthetase. In the majority of selenoproteins there is a single 
selenocysteine at the active site of the enzyme, which plays a pivotal role in a redox 
reaction; in contrast, mouse and human Sepp1 has ten selenocysteines at the active site 
(Hill et al., 2003). The first selenocysteine of Sepp1 functions as an antioxidant seleno-
enzyme whilst the other nine function as Se transporters/suppliers (Saito et al., 2004). 
Sepp1 carries 40-60% of Se in plasma, transporting Se to peripheral tissues. Sepp1 is 
capable of associating with endothelial membranes and restoring GPx and TR activity 
in endothelial cells, preventing oxidative damage (Steinbrenner et al., 2006). The GPx 
and TR genes contain antioxidant response elements within their promoter regions. The 
four glutathione peroxidase enzymes (classical GPx1, gastrointestinal GPx2, plasma 
GPx3, phospholipid hydroperoxide GPx4) catalyse the reduction of peroxides 
preventing oxidative intra- and extra- cellular damage. Glutathione represents the major 
low molecular weight antioxidant redox recycling thiol in mammalian cells and plays a 
central role in the cellular defence against oxidative damage. Thioredoxin reductase 
(TR) provides a ubiquitous intracellular oxidoreductase system, with antioxidant and 
redox regulatory roles, catalysing the NADPH dependent reduction of thioredoxin 
(Trx). TR can reduce multiple substrates involved in the antioxidant network and 
cellular proliferation by providing reducing equivalents either directly or via Trx.  The 
TR-Trx system also maintains the redox state of many transcription factors including 
p53, AP-1 and NF-B (Smart et al., 2004, Gebel and Muller, 2001). Selenoproteins K 
and W also protect against oxidative stress and are highly expressed in the heart and 
proliferating myoblasts respectively (Loflin et al., 2006, Lu et al., 2006a).
Selenomethionine and Protein Function
As tRNAmet cannot discriminate between selenomethionine and methionine, local 
availability rather than specific tRNAmet signalling determines the inclusion of 
selenomethionine into proteins. Thus, the less methionine present, the more 
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selenomethionine is incorporated into proteins and the less is metabolised to 
chemopreventive forms (Ip, 1988). Where selenomethionine is incorporated near the 
active site of enzymes, it can affect enzyme activity in comparison to the incorporation 
of methionine. The replacement of more than half the 150 methionine amino acids in -
galactosidase of E. coli by selenomethionine results in the inactivation of the enzyme 
(Huber and Criddle, 1967), whilst selenomethionine substitution in thymidylate 
synthase of E. coli causes a 40 % increase in its activity and an 8-fold lower thermal 
stability (Boles et al., 1991).
1.4.3 Dietary Sources of Selenium
Se belongs to the group VI transitional metals and can exist in four oxidation states (-2, 
+1, +2 and +4). The main human dietary foods contain very little Se (only 0.01 – 0.1 
mg/kg) (Morris and Levander, 1970). Most of this trace nutrient is obtained from the 
ingestion of cereal grains, meats and seafood (Wen et al., 1997). Se intake varies 
depending upon food types consumed and the regional Se content of the staple cereal 
crops. This in turn is determined by the content and bioavailability of inorganic Se 
compounds to plants in the local soil. The poor content and/or bioavailability of Se in 
the soils of certain provinces of China, Finland, New Zealand and the UK are manifest 
in the local population’s absolute or relative Se deficiency. Conversely, the high Se 
content and bioavailability in most of North America explains the high Se content of 
North American people’s body tissues.  The principle Se compound in the normal diet 
is selenomethionine with small quantities of selenite and other chemical forms such as 
Se-methylselenocysteine (MSC) and selenocysteine (Guo and Wu, 1998). One of the 
few foods naturally rich in Se is the Brazil nut (0.25 mg/kg). By comparison, offal 
contains 0.42 mg/kg, fish 0.32 mg/kg, eggs 0.16 mg/kg and cereals 0.02 mg/kg 
(Minerals, 2003). In seleniferous corn, wheat and soybeans, selenomethionine accounts 
for 80% of total Se (Yang et al., 1997); whilst in selenium-enriched garlic and broccoli, 
MSC is the principle selenocompound (Cai et al., 1995).
1.4.4 Normal Daily Intake of Selenium
Se is an essential dietary nutrient for all mammalian species. The normal dietary 
requirement of Se in mammalian animal diets is between 0.1 and 1 part per million 
(ppm) or mg/kg of Se (Jacobs and Forst, 1981b, Jacobs and Forst, 1981a). This can be 
met by ingestion of 55 g of Se a day in women and men. The daily intake of Se in 
American adults varies between 80 and 165 g/day (Schrauzer and White, 1978). 
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Although the US Institute of Medicine, Food and Nutrition Board reduced the 
recommended daily reference intake of Se from 70 to 55 g/day for adults in 2000 
(Institute of Medicine, 2000), intakes up to 700 g/day appear to be safe, leading to the 
recommendation that total daily intake via food and supplements should not exceed 
350-450 g/day (Minerals, 2003, Patterson and Levander, 1997). The WHO has set a 
lower limit of safe daily intake at 40 g/day. Selenomethionine is absorbed from the 
small intestine. Any excess, not immediately metabolised, is stored in organs with high 
rates of protein synthesis. These include skeletal muscle, erythrocytes, liver, pancreas, 
kidney and the mucosa of the gastrointestinal tract. The Se content of human skeletal 
muscle correlates with dietary selenomethionine intake, being highest in adult Japanese 
(1700 ng/g), followed by Canadians (370 ng/g), Americans  (240 ng/g) and lowest in 
New Zealanders  (61 ng/g) (Oster et al., 1988). In plasma, selenomethionine is found 
mostly in the albumin fraction. The percentage contribution of albumin 
selenomethionine to total plasma Se varies from 20% in the Se deficient to 47% in those 
replete in the micronutrient (Whanger and Butler, 1994).
1.4.5 Selenium Deficiency
In humans, Se deficiency occurs when daily intake falls below 40 g/day. Severe Se 
deficiency is associated with two illnesses: Keshan and Kashin-Beck diseases. In 
Keshan disease a cardiomyopathy is seen principally in children and pre-menopausal 
women endemically in areas of China and North-East Asia, whilst sufferers of Kashin-
Beck disease experience a musculoskeletal disorder. Se deficiency is inducible in 
laboratory mammals by feeding a diet containing < 0.01 ppm selenium. The essential 
requirement for Se in trace quantities (50 nmol/l) in cell culture has been recognised for 
many years (McKeehan et al., 1976). Supplementation of selenium-free media such as 
RPMI-1640 with 5% foetal calf serum, which contains 13 nM Se, is sufficient to meet 
physiological requirements of Se (Zhao et al., 2004). In the last decade, Zeng et al 
demonstrated the up-regulation of several key cell cycle related gene transcripts in 
HL60 cells grown in serum-free RPMI media with 0.25 M selenomethionine or 
selenite compared to HL60 cells grown in the selenium-free media (Zeng, 2002). The 
cells grown in the presence of Se proliferated, with removal of the G2/M block seen in 
the selenium-deprived cells. In addition, the cells grown in the presence of low-level Se 
had a >50% increase in total protein phosphorylation compared to the cells grown 
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without Se (Zeng, 2002). Se deficiency therefore has far-reaching effects on cell cycle 
regulation and protein phosphorylation.
1.4.6 Selenosis: Selenium Toxicity
In excess, Se compounds are toxic to mammals and their cells in vitro (Buell, 1983, 
Spallholz, 1994). The toxicity is cumulative. Se toxicity is inducible in laboratory 
mammals by feeding a diet containing 8-10 ppm Se (Jacobs and Forst, 1981b, Jacobs 
and Forst, 1981a). Signs of toxicity induced by selenite include skin lesions, 
degeneration of the muscles, bone marrow and liver necrosis (Herigstad et al., 1973). 
The toxicity of Se can be ascribed, in part, to the oxidation of thiols and the generation 
of superoxide (Yan and Spallholz, 1993). In humans both acute and chronic toxicity 
syndromes have been described. Acute toxicity is characterised by vomiting, 
hypersalivation and a garlic odour on the breath due to excretion of the volatile Se 
metabolite dimethylselenide. Additional symptoms and signs that may be present are 
diarrhoea, severe vomiting, hair loss, restlessness, spasms, tachycardia and lethargy. 
Acute Se poisoning occurs at doses >500 g/kg body weight. Selenosis, or chronic Se 
poisoning manifests as nail and hair changes and loss, skin lesions and neurological 
effects, which begin as altered sensation with hypoaesthesia, acroparasthaesia, pain and 
hyperreflexia, and progress on to convulsions, numbness and paralysis. For selenosis to 
develop in humans an intake in excess of 910 g/day (equivalent to 14 g/kg/day for a 
60 kg person) is required and was found to range from 3.2-7.0 mg/day in areas with 
endemic selenosis in China (Yang and Zhou, 1994, Yang et al., 1989a, Yang et al., 
1989b).
1.4.7 Selenium Metabolites And Chemoprevention
The biological activity of Se comes not from the element per se but from Se in a diverse 
assortment of chemical compounds, both organic and inorganic. Small changes in the 
structure of Se compounds can lead to dramatic changes in biological activity and 
toxicity in vitro and in vivo (Ip, 1998). Furthermore, the observation by Ip et al 1989 
that selenomethionine was less effective than selenite in preventing the development of 
breast cancers in rats poisoned with DMBA (7,12-dimethylbenz(a)anthracene) despite 
achieving higher blood and tissue Se levels suggested that the metabolites of Se 
compounds determine the parent compound’s efficacy as a chemopreventive agent (Ip 
and Hayes, 1989). Two inter-related pathways for Se compound metabolism are 
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recognised: the ‘hydrogen selenide pool’ and the ‘methylselenol pool’ (depicted in 
Figure 1.16).
The Hydrogen Selenide Pool
Sodium selenite, selenate, selenomethionine and other compounds, such as 
selenodioxide and selenocystine, are referred to as belonging to the ‘hydrogen selenide 
pool’ (Figure 1.16). The metabolism of sodium selenite involves serial reduction by 
glutathione first to selenodiglutathione (SDG; GSSeGS) and then to glutathione 
selenopersulphide (GS-SeSH), before conversion to the highly toxic hydrogen selenide 
(H2Se) (Ganther, 1968, Hsieh and Ganther, 1977). Selenomethionine and the benzyl 
selenocyanates are metabolised, principally in the liver, by a multi-step trans-
sulphuration pathway and are ultimately reduced to hydrogen selenide. The fate of 
hydrogen selenide depends on the Se status of the treated cells and animal. Under 
normal physiological conditions, hydrogen selenide is converted to the amino acid 
selenocysteine prior to incorporation into selenoproteins under the control of the 
translational code UGA (Stadtman, 1996). Where hydrogen selenide is generated 
beyond physiological requirements of Se, it is detoxified by methylation to mono-, di-
and tri-methylated derivates prior to excretion. The monomethylated derivative, 
methylselenol (CH3SeH), is unstable and, like hydrogen selenide, highly toxic. The 
dimethyl metabolite, dimethylselenide ((CH3)2Se) is excreted in the breath (giving it a 
garlic odour) and trimethylselenide ((CH3)3Se+), the trimethylated derivative of 
hydrogen selenide, is excreted in the urine. Trimethylselenide excretion predominates 
over that of dimethylselenide, except during Se toxicity when the further methylation 
from di- to tri-methylselenide becomes rate-limiting (Foster et al., 1986).
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Figure 1.16 Selenium Metabolic Pathways: the Hydrogen Selenide and the 
Methylselenol Pools Adapted from (Schrauzer, 2000, Ip, 1998, Ganther and Lawrence, 1997)
Although selenite can inhibit cell growth (Ip et al., 1981, Fico et al., 1986), cell 
attachment (Yan and Frenkel, 1992), microtubule formation (Leynadier et al., 1991)
and the syntheses of DNA, RNA and protein (Medina and Oborn, 1984, Cox, 1985, 
Jiang et al., 1992, a lag period of 24 hours has been reported repeatedly before the in 
vitro activity of selenite is seen {Lanfear, 1994 #390). This is indicative of the need for 
selenite to be converted to more active metabolites before activity is seen. Evidence in 
support of this hypothesis includes:
i. the demonstration of increased efficacy of selenite in vitro upon the 
simultaneous addition of glutathione, critical for its efficient serial reduction to 
hydrogen selenide (Kuchan and Milner, 1991)
ii. selenite activity varies depending upon the intracellular glutathione level 
(Kuchan and Milner, 1992)
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iii. SDG, the principle metabolite of selenite, is significantly more toxic than 
selenite in vitro (Lanfear et al., 1994, Poirier and Milner, 1983)
iv. no lag period is observed as regards the in vitro activity of SDG in comparison 
to sodium selenite (Lanfear et al., 1994).
The Methylselenol Pool
The formation of hydrogen selenide was shown to be unnecessary for Se compounds to 
exert chemopreventive activity, provided that the compounds produced 
monomethylated Se metabolites (Ip et al., 1991) (Figure 1.16). In the presence of the 
intracellular enzyme -lyase, selenomethionine and the plant organic Se compound 
MSC (CH3SeCH2CH(NH2)COOH) are converted to the highly active methylselenol 
(Foster et al., 1986). Because methylselenol is highly reactive, it cannot be studied 
directly, but rather needs to be locally generated from precursors such as MSC, and the 
-lyase independent methylseleninic acid (MSA). In comparative, in vivo rat studies of 
selenite, selenomethionine and MSC, MSC was found to be the most effective 
chemopreventive agent (Ip et al., 1991, Ip and Ganther, 1990, Ip and Ganther, 1992). 
The dose of Se required to induce 50% tumour inhibition was 2 ppm Se for MSC, 3 
ppm Se for selenite and 4-5 ppm Se for selenomethionine (Ip et al., 1999, Ip and 
Ganther, 1992, Ip and Hayes, 1989, Ip et al., 1991). Furthermore, MSC is not 
incorporated into proteins as occurs with selenomethionine. In contrast to 
methylselenol, the dimethyl and trimethyl metabolites of hydrogen selenide are 
ineffective as chemopreventive agents in vivo, not in small part due to their rapid 
elimination via the breath and urine respectively (Ip and Ganther, 1988, Ip et al., 1991, 
Vadhanavikit et al., 1993).
1.4.8 Selenium Intake and Cancer Risk
Observational Studies
Two types of epidemiological study, namely geographic correlation and case-control 
studies, have produced data indicating that Se can protect humans from cancer. A 
possible protective effect of Se against human malignancy was first suggested in 1969, 
following the observation of a decreased cancer incidence in populations of the US with 
a relatively higher Se intake (Shamberger and Frost, 1969). Subsequent epidemiological 
evidence in support of this observation has been mixed. Many studies have 
demonstrated a similar inverse association whilst others found no relationship between 
Se intake and cancer risk. Two important epidemiological papers, however, have led 
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many to conclude that an inverse association does exist. The first noted an inverse 
relationship between forage-crop Se and county cancer incidence in the US (Clark et al., 
1991) and the second revealed an inverse correlation between dietary Se intake and total 
age-adjusted cancer mortality in more than 25 countries (Schrauzer et al., 1977).
Prospective case-control studies have demonstrated an association between low-blood 
Se and cancer in the US population and in Finland when the population was Se deficient 
(Salonen et al., 1984, Salonen et al., 1985, Willett et al., 1983, Comstock et al., 1992). 
For prostate cancer in particular, an inverse association between serum or toenail Se and 
the subsequent risk of developing prostate cancer was shown by several 
epidemiological studies (Brooks et al., 2001, Helzlsouer et al., 2000, Nomura et al., 
2000, Willett et al., 1983, Yoshizawa et al., 1998) but not all (Ghadirian et al., 2000). 
Clarke et al found that serum Se at the time of diagnosis was lower in patients with skin 
cancer or adenomatous colonic polyp than in matched controls and a Canadian group 
observed a statistically significant inverse association between toenail Se level and the 
risk of colon cancer (OR, 0.42; 95% CI 0.19-0.93; P = 0.009) (Clark et al., 1984, Clark
et al., 1993, Ghadirian et al., 2000). However, other studies have failed to find an 
association between higher Se serum/tissue content and reduced colorectal-cancer 
incidence in Finland (Knekt et al., 1988), lung-cancer incidence in the US (Menkes et 
al., 1986) and overall cancer incidence in US citizens (Coates et al., 1988, Ringstad et 
al., 1988, Nomura et al., 1987). Recent results from the US Third National Health and 
Nutrition Examination Survey Study found a nonlinear association between serum Se 
levels and all-cause and cancer mortality (Bleys et al., 2008). This survey involved 
13,887 healthy adults, who were recruited between 1988 and 1994, and followed up for 
mortality for up to 12 years. The mean serum Se level of the study participants was 
125.6 ng/ml and the multivariate adjusted hazard ratios comparing the highest (>130.39 
ng/ml) with the lowest (< 117.31 ng/ml) serum Se level tertile were 0.83 (95% CI= 
0.72-0.96) for all-cause mortality, 0.69 (95% CI= 0.53-0.90) for cancer mortality, and 
0.94 (95% CI= 0.77-1.16) for cardiovascular mortality. There was an inverse 
association at low Se levels (< 130 ng/ml) and a modest increase in mortality at high Se 
levels (> 150 ng/ml).
Taken together, these observational studies in humans suggest an inverse association 
between Se consumption, as assessed by serum or tissue levels, and subsequent risk of 
developing cancer and the possibility of a threshold level beyond which serum selenium 
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modestly increases mortality. This data is considerably strengthened by the 
interventional study results described in the next subsection.
Intervention Studies: Selenium Supplementation In Animal Models of Cancer
Many of the intervention studies performed in laboratory animal models of cancer have 
used the inorganic Se compound sodium selenite or the organic compound 
selenomethionine, due to their cheap and easy commercial availability. Most studies 
have increased dietary intake from the normal nutritional requirement of ~ 0.1 ppm to 
between 1 to 5 ppm Se (Medina, 1986, Thompson et al., 1984, Ip, 1986, Medina and 
Morrison, 1988). Se chemoprevention, without apparent signs of toxicity, occurred in a 
dose-dependent manner (Clark et al., 1996, Clark and Jacobs, 1998, Medina et al., 
2001, Duffield-Lillico et al., 2002, el-Bayoumy, 1994, Rao et al., 2001, Reddy et al., 
1994, Ip and White, 1987, Davis et al., 2002). In the last 15 years, attempts to refine the 
chemopreventive effects of Se have led investigators to experiment with novel organic 
selenocompounds such as the synthetic benzyl selenocyanates (due to their superior 
therapeutic index compared to selenite and selenomethionine) and the naturally 
occurring plant Se compound MSC, which is readily converted to the putative highly 
active chemopreventive metabolite methylselenol in vivo. Selenocompounds have been 
proven to reduce the incidence of tumours of the colon, breast, pancreas, liver, lung, 
skin and several other sites in organ-specific carcinogen models (Thompson et al., 
1984, el-Bayoumy, 1985, Tanaka et al., 1985, el-Bayoumy et al., 1993, Reddy et al., 
1994). The chemopreventive effect of Se compounds occurs at the early stages of 
carcinogenesis, at both the initiation (the prevention of DNA damage by carcinogens) 
(Ejadi et al., 1989, el-Bayoumy et al., 1992, Fiala et al., 1991) and post-initiation stages 
(Medina, 1986, Ip, 1998, Thompson et al., 1984). In addition to a reduction in the 
incidence of carcinogen-induced cancers, experiments have demonstrated the 
prevention of spontaneous cancers and a reduction in the number and size of 
transplanted tumours in different animal models through Se supplementation (Watrach
et al., 1982, Poirier and Milner, 1983, Schrauzer, 1992, Yan et al., 1997).
Human Selenium Supplementation Trials: The Clark Study
Clark et al conducted the first double-blind, randomised, placebo-controlled trial of Se 
supplementation (Clark et al., 1996). It began in 1986 and closed early in 1992, due to 
the results detailed below. Patients with a history of resected non-melanomatous skin 
cancer (i.e. squamous and basal cell carcinomas) were randomised to receive placebo or 
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selenised brewer’s yeast equivalent to 200 g of Se a day. Selenised brewer’s yeast 
contains a variety of Se compounds dominated by selenomethionine. Patients received 
placebo or supplementation for a mean of 4.5 years, giving 1271 years of follow-up for 
the 1312 patients enrolled to the study. No difference in the incidence of further 
squamous and basal-cell carcinomas was found between the treatment and control arms 
of the study. Unfortunately with further follow-up Se supplementation remained 
ineffective at preventing basal cell carcinoma and it increased the risk of squamous cell 
carcinoma (hazard ratio, HR = 1.25, 95% CI = 1.03 to 1.51) (Duffield-Lillico et al., 
2003). The adverse effect of Se supplementation appeared to increase with increasing 
baseline plasma Se concentration; skin cancer patients with baseline plasma Se in the 
upper tertile (>122.4 ng/ml) experienced a 60% increase in probability of a new skin 
cancer as a result of Se supplementation, compared to no increased risk in the lower two 
tertiles. A disappointing answer at odds with findings that topical application of 
selenium protects humans against ultraviolet B radiation, the protective effect of 
selenomethionine against skin cancer development in mice subjected to ultraviolet 
irradiation and the result of Clarke’s observational study (Uddin et al., 2005, Oh et al., 
1995, Burke et al., 1992, Clark et al., 1984). Thus, the initiation of Se supplementation 
may need to begin many years before the overt development of skin cancer (due to the 
natural lifelong exposure to ultraviolet light), require co-administration of vitamin E 
(Uddin et al., 2005) or be restricted to those with a serum Se of <105.2 ng/ml (Duffield-
Lillico et al., 2003); or Se deficiency may simply not be an aetiological factor in skin 
carcinogenesis. However, Se treatment decreased total cancer incidence by a 
statistically significant 25%, with the incidence and deaths from three of the most 
common solid organ cancers, namely prostate, lung and colon, were significantly 
reduced. The relative risks of developing cancer of the prostate, lung and colon were 
0.42 (P = 0.03), 0.54 (P = 0.04) and 0.37 (P = 0.002) in the selenised brewer’s yeast vs. 
placebo arms (Clark et al., 1996). In 2002 an updated analysis of the data with an 
additional six years follow-up found the benefits of Se supplementation had diminished 
(Duffield-Lillico et al., 2002). Total cancer incidence was still reduced (HR = 0.75, 
95% CI = 0.58-0.97) as was prostate cancer incidence (HR = 0.48, 95% CI = 0.28-0.80) 
but the incidence of lung cancer (HR = 0.74, 95% CI = 0.44-1.24) and colorectal cancer 
(HR = 0.46, 95% CI = 0.21-1.02) was no longer significantly reduced. The protective 
effect of Se supplementation was confined to males (HR = 0.67, 95% CI = 0.50-0.89) 
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and was most pronounced in former smokers. Participants with baseline plasma Se 
concentrations in the lower two tertiles (<121.6 ng/ml) experienced reductions in total 
cancer incidence, whereas those in the highest tertile showed a nonsignificant elevated 
incidence (HR = 1.20, 95% CI = 0.77-1.86) (Duffield-Lillico et al., 2002).
Although numerous studies have demonstrated a chemopreventive effect of Se 
compounds against carcinogen-induced breast and colon cancers in animal models, 
breast cancer incidence was unaffected and colon cancer was reduced only during the 
initial study period and not during the extended follow-up period in the selenised yeast 
arm of the Clark study. Three possible explanations for these observations are:-
1 That too few cases of each cancer occurred in this patient group to provide the 
requisite statistical power
2 That supplementation was stopped too soon whilst follow-up continued years 
beyond the end of the trial and long after any chemopreventive action had worn 
off (as in the Yu study below). Indeed for aspirin to reduce the risk of colorectal 
cancer it needs to be taken for a minimum of five years with a latency of 10 
years before benefit is seen (Flossmann and Rothwell, 2007).
3 That Se deficiency and Se supplementation are respectively irrelevant to the 
aetiology and prevention of breast and colon cancers in humans.
An important observation in the Clark study was that the chemopreventive effect was 
strongest in those subjects with the lowest plasma Se level before supplementation. A 
physiological threshold for Se may therefore exist, below which supplementation is 
beneficial and above which it is inconsequential or potentially harmful.
Human Supplementation Trials: The Yu Study
The Yu study was a population-based study in 130,000 people in an area of China with 
low Se intake, a 15% prevalence rate of hepatitis B, and an incidence of primary liver 
cancer of ~ 50/10,000/annum (Yu et al., 1997). After eight years of intervention with 
selenised table salt, the incidence of primary liver cancer had fallen by 35% in the 
intervention-township vs. the non-supplemented control townships. On withdrawal of 
Se from the treated group, primary liver cancer incidence rate began to increase. 
However, the inhibitory response to hepatitis B was sustained during the three years of 
follow-up beyond the cessation of treatment. An associated clinical sub-study among 
226 hepatitis B surface antigen positive persons provided either daily 200 g of Se in 
the form of a selenised yeast tablet or an identical placebo yeast tablet for four years. 
Chapter 1
91
This sub-study showed that seven of 113 subjects were diagnosed as having primary 
liver cancer in the placebo group, whereas no incidence of primary liver cancer was 
found in 113 subjects supplemented with selenium. Again on cessation of treatment, 
primary liver cancer developed at a rate comparable to that in the control group. Yu et 
al concluded that a continuous intake of Se is essential to sustain its chemopreventive 
effect.
Human Supplementation Trials: The SU.VI.MAX Study
This French randomised, double-blind, placebo-controlled primary prevention trial 
investigated a daily capsule of combined antioxidants (120 mg vitamin C, 30 mg 
vitamin E, 6 mg beta-carotene, 100 g Se, and 20 mg zinc) vs. a placebo (Hercberg et 
al., 2004). Just over 13,000 French adults (7876 women aged 35-60 years and 5141 men 
aged 45-60 years) were recruited and followed up for 7.5 years. Low-dose antioxidant 
supplementation lowered total cancer incidence in men (relative risk, 0.69; 95% CI 
0.53-0.91) and all-cause mortality in men (relative risk, 0.63; 95% CI 0.42-0.93) but not 
in women. The risk of non-melanomatous skin cancer was unaffected by taking the 
antioxidant combination in either sex, but there was a increased incidence of melanoma 
in the women who received the supplement, although the number of events was small 
(adjusted HR = 4.31; P = 0.02) (Hercberg et al., 2007).
Human Supplementation Trials: The Linxian Study
Between March 1986-May 1991 29,584 adults were recruited in Linxian County, China, 
which has one of the world's highest rates of gastro-oesophageal cancer and a 
population with chronically low intake of several micronutrients, to a primary 
chemoprevention trial (Blot et al., 1993). The subjects were randomly assigned four 
combinations of nutrients: (A) retinol (5000 IU, as retinol palmitate) and zinc (22.5 mg, 
as zinc oxide); (B) riboflavin (3.2 mg) and niacin (40 mg); (C) vitamin C (120 mg) and 
molybdenum (30 µg, as molybdenum yeast complex); and (D) beta-carotene (15 mg), 
alpha-tocopherol (30 mg), and selenium (50 µg, as selenium yeast) i.e. all doses 1-2 
times U.S. Recommended Daily Allowances. During the 5-year intervention period 
2,127 deaths occurred amongst the trial subjects, with cancer being the leading cause of 
death. Indeed, 32% of all deaths were due to gastro-oesophageal cancer. Total mortality 
was significantly lowered only by factor D (beta carotene, vitamin E, and selenium; 
relative risk = 0.91, 95% CI = 0.84–0.99). This reduction was largely due to lower total 
cancer rates (RR = 0.87; 95% CI = 0.75–1.00), particularly stomach cancer (RR = 0.79; 
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95% CI = 0.64–0.99). The reduction in risk began between one to two years after the 
start of supplementation. These results are provocative, as the dose of Se was 
physiological rather than the equivalent chemopreventive doses using in animals. 
Unanswered questions include ‘how relevant are the results to Western populations?’, 
where micronutrient deficiency is unusual, and ‘are all three supplements needed?’, 
particularly as beta carotene supplementation is detrimental in smokers.
Human Supplementation Trials: The Limburg Study
Limburg et al conducted a randomised, placebo-controlled chemoprevention trial in 
Linxian province, China, where oesophageal cancer is the leading cause of cancer 
mortality (Limburg et al., 2005). The aim was to prevent the development of squamous 
cell cancer of the oesophagus from its precursor squamous dysplasia using a Se 
compound and/or a COX-2 inhibitor. Two hundred sixty-seven asymptomatic adults, 
with histologically confirmed mild or moderate oesophageal squamous dysplasia, were 
randomised to receive placebo or 200 g selenomethionine daily and 200 mg celecoxib 
twice daily or placebo (‘2 x 2’ factorial design). After 10 months of intervention 
selenomethionine demonstrated a chemopreventive effect, favourably changing 
dysplasia grade among the 115 subjects with mild oesophageal squamous dysplasia at 
baseline (P = 0.02), but not among the 123 subjects with moderate oesophageal 
squamous dysplasia at baseline (P = 1.00). Celecoxib status did not influence changes 
in dysplasia grade overall (P = 0.78) or by baseline histology subgroup. This is the first 
report of a possible chemopreventive agent in mild squamous dysplasia of the 
oesophagus.
Summary of Human Supplementation Trials
These five studies still require further investigation. Should only Western men and 
those with serum Se levels <130 g/l receive Se supplementation? What dose and Se 
compound should be used? Are the doses and duration of intervention different in the 
primary and secondary cancer chemoprevention settings? In the field of prostate cancer 
large-scale phase III, double-blinded, randomised placebo-controlled studies are being 
undertaken with the PRECISE trial in Europe and the SELECT (Selenium and Vitamin 
E Cancer Prevention Trial) trial in the US, which is investigating Se supplementation in 
32,000 men prospectively for 12 years (Klein et al., 2000).
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1.4.9 The Selenoproteome and Cancer
Understanding of the selenoproteome’s influence on carcinogenesis is beginning to 
emerge. Transgenic mice displaying reduced selenoprotein synthesis due to a mutant 
selenocysteine transfer RNA gene, were found to exhibit increased colon cancer 
susceptibility (Irons et al., 2006). Bigenic mice co-exhibiting reduced selenoprotein 
levels due to expression of an altered selenocysteine-tRNA (i6A-) and targeted 
expression of SV40 large T and small t oncogenes in prostate were found to develop 
precancerous prostate lesions faster than control WT/Tag mice (Diwadkar-Navsariwala
et al., 2006). Similarly, mice with a double knock-out for GPx-1 and -2 exhibit an 
increased incidence of gastrointestinal tumours (Chu et al., 2004). GPx-1 loss of 
heterozygosity (LOH) is frequently seen in human breast and colon cancers (Hu et al., 
2005, Hu and Diamond, 2003). Whilst, enforced expression of GPx-1 resulted in 
resistance to doxorubicin and inhibition of Fas-induced effector caspase activation, 
DNA fragmentation, and apoptotic cell death human breast cancer T47D cells (Gouaze
et al., 2001, Gouaze et al., 2002). Sepp1 has been shown to be downregulated in murine 
and human prostate cancer cell-lines and primary human prostate carcinomas compared 
to normal prostate tissue (Calvo et al., 2002) and Sepp1 mRNA expression is 
significantly reduced or lost in human colon cancers (Al-Taie et al., 2004). Increased 
levels of Trx-1 in human tumours can lead to functional inhibition of PTEN (Meuillet et 
al., 2004) and Trx-1 protein levels are significantly elevated in several human cancers 
and are an independent poor prognostic factor in colon cancer (Raffel et al., 2003). A 
positive correlation between Trx-1 expression and cisplatin resistance was observed in a 
panel of 11 ovarian cancer cell-lines (Yamada et al., 1996). Overexpression of 
selenophosphate synthetase (sps1) results in increased sensitivity in vitro to radiation 
through upregulation of p53 (Chung et al., 2006). In humans, TR-1 expression is 
increased in several cancers and is associated with aggressive tumour growth and 
decreased patient survival (Engman et al., 2006). In vitro, TR-1 overexpression results 
in increased tumour growth, HIF-1 and VEGF levels (Lincoln et al., 2003) and TR-1 
inhibition/siRNA knockdown results in cell death and malignant cell phenotype 
recapitulation (Lu et al., 2006b, Yoo et al., 2006). p53 activity has a specific 
requirement for an intact Trx system (Merwin et al., 2002). Chemical (electrophilic 
disruption of the C-terminal selenocysteines) and mutational (lacking the two C-
terminal selenocysteines) modification of TR-1 results in two gain-of-function roles for 
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modified TR-1: conformational misfolding of p53, rendering p53 incapable of 
transactivation of its effector genes; and, despite inactivation of p53, induction of 
apoptosis via caspase-3 activation (Anestal and Arner, 2003, Cassidy et al., 2006). 
Reduction of TR-1 levels protected p53 conformation in colon and breast cancer cells 
treated with endogenous electrophiles and also antagonised electrophile-induced 
apoptosis (Cassidy et al., 2006).
1.4.10 Molecular Mechanisms of Selenium Chemoprevention
The hydrogen selenide pool members such as selenite exert their activity in part through 
the generation of ROS, which can induce general or specific DNA damage (Zhou et al., 
2003, Stewart et al., 1999). Selenite is also reported to cause topoisomerase II/DNA 
cleavable complex formation resulting in double-strand DNA breaks and apoptosis 
(Zhou et al., 2003). This activity resulted from the modification of important thiol 
groups in topoisomerase II by selenite generated ROS, an action reversed by 
glutathione.
Intracellular Se compounds (not incorporated into proteins) can alter the activity of 
transcription factors and kinases, such as c-Jun N-terminal kinase (JNK) and caspase-3, 
by oxidation of reactive cysteine residues within the proteins (Park et al., 2000, 
Ganther, 1999, Adler et al., 1996). Both in vitro and in vivo, Se can mimic insulin 
(Stapleton, 2000), and can activate the signal transduction factors mitogen-activated 
protein kinase -1 (MAPK1/ERK2) and -3 (MAPK3/ERK1) (Stapleton et al., 1997, Hei
et al., 1998).
MSA and MSC both induce phase II liver and kidney detoxification enzymes, so by 
detoxifying carcinogens by glucuronidation, as part of their mode of cancer 
chemoprevention against carcinogens (Zhao et al., 2004, Ip and Lisk, 1997). Recently 
human tissue expression profiling results suggest that Se supplementation enhances 
immune surveillance against premalignant cells (Joshi et al., 2006).
The original hypothesis to explain the inverse association between Se status and cancer 
risk was that optimal activity of the antioxidant seleno-enzymes glutathione peroxidase 
and TR eliminated tumour promoting reactive oxygen species (ROS). However, from 
animal supplementation experiments (as mentioned above) the quantity of Se that must 
be ingested to demonstrate a chemopreventive effect is >10 times (1-30 ppm Se/day) 
that required to restore enzyme function to 100% (~0.1 ppm Se/day). Furthermore null 
mice lacking the Gpx1 gene, which codes for the cytosolic and most abundant 
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glutathione peroxidase, are no more susceptible to cancer than wild-type mice up to an 
age of 15 months (Cheng et al., 1997, Ho et al., 1997). Indeed Gpx1-/- appear 
phenotypically normal until subjected to oxidative stress (Cheng et al., 1998). In 
contrast, mice overexpressing Gpx1 developed more skin cancers following carcinogen 
exposure than their normal counterparts (Lu et al., 1997). As regards TR, the enzyme 
can be inhibited by high levels of Se supplementation due to thiol cross-linking of 
cysteine residues within its catalytic domain (Ganther, 1999). The molecular 
mechanisms by which Se supplementation prevents cancer are thus still being 
determined as will be described in Chapter 4. One intriguing observation is that the 
effectiveness of Se compounds in vitro, in terms of growth inhibition and cell death 
induction, occurs irrespective of functional p53 status (Kaeck et al., 1997, Lanfear et 
al., 1994).
1.4.11 The Rational Research Strategy: Identification of Gene Expression 
Signatures Predictive of Outcome in DLBCL
The rational process was used to construct a research programme to discover prognostic 
factors and potential therapeutic targets in DLBCL as follows: “DLBCL is a 
heterogeneous disease where the genetic aberrations of each tumour determine the 
genes and proteins expressed. Each tumour’s molecular genotype determines its 
phenotype, which in turn determines its chemosensitivity or resistance and therefore the 
response and long-term outcome to treatment for the patient. Global assessment of gene 
expression in DLBCL material from patients that succumbed or were cured of their 
DLBCL should therefore yield distinct expression profiles reducible to a small subset of 
common genes”. The modern rational approach adopted, utilised the recently developed 
technique of gene expression profiling using Affymetrix oligonucleotide microarrays. 
This technique allows the simultaneous and parallel measurement of the transcriptional 
expression of thousands of genes, escaping the need for a priori empiric knowledge of 
association and activity of individual genes in carcinogenesis and chemosensitivity. 
RNA from archived, presentation DLBCL material would therefore be prepared and 
arrayed and the resultant dataset explored for transcriptional profiles associated with 
long-term outcome to treatment. If this rational strategy indeed yielded a group of genes 
whose profiles were strongly linked to treatment outcome in DLBCL, the genes with 
feasible molecular roles in lymphocyte biology would be investigated as rational drug 
targets. Demonstration of novel molecular drug targets would strengthen the argument 
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of a causative rather than correlative association between expression of the genes 
concerned and outcome to treatment.
Evidence in support of genetic aberrations underlying the transcriptional differences 
seen in tumours compared to their normal tissue counterparts comes from many studies 
of single gene or chromosomal changes as well as more recently from genome-wide 
surveys linked to the corresponding transcriptome. In regard to tumour suppressor gene 
mutation and consequent expression alteration, mutation of TP53 has been repeatedly 
demonstrated to result in excessive, abnormal protein expression in DLBCL, other 
NHLs and cancers (Koduru et al., 1997). The c-Myc oncogene is translocated to an 
immunoglobulin gene locus in all cases of BL and 10% of DLBCL, and amplified in 
16% of DLBCL, with the consequence of several fold increased c-Myc RNA expression 
(Kawasaki et al., 2001, Maguire et al., 1983, Rao et al., 1998). The far-reaching 
expressional consequences of c-Myc gene amplification and overexpression have been 
confirmed by the discovery that no less than 15% of ~500 genes examined in a genome-
wide survey were transcriptionally activated by c-Myc (Li et al., 2003). Demonstration 
of the impact of genetic copy number changes on gene expression due to partial 
chromosomal deletions and amplifications comes from investigations of trisomy 8 in 
AML, where numerous chromosome 8 genes were proportionally over expressed 
(Virtaneva et al., 2001). Similarly, scrutiny of the expression patterns of genes from 
chromosome 17 in breast cancer, where 30% of cases have partial gains and/or losses in 
chromosome 17, revealed an appropriate increase or decrease in gene expression 
according to whether the respective segment of chromosome 17 was deleted or 
amplified. Genes affected included c-erbB2, which was overexpressed due to its region 
of chromosome 17 being amplified. c-erbB2 not only has prognostic significance in 
breast cancer but also predictive significance for response to trastuzumab monoclonal 
antibody therapy (Orsetti et al., 2004). In DLBCL, amplification of the oncogene BCL-2 
has been associated with overexpression of Bcl-2 protein and altered mRNA expression, 
the level of which predicts Bcl-2 protein expression (Shen et al., 2004, Monni et al., 
1997).
In the light of these examples, and many others, examination of the transcriptome for 
molecular signatures of prognosis was not only a valid and rational strategy, but 
transcriptional profiles can be anticipated to reflect and reveal the genomic changes 
unique and necessary for DLBCL.
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1.4.12 An Introduction to Microarray Technology
The means of discovery of molecular signatures of response, long-term outcome and 
subtype definition took a great leap forward with the advent of microarray technology 
(Pease et al., 1994, Schena et al., 1995). By allowing the simultaneous measurement of 
the mRNA expression of hundreds to thousands of genes from across the genome, array 
technology offered the potential to screen thousands of genes without the need for 
preconceived hypotheses.
Microarrays can investigate mRNA or genomic DNA. mRNA targeted arrays allow 
gene expression to be studied, whilst genomic DNA arrays can take two forms: CGH 
arrays where bacterial artificial chromosome clones are arrayed and used to reveal 
partial chromosomal gains and losses with much greater definition than the 20Mb of 
conventional CGH and SNP arrays, which allow the detection of genetic mutations and 
polymorphisms. An array is constructed on a solid substrate, often termed the 
‘platform’, made of either glass (microarray) or nitrocellulose or nylon (macroarrays). 
On the substrate, hundreds (macroarrays) to thousands (microarrays) of cDNA 
amplicons or oligonucleotides are immobilised in an ordered, grid pattern. Confusingly, 
the arrayed cDNA amplicons or oligonucleotides are called ‘targets’ in most systems 
but ‘probes’ in Affymetrix chips. As this thesis refers to the use of the Affymetrix 
system, the cDNA amplicons or oligonucleotides will be referred to as ‘probes’
henceforth. To the ‘probes’, labelled complementary RNA (cRNA), cDNA or genomic 
DNA is hybridised in a manner similar to that of Southern and Northern blotting. In the 
Affymetrix system, and the remainder of this thesis, the labelled cRNA, cDNA or 
genomic DNA is referred to as the ‘target’, whilst in most other systems it is referred to 
as the ‘probe’. Each of the immobilised ‘probes’ acts as an assay for its specific partner 
strand in the complex nucleic acid mixture of the ‘targets’. The ‘target’ labels can be 
fluorophores, biotin or radioactive phosphorus. By quantifying the intensity of label 
signal from each hybridised ‘probe-target’ set, the relative expression of each gene, 
presence or absence of a chromosomal region or SNP is detected. Arrays designed for 
radioactive labelled ‘target’ (macroarrays) require as little as 50 ng RNA (5,000 cells), 
compared to the minimum of 5 g (500,000 cells) required for fluorescent systems. 32P -
based arrays, however, produce reliable read-outs only for highly expressed genes, 
which are the minority. Fluorecence-dependent arrays allow detection of low and 
medium abundance genes, which are the majority, as well as those genes highly 
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expressed at the mRNA level. It is the fluorescence-dependent arrays that have been 
used to great effect in the study of clinical material, including DLBCL, and that will 
now be described in more detail.
Two types of array dominate the expression profiling field: ‘chips’ where 
oligonucleotide ‘probes’ are grown out from the substrate surface and ‘dot-blot’ slides 
or membranes, where tiny dots of probe solution are blotted on to the substrate. A third 
type of array has been developed called ‘Oligonucleotide Ink-Jet/Piezo’ and will be 
briefly described.
1.4.13 The Different Types of Microarray Platform
‘Dot-blot’ Arrays
The ‘probes’ for ‘dot-blot’ slides are created from cDNA clone libraries using the PCR 
to amplify part of the cDNA clone insert of each bacteriophage in the library. The 
arrayer, a robot, arrays 0.25-1 nl of probe cDNA solution in the same place on the 20+ 
chemically-treated slides under production. Up to 40,000 different ‘probes’ can be 
arrayed per standard size slide. After the probe solutions have dried, the ‘probes’ are 
covalently fixed to the slide using UV light. Maintaining the clone libraries required for 
‘dot-blot’ slides makes slide manufacture too expensive for all but the largest non-
commercial organisations, unless the number of ‘probes’ arrayed is compromised, and 
has sensibly led to the establishment of core facilities capable of providing arrays to a 
network of labs.
Because the volume of each probe spot deposited can vary, apparent expression changes 
can be produced by spot differences alone. To compensate for this artefact, two ‘target’
samples are used, the test sample and a reference RNA. The reference or control RNA is 
usually created from pooled cell-lines in sufficient quantity to be used with all the test 
samples in a particular experiment. In time exposure experiments, the time zero sample 
is used as the reference. The test sample RNA is converted into labelled cDNA ‘target’
using one fluorophore whilst the reference RNA is converted into labelled cDNA 
‘target’ using a different fluorophore. Equal amounts of test and control ‘target’ are 
added to each array, allowing the test and reference cDNA fragments to competitively 
hybridise with the ‘probes’. If a test cDNA is in excess the resultant signal will come 
from its fluorophore, if the control cDNA dominates the fluorescence detected will 
come from the control cDNA. By employing competitive hybridisation the problem of 
dot variability is overcome.
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‘Oligonucleotide Ink-Jet/Piezo’ Arrays
A development from ‘dot-Blot’ arrays, ‘Oligonucleotide Ink-Jet/Piezo’ arrays use no-
contact, less wasteful piezo electric pulse or ink-jet technology to propel a tiny volume 
of synthesised oligonucleotide solution on to the platforms. Oligomers of 60 bp length 
were found to offer optimal sensitivity and specificity by Hughes et al (Hughes et al., 
2001). Sensitivity down to one transcript per cell can be achieved. Standard and 
custom-made 25- or 60-mer oligonucleotide arrays are available from several 
commercial sources (e.g. Agilent Technologies, Santa Clara, USA). The release of the 
POSaM (piezoelectric oligonucleotide synthesiser and microarrayer) platform for 
academic research allows the production of multiple microarrays of up to 9,800 unique 
reporter sequences on modified glass microscope slides (Lausted et al., 2004). The 
microarray synthesis is relatively cheap and certainly rapid with new arrays ready for 
hybridisation the same day that they are designed (if all goes according to plan).
‘Chip’ Arrays
‘Chip’ arrays consist of oligonucleotide ‘probes’ synthesised in situ on silica wafers 
under the control of photolithographic chemistry (Lockhart et al., 1996). The lengths of 
both the ‘probes’ and ‘targets’ are critical to the sensitivity and specificity of the 
hybridisation reactions. Probe oligomers between 20 and 60 bases in length provide the 
best balance between discriminate and sensitive hybridisation. In the Affymetrix system 
(see www.affymetrix.com/), the sense ‘probes’ are 25-mer (high specificity but reduced 
sensitivity cf. longer oligomers) and are referred to as ‘Perfect Matches’. As well as the 
correct oligonucleotides, missense oligonucleotides are created in parallel for each 
probe. The missense ‘probes’ are termed ‘Mismatches’, differing from their sense probe 
by just their middle i.e. 13th base. This allows the specificity of the hybridisation 
reaction to be determined by comparison of the extent of hybridisation to the missense 
and sense ‘probes’, as well as background noise reduction by subtraction of missense 
from sense signal. The lower the value of the missense:sense signal ratio, the better. For 
each gene, a set of 11 - 20 perfect match and mismatch probe pairs is laid down, which 
increases the sensitivity for detecting a gene transcript to, at best, 1 in 300,000 
transcripts. The area each oligomer is arrayed into is called the ‘feature’. Through the 
reduction in ‘feature’ size from 20 to 11 m and probe sets per gene, up to 54,000 gene 
‘probes’ can be included on one chip. As with ‘dot-blot’ slides, the ‘target’ for 
oligonucleotide chips is created from test sample RNA. The RNA is reverse transcribed 
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into cDNA followed by transcription back to RNA, as cRNA. Because this two-step 
procedure results in amplification of the mRNA, less RNA is required for chip arrays 
compared with ‘dot-blot’ arrays (5-10 g vs. 30 g). To produce the labelled ‘target’, 
biotin-conjugated bases are used in the synthesis of the cRNA. The labelled cRNA 
requires fragmentation into lengths of 20 to 200 bp, followed by denaturing before 
application to the array. Unlike ‘dot-blot’ arrays, competitive hybridisation and the need 
for a reference RNA are not required for inter-chip array expression profile comparison. 
This is because the oligonucleotide synthesis of each ‘feature’ is so precisely controlled 
that inter-chip variation is minimal. The cost of commercially available generic chips 
has reduced substantially since their introduction, making the technology affordable to 
an increasing number of research facilities. Furthermore customised chips can be 
ordered containing only the gene feature of interest from previous experiments or 
considered critical to a particular illness, tissue or set of experimental conditions.
1.4.14 Expression Profiling in Cancer and DLBCL
From Schena et al’s proof-of-principle paper of 1995 that a high-capacity system could 
monitor the expression of genes in parallel using a ‘dot-blot’ cDNA array for just 45 
Arabidopsis genes, the first report of the use of a microarray platform to investigate the 
gene expression of cancer was the following year in 1996 using a high-density ‘dot-
blot’ array containing 1,161 cDNAs (Schena et al., 1995, DeRisi et al., 1996). DeRisi et 
al looked for expression differences between the parent melanoma cell-line UACC-903 
and its less tumourigenic derivative with an inserted normal chromosome 6. Without 
using sophisticated analysis tools, gene expression differences were clearly apparent in 
a range of mostly unexpected genes. In 1998 the first report of microarrays being used 
to search for transcriptional changes unique to a particular type of neoplasm were 
reported (Khan et al., 1998). Using a ‘dot-blot’ array of 1,238 cDNAs and the data 
handling technique of multidimensional scaling seven alveolar rhabdomyosarcoma cell-
lines were clustered together and distinguished from control cell-lines. In 1999 the 
potential of the oligonucleotide array for molecular classification of human malignant 
tissue was first described (Golub et al., 1999). Using the Affymetrix Hu6800 chip 
containing oligonucleotides for 6,817 genes, 38 AML and acute lymphoblastic 
leukaemia (ALL) specimens were arrayed and the resultant dataset subjected to a 
newly-devised type of mathematical cluster analysis called self-organising maps 
(SOMs), that was capable of recognising and classifying features within the complex, 
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multidimensional data (Tamayo et al., 1999). Distinguishing the AML from the ALL 
samples based upon transcriptional differences proved possible. Furthermore, the 
derived class predictor was able to correctly classify additional AML and ALL samples, 
confirming the general strategy of using microarrays for discovering and predicting 
cancer classes independent of previous biological knowledge. When a four-cluster SOM 
was created, the first subgroup was exclusively AML, the second subgroup contained 
all eight T-ALLs, and the third and fourth subgroups contain the majority of the B-ALL 
samples. This further subdivision of the tumour samples indicated for the first time that 
transcriptional signatures would allow increasingly sophisticated molecular 
subclassification of cancer. Expression profiling experiments have subsequently been 
reported for all the common cancers and many rare tumours.
The variability in clinical response and course of DLBCL and the recognition of 
morphological subtypes and nuances has led to the hypothesis that DLBCL is in fact 
composed of several distinct subtypes with differing outcomes to treatment. As such 
subtypes cannot be successfully reproduced on the basis of morphological appearance 
alone, the search for molecular methods of subdividing DLBCL into meaningful clinical 
subtypes has long been the goal of lymphoma clinicians, pathologists and scientists.
The two major platforms for expression profiling have been used in DLBCL and have 
produced remarkable and reproducible expression signatures that reveal molecularly 
defined subtypes of DLBCL and predict for response to treatment and long-term 
outcome (Shipp et al., 2002, Rosenwald et al., 2002, Alizadeh et al., 2000). Indeed 
these papers were the first to specifically search for and find gene expression profiles 
predictive of long-term outcome. The Shipp et al paper is the subject and basis of 
Chapter 5.
In the Alizadeh et al and Rosenwald et al papers, the clustering analyses were 
performed using a different approach termed hierarchical clustering (Eisen et al., 1998). 
Alizadeh et al demonstrated that molecular subclassification of DLBCL on the basis of 
gene expression was possible. The two subtypes produced had expression profiles 
similar to those of different putative cells of origin (Alizadeh et al., 2000). This finding 
was confirmed and extended in the much larger series of Rosenwald et al, in which 
DLBCL was divided into three subtypes termed germinal centre-like, activated B-cell-
like and Type 3 DLBCL (Rosenwald et al., 2002). In both papers, the patients with 
lymphomas subclassified as germinal centre-like fared better than the patients with 
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lymphoma subclassified as activated B-cell-like, suggesting clinical relevance to 
DLBCL subclassification according to the putative cell of origin.
1.4.15 Exploration and Validation of The Empirical and Rational Research 
Strategy Results
Both research strategies proved fruitful: the empirically driven investigation discovered 
that presentation serum Se was predictive of chemotherapy dose-delivery, response to 
chemotherapy, first remission Duration and OS in DLBCL and associated aggressive 
NHLs (subject of Chapter 3); the rational approach of gene expression profiling 
archived, diagnostic lymph node material from DLBCL patients also proved to be 
worthwhile, as the gene expression signatures created were independently capable of 
outcome prediction for the patients whose material was arrayed (subject of Chapter 5). 
In particular, a model composed of just 13 genes proved capable of accurately 
delineating the patients from whom the samples came into ‘alive and cured’ and ‘dead 
from disease/refractory’ groups. These results opened new avenues for exploration and 
validation, which have grown to become the subjects of Chapters 4 and 6.
Investigation of Selenium Compounds For Causality And As Novel Treatment 
Targets
Following the empirically led discovery of serum Se as a prognostic factor in DLBCL, I 
chose two Se compounds to study in vitro, one from the methylselenol pool (MSA) and 
one from the hydrogen selenide pool (SDG) of Se compound metabolic pathways. SDG 
had not been studied in human lymphoma cells in vitro before, yet had demonstrated 
activity in other cell culture systems and was an active metabolite of the naturally 
occurring inorganic sodium selenite. MSA is known to be readily converted to the 
highly active methylselenol in vitro without the need for -lyase. As -lyase is not 
present in lymphocytes, study of other methylselenol pool members (e.g. 
selenomethionine and MSC) would have proved ineffective in vitro. MSA, like SDG, 
was also appealing, as it had not previously been studied in human NHL cell-lines and 
primary cultures (see Chapter 4).
Investigation of Components of The 13-Gene Model For Causality And as Novel 
Treatment Targets
Of the different gene expression signatures created that could predict for outcome in the 
DLBCL patients from whom the diagnostic material came, the model containing just 
13-genes proved to be the most robust. To validate members of this 13-gene model and 
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to search for rational novel treatments for DLBCL, inhibitors of two of the 13-gene 
model genes, PKC and PDE4B (phosphodiesterase-4B), were studied in established 
DLBCL cell-lines and primary lymphoma cell cultures searching for cytostatic and 
cytotoxic activity. I chose PKC and PDE4B as the two targets for further investigation 
because: -
i. The expression PKC and PDE4B was predictive of poor OS in the series 
described in Chapter 5: both genes were significantly overexpressed in DLBCL 
that proved fatal/refractory, as opposed to curable.
ii. Furthermore, PKC and PDE4B were predictive of OS in the series described by 
Alizadeh et al (Alizadeh et al., 2000).
iii. The alternatively-spliced PKC1 and PKC2 isoforms are the major PKC 
isoforms expressed by B-lymphocytes (Mischak et al., 1991). PKC-deficient 
mice have profoundly impaired humoral and B-cell proliferative responses, 
indicating a critical role for PKC in B-cell signalling and survival (Leitges et al., 
1996). In vitro the consequences of B-cell receptor (BCR) signalling have been 
shown to be dependent upon PKC activation (King et al., 1999). In the presence 
of an intact PKC pathway, B-cell–receptor engagement resulted in B-cell 
proliferation; however, B-cell–receptor signalling induced apoptosis when mature 
B-cells are either PKC depleted or stimulated in the presence of PKC inhibitors. 
These data suggest that PKC activity enhances B-cell proliferation and survival 
and therefore that PKC overexpression could contribute to a fatal/refractory 
DLBCL phenotype.
iv. PDE4B is a class-4 cyclic AMP (c-AMP)-specific phosphodiesterase. PDE4 is the 
predominant class of PDEs in lymphocytes, where they catalyse the hydrolysis of 
c-AMP, so by terminating its activity (Manning et al., 1999, Lerner et al., 2000). 
c-AMP-dependent protein kinase A (PKA) signalling inhibits lymphocyte 
chemotaxis, cytokine release and cellular proliferation (Manning et al., 1999). 
Because PDE4B reduces c-AMP availability, the PDE also limits the negative 
effects of PKA signalling in lymphocytes. For this reason, PDE4A and -4B 
inhibitors are being evaluated in the treatment of CLL/SLL (small lymphocytic 
lymphoma) where they are reported to induce B-cell apoptosis (Moon et al., 2002, 
Moon and Lerner, 2003). These facts suggested that PDE4B overexpression in 
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presentation DLBCL material may be causally related to the chemoresistance and 
poor outcome of the affected patients and their DLBCLs.
These facts suggested that the applicability of PKC and PDE4B as poor prognostic 
markers in DLBCL is likely to be genuine and that a causal relationship between their 
expression and the presence of a chemoresistant phenotype is more likely.
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CHAPTER 2. MATERIALS AND METHODS
2.1 Microarray and Expression Validation Materials and Methods
2.1.1 Patients and their Samples
Samples were chosen on the basis of the following criteria: snap-frozen and archived at 
–80oC, presentation lymph node material with a diagnosis of DLBCL or FL; treatment 
with an anthracycline-based chemotherapy regimen for the DLBCL patients; 
availability of comprehensive clinical data and follow-up; histological confirmation of 
original diagnosis with exclusion of DLBCL variants such as T-cell-rich and 
mediastinal large B-cell DLBCL and tumours with excessive necrosis. After application 
of these criteria and exclusion of samples where production of an array of sufficient 
quality was not possible, 58 DLBCL cases and 19 FL were investigated. For each of the 
DLBCL patients the presentation IPI was calculated and response to treatment, date and
outcome of relapse and OS updated. The 58 patient’s IPI, OS and living status are given 
in Table 2.1.
Nineteen of the DLBCL cases were treated at SBH (Table 2.2). Prior to their addition to 
the Dana Farber Cancer Institute (DFCI) cohort, no significant results were produced, 
not least due to significantly shorter follow-up. Eleven of the SBH patients were male 
and eight were female. The median age of the 19 was 55 years old, with 58% of them 
being less than 60 years old. Four had stage I disease, six stage II, five stage III and four 
stage IV disease at presentation. Eleven of the 19 had a low-risk total IPI score, five had 
an intermediate-risk score and two had a high-risk score. The IPI was not known for one 
case. Twelve of the 19 patients (63%) were alive and disease-free as of April 2000 (the 
month and year of data censorship) and seven (37%) were ‘dead from disease’.
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Sample FullIPI OS Status Outcome Sample
Full
IPI OS Status Outcome
DLBCL1 Low 72.9 Alive w/o disease 0 DLBCL40 High 3.2 Dead w/disease 1
DLBCL2 Low 143.1 Alive w/o disease 0 DLBCL41 L/I 4.9 Dead w/disease 1
DLBCL3 L/I 144.2 Alive w/o disease 0 DLBCL42 H/I 12 Dead w/disease 1
DLBCL4 H/I 61 Alive w/o disease 0 DLBCL43 H/I 60.4 Dead w/disease 1
DLBCL5 Low 86.5 Alive w/o disease 0 DLBCL44 L/I 16.3 Dead w/disease 1
DLBCL6 Low 84.2 Alive w/o disease 0 DLBCL45 H/I 16.4 Dead w/disease 1
DLBCL7 H/I 112.5 Alive w/o disease 0 DLBCL46 H/I 9.5 Dead w/disease 1
DLBCL8 Low 133.2 Alive w/o disease 0 DLBCL47 H/I 15.6 Dead w/disease 1
DLBCL9 Low 22.1 Alive w/o disease 0 DLBCL48 H/I 17.8 Dead w/disease 1
DLBCL10 L/I 182.4 Alive w/o disease 0 DLBCL49 L/I 56.9 Dead w/disease 1
DLBCL11 Low 66.4 Alive w/o disease 0 DLBCL50 Low 13.3 Dead w/disease 1
DLBCL12 . 146.8 Alive w/o disease 0 DLBCL51 L/I 12.3 Dead w/disease 1
DLBCL13 L/I 62.9 Alive w/o disease 0 DLBCL52 Low 44.6 Alive w/disease 1
DLBCL14 L/I 50.9 Alive w/o disease 0 DLBCL53 H/I 4.6 Dead w/disease 1
DLBCL15 Low 26.3 Alive w/o disease 0 DLBCL54 High 7.5 Dead w/disease 1
DLBCL16 . 48.6 Alive w/o disease 0 DLBCL55 H/I 19.3 Dead w/disease 1
DLBCL17 H/I 55.9 Alive w/o disease 0 DLBCL56 Low 30.1 Dead w/disease 1
DLBCL18 Low 12.6 Dead w/o disease 0 DLBCL57 Low 33.6 Alive w/disease 1
DLBCL19 L/I 50.2 Dead w/o disease 0 DLBCL58 H/I 13.9 Dead w/disease 1
DLBCL20 H/I 58 Alive w/o disease 0 FL1
DLBCL21 L/I 66.4 Alive w/o disease 0 FL2
DLBCL22 Low 65.7 Alive w/o disease 0 FL3
DLBCL23 Low 50.2 Alive w/o disease 0 FL4
DLBCL24 Low 26.9 Dead w/o disease 0 FL5
DLBCL25 Low 34.4 Alive w/o disease 0 FL6
DLBCL26 Low 26 Alive w/o disease 0 FL7
DLBCL27 Low 30 Alive w/o disease 0 FL8
DLBCL28 L/I 31.7 Alive w/o disease 0 FL9
DLBCL29 Low 32.2 Alive w/o disease 0 FL10
DLBCL30 Low 19.2 Alive w/o disease 0 FL11
DLBCL31 Low 33 Alive w/o disease 0 FL12
DLBCL32 Low 21.4 Alive w/o disease 0 FL13
DLBCL33 Low 15.7 Dead w/disease 1 FL14
DLBCL34 H/I 11.6 Dead w/disease 1 FL15
DLBCL35 H/I 3.4 Dead w/disease 1 FL16
DLBCL36 Low 36.6 Dead w/disease 1 FL17
DLBCL37 H/I 5.0 Dead w/disease 1 FL18
DLBCL38 Low 9.5 Dead w/disease 1 FL19
DLBCL39 High 3.2 Dead w/disease 1
Table 2.1 Sample Identification and associated Patient characteristics
OS = overall survival in months; w/o without; w/ with. Cases in red are from SBH
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Variable Number Percentage
Gender Male : Female 11: 8 58% : 42%
Age Median (Range) 55 23-83
Age <60: >60 years old 11 : 8 58% : 42%
Stage I 4 21%
Stage II 6 32%
Stage III 5 26%
Stage IV 4 21%
LDH   < Upper Limit of Normal: > ULN
- Presentation LDH unavailable for one case
12 : 6 63% : 32%
Extranodal Sites <2: >2 18 : 1 95% : 5%
IPI Low Risk 11 58%
IPI Intermediate Risk 5 26%
IPI High Risk 2 11%
IPI Unknown 1 5%
Response to Treatment
CR/CRu: PR: Fail
12 : 5 : 2 63% :26% :11%
Long-term Outcome
‘Alive and cured’: ‘Dead from disease’
12 : 7 63% : 37%
Table 2.2 Characteristics of the 19 SBH Patients Arrayed
2.1.2 ‘Target’ preparation for Microarray
Total RNA was extracted from each frozen tumour specimen and converted to double-
stranded cDNA. Tissue samples were homogenised (Polytron, Kinematica, Lucerne) in 
guanidinium isothiocyanate and RNA was isolated by centrifugation over a CsCl 
gradient. RNA integrity was assessed either by northern blotting or by gel 
electrophoresis. The amount of starting total RNA for each reaction varied between 10 
and 12 g. First strand cDNA synthesis was generated using a T7-linked oligo-dT 
primer, followed by second strand synthesis. An in vitro transcription reaction was done 
to generate the cRNA containing biotinylated UTP and CTP, which was subsequently 
chemically fragmented at 95 C for 35 minutes. Ten g of the fragmented, biotinylated 
cRNA was hybridised in MES buffer containing 0.5 mg/ml acetylated bovine serum 
albumin (Sigma, St. Louis) to Affymetrix (Santa Clara, CA) HU6800 oligonucleotide 
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arrays at 45 C for 16 hours. The HU6800 arrays contained 5920 known genes and 897 
expressed sequence tags (total = 6,800). Arrays were washed and stained with 
streptavidin-phycoerythrin (SAPE, Molecular Probes). Signal amplification was 
performed using a biotinylated anti-streptavidin antibody (Vector Laboratories, 
Burlingame, CA) at 3 g/ml. A second staining with SAPE followed this. Normal goat 
IgG (2 mg/ml) was used as a blocking agent. Scans were performed on Affymetrix 
scanners and the expression value for each gene was calculated using Affymetrix 
GeneChip software. Minor differences in microarray intensity were corrected using a 
linear scaling method as detailed in the next section.
2.1.3 Data processing and analysis 
The raw expression data from the HU6800 GeneChips was rescaled to account for 
differences in intensities between chips. Each column (sample) in the dataset was 
multiplied by 1/slope of a least squares linear fit of the sample vs. the reference (the 
first sample in the dataset). This linear fit was done using only genes that have 'present'
calls in both the sample being re-scaled and the reference. The reference sample was 
chosen from the series on the basis of it having the number of 'present' calls closest to 
the average over all samples in the dataset. A ceiling of 16,000 ‘average difference’ 
units was chosen due to fluorescence saturation of the scanner at and above this level. A 
lower threshold for expression levels was set at 20 ‘average difference’ units to 
minimise noise effects while avoiding missing any potentially informative marker 
genes. After this pre-processing, gene expression values were subjected to a variation 
filter that excluded genes showing minimal variation across the samples being analysed. 
The variation filter tested for both a fold-change and absolute variation over samples 
(comparing maximum/minimum and maximum-minimum with predefined values and 
excluding genes not obeying both conditions). For maximum/minimum fold variation, 
genes were excluded with <3-fold variation and, for maximum-minimum absolute 
variation, genes were excluded with <100 units absolute variation.
A supervised classifier was built as follows: a target class was defined based on 
morphology, tumour class or treatment outcome information. The ‘marker’ genes with 
the highest correlation with the target class using a class separation statistic (signal-to-
noise ratio) were selected. The class separation statistic used was ‘signal-to-noise ratio’, 
where class-0 and class-1 were identified by sorting all of the genes on the array 
according to the signal-to-noise statistic (class-0 - class-1)/( class-0 + class-1), 
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with  and  representing the mean and standard deviation of expression for each class 
respectively (Golub et al., 1999). A permutation test was also applied to the top ranked 
genes to assess their class-correlation statistical significance. The permutation test was 
applied to answer the following question: what was the likelihood that the set of marker 
genes selected by the signal-to-noise of phenotype (FL vs. DLBCL or ‘alive and cured’
vs. ‘fatal/refractory disease’) was due to chance correlations and not the hoped-for 
biological determinants. The algorithms used to classify according to phenotype 
distinction were weighted voting, -nearest neighbours and support vector machines. 
Hierarchical clustering was used to reassess the Alizadeh et al dataset reduced to just 
the 90 genes common to the ‘Lymphochip’ and the Affymetrix HU6800. A classifier 
was built through cross-validation using the leave-one-out technique. One sample was 
removed and the remaining samples used as a training set. This reduced the risk of over-
fitting whilst acknowledging the limitation of a relatively small cohort size. Ideally, the 
classifier would have been built using a training set of samples and validated in a 
second cohort. Several models were built using different numbers of marker genes, 
allowing the final model to be chosen with the lowest error rate in cross-validation. The 
Kaplan-Meier method was used to calculate predicted OS curves and the log rank test 
was used to calculate the respective P values (Kaplan and Meier, 1958). These marker 
genes were used to build the -nearest neighbour and weighted voting classifiers. 
Support vector machines used different methods to select marker genes.
2.1.4 Immunohistochemical Staining 
For a subset of the DFCI patients only (n = 21), five representative 0.6 mm cores were 
obtained from diagnostic areas of each paraffin-embedded formalin-fixed DLBCL and 
inserted in a grid pattern in a single recipient paraffin block using a tissue arrayer 
(Beecher Instruments, Silver Spring, MD). Five m sections cut from this “tissue array” 
were stained for PKC using an immunoperoxidase method. Slides were deparaffinised 
and pre-treated in 1 mM EDTA, pH 8.0, for 20 minutes at 95°C. All further steps were 
performed at room temperature in a hydrated chamber. Slides were pre-treated with 
peroxidase block (DAKO, USA) for 5 minutes to quench endogenous peroxidase 
activity, and a 1:5 dilution of goat serum in 50 mM Tris-Cl, pH 7.4, for 20 minutes to 
block non-specific binding sites. Primary antibody (murine monoclonal antibody 
specific for PKC (Serotec, UK)) was applied at a 1:1000 dilution in 50 mM Tris-Cl, 
pH 7.4 with 3% goat serum for 1 hour. After washing, secondary goat anti-mouse 
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horseradish peroxidase-conjugated antibody (Envision detection kit, DAKO, USA) was 
applied for 30 minutes. After further washing, immunoperoxidase staining was 
developed using a DAB chromogen kit (DAKO, USA) as per the manufacturer’s 
instructions. Following counterstaining with haematoxylin, immunoperoxidase staining 
within the malignant cell population of each core was scored in a blinded fashion with 
respect to clinical outcome and expression profile results by three pathologists (Jon 
Aster, Andrew Weng, Jeffery Kutok). The intensity of staining on each core was graded 
from 0 (no staining) to 3 (maximal staining), and an average staining intensity (the 
mean of all five cores) was generated for each tumour. The P value for the association 
between staining intensities and the array-based transcript levels was evaluated by using 
the median to divide measured intensities into two levels and then using Fisher’s exact 
test to evaluate the degree of association between the quantified measurements.
2.2 Presentation serum selenium materials and methods
2.2.1 Patient Samples, Histology and Clinical Variables Investigated
To ensure adequate patient follow-up, presentation serum samples were selected that 
had been archived between July 1986 and March 1999. The NHL classification system 
in operation at SBH during this time was the Kiel classification in which the different 
NHL subtypes were grouped into three broad categories termed low-, intermediate- and 
high-grade NHLs of B- or T-cell type. Therefore serum was searched for where a 
diagnosis of high-grade B-cell NHL had been made, as this Kiel subgroup would 
contain all the REAL and WHO defined DLBCL cases. Of the 383 patients with such a 
diagnosis, 143 had serum samples from presentation still archived. Only those samples 
that were haem-free were selected, as intracellular Se is released from lysed red cells, 
resulting in elevation of serum Se content. One hundred of the 143 archived sera were 
macroscopically haem-free. The histological subtype of the 100 high-grade B-cell 
NHLs with suitable archived sera was updated to the WHO classification by Dr Andrew 
Norton, Department of Pathology, SBH (Table 2.3).
The clinical variables investigated for an association with dose-delivery, response to 
first treatment and/or OS were serum Se, gender, and the recognised prognostic factors 
of age, B symptoms, stage, retrospective performance status, LDH (or hydroxybutyrate 
dehydrogenase if the patient presented prior to mid-1989), and number of extranodal 
sites (Table 2.4). The IPI score was calculated for the 95 patients with complete IPI data 
(Table 2.4).
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WHO Histological Subtype No of Cases
Diffuse large B-cell Lymphoma 77
Mediastinal Large B-cell Lymphoma 14
DLBCL, T-cell-rich 3
Lymphoplasmablastic Lymphoma with a High Content of Blasts 2
Angioimmunoblastic T-cell Lymphoma 2
Burkitt Lymphoma 1
Mantle Cell Lymphoma with a High Contents of Blasts 1
Total 100
Composite or Discordant Histology 15
Table 2.3 Revised Histological Classification According to WHO of the 100 
Patients
Variable N = 100
Serum Selenium (mol/l) Mean 0.92
Range 0.33-1.51
Gender Male : female 56 : 44
B symptoms Present : Absent 15 : 85
Age, years old Median 57
Range 19-87
Stage I, IE 25
II, IIE 23
III 13
IV 39
ECOG Performance 0 34
Status*  (96/100) 1 43
2 19
LDH* (98/100) < ULN 49
> ULN 49
Number of extranodal 0 33
Sites* (98/100) 1 53
2 12
IPI* (95/100) 0 17
1 24
2 23
3 23
4 7
5 1
Table 2.4 Clinical Characteristics of the 100 Patients
Abbreviations: ULN, upper limit of normal; ECOG, Eastern Co-operative Oncology Group.
*Available for the number of patients in brackets only.
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2.2.2 Treatment
All patients bar one (who died before treatment could begin) were treated with curative 
intent with anthracycline-based combination chemotherapy, radiotherapy or both (Table 
2.5). Comprehensive dose-delivery data was available for 87 of the 93 patients given 
chemotherapy. By July 3 2000, the date up to which survival data was analysed, 47 of 
the 100 patients had died (43 from DLBCL), two had been lost to follow-up and 49 
were alive. Thirty-six patients had relapsed by the date up to which survival data was 
analysed, only five of which received high-dose consolidation with autologous stem cell 
support as part of retreatment.
First Treatment 
Regimen
Regimen Details Number of 
Cases
VAPEC-B
An alternating anthracycline-based weekly 
schedule given for 12 weeks of
Vincristine, doxorubicin, prednisolone, 
etoposide, cyclophosphamide and bleomycin
64
VAPEC-B Variant 11
CHOP Cyclophosphamide doxorubicin, vincristine, and prednisolone 12
MACOP Methotrexate, doxorubicin, cyclophosphamide vincristine, and prednisolone 6
Radiotherapy 6
No treatment Died before treatment could commence. 1
Total 100
Table 2.5 First Treatment Details for the 100 Patients used for the Presentation 
Serum Selenium Research
2.2.3 Selenium Concentration Measurement
Inductively coupled plasma mass spectrometry was used to measure total serum Se 
content. Christine Sieniawska undertook the measurement under the supervision of 
Trevor Dells in the Trace Elements Unit, Southampton General Hospital, Southampton, 
UK. Selenium-78, as the principle Se isotope, was assayed after a 1:15 dilution with 
0.5% butan-1-ol and the addition of tellurium as an internal standard. In the five 
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samples with a high iodine content, caused by use of iodine as an antiseptic during their 
recent surgical procedure, performed to obtain tissue to reach their diagnosis of NHL, 
indium-115 was used as the internal standard. This was because of the overlap of the 
principal tellurium mass spectrometry peak with that of one of the principal iodine 
isotopes. Each sample was tested in duplicate, with standards of 0.2, 0.6, 1.2 and 1.7 
mol/l being run per 10 test duplicates. The between run precision ranged from 3.7% to 
5.9% relative standard deviation and a within-run precision of 2.3% to 9.3% over the 
concentration range 0.25 to ± 1.75 mol/l selenium.
2.2.4 Statistical Methods
Dose-Delivery Analysis
Dose-delivery associations were sought between the clinical variables investigated and 
doxorubicin, cyclophosphamide and vincristine. An area-under-the-curve summary 
measure, AUCratio was created by Victoria Cornelius, CR-UK Department of Statistics, 
Oxford, UK due to the inadequacy of ‘relative dose’ and ‘cumulative dose’ as dose-
delivery summary measures. Neither ‘relative dose’ nor ‘cumulative dose’ dose-
delivery measures could accurately account for variation in dosing schedules in both 
quantity and time duration. Relative dose intensity was not used, as this method merely 
calculates the rate of dose-delivery and takes no account of total dose delivered e.g. if a 
patient receives just two of six cycles of treatment, their relative dose intensity will be 
the same as that of a person receiving all six cycles assuming all courses were given on 
time. Cumulative dose was equally poor as a summary measure, as it only reveals dose 
differences between patients, taking no account of differences in time needed to deliver 
treatment. Taking the mean of the relative dose intensity for each course of 
chemotherapy will produce an indictor of the dose intensity but takes no account of 
when time delays occurred in treatment schedule. Our AUC methodology was created 
in order to more accurately reflect the temporal as well as quantity dimensions of dose 
intensity. The standard AUC measure used to distil serial measurements was adapted to 
account for variations in dosing schedules in terms of quantity and time duration 
(Matthews et al., 1990). Comparing actual to planned AUCs of the proportion of 
cumulative dose vs. time created a standardised summary measure evaluable between 
patients regardless of regimen variant used. The AUCratio of cumulative dose vs. time 
reveals not only variation in time taken and dose administered, but also distinguishes 
between dose reductions and delays incurred at the beginning from those incurred at the 
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end of treatment. AUCratio therefore factors for the premise that timely dose-delivery 
early is more critical than toward the end of therapy.
For a schedule of n doses, where the proportion of cumulative dose at time t(i) was y(i) 
(where i = 1 to n) the AUC was defined as:
The proportion of cumulative dose was plotted against time for both the planned and 
actual dosing schedules, followed by calculation of the AUC of the planned and actual 
schedules (AUCplanned and AUCactual). The summary measure used, AUCratio, was then 
created by dividing AUCactual by AUCplanned. AUCratio therefore represented the 
proportion of actual dose to planned dose over the duration of the treatment time. If the 
full planned dose was not given or a dose was delayed then AUCratio decreased from its 
maximum of 1.
Where actual doses were given after the final planned time, the time axis for the 
planned regimen was extended and the contribution was weighted using the formula:
Where t1 is the time from the first planned dose to the final planned dose, t2 is the time 
from the first administered dose to the final administered dose and n is the number of 
planned doses. For those patients where treatment stopped early because of death or 
disease progression, the planned dose intensity was censored at the time of death or 
disease progression. An example of dose intensity calculation is illustrated in Table 2.6 
and Figure 2.1.
Variables were included in the logistic regression and Cox multivariate models for
dose-delivery if they had obtained significance at the univariate level (P <0.1). Age and 
Se were treated as continuous variables and the remaining variables as categorical.
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t1 y1 t2 y2
Planned 
dose 
days
Planned
Dose
Planned 
cumulative 
dose
Proportion 
of planned 
cumulative 
dose
Actual 
dose 
days
Actual
dose
Actual 
cumulative 
dose
Actual dose 
as prop’n 
of planned 
cumulative 
dose
0 49 49 0.16 0 49 49 0.16
14 49 98 0.32 14 49 98 0.32
28 49 147 0.48 29 49 147 0.48
42 49 196 0.64 50 49 196 0.64
56 54 250 0.82 63 49 245 0.80
70 55 305 1.00 74 55 300 0.98
Table 2.6 Cumulative Dose of Doxorubicin (mg) for a Patient Receiving VAPEC-B 
(Doxorubicin Fortnightly At 35mg/m2). Initial BSA (body surface area) = 1.39 m2 increasing to 
1.57 m2. AUCplanned = 43.76, AUCactual = 40.27, AUC = 0.92
Figure 2.1 Cumulative Dose of Doxorubicin (mg) for a Patient Receiving VAPEC-
B (Doxorubicin Fortnightly At 35mg/m2). The x-axis intersection indicates the actual end of 
treatment administration 4 days later than the planned schedule.
0 10 20 30 40 50 60 70 80
Time in days
planned
actual
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Response Analysis
Response criteria in use at SBH during the years of patient presentation were different 
from the later 1997 consensus statement (Cheson et al., 1999, Dhaliwal et al., 1993). 
The definitions for complete response (CR) are the same, whereas good partial response 
(GPR) is comparable to CR uncertain and poor partial response (PPR) to partial 
response. Response was categorised into two groups according to similar OS observed 
amongst the 100 patients studied: complete response/good partial response and poor 
partial response/treatment failure/treatment-related death (Figure 2.2).
Figure 2.2 Overall Survival of The 100 Patients Grouped According to Response to 
First Treatment, from Response Documentation.
Logistic regression was fitted to estimate the odds ratio (OR), following 
employment of the 2 test and T-test to compare groups at the univariate level. The 
0 1 2 3 4 5 6 7 8
Survival time in years
complete response
poor partial response
good partial response
fail or Rx related death
Logrank stat istic = 57.2
p value < 0.01
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patients were divided into quartiles, as defined by presentation serum Se concentration, 
and tested univariately with regard to response and response duration.
Survival Analysis
Survival curves were estimated using Kaplan-Meier methods and the log-rank test. The 
patients were divided into quartiles, as defined by presentation serum Se concentration, 
and tested univariately with regard to OS. Survival time was analysed using a Cox 
proportional hazards model (Cox, 1972).
2.3 In Vitro Target Validation Materials and Methods
2.3.1 Established Tumour Cell-lines
Four DLBCL/transformed FL cell-lines were used in these studies. DHL4 (t(8:14)) was 
obtained from the DFCI (gift from Dr Margaret Shipp), and DoHH2 (t(14:18)) (Kluin-
Nelemans et al., 1991), SUD4 (t(14:18)) (Epstein et al., 1978) and CRL-2261 (t(14:18)) 
(Beckwith et al., 1995) were provided by CR-UK cell services. The characteristics of 
the cell-lines are detailed in Table 2.7.
Table 2.7 Characteristics of the Cell-lines used for in vitro experiments
GC vs. ABC like phenotype = Germinal centre vs. activated B-cell like phenotype
Tx FL = Transformed follicular lymphoma.
1 (Strauss et al., 2007) and personal communication from PhD thesis
2 (Smith et al., 2005)
3 (Kluin-Nelemans et al., 1991)
4 (Beckwith et al., 1995)
5 (Epstein et al., 1978)
Cell-lines Origin Translocation TP53 Status
GC vs. 
ABC like 
phenotype
Chemosensitive 
or resistant?
DHL4
DLBCL
(38 years 
old male 
1975)
Complex karyotype 
including 
t(8;14)(q24;q32) 1
Homozygous 
mutated & non-
functional p53 1
GC like 2 Resistant 1
DoHH2
Tx FL
(60 years 
old male 
1991) 3
Complex karyotype 
including 
t(14;18)(q32;q21) 1
Heterozygous 
mutated & 
functional p53 1
GC like 1 Highly sensitive 1
CRL-2261
DLBCL
(52 years 
old male 
1989) 4
Complex karyotype 
including 
t(14;18)(q32;q21)1 & 
4
Homozygous 
mutated & non-
functional p53 1
GC like 1 Sensitive 1
SUD4 DLBCL 5
Complex karyotype 
including 
t(14;18)(q32;q21) 1
Homozygous 
mutated & non-
functional p53 1
GC like 1 Sensitive 1
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The cell-lines were maintained in suspension in RPMI-1640 growth media (Sigma, 
Poole, UK) supplemented with 10% foetal calf serum, 1% L-glutamine and 1% 
penicillin/streptavidin (all Sigma, Poole, UK) and kept at 37oC in an humidified 
atmosphere containing 5% CO2.
2.3.2 3-day Cell-line Exposure Experiments
Only exponentially growing cells with viability >90% were used. Cells were plated at 1-
2x105 cells/ml in 5ml of RPMI-1640 supplemented with 10% foetal calf serum, 1 % L-
glutamine and 1% penicillin/streptavidin in 6-well plates or in 2ml in 24-well plates. 
The cytostatic, cytotoxic and/or anti-proliferative activity of the different drugs against 
the cell-lines was investigated after continuous exposure for three days to a minimum of 
five non-zero drug concentrations. Cell number and viability were determined by light 
microscopy following trypan blue staining. Proliferation was estimated using the MTS 
assay described below. The data presented is the mean of a minimum of three 
experiments, unless otherwise stated. EC50s (Effective Concentration to achieve 50% 
response) were calculated as detailed below using GraphPad Prism (San Diego, CA, 
USA).
Drug Stock Solutions
MSA (PharmaSe, Lubbock, USA) was prepared in DMSO at a concentration of 80 mM 
and SDG (PharmaSe, Lubbock, USA) was dissolved in 0.05M HCl at a concentration of 
10 mM. SC-236 was a generous gift of Pharmacia UK. A stock solution of SC-236 of 
10 mM was made in 60% ethanol, 40% sterile water. Piclamilast was a gift of Altana 
Pharma, Bad Homburg, Germany. A 10 mM stock solution of piclamilast using DMSO 
was made. Rolipram (Sigma chemicals, Poole, Dorset UK) was made up as 100 mM 
stock solution in 100% DMSO; forskolin (Sigma chemicals, Poole, Dorset UK) was 
made up as a 10 mM stock solution using anhydrous DMSO. Doxorubicin (Sigma 
chemicals, Poole, Dorset UK) was prepared using sterile water at a concentration of 1 
mM. Cytosine arabinoside (ara-c; Sigma chemicals, Poole, Dorset UK) was dissolved in 
sterile water to create a stock solution of 0.1 mM. The final DMSO concentration was 
<1% in all cultures. The stock solutions were stored at –40 or -80oC for up to three 
months. The stock solutions were diluted with RPMI-1640 media to make working drug 
concentrations on the day required.
Sigmoidal Dose/Concentration–Response Model
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‘Dose-response’ curves were used to plot the results of the drug experiments using the 
sigmoidal dose–response model (GraphPad Prism, San Diego, CA, USA). The X-axis 
was used to plot the concentration of the drug under investigation and the Y-axis to plot 
the response, which was cell count, viability or proliferation relative to no treatment 
controls. As the term ‘dose’ refers to ‘concentration’ in cell-line in vitro experiments, 
the term ‘concentration-response curve’ is a more precise label for the results of these in 
vitro experiments.
The steepness of concentration-response curves is quantified by the slope factor, 
referred to as the sigmoid factor in sigmoidal concentration-response curves. A 
concentration-response curve with a standard slope has a slope factor of 1.0. For the 
experiments undertaken, the anticipated activity of each drug was expected to be 
antagonistic i.e. reducing cell count, viability or proliferation with increasing 
concentrations of drug relative to no treatment controls. The curves created were 
therefore expected to go downhill and the slope factor to be negative. A standard curve 
in such circumstances has a slope factor of –1, a steeper curve a higher slope factor e.g. 
-8 and a shallower curve a lower slope factor e.g. -0.5. The mid-point of such curves is 
the EC50.
Curve fitting finds the curve that minimises the sum-of-squares of the vertical distance 
from the data points. By using an equation to fitting the concentration-response curve to 
the logEC50 rather than the EC50, the curve itself isn’t fitted better but it dramatically 
improves the accuracy of the standard error and CI calculated. The reason being that the 
uncertainty of the EC50 is not symmetrical, causing the SE and CI to be highly 
asymmetric. Without the log transformation of the x-axis data this cannot be accounted 
for, resulting in the lower 95% CI frequently having a negative lower value – an 
impossibility in reality. Switching from a linear to log scale turns a symmetrical CI into 
a very asymmetrical interval, which can be reported. As the SE represents a distance 
along the x-axis rather than a point on the axis, to convert the SE of the log EC50 to the 
SE for the EC50 it needs to be considered as a multiplier. To calculate the 95 % CI for 
the EC50 the antilog of the SE was taken, the answer multiplied by a constant from the t 
distribution for 95% confidence and the appropriate number of degrees of freedom, 
lastly the best-fit EC50 was divided and multiplied by the result to produce the lower and 
upper 95% CI. Under normal circumstances, concentration-response graphs for cell 
count, viability and proliferation will follow a sigmoidal shaped curve when plotted 
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with log concentration values on the x-axis – hence the term sigmoidal concentration-
response curve.
Therefore to fit a sigmoidal concentration-response curve with Prism, it was necessary 
to transform the concentration (x-axis) values to the logarithm of concentration. To this 
end the Prism software transforms the entered concentration values on your behalf. As 
the log of zero is undefined, all no treatment controls needed to be entered as low 
concentrations one or two log units below the lowest concentration for that experiment 
series. Because for virtually all the cell-line experiments performed there were plenty of 
data points due to using at least five different concentrations of each drug, the data was 
analysed using the ‘sigmoidal dose-response curve with a variable slope’ equation. 
Where the data points were scanty (as in some of the primary cell culture drug exposure 
experiments) the sigmoidal dose-response equation with a standard slope of –1 was 
used. After creation of a data table for all the replicates from a particular series of 
experiments, the Prism software calculated the mean value for the replicates at each log 
concentration value. To create a sigmoidal concentration-response curve from the now 
transformed mean values, the ‘non-linear regression’ tab was selected from the analysis 
list and then ‘sigmoidal dose-response variable or standard slope’ from the list of classic 
equations. Because all data points were relative to the no treatment controls, the data 
was in effect normalised.  Therefore the maximal response possible was zero and the 
minimal response possible was one for all cell count, viability and proliferation 
assessments. The consequence of having normalised data for any Prism analysis was 
that there was no need for the software to attempt to fit the top and bottom values as 
well as the logEC50 and the slope factor. The top value was therefore constrained to 
constant equal to zero and the bottom value to a constant equal to one. The Prism 
software therefore only had to fit two of the four possible parameters. The equation 
used by the Prism software is:
Y=Bottom + (Top-Bottom)/(1+10((LogEC50-X)*Hill Slope))
Cell Count and Viability Assessment by Trypan Blue Exclusion Staining
Trypan blue is a vital dye, which requires a damaged cell membrane for its negatively 
charged chromopore to be able to interact with the cell. Therefore cells stained blue are 
dying/dead and unstained cells are alive and viable. Cell number and viability were 
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determined by light microscopy following trypan blue staining using a 1:1 ratio of cell 
solution:trypan blue. This mixed solution was added to a haemocytometer. Only 
unstained cells were counted as viable and only cells stained blue were counted as dead. 
All data were expressed relative to control (untreated) cells and EC50 concentrations 
derived using a sigmoidal dose-response model in GraphPad Prism (San Diego, CA, 
USA). Final DMSO concentration was <1% in all cultures. The data presented is the 
mean of a minimum of three experiments.
MTS Cell Viability Assay
The CellTiter 96 Aqueous One Solution cell proliferation assay (Promega Wizard, 
Southampton, UK) was used to determine the number of viable cells. This solution 
contains a novel MTS tetrazolium compound, which is stabilised by the presence of an 
electron coupling reagent , PES (phenazine ethosulphate). The MTS tetrazolium 
compound is reduced to a soluble formazan product, changing the culture medium 
colour from yellow to brown. This reaction is due to the presence of dehydrogenase 
enzyme in metabolically active cells, which produce nicotinamide adenine dinucleotide 
phosphate (NADPH) or NADH. The rate of colour change is proportional to the number 
of viable cells present in the culture medium. The assay was carried out according to 
manufacturer’s guidelines. In brief, 1-2x105 cells in 100l of RPMI-1640 supplemented 
with 10% foetal calf serum, 1% L-glutamine and 1% penicillin/streptavidin were added 
to the inner 60 wells of 96 well plates. Drug or vehicle were added in a volume of 100l 
to give a final volume per well of 200l. 200l of Hank’s balanced salt solution was 
added to the outer 36 wells. 3 days later, 40l CellTiter 96 Aqueous One reagent was 
added to each well and plates were incubated for 2 to 4 hours. Absorbance was then 
read at 490nm using a 96-well plate reader (Fluorostar optima).
2.3.3 Flow Cytometry and Staining Procedure
Cell Cycle Distribution
After washing in ice-cold nucleus buffer (0.15 M NaCl, 5 mM KH2PO4, 1 mM EGTA, 
0.1 mM dithiothreitol, 10 % glycerol in distilled water pH 6.5) cells (1x106) were 
resuspended in 4 ml of permeabilising solution (0.35% Triton X-100, 0.1 mM PMSF in 
nucleus buffer), and mixed by rotation at 4oC for 20 min. Cells were then fixed in ice-
cold methanol for 30 minutes and washed with ice-cold PBS (phosphate buffered 
saline) before staining with 500l of PI stain (50g/ml PI and 50g/ml RNAse A in 
PBS). Acquisition of data was performed within 1 hour. Five to ten thousand cells were 
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collected and analysed for each data point using a FACSCalibur flow cytometer (Becton 
Dickinson, Oxford, UK) with the CellQuest software, and the percentage of cells in the 
sub-G1 (apoptotic fraction), G1, S and G2/M phases were analysed using a cell cycle 
analysis program (WinMDI 2.4).
Detection of Apoptosis
Apoptosis was confirmed by dual labelling using PI/annexin V staining of unfixed cells 
(Sigma, Poole Dorset, UK). After resuspending 1x106 cells in 500l of binding buffer 
(HEPES with NaOH, NaCl and CaCl2), 5 l annexin conjugate was added and the 
samples incubated for 10 minutes at room temperature in the dark. Propidium iodide (10 
l of 100 g/ml) was then added, and the sample immediately analysed on a 
FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK) using CellQuest 
software.
2.3.4 Primary Cell Culture
For primary culture experiments B-cell suspensions were prepared from ascitic fluid, 
peripheral blood or lymph nodes collected as part of normal clinical management from 
patients with histologically confirmed B-cell lymphoma or chronic lymphocytic 
leukaemia. A FL sample (01), a CLL/SLL sample (02) and two MCL samples (03) and 
(04) were used. All four patients from whom the samples came had been multiply 
pretreated for their malignancy and had chemoresistant/refractory disease. In addition, a 
pooled normal B-cell sample obtained from buffy coat from multiple blood donors was 
used. Local ethics committee approval was obtained and all patients gave informed 
consent. After disaggregation and/or density gradient separation, cells were plated at a 
density of 5x105 cells/well into 96-well plates containing CHO cells transfected with the 
Cdw32Fc receptor , which, when irradiated to prevent further proliferation, provided a 
stromal layer supporting B-cell proliferation. Malignant or normal B-cells were cultured 
in IMDM medium supplemented with 10% human serum and 2ng/ml interleukin-4 (IL-
4), cells could be maintained for up to eight days whilst retaining close phenotypic 
resemblance to the original sample, confirmed by flow cytometric quantitation of cell 
surface markers (personal communication Lenushka Maharaj). After 24 hours, drug was 
added at varying concentrations in at least triplicate, and cell number and viability were 
assessed after a further 48 hours using the trypan blue exclusion assay.
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2.3.5 Western Blotting
Immunoblot Analyses
To confirm the mechanism of cell death induced by Se compounds, cell extracts were 
analysed for caspase and poly(ADP-ribose) polymerase (PARP) cleavage. Cells were 
exposed to an EC50 concentration of either MSA or SDG for 3 days, after which cell 
lysates were prepared using lysis buffer (75%) containing protease inhibitors and 
NuPAGE sample buffer (25%) 100l per million cells (all Invitrogen Ltd, Paisley, UK). 
Prior to electrophoresis samples were diluted with NuPAGE reducing agent (Invitrogen 
Ltd, Paisley, UK) and heated at 70oC for 10 minutes before gel loading. Proteins were 
resolved by SDS-PAGE electrophoresis using a 5% stacking gel and 12% running gel, 
electroblotted onto nitrocellulose membranes and then probed using primary antibodies 
against caspase-8 (1:100), caspase-9 (1:100) or PARP (1:100), (all Oncogene research 
Product, Boston, MA). Gel loading was controlled by probing for -actin (1:2000, Dako 
Ltd, Cambridge UK). A horseradish peroxidase-conjugated anti-mouse IgG1 (1:1000,
Source) was used as the secondary antibody for all immunoblots except caspase-9, 
where an anti-rabbit IgG antibody (1:2000) was used (both Dako Ltd). Bands were 
visualised using the ECL-plus detection system (Amersham Life Sciences, Little 
Chalfont, UK).
2.3.6 Measurement of Reactive Oxygen Species
To determine ROS generation, experiments were conducted at the cytotoxic EC50
concentration of either MSA or SDG for each cell-line. Cells were resuspended in PBS 
(1x106/ml) and incubated in 20 M 2’7’-dichlorodihydrodifluoroscein diacetate (DCF-
DA, Molecular Probes, Oregon, USA) for 15 minutes at 37oC in 5% CO2. After the 
addition of MSA, SDG, 25 M H2O2 (positive control) or no treatment control (0.75% 
DMSO, equivalent to the highest concentration used in drug incubations for each cell-
line) cells were incubated for a further 30 minutes. ROS generation was then 
immediately determined by measuring the mean fluorescent intensity of 10,000 cells at 
530 nM on a FACSCalibur flow cytometer (Becton Dickinson, Oxford, UK) using 
CellQuest software.
To investigate the possible influence of ROS on the activity of SDG and MSA, cells 
were treated at the EC50 concentration of either drug for 3 days in the presence of 2.5 
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mM N-acetyl cysteine (NAC) (Sigma chemicals, Poole, Dorset UK) after which cell 
number and percentage viability, relative to controls, were determined.
2.3.7 Measurement of c-AMP
To measure intracellular c-AMP concentration, the c-AMP Biotrak 
Enzymeimmunoassay (EIA) System (96 wells) kit was used (Amersham Biosciences, 
Little Chalfont, Buckinghamshire, UK). One hundred l of each cell-line suspension 
was seeded at 5 x 105 cells/ml in a 96-well plate and incubated overnight at 37oC in 5% 
CO2. The following morning cell counts were performed for each cell-line and 100 l of 
drug at 2 x desired concentration was added to the wells and the plate returned to the 
incubator for four hours. The plate was centrifuged to pellet the cells and the media 
aspirated. Cells were resuspended in 200 l of lysis reagent 1B 
(dodecyltrimethylammonium bromide 0.25%) and agitated until lysis was complete. 
Working on ice, the kit 96-well microplate was loaded with prepared standards (12.5 to 
3200 fmol c-AMP/well) and controls and 100 l of each cell-line lysate into respective 
wells. One hundred l of antiserum was then added to all wells except the blank and 
non-specific binding wells. After two hours incubation at 3-5oC, 50 l of c-AMP 
peroxidase conjugate was added to all wells except the blank wells. After a further 
hour’s incubation at 3-5oC, all wells were washed four times with 400 l of wash 
buffer. To the blotted wells 150 l of enzyme substrate was added to each well and the 
plate agitated at room temperature for 60 minutes. One hundred l of 1 M sulphuric 
acid was then added to each well to halt the reaction. The plate was then inserted into 
the fluorstar plate reader and the optical density of each well determined at 450 nm 
within 30 minutes. The average of the replicates was calculated and a standard curve 
constructed to allow sample well c-AMP content to be generated.
2.4 Ethical Considerations
The studies using clinical material had the approval of the East London and The City 
Health Authority Ethic Committee, and their stipulations regarding to matters of patient 
consent, confidentiality and data protection were followed. To ensure patient 
anonymity, archival DNA and tissue samples are labelled with a reference number and 
location position.  The patient name and hospital number are held separately in a 
password protected computer file.  The medical oncology department data managers 
hold patient identifiable clinical details separately. Correlation between patient 
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identifiable clinical details and laboratory results was made solely through these 
individuals.
2.5 Statistics
To assess the significance of differences observed between drugs, concentrations, 
combinations and cell-lines in the in vitro experiments one-way analysis of variance 
(ANOVA) was performed, controlling for cell-line and/or treatments. To ensure that the 
overall type I error rate remained 0.05, Bonferoni’s method was used to calculate the 
type I error rate for individual paired t test comparisons. A P value of <0.05 was taken 
as the cut-off for statistical significance. These tests were performed using the statistical 
package incorporated into the GraphPad Prism software (San Diego, CA, USA).
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CHAPTER 3: INVESTIGATION OF PRESENTATION SERUM SELENIUM AS 
A PROGNOSTIC FACTOR IN DLBCL
3.1 Chapter Summary
Serum Se was measured using inductively coupled plasma mass spectrometry in 
archived presentation sera from 100 patients with high-grade NHL (78% DLBCL). 
Ninety-three of the 100 patients were treated with CHOP-like chemotherapy, six with 
radiotherapy and one received no treatment. Four outcome measures were studied for an 
association with presentation serum selenium: chemotherapy dose-delivery, response to 
treatment, first remission duration and OS. Serum Se closely correlated with 
performance status but no other clinical variable. Significant inverse associations were 
found for serum Se and all four of the outcome measures investigated (dose-delivery, 
response to treatment, first remission duration and OS).
3.2 Introduction
The empirical scientific reasons for investigating serum Se as a potential prognostic 
factor were multiple and included the following. The epidemiological observation of an 
inverse association between Se intake and cancer risk, the chemopreventive effect of Se 
compounds against tumour formation in more than a hundred animal studies, the 
demonstration of a similar chemopreventive effect in several human Se supplementation 
trials and limited data indicating reduced serum Se levels in cancer patients. The clinical 
reasons for undertaking the research were threefold: if serum Se should prove 
prognostic, that sample collection during routine blood testing would be straight 
forward; and that the affordability of testing for serum Se would make it feasible to 
introduce as an additional clinical investigation for research or routine practice. More 
ambitiously, it was hoped that if serum Se was predictive of outcome following 
intervention in DLBCL, then Se supplementation might offer a novel therapeutic 
adjunct to conventional poly-chemotherapy. The empirical hypothesis tested was that 
serum Se at presentation would predict for response to first treatment, dose-delivery, 
and OS in patients with DLBCL.
3.3 Methods
I identified the patient samples and Andy Wilson and I extracted relevant clinical data 
from the departmental database and the patients case notes. Reclassification of the 
corresponding presentation NHL histological material to the serum samples was 
undertaken by Dr Andrew Norton, Department of Histopathology and where bone 
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marrow material Dr John Amess Department of Haematology, St Bartholomew’s 
Hospital, London, UK. The mesurement of the Se content of the frozen sera was 
conducted by Dr Trevor Delves and Dr Christine Sieniawska Trace Elements Unit, 
Southampton General Hospital, Southampton, UK. Victoria Cornelius, CR-UK 
Department of Statistics, Oxford, UK, performed all statistical analyses for the research 
described in this Chapter.
Between July 1986 and March 1999 of the 383 patients with a diagnosis likely to be 
DLBCL on updated classification, frozen, archived, presentation serum from 100 
patients was suitable for measurement of serum Se. The updated histological subtype of 
NHL according to the WHO classification is illustrated in Table 2.3. The clinical 
variables investigated for an association with dose-delivery, response to first treatment 
and/or OS were serum Se, gender, and the recognised prognostic factors of age, B 
symptoms, stage, retrospective performance status, LDH (or hydroxybutyrate 
dehydrogenase if the patient presented prior to mid-1989), and number of extranodal 
sites (Table 2.4). The IPI score was calculated for the 95 patients with complete IPI data 
(Table 2.4). All patients bar one (who died before treatment could begin) were treated 
with curative intent with anthracycline-based combination chemotherapy, radiotherapy 
or both (Table 2.5). Comprehensive dose-delivery data was available for 87 of the 93 
patients given chemotherapy. Survival data was analysed up until July 3 2000. Total 
serum Se content was measured by inductively coupled plasma mass spectrometry. 
Dose-delivery associations were sought between the clinical variables investigated and 
doxorubicin, cyclophosphamide and vincristine. An area-under-the-curve summary 
measure, AUCratio was created especially for the project by Victoria Cornelius (see also 
Chapter 2.2.4). The AUCratio of cumulative dose vs. time revealed not only variation in 
time taken and dose administered, but also distinguishes between dose reductions and 
delays incurred at the beginning from those incurred at the end of treatment. AUCratio
therefore factors for the premise that timely dose-delivery early is more critical than 
toward the end of therapy. 
3.4 Results
3.4.1 Serum Selenium
The presentation serum Se concentration was normally distributed for the 100 patients 
with a mean of 0.92 mol/l (standard deviation = 0.25) and range of 0.33 to 1.51 
mol/l. A trend of decreasing mean serum Se was observed with increasing year of 
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presentation. Seventy-three patients had a Se level below the UK reference range from 
the early 1980’s (UK adult reference range = 1.07-1.88 mol/l (Matthews et al., 1990)). 
Serum selenium concentration was highly associated with performance status but no 
other clinical variable (P <0.001). As a consequence of this association, only one of 
these variables was included in the multivariate analyses at the same time, as they 
explained similar variation. As the primary interest was in assessing the relationship 
between Se levels, response, dose-delivery and survival rather than developing a new 
prognostic model, the multivariate analyses containing the Se variable are presented 
here. Exchanging Se with performance status gave similar results. Logistic regression 
and Cox multivariate models for dose-delivery, response, OS were performed on 
variables if had obtained significance at the univariate level (P <0.1). Survival curves 
were estimated using Kaplan-Meier methods and the log-rank test. The patients were 
divided into quartiles, as defined by presentation serum Se concentration, and tested 
univariately with regard to OS.
3.4.2 Dose-delivery
In the 93 patients with complete treatment data, there were 129 treatment delays and/or 
dose reductions, associated with 42 in-patient episodes for neutropenic fever/sepsis, 29 
admissions for other treatment-related complications, 45 episodes of neutropenia 
without fever and 13 delays for other reasons.
At the univariate level (P <0.1), two variables correlated positively with the dose-
delivery summary measure AUCratio: age and serum selenium; and one variable 
correlated negatively: stage (Table 4.1). Stepwise inclusion of these three variables in 
the multivariate model revealed that a significantly better dose-delivery (summarised by 
AUCratio) was associated with younger age, advanced stage, and higher serum Se (see 
Table 3.2).
Chapter 3
129
Clinical variable Dose-delivery  Response  Survival time 
Age <0.001 0.532 0.042
Selenium 0.063 0.009 0.026
Gender 0.175 0.156 0.092
Stage 0.053 0.517 0.089
B symptoms 0.786 0.791 0.570
Performance status 0.234 0.007 <0.001
LDH 0.403 0.892 0.280
No. of extranodal sites 0.282 0.265 0.383
Table 3.1 Univariate Analysis With Probability Values
The P values are derived from:  significance of regression coefficient (H0: =0); -  for categorical 
and ANOVA for continuous variables;  log rank test for categorical and significance of hazard ratio 
for continuous variables.
 - variables indicating significance at the univariate level (P < 0.1).
Clinical 
Variable
Dose-delivery Response Survival time
Regression 
Coefficient
(Standard Error)
P
value
Odds Ratio
(95% CI)
P
value
Hazard 
Ratio
(95% CI)
P
value
Age -0.006 (0.001) <0.001 - -
1.09
(0.99, 1.18)
0.066
Selenium 0.215 (0.099) 0.032
0.62
(0.43, 0.90)
0.011
0.76
(0.60, 0.95)
0.018
Gender - - - - 1.66 (0.94, 2.93) 0.083
Stage 0.051 (0.015) 0.001 - - - -
Table 3.2 Multivariate Analyses With Probability Values
The Regression Coefficient is the change in AUC for a one-unit increase in that variable.
 - for 5-year change in age.  for 0.2 mol/l change in serum selenium.
 indicates significance at the multivariate level (P <0.01)
3.4.3 Response To Therapy
Only two patient variables, Se concentration and performance status, were associated 
with response to first treatment at the univariate level (using a statistical significance of 
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10%) (Table 3.1). Fitting a logistic regression model produced an odds ratio of 0.62 for 
every 0.2 mol/l increase in serum Se (95% CI 0.43, 0.90) and P = 0.011 (Table 3.2). A 
higher Se level was therefore associated with a lower probability of having a poor 
outcome to treatment (i.e. PPR, treatment failure or treatment-related death). For 
example, a patient with a serum Se of 0.8 mol/l has estimated odds of CR or GPR 38% 
lower than a patient with a serum Se level 1.0 mol/l. Similar results were obtained by 
exchanging the variable performance status with Se in the logistic regression model. A 
cross-tabulation of response and IPI score revealed no obvious association between IPI 
and response to first treatment ( 2 P = 0.45). Table 3.3 displays response according to 
Se quartiles (2=9.52, P = 0.023).
Response Lowest quartile 3rd quartile 2nd quartile
Highest 
quartile
CR/GPR Number 13 14 14 22
% 54.2% 56.0% 56.0% 88.0%*
PPR/ fail/ 
Treatment -
related death
Number 11 11 11 3
% 45.8% 44.0% 44.0% 12.0%
Table 3.3 Response to First Treatment According to Selenium Quartiles.
There were 99 assessable patients as one died before treatment could commence.
* significantly different compared to the other quartiles (2=9.52, P = 0.023).
3.4.4 Remission Duration
When treated as a continuous variable, serum Se was not significant at the univariate 
level (p = 0.298). However, when serum Se was treated as a categorical variable (4 
quartiles) it was significant with regard to remission time (log rank test = 4.38, P = 
0.036). This difference was due to response to treatment only being significantly better 
in the top quartile of patients as defined by serum Se level. This result suggests that 
above a threshold of 1.096 Mol/l, response is significantly improved. Performance 
status was also significant with regard to remission time (log rank = 15.7, P < 0.001) 
whilst LDH indicated significance at the univariate level (P = 0.07).
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3.4.5 Overall Survival
The OS of the 100 studied patients did not differ significantly from the 283 remaining 
aggressive B-cell NHL patients who did not have archived presentation sera (Figure 
3.1).
Figure 3.1 Overall Survival for the patients included in and excluded from the 
study
OS from diagnosis of the 283 patients treated between July 1986 and March 1999 without 
available presentation frozen sera.
OS from diagnosis of the 100 patients investigated in the study.
The median OS of the 100 patients was 6.2 years (range one week to 13 years, 95% CI 
1.9, 10.7) and 6.1 years for the 51 surviving patients (range 4 months [1 patient lost to 
follow-up at 128 days] -13.5 years). When considering IPI as a continuous variable, it 
was found to be prognostic with regard to OS with a hazard ratio of 1.58 (95% CI 1.18, 
2.13). The results of univariate analysis indicated that age, Se concentration, gender, 
stage and performance status correlated with survival time (Table 3.1). On multivariate 
analysis, using a Cox model and excluding PS, Se was the most significant factor, with 
a hazard ratio of 0.76 for every increase of 0.2 mol/l in serum Se level (Table 3.2). 
Thus, a lower serum Se concentration was associated with shorter survival. For 
0 1 2 3 4 5 6 7 8
Survival time in years
patients not in study
patients in study
Logrank stat istic = 2.9
p value = 0.09
.…….
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example, a patient with a serum Se concentration of 1.0 mol/l had a 24% lower risk of 
death than a patient with a concentration of 0.8 mol/l, over the duration of the study. 
Replacing Se with performance status gave similar results i.e. a decrease in performance 
status was significantly associated with shorter survival . OS for each Se quartile is 
displayed in Figure 3.2.
Figure 3.2 Overall survival, from diagnosis, of the 100 patients According to serum 
Selenium quartiles 
Lowest quartile = serum Se from 0.33 to 0.74   Mol/l
Second quartile = serum Se from 0.75 to 0.91   Mol/l
Third quartile = serum Se from 0.92 to 1.095 Mol/l
Highest quartile = serum Se from 1.096 to 1.51   Mol/l
0 1 2 3 4 5 6 7 8
Survival time in years
lower 25%
25 - 50%
50 - 75%upper 75%
Logrank stat istic = 9.0
p value = 0.03
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3.5 Discussion
This study was undertaken to test the hypothesis that serum Se at presentation would 
predict for either response to first treatment, dose-delivery or OS in patients with 
DLBCL, the commonest NHL (Armitage and Weisenburger, 1998). Correlations 
between presentation serum Se, dose-delivery, response to first therapy, first remission 
duration and OS were discovered in patients with aggressive NHL, the majority of 
which were DLBCL or the related mediastinal large B-cell lymphoma (94/100) on 
histology re-evaluation. Dose-delivery, assessed using actual to planned AUCs, was 
also associated with stage and inversely associated with age. Serum Se was therefore 
found to be a prognostic factor in DLBCL. As all but one of the patients received 
treatment i.e. no best supportive care cohort of patients, it was not possible to identify if 
serum Se was a pure prognostic factor or also a predictive factor for outcome measures 
to CHOP-like treatment.
Performance status was the only clinical variable that was highly associated with serum 
selenium. This correlation may be the result of general nutritional deficiency in the 
months and weeks pre-diagnosis and/or an acute phase response of serum Se to illness 
(Nichol et al., 1998). The associations found in this study could therefore be due to a 
bystander phenomenon with no causality related to Se level. Alternatively, the 
correlations described may indeed reflect a causal relationship and account, in part, for 
the prognostic power of performance status in aggressive NHL. As regards the 
possibility of the low Se values seen in this study being partly due to an acute phase 
response, this need not imply lack of causality nor scope for therapeutic intervention. 
For example, the low serum Se seen in patients with acute pancreatitis (Wereszczynska-
Siemiatkowska et al., 2004) has been reported to respond to supranutritional 
intravenous infusions of Se, resulting in a marked decline in the mortality rate 
associated with this frequently fatal condition (Kuklinski et al., 1991, Kuklinski et al., 
1995) and aggressive selenite supplementation of Se deficient patients with severe 
sepsis on a medical intensive care unit (with performance status IV) resulted in reduced 
morbidity (Angstwurm et al., 2004).
The importance of these findings is unknown at present and will require validation in 
other patient series in the first instance. Critical to their relevance is the issue of whether 
causality exists in the relationships discovered. Does Se deficiency, as indicated by 
reduced serum Se, cause side-effects of treatment to be worse, allow chemoresistance to 
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develop more readily and impair an immune response to tumour?  A second question 
arises upon assumption of causality in associations described, namely in what direction 
does the causality exist?  Does Se deficiency cause/predispose to the tumour, as is 
evident from the epidemiological data described earlier, or does the tumour cause the 
observed Se deficiency?  The animal data reviewed indicates that Se supplementation 
can prevent the initiation of cancer and kill preneoplastic cells in the early post-
initiation stage and reduce the growth of xenografts. The recovery of serum Se levels to 
normal on successful treatment of acute myelogenous leukaemia implies that the illness 
causes the deficiency in Se (Beguin et al., 1989). Some take such a scenario to mean 
that intervention will be fruitless. Such a nihilistic viewpoint overlooks the possibility 
that advanced, clinically apparent tumours, may obtain a survival advantage from 
inducing a Se deficiency state, an advantage that could be corrected by Se 
supplementation as an adjunct to conventional therapy. Others have shown the opposite 
to occur: that Se status remains suboptimal despite successful cancer treatment (Ujiie 
and Kikuchi, 2002), a result supporting the former relationship of low Se predisposing 
to neoplasia.
In the laboratory, in vitro and in vivo experiments have revealed that Se compounds can 
exert cytotoxic activity, synergise with cytotoxic agents and favourably influence cancer 
cell phenotype (Thompson et al., 1994, Vadgama et al., 2000, Caffrey and Frenkel, 
2000). No clinical evidence confirming Se as a disease-modifier in patients with 
established cancer so far exists. If proven, the argument for exploration of Se 
compounds as a therapy adjunct to aid improvement of the long-term remission rate of 
only 40-50% in this illness would be strengthened. Indirect evidence supporting an 
association between Se and the clinical course of lymphoma comes from a study, which 
found that pre-treatment serum Se concentration correlated with response to treatment 
in a group of 51 epidermotrophic T-cell lymphomas, and the observation that serum Se 
levels were significantly lower in patients with NHL than in normal controls (Deffuant
et al., 1994, Avanzini et al., 1995).
Several compatible mechanisms may underlie the prediction of dose-delivery, response 
and outcome by presentation serum selenium. These include prevention of 
chemoresistance, enhancement of immune function, direct cytotoxic activity of Se 
compounds and reduction of treatment-related side-effects. Evidence of Se preventing 
chemoresistance comes from in vitro and mouse studies. No confirmatory in vivo
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human data yet exists. Selenite prevented melphalan resistance and cisplatin cross-
resistance when co-administrated with low-dose melphalan to the human ovarian cancer 
cell-line A2780 in vitro (Caffrey et al., 1998). A2780 xenografts in nude mice readily 
develop melphalan and cisplatin resistance upon low-dose melphalan or cisplatin 
administration (Caffrey and Frenkel, 2000, Caffrey et al., 1998). Concurrent 
administration of selenite or selenomethionine prevented chemoresistance development 
(Caffrey and Frenkel, 2000, Caffrey et al., 1998). Also in a murine model, using 
Dalton's lymphoma, pre-inoculation with selenomethionine increased survival by 31 
and 112% compared to those mice that received selenomethionine at inoculation and 
those that received no selenomethionine supplementation (Rana et al., 1996). Multiple 
processes are likely to account for this survival advantage. Although limited, evidence 
suggesting a role for Se in immune response enhancement includes a study where 
selenite, given to volunteers with normal Se levels, resulted in clonal expansion of 
activated T-cells in response to in vitro incubation with a cancer cell-line. T-cell 
cytotoxicity increased by 118% and natural killer cell-mediated lytic activity by 82% 
compared with baseline (P values < 0.05) (Kiremidjian-Schumacher et al., 1994, Roy et 
al., 1994). The same researchers conducted a randomised, double-blind, placebo-
controlled trail of sodium selenite 200 g/day vs. placebo in patients beginning 
treatment for their head and neck squamous cell carcinomas (Kiremidjian-Schumacher
et al., 2000). They found that the selenium-supplemented group experienced a 
significantly enhanced cell-mediated immune responsiveness both during therapy and 
after its completion compared to a decline in immune responsiveness in the control 
group during treatment (Kiremidjian-Schumacher et al., 2000). A recent report from the 
UK assessed gene expression in lymphocytes isolated from 39 healthy subjects pre- and 
post- 6-weeks of 100 g sodium selenite a day (Pagmantidis et al., 2008). Upregulation 
of ribosomal protein and translation factor genes were seen in response to Se 
supplementation. More convincing evidence in support of the immunomodulatory
potential of Se supplementation comes from the microarray results from pre and post 
10-month Se supplementation in people with asymptomatic oesophageal squamous 
dysplasia (Joshi et al., 2006). Only genes related to the immune response pathway were 
significantly overrepresented in the 149 genes differentially expressed between samples 
from patients whose dysplasia regressed and those whose dysplasia worsened. The 
cytostatic and cytotoxic activity of different Se compounds has been confirmed in 
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numerous in vitro and animal experiments (Ip, 1998, Lanfear et al., 1994, Medina et al., 
2001). Vadgama et al noted synergy between Se and the cytotoxic agents paclitaxel and 
doxorubicin (in terms of increased cell death and growth arrest) in the majority of cell-
lines investigated (Vadgama et al., 2000). A possible means of Se enhancing dose-
delivery may be through reducing the side-effects of therapy. Se supplementation has 
been shown to reduce cisplatin-induced nephrotoxicity and bone marrow suppression in 
a crossover patient study and prevent doxorubicin-induced cardiomyocyte cytotoxicity 
in vitro (Hu et al., 1997, Yoshida et al., 2000, Kotamraju et al., 2000). One potential 
explanation for this effect may be a differential alteration in the apoptotic threshold 
between Se replete normal cells (threshold raised, so that cells are able to repair damage 
rather than die) and malignant cells (threshold lowered so that cells more prone to 
undergo programmed cell death rather than DNA repair). This hypothesis is supported 
by two reports. One in elderly dogs where Se supplementation caused the amount of 
DNA damage in peripheral blood mononuclear cells to be lower in supplemented 
animals vs. controls, while the number of apoptotic cells in prostate epithelium was 
increased vs. controls (Waters et al., 2003). The second study found that Se 
supplementation encouraged DNA repair via p53 in normal cells but promoted cell 
apoptosis in malignant cells with mutated TP53 and null for p53 protein (Fischer et al., 
2007).
A recent report also described reduced side-effects of chemotherapy as a result of Se 
supplementation, suggesting that Se status may affect chemotherapy dose-delivery in 
cancer and lymphoma patients through protection of normal tissues from cytotoxic 
damage (Sieja and Talerczyk, 2004). The less well a patient is at the start of treatment, 
the more likely they will experience side-effects from chemotherapy and the less likely 
they are to respond to treatment.
The majority of the patients investigated (73%) had a serum Se concentration below the 
UK reference range from the early 1980’s. This finding is consistent with the reporting 
of lower Se levels in cancer and lymphoma patients compared to the general population 
(Alaejos et al., 2000, Deffuant et al., 1994), to the decline in Se intake in the UK 
population (attributed to the cessation of Canadian wheat importation) since this 
reference range was generated (Group, 1997, Group, 1999), and to the afore mentioned 
fall in serum Se as part of the acute phase response to illness (Nichol et al., 1998).
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The extent of Se deficiency in aggressive NHL patients, as assessed by serum Se levels, 
coming from general populations replete in Se remains to be seen. Se levels vary around 
the world from extremely low in areas of China, to low in many parts of Europe 
compared to the high-normal levels in most areas of North America and Japan. If Se is 
important in aggressive NHL phenotype evolution and treatment success, countries with 
a high-normal Se level in the population might be expected to have a better OS for 
aggressive NHL than countries with a low Se intake. This is not apparent, as UK 
survival rates are comparable to those in North America. Whether this reflects the need 
for supernormal Se intakes to alter disease outcome at the population level, or to 
aggressive NHL resulting in low Se levels regardless of premorbid Se status will require 
further investigation. The Se chemoprevention study performed in former non-
melanomatous skin cancer patients, took place in the US (Clark et al., 1996). Se 
supplementation was beneficial even in those replete in the micronutrient, although the 
benefit was greatest in the lower tertile of patients (serum Se <1.35 mol/l) (Rayman 
and Clark, 2000). All but three patients in this study had a serum Se concentration 
within this tertile.
Prospective, multicentre/country substantiation of the findings described will be 
required. The discovery of presentation serum Se as a potential prognostic factor in 
aggressive NHL raises the possibility of investigating Se compounds as a novel strategy 
for both disease and outcome modification in this frequently curable malignancy. In 
search of empirical scientific evidence in support of a causal relationship in the 
associations found, I proceeded to study two Se compounds, MSA and SDG, for 
cytostatic and cytotoxic activity alone and in combination with established cytotoxics in 
a panel of B-cell NHL cell-lines and primary cultures.
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CHAPTER 4: IN VITRO INVESTIGATION OF SELENODIGLUTATHIONE 
(SDG) AND METHYLSELENINIC ACID (MSA)
4.1 Chapter Summary
In the light of the positive results described in Chapter 3, the research in this Chapter 
was undertaken to establish if Se compounds could inhibit cell growth and viability in a 
panel of human DLBCL cell-lines and in a selection of primary lymphoma samples 
from multiply treated patients using a primary cell culture system. This research has not 
been previously reported. The two Se compounds selected, SDG and MSA, proved to 
exert concentration dependent cytostatic and cytotoxic actions against the DLBCL cell-
lines and primary lymphoma samples but were much less effective against the pooled 
normal B-cell sample, raising the possibility of a therapeutic index between malignant 
and normal cells for both SDG and MSA. Next, the effect of the Se compounds on the 
cell cycle and the mode of cell death induced were investigated. Neither SDG nor MSA 
caused a block at a specific phase of the cell cycle and both caused apoptotic cell death 
through caspase-8 and -9 activation and PARP cleavage. Finally, the generation of ROS 
by SDG and MSA and the importance of ROS generation for effect cell death by the 
two Se compounds were investigated in the DLBCL cell-line panel. MSA was shown to 
exert its cytotoxic activity independent of ROS, as ROS generation did not occur to a 
significant degree with any of the cell-lines. In contrast, exposure to SDG led to ROS 
generation within 30 minutes in three of the four cell-lines and was critical to the 
cytotoxicity of SDG in two of the four cell-lines tested. In summary, SDG and MSA 
were active against DLBCL cell-lines and primary lymphoma samples, induced 
apoptotic cell death and acted via different mechanisms.
4.2 Introduction
In vitro investigations in DLBCL cell-lines and primary cell cultures using Se 
compounds were conducted for two reasons: to provide evidence in favour of a causal 
relationship between the associations described in Chapter 3 between presentation 
serum Se the clinical outcome measures of dose-delivery, response and OS and to 
investigate Se compounds as novel treatments for DLBCL. A number of Se compounds 
have been shown to be cytostatic and cytotoxic to cancer cell-lines and to exhibit 
chemopreventive activity in animal models of cancer. Se compounds are also effective 
in cell-lines lacking functional p53. For example, in the TP53 mutated colon cancer 
cell-line HT29, selenomethionine inhibited cell growth in a concentration-dependent 
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manner (Redman et al., 1997), whilst the synthetic, organic methylselenocyanate 
induced apoptosis in the TP53 null mouse MOD mammary cancer cell-line (Kaeck et 
al., 1997), and SDG has equivalent cytostatic and cytotoxic activity in mutated p53 cells 
as in wild-type p53 cells (Lanfear et al., 1994). For the experiments conducted in this 
Chapter the choice of compound included three Se compounds from the hydrogen 
selenide pool, namely selenite, SDG and 1,4-phenylenebis(methylene)selenocyanate (p-
XSC) and three compounds from the methylselenol pool: selenomethionine, MSC and 
MSA. A summary of the data on each of these six will now be presented and an 
explanation for the choice of SDG and MSA.
Selenite
Selenite inhibits cell growth and DNA synthesis, induces cell cycle arrest and cell death 
in a range of cell-lines (Lu et al., 1995, Lu et al., 1994, Kaeck et al., 1997). The activity 
of selenite is concentration-dependent and occurs in the low micromolar range. Cell 
death is dominated by necrosis although apoptosis is also induced (Lu et al., 1995, Lu et 
al., 1994, Kaeck et al., 1997, Stewart et al., 1999). Genotoxicity is induced by selenite, 
as an early event, in a concentration-dependent manner, as evidenced by single- and 
then double-strand DNA breaks, an effect independent of apoptosis (Lu et al., 1994, Lu
et al., 1995, Jiang et al., 2001). The cell death and DNA laddering caused by selenite 
occurs at an 8-10 fold lower concentration than is required for selenomethionine and 
MSC (Stewart et al., 1999). Selenite induces the generation of the ROS superoxide in 
the presence of glutathione and mitochondria; an effect abolished by the addition of a 
superoxide scavenger (Kim et al., 2003b). Although sodium selenite has a proven track 
record as a cytotoxic agent in vitro and a chemopreventive agent in vivo, I did not 
choose it for my in vitro studies for two reasons. Firstly, the lag time of 24 hours or 
more until cytotoxic activity commences in vitro; and secondly because selenite has one 
of the narrowest therapeutic indices of the Se compounds in vivo.
1,4-phenylenebis(methylene)selenocyanate (p-XSC)
p-XSC was the most promising of several aromatic Se compounds developed in an 
attempt to widen the therapeutic index seen with selenite and selenomethionine in 
animal experiments (el-Bayoumy, 1985). The maximum tolerated dose of dietary p-
XSC in rats was 32.5 ppm Se compared to <5 ppm Se for sodium selenite (Fan and 
Kizer, 1990, Conaway et al., 1992). In vitro, the intracellular accumulation of Se was 3-
6 fold higher following treatment with p-XSC than the equivalent dose of selenite and 
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the percentage of apoptotic cells was greater (Thompson et al., 1994). Both the 
initiation and post-initiation/tumour promotion stages of carcinogenesis were inhibited 
by p-XSC in a rat DMBA breast cancer model and a rat azoxymethane colon cancer 
model (Reddy et al., 1994, Ip and Lisk, 1994, el-Bayoumy et al., 1992). The 
chemopreventive index of p-XSC appeared to be four times that of selenite (Ip et al., 
1994). p-XSC appears to have intrinsic activity as well as activity derived from its 
metabolism to hydrogen selenide (Thompson et al., 1994, Ip and Lisk, 1994, el-
Bayoumy et al., 1993).
SDG
The variable efficacy of selenite in vitro is not seen with SDG. Fleming et al found 50 
M selenite to produce only 20% reduction in viability after 3-day exposure 
experiments compared to 100% for just 5 M of SDG (Fleming et al., 2001). They went 
on to confirm the metabolism of selenite to SDG in the presence of glutathione 
(Fleming et al., 2001). Indeed SDG can be produced within the cell by the reaction of 
selenite or selenodioxide with glutathione. SDG is reduced to the selenopersulphide 
anion and then hydrogen selenide with the generation of superoxide by redox cycling 
(Spallholz, 1994).
Lanfear et al demonstrated the in vitro potency of SDG when they compared the effect 
of different Se compounds upon cell number after 3-day treatment of the mouse 
erythroleukaemia cell-line MEL and the ovarian carcinoma cell-line A2780. From these 
results it is evident that SDG was ten times more potent than selenite, 
dimethylselenoxide and MSC. The latter two Se compounds had widely different 
efficacies in the two cell-lines. MEL cells were resistant to MSC but sensitive to 
dimethylselenoxide, whilst A2780 cells were sensitive to MSC but resistant to 
dimethylselenoxide (Lanfear et al., 1994). Morphologically the changes induced by 
SDG in MEL resemble those of anti-cancer agents such as cisplatin and etoposide 
(Lanfear et al., 1994). The percentage of apoptotic cells increased from 1% in no 
treatment controls to ~10% following 6 hours treatment of MEL cells with 3 M of 
SDG (Lanfear et al., 1994). SDG was chosen for investigation because of its superior in 
vitro efficacy compared to selenite.
Selenomethionine
As the majority of Se in selenised yeast is in the form of selenomethionine (85%) and is 
more bioavailable than inorganic forms such as sodium selenite, animal and in vitro 
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investigation of selenomethionine has been pursued. In nude mice topical 
selenomethionine alone and combined with vitamin E provided protection from 
ultraviolet light-induced skin damage (Burke et al., 2003). When given to elderly dogs 
for 7 months, selenomethionine reduced the DNA-damage detectable in peripheral 
blood lymphocytes and increased the percentage of apoptotic prostate epithelial cells 
(Waters et al., 2003). Furthermore, selenomethionine at 3 ppm proved chemopreventive 
in the rat DMBA mammary carcinoma model (Ip, 1988). In vitro the 3-day cell 
proliferation IC50’s (assessed by crystal violet) for selenomethionine were 1, 70 and 90 
M respectively for LNCaP, PC-3 and DU145 human prostate cancer cell-lines (Menter
et al., 2000) and ranged from 30-130 M in a panel of lymphoma, leukaemia and 
hepatoma cell-lines (Kajander et al., 1990). Selenomethionine is principally 
metabolised in the liver by -lyase to a monomethylated intermediate for the expression 
of its anticancer activity and epithelial tissues typically retain a low capacity to generate 
a mono-methylated Se-metabolite from selenomethionine (Ip, 1998). Consequently 
concentrations of selenomethionine that are 20 - 100 times above those needed to meet 
physiological requirements have been used in many cultured cells, including 
lymphocytes. For this reason selenomethionine was not selected as the methylselenol 
pool member for the in vitro experiments.
Se-Methylselenocysteine (MSC)
MSC is a water-soluble organic form of Se that is naturally found in selenium-enriched 
plants, such as broccoli and garlic. It is converted to methylselenol in vivo, an event 
considered critical for its chemopreventive properties (Foster et al., 1986). In a rat 
mammary carcinogenesis model, 2 ppm Se supplementation as MSC produced a 50% 
reduction in tumour formation (EC50 tumour yield), a dose 10-fold higher than required 
for restoration of seleno-enzyme function (Ip et al., 1991). As with selenomethionine, 
the metabolism of MSC requires the action of -lyase, an enzyme present in the liver, 
kidney, intestine and mammary glands but frequently absent in malignant cells (Ip et 
al., 1999). As a consequence, MSC is less potent than selenite in cell culture 
experiments, causing less growth inhibition and cell death (Ip, 1998). The cell death 
seen is largely apoptotic in contrast to the necrotic cell death of selenite, without the 
DNA breaks seen with selenite. The dependence upon -lyase activity for MSC to have 
efficacy in vitro was demonstrated by Dong et al, where a concentration of 200 M 
MSC and 72 hours exposure was required before even a modest effect upon cell number 
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was seen in MCF10AT1, a human premalignant mammary epithelial cell-line, whilst 
just 2.5 M of MSA induced a 70% reduction in cell number by 48 hours of treatment 
(Dong et al., 2002). Because malignant cells contain little -lyase, MSC was not chosen 
for in vitro study.
MSA
Methylselenol is considered to be the dominant in vivo chemopreventive metabolite of 
Se (Sinha et al., 2001). The production of methylselenol from MSC and 
selenomethionine is believed to underlie much of the chemopreventive effects of Se 
supplementation in animal models  (Ip et al., 2000). MSA is a simplified form of MSC, 
lacking the amino acid moiety of MSC which -lyase catalyses the cleavage of to 
produce methylselenol. Methylselenol is therefore formed intracellularly from MSA by 
facile reduction without the need for -lyase. This facile reduction is anticipated to be 
both non-enzymatic by reaction with thiols to produce methylselenenylsulphide and 
then methylselenol, and enzymatic where the glutathione derived thiol intermediary 
CH3Se-SG would be reduced by glutathione reductase in the presence of NADPH to 
CH3SeH (Ganther and Lawrence, 1997). Thus MSA is a -lyase-independent synthetic 
precursor of methylselenol, merely requiring the presence of NADPH and glutathione 
for methylselenol to be generated in vitro in cells lacking -lyase (Ip et al., 2000). In 
vitro, MSA acts more rapidly and more potently upon cell number (assessed using 
crystal violet staining), at one-tenth the concentration of MSC (Ip et al., 2000). After 24 
hours exposure to 5 M MSA the cell number reduced to 44% and 46% relative to no 
treatment controls in the mouse mammary epithelial cell-lines TM2H and TM12 
respectively. In comparison, 24-hour exposure to 50 M of MSC marginally decreased 
the cell number of TM2H and TM12 to 97% and 84% respectively, relative to no 
treatment controls. Unlike selenite, MSA is not genotoxic and can induce apoptosis in 
TP53 null cells as well, as TP53 wild type cells (Ip et al., 2000).
Therefore, on the basis of the ability of MSA to overcome the dependence on -lyase to 
produce monomethylated Se metabolites, MSA was chosen as the methylselenol pool 
member for the in vitro research described below.
4.3 Methods
The collection of human DLBCL cell-lines (SUD4, CRL, DoHH2 and DHL4) and 
primary lymphoma samples were cultured and used for 3-day and 2-day drug exposure 
experiments as described in Chapter 2. I performed this work with help and support, 
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particularly with the primary cell culture experiments, from Lenushka Maharaj. Each 
experiment was performed on at least three separate occasions unless stated. Cell count 
and viability were assessed by trypan blue exclusion assay as described in Chapter 2. 
For each cell-line the EC50 was calculated using the non-linear regression sigmoidal 
concentration–response model according to the GraphPad prism software (as described 
in Chapter 2.3.2). I assessed cell cycle phase distribution by FACS scanning of PI 
stained cells. Sandra Strauss looked for evidence of caspase-8, caspase-9 and PARP 
cleavage by western blotting following cell-line exposure to SDG and MSA. Jackie 
Perrie carried out FACS analysis of PI and annexin V stained cells to confirm the 
induction of apoptosis following exposure of cells to SDG and MSA. The production of 
ROS by the DLBCL cell-lines was assessed using DCF-DA, which generates a 
fluorescent product in the presence of ROS by Jackie Perrie. The established positive 
control, 25 M H2O2, was used in each experiment. To assess the importance of ROS 
generation to the cytotoxicity of SDG and MSA, the free-radical scavenger and 
glutathione precursor N-acetyl cysteine (NAC) was employed. Lenushka Maharaj 
undertook the NAC exposure experiments.
4.4 Results
4.4.1 Cell Count and Viability in DLBCL Cell-lines after 3-day exposure to 
SDG
Cell count and viability of the DLBCL cell-lines SUD4, CRL, DoHH2 and DHL4 
following 3-day exposure to SDG are illustrated in Figures 4.1 and 4.2. The EC50s are 
displayed in Table 4.1 and the raw data for all four cell-lines in Appendix Tables A4.1 
through A4.8. All four cell-lines were sensitive to SDG with very steep concentration-
response curves for both cell count and viability. The concentration-response curves 
were steeper for SDG than MSA, particularly for SUD4 and DoHH2 where the sigmoid 
factor was –8.3 and –16.2 for SUD4 and DoHH2 SDG cell count compared to –2.5 and 
–1.9 for SUD4 and DoHH2 MSA cell count respectively; and –8.4 and –10.1 for SUD4 
and DoHH2 SDG viability compared to –3.5 and –1.9 for SUD4 and DoHH2 MSA 
viability respectively. Consequently, although a number of drug concentrations were 
investigated across a relatively small range, it was difficult to obtain data points lying 
between the 20 % and the 80% cell number and viability effects. This is indicative of a 
trigger concentration above which, the effect was near maximal.
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In summary SDG proved cytostatic and cytotoxic in the three TP53 mutated/null cell-
lines (SUD4, CRL, and DHL4) and the TP53 heterozygous wild type/null DoHH2. This 
is a novel finding, as SDG has not previously been studied in human DLBCL cell-lines.
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Figure 4.1 Cell-line Cell Count after 3-day exposure to SDG
After 3-day exposure to SDG the cell count of the cell-lines was assessed by trypan blue exclusion assay. 
The mean cell count (n = 4) is shown as a percentage relative to the no treatment control cells for each 
experiment. A concentration-response curve has been fitted using non-linear regression analysis. Error 
bars represent the standard deviation.
A = SUD4 B = CRL C = DoHH2 D = DHL4
SDG = selenodiglutathione
A
B
C
D
SUD4
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Figure 4.2 Cell-line Viability after 3-day exposure to SDG
After 3-day exposure to SDG the viability of the cell-lines was assessed by trypan blue exclusion assay. 
The mean viability (n = 4) is shown as a percentage relative to the no treatment control cells for each 
experiment. A concentration-response curve has been fitted using non-linear regression analysis. Error 
bars represent the standard deviation.
A = SUD4 B = CRL C = DoHH2 D = DHL4
SDG = selenodiglutathione.
A
B
C
D
DB
SUD4
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SDG
Cell Count
EC50
M
95% CI M sdfsfh
SDG
Viability
EC50
M
95% CI M
SUD4 3.5 3.3 to 3.7 SUD4 4.4 4.3 to 4.5
CRL 6.9 6.3 to 7.5 CRL 9.0 8.5 to 9.6
DoHH2 4.1 3.3 to 5.1 DoHH2 4.2 4.0 to 4.4
DHL4 5.5 4.2 to 7.4 DHL4 6.8 6.3 to 7.3
MSA
Cell Count
EC50
M
95% CI M
MSA
Viability
EC50
M
95% CI M
SUD4 5.9 5.1 to 6.8 SUD4 10.2 9.7 to 10.7
CRL 4.9 4.6 to 5.1 CRL 9.2 8.7 to 9.7
DoHH2 1.0 0.9 to 1.2 DoHH2 1.9 1.7 to 2.2
DHL4 2.4 2.0 to 2.9 DHL4 166 143 to 193
Table 4.1 EC50s for SDG and MSA in DLBCL Cell-lines The 3-day EC50 for cell count 
and viability for SDG and MSA in the cell-lines was calculated from the trypan blue exclusion assay data 
from a minimum of three experiments using GraphPad prism software. The 95% confidence interval is 
given.
SDG = selenodiglutathione, MSA = methylseleninic acid and CI = Confidence Interval
4.4.2 Cell Count and Viability in DLBCL Cell-lines after 3-day exposure to 
MSA
MSA caused cytostasis in the low micromolar range in all four cell-lines. In terms of 
cytotoxicity DoHH2 was more sensitive than SUD4 and CRL with 3-day EC50s for 
viability also in the low micromolar range. DHL4, however, was much less sensitive to 
the cytotoxic effects of MSA, with a 3-day viability EC50 of 166 M. Low concentration 
MSA did not cause a potentiation of cell number in any of the four cell-lines. Cell count 
and viability of the DLBCL cell-lines SUD4, CRL, DoHH2 and DHL4 following 3-day 
exposure to SDG are illustrated in Figures 4.3 and 4.4, the EC50s are displayed in Table 
4.1 and the raw data for all four cell-lines in Appendix Tables A4.9 through A4.16.
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Figure 4.3 Cell-line Cell Count after 3-day exposure to MSA
After 3-day exposure to MSA the cell count of the cell-lines was assessed by trypan blue exclusion assay. 
The mean cell count (n = 4) is shown as a percentage relative to the no treatment control cells for each 
experiment. A concentration-response curve has been fitted using non-linear regression analysis. Error 
bars represent the standard deviation.
A = SUD4 B = CRL C = DoHH2 D = DHL4
MSA = methylseleninic acid
A
B
C
D
SUD4
DB
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Figure 4.4 Cell-line Viability after 3-day exposure to MSA
After 3-day exposure to MSA the viability of the cell-lines was assessed by trypan blue exclusion assay. 
The mean viability (n = 4) is shown as a percentage relative to the no treatment control cells for each 
experiment. A concentration-response curve has been fitted using non-linear regression analysis. Error 
bars represent the standard deviation. 
A = SUD4 B = CRL C = DoHH2 D = DHL4
MSA = methylseleninic.
A
B
C
D
B D
SUD4
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4.4.3 Cell Count and Viability after 2-day Exposure to SDG in Primary Cell 
Cultures
SDG caused a concentration-dependent decrease in percentage cell count and viability 
following 2-day exposure to the primary NHL tumours and the pooled normal B-cell 
sample, as illustrated in Figures 4.5 and 4.6 and the EC50s in Table 4.2. The raw data are 
displayed in Appendix Tables A4.17 through A4.26. The effect of SDG on cell count 
was variable with one of the two MCLs exhibiting sensitivity (03), the CLL/SLL (02) 
and the other MCL (04) showing relative sensitivity whilst the FL (01) and particularly 
the pooled normal B-cell sample were much less sensitive. The cytotoxic effect of SDG 
was more uniform. All four primary tumours had a similar 2-day EC50 that ranged 
between 15 and 28 M. The viability 2-day EC50 for the pooled normal B-cell sample 
was considerably higher than that of the primary tumours at 109 M. This result 
suggests that a therapeutic index may exist between malignant and normal lymphocytes 
for SDG in vivo. One surprising finding was that although SDG was not obviously 
stimulatory in terms of cell number at low concentration, the EC50s for cell count were 
higher than the EC50s for viability in 01, 02, 04 and the pooled normal B-cell sample.
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Figure 4.5 Cell Count of Primary Cell Cultures after 2-day exposure to SDG
After 2-day exposure to SDG the cell count of the primary cultures was assessed by trypan blue exclusion 
assay. The mean cell counts (n = 6-18*) are shown relative to that of the no treatment control cells. A 
concentration-response curve has been fitted using non-linear regression analysis. Error bars represent the 
standard deviation. SDG = selenodiglutathione
* additional concentrations were tested for 03 to define better the EC50s due to the very steep 
concentration-response curve seen with SDG
A = 01 B = 02 C = 03        D = 04 E = Pooled normal 
B-cell sample
B
C
A D
E
Normal
B-cell 
Sample
   n = 6
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Figure 4.6 Viability of Primary Cell Cultures after 2-day exposure to SDG
After 2-day exposure to SDG the viability of the primary cultures was assessed by trypan blue exclusion 
assay. The mean viabilities (n = 6-18*) are shown relative to that of the no treatment control cells. Error 
bars represent the standard deviation. SDG = selenodiglutathione
01: Follicular lymphoma 02: small lymphocytic lymphoma
03: mantle cell lymphoma 04: mantle cell lymphoma
Pooled normal B-cell sample
* Additional concentrations were tested for 03 to define better the EC50s due to the very steep 
concentration-response curve seen with SDG
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SDG Cell Count EC50 M 95% CIM sssh SDG Viability EC50 M 95% CIM
01 170 100 to 300 01 18 11 to 30
02 47 36 to 61 02 28 22 to 35
03 12 10 to 14 03 15 12 to 20
04 39 31 to 49 04 21 11 to 43
Normal B-cell
Sample 290 150 to 550
Normal B-cell
Sample 110 61 to 200
MSA Cell 
Count EC50 M 95% CIM MSA Viability EC50 M 95% CIM
01 85 41 to 180 01 100 88 to 120
02 23 7.1 to 78 02 68 57 to 82
03 130 73 to 240 03 300 150 to 580
04 46 23 to 94 04 39 26 to 60
Normal B-cell
Sample 880 240 to 3200
Normal B-cell
Sample 1070 480 to 2400
Table 4.2 EC50s for SDG and MSA in NHL Primary Cell Cultures
The 2-day EC50 for cell count and viability for SDG and MSA in the primary culture samples was 
calculated from the trypan blue exclusion assay data using GraphPad prism software. The 95% 
confidence interval is given. SDG = selenodiglutathione, MSA = methylseleninic acid and CI = 
confidence interval
4.4.4 Cell Count and Viability after 2-day Exposure to MSA in Primary Cell 
Cultures
MSA proved to be less efficacious in the primary tumours than in the NHL cell-lines 
(Figures 4.7 and 4.8, EC50s in Table 4.2 and raw data in Appendix Tables A4.27 
through A4.36.). Two primary tumours, 01 (FL) and 03 (MCL) were poorly sensitive to 
both the cytostatic and cytotoxic effects of MSA, 02 (CLL/SLL) displayed relative 
cytostatic sensitivity with a 2-day cell count EC50 of 23 M but was less sensitive to the 
cytotoxic actions of MSA with a 2-day viability EC50 of 68 M. The final primary 
tumour 04 (MCL) exhibited relative cytostatic and cytotoxic sensitivity but at a level of 
MSA not achievable in vivo (2-day cell count and viability EC50s of 46 and 39 M 
respectively). Of concern, MSA stimulated proliferation at low concentration in the two 
resistant primary tumours (01 and 03), which raises the possibility of a similar effect in 
vivo. In contrast, one encouraging observation was that the pooled normal B-cell sample 
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was resistant to MSA in terms of both 2-day cell count and viability EC50s, which were 
878 and 1071 M respectively.
Figure 4.7 Cell Count of Primary Cell Cultures after 2-day exposure to MSA
After 2-day exposure to MSA the cell count of the primary cultures was assessed by trypan blue 
exclusion assay. The mean cell counts (n = 6) are shown relative to that of the no treatment control cells. 
A concentration-response curve has been fitted using non-linear regression analysis. Error bars represent 
the standard deviation. MSA = methylseleninic acid
A = 01 B = 02 C = 03        D = 04 E = Pooled normal 
B-cell sample
B
C
A D
E
Normal
B-cell 
Sample
   n = 6
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Figure 4.8 Viability of Primary Cell Cultures after 2-day exposure to MSA
After 2-day exposure to MSA the viability of the primary cultures was assessed by trypan blue exclusion 
assay. The mean viabilities (n = 6) are shown relative to that of the no treatment control cells. Error bars 
represent the standard deviation. MSA = methylseleninic acid
01: Follicular lymphoma 02: small lymphocytic lymphoma
03: mantle cell lymphoma 04: mantle cell lymphoma
Pooled normal B-cell sample
Methylseleninic Acid M
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4.4.5 Effect of SDG and MSA on Cell Cycle Distribution
The effects of SDG and MSA on cell cycle distribution and any induction of a sub-G1 
(apoptotic) fraction were assessed by flow cytometry of PI stained cells in all four cell-
lines. The data revealed that increasing concentrations of SDG and MSA caused an 
emptying of the G1 fraction without an obvious phase-specific cell cycle block (Figures 
4.9 and 4.10 for MSA; Figures 4.11 and 4.12 for SDG; and raw data in Appendix 
Tables A4.37 and A4.38).
Figure 4.9 Cell Cycle Distribution Changes after 3-day Exposure of SUD4 and 
CRL to MSA Changes in cell cycle distribution were assessed by FACS analysis following propidium 
iodide staining. Cells were continuously exposed to increasing concentrations of MSA for three days. No 
clear arrest in a specific phase of the cell cycle was seen in either cell-line. Apoptotic cells (sub-G1, 
where low molecular weight, fragmented DNA is extracted during cell fixation) were apparent in SUD4 
(A) AND CRL (B) cells.
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SDG and MSA produced a concentration-dependent increase in the sub-G1 population 
in all four cell-lines, with the exception of MSA and DHL4 where the apoptotic fraction 
barely changed compared to untreated cells.
Figure 4.10 Cell Cycle Distribution Changes after 3-day Exposure of DoHH2 and 
DHL4 to MSA Changes in cell cycle distribution were assessed by FACS analysis following 
propidium iodide staining. Cells were continuously exposed to increasing concentrations of MSA for 
three days. No clear arrest in a specific phase of the cell cycle was seen in either cell-line. Apoptotic cells 
(sub-G1) were apparent in the sensitive DoHH2 (A) cells but not so in the markedly less sensitive DHL4 
(B) cells.
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Figure 4.11 Cell Cycle Distribution Changes after 3-day Exposure of SUD4 and 
CRL to SDG Changes in cell cycle distribution were assessed by FACS analysis following propidium 
iodide staining. Cells were continuously exposed to increasing concentrations of SDG for three days. No 
clear arrest in a specific phase of the cell cycle was seen in either cell-line. Apoptotic cells (sub-G1) were 
apparent in both SUD4 (A) and CRL (B) cells.
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Figure 4.12 Cell Cycle Distribution Changes after 3-day Exposure of DoHH2 and 
DLH4 to SDG Changes in cell cycle distribution were assessed by FACS analysis following 
propidium iodide staining. Cells were continuously exposed to increasing concentrations of SDG for 
three days. No clear arrest in a specific phase of the cell cycle was seen in either cell-line. Apoptotic cells 
(sub-G1) were apparent in DoHH2 (A) and DHL4 (B) cells.
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The effect of SDG on cell cycle phase distribution and induction of a sub-G1 population 
of cells was studied in two of the primary lymphoma samples, (03) and (04). In both, 
apoptosis was induced (as shown by the increase in sub-G1 cell fraction) without arrest 
during a specific phase of the cell cycle (Figure 4.13 and Appendix Table A4.39).
Figure 4.13 Cell Cycle Distribution Changes for Primary MCLs (03) and (04) after 
2-day Exposure to SDG Changes in cell cycle distribution were assessed by FACS analysis 
following propidium iodide staining. Cells were continuously exposed to increasing concentrations of 
SDG for two days. No clear arrest in a specific phase of the cell cycle was seen in either primary MCL 
sample. Apoptotic cells (sub-G1) were apparent in both (03) and (04).
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Investigation of the effect of 2-day MSA and SDG exposure on cell cycle phase 
distribution and induction of a sub-G1 fraction was undertaken in the pooled normal B-
cell sample. Neither MSA nor SDG produced a cell cycle arrest or significant apoptosis 
induction (as shown by the lack of increase in sub-G1 cell fraction) (Figure 4.14 and 
Appendix Table A4.39).
Figure 4.14 Cell Cycle Distribution Changes after 2-day exposure of the Pooled 
Normal B-cell Sample to SDG Changes in cell cycle distribution were assessed by FACS analysis 
following propidium iodide staining. Cells were continuously exposed to increasing concentrations of 
MSA  (A) or SDG (B) for two days. No clear arrest in a specific phase of the cell cycle was seen. 
Apoptotic cells (sub-G1) were barely apparent for MSA (A) or SDG (B).
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4.4.6 Apoptotic Cell Death Induction by SDG and MSA
FACS analysis of PI- and annexin V-stained cells, treated for three days at the viability 
EC50 for SDG or MSA, was performed to explore the nature of the cell death induced by 
both agents. A shift in cells from the lower left to the lower right quadrant was followed 
by a shift to the upper right quadrant. This transition from staining by annexin V to 
staining by both annexin V and PI indicates that cell death was by apoptosis, as 
illustrated in Figure 4.15.
Figure 4.15 Annexin V and Propidium Iodide Staining after 3-day Exposures to 
the cytotoxic EC50 concentrations of SDG or MSA
Dual labelling with propidium iodide (FL3-H) and annexin V (FL1-H) in cells treated with the positive 
control staurosporine (24 hours), or the cytotoxic EC50 concentrations of SDG or MSA for 3 days 
(percentage of cells in each quadrant). Cell death with SDG and MSA was associated with increased 
signal from both labels, confirming cell death by apoptosis.
A = DHL4 B = SUD4 SDG = selenodiglutathione MSA = methylseleninic acid
A B
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Confirmation and elaboration of this finding for MSA and SDG was produced by the 
western blot results for caspase-8, caspase-9 and PARP, illustrated in Figures 4.16 and 
4.17. Both SDG and MSA led to cleavage of full length PARP (116 kDa) to its 85 kDa 
product and to smaller products as the concentrations of MSA and SDG were increased 
further.
Figure 4.16 Effect of 3-day Exposure to SDG EC50 Viability on PARP, Caspase-8 
and Caspase-9 Cleavage in the DLBCL Cell-lines The actual percentage viability relative to 
untreated cells for each of the cell-lines in the experiment is given below the respective lane.
- = untreated controls; + = cell-line exposed to EC50 viability SDG;  actin = positive control
Via
bili
93 45 99 29 90 15 93 57
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Figure 4.17 Effect of 3-day Exposure to MSA EC50 Viability on PARP, Caspase-8 
and Caspase-9 Cleavage in the DLBCL Cell-lines The actual percentage viability relative to 
untreated cells for each of the cell-lines in the experiment is given below the respective lane.
- = untreated controls; + = cell-line exposed to EC50 viability SDG;  actin = positive control
PARP cleavage was associated with cleavage of the full length caspase-8 (56 kDa) and 
caspase-9 (46.5 kDa) for cells incubated with SDG or MSA. These results suggest that 
SDG and MSA induced apoptosis through activation of both the intrinsic and the 
extrinsic apoptotic pathways leading to caspase-3 activation and PARP cleavage. The 
only exception was DHL4 following exposure to SDG, where only cleavage of caspase-
8, and not caspase-9, was demonstrated. 
Via
bili
ty
93 50 99 14 90 50 93 44
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4.4.7 Evidence of ROS generation by SDG and MSA
The production of ROS by the DLBCL cell-lines was assessed using DCF-DA, which 
generates a fluorescent product in the presence of ROS. The generation of ROS varied 
between the cell-lines following 30-minute exposure to 25 µM H2O2. Compared to no 
treatment controls, H202 did not result in a significant change in DCF-DA fluorescence 
in DoHH2 and DHL4, whilst ROS increased significantly in CRL and SUD4 (Figure 
4.18 and Appendix Table A4.40). In DHL4, CRL and SUD4 30-minute exposure to the 
3-day viability EC50 concentration of SDG generated significant increases in ROS 
compared with no treatment controls and greater than the H2O2 positive control. For 
MSA, 30-minute exposure to the respective 3-day viability EC50 concentration did not 
produce ROS in CRL, DoHH2 or DHL4 and showed only a minor but significant rise in 
SUD4 to a level less than that achieved using 25 M H2O2.
Next the effect of ROS on the cytotoxic activity of SDG or MSA was investigated by 3-
day incubation of SUD4, CRL, DoHH2 and DHL4 with the glutathione precursor NAC 
alone or with the 3-day viability EC50 concentration of SDG or MSA in the presence or 
absence of NAC, as depicted in Figure 4.19 and Appendix Table A4.41. As expected, 
NAC alone had no effect on cell viability and NAC added to MSA had no effect on the 
activity of MSA in any of the cell-lines studied. Similarly, in DoHH2, in which SDG 
did not generate ROS, the addition of NAC had no effect on the activity of SDG. In 
contrast, the cytotoxic activity of SDG was dramatically reduced by NAC in DHL4 and 
SUD4 cells, in which SDG resulted in significant increases in ROS. Indeed in SUD4, 
where the EC50 viability concentration of SDG resulted in a 450% increase in ROS 
compared to no treatment controls (Figure 4.18), 30-minute co-exposure with NAC 
almost abolished the cell kill activity of SDG (Figure 4.19). In CRL, where exposure to 
H202 or SDG produced ROS, the cell-kill activity of SDG was unaffected by co-
incubation of CRL with NAC and SDG. This surprising result confirms that SDG can 
produce its in vitro cytotoxicity via ROS dependent and independent mechanisms.
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Figure 4.18 ROS Generation after 30-minute Exposures to the Cytotoxic EC50 
Concentrations of SDG or MSA The generation of ROS in lymphoma cells relative to control 
(0.75% DMSO) after exposure to selenium compounds for 30 minutes at the 3-day cytotoxic EC50 
concentration of SDG or MSA. 25 M H2O2 was used as the positive control.
SDG = selenodiglutathione MSA = methylseleninic acid
* significantly different compare to no treatment controls # SDG significantly different to MSA
            = DoHH2 = DHL4 = CRL = SUD4
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Figure 4.19 Effect of N-acetyl cysteine on the Cytotoxicity of SDG and MSA after 
3-day Exposures to the cytotoxic EC50 Concentrations of SDG or MSA Cells were 
continuously co-exposed to EC50 viability concentrations of SDG or MSA ± N-acetyl cysteine (NAC) or 
N-acetyl cysteine alone. SDG concentration: SUD4, CRL, DoHH2, DHL4 and cells = 4.0, 9.0, 4.2 and 
7.0 µM, respectively; MSA concentration SUD4, CRL DoHH2 and DHL4 cells 10.0, 9.0, 1.9 and 166  
µM, respectively, N-acetyl cysteine 2.5 µM throughout. * P = 0.0008 and 0.0053 respectively for SUD4 
and DHL4 SDG vs. SDG + NAC.
A = SUD4 B = CRL C = DoHH2 D = DHL4
SDG = selenodiglutathione MSA = methylseleninic acid NAC = N-acetyl cysteine
4.5 Discussion
4.5.1 Review of Experiment findings in Comparison with Published Data
Cytostatic and Cytotoxic Activity of SDG and MSA
Following the observation that presentation serum selenium was an independent 
predictor of response to treatment and OS in patients with aggressive NHL, the activity 
of specific selenium compounds has now been studied for the first time in a panel of 
DLBCL cell-lines and in a primary lymphoma culture system. Dietary forms of Se, such 
as selenomethionine, require activation by ß-lyase, typically in the liver, so have little in 
vitro activity. Activated selenium species were therefore used in these studies, namely 
MSA, which is rapidly converted to the highly reactive methylselenol, and SDG (an 
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active metabolite of the naturally occurring sodium selenite), which is activated further 
to hydrogen selenide with the generation of ROS.
Both SDG and MSA demonstrated cytostatic and cytotoxic activity in DLBCL cell-
lines and NHL primary tumours. Relative cytotoxicity insensitivity was only 
encountered for MSA in DHL4. Both SDG and MSA induced cytostasis and 
cytotoxicity in a concentration and time-dependent manner in the lymphoma cell-lines 
studied. The MSA cell count EC50 (1–7 µM) or percentage viability EC50 (2–10 µM; 
DHL4 166 µM) is in the range reported by others using human cancer cell-lines of 
epithelial origin [15–17], and the activity of SDG is in keeping with that found in 
primary cultures of oral carcinomas by Ghose et al (Ghose et al., 2001). It is noteworthy 
that the concentration effect curves were much steeper for SDG than for MSA, most 
notably so in DoHH2 and SUD4 cells (sigmoid factor for DoHH2 and SUD4 cells –16.2 
and –8.3, respectively, for cell number and –10.1 and –8.4, respectively, for percentage 
viability). This suggests a threshold concentration, above which the effect increases 
dramatically.
SDG and MSA Activity is Independent of p53 Status
The activity of SDG and MSA proved independent of TP53 status in the cell-lines 
studied, as three of the four (SUD4, DHL4 and CRL) are TP53 homozygous mutated 
and produce non-functional p53 and the fourth cell-line (DoHH2) is TP53 heterozygous 
((Strauss et al., 2007); Richard Camplejohn, personal communication). The results set 
out in this Chapter confirm previous reports that although SDG induces functional p53, 
this is in response to DNA damage and is not required for the induction of apoptosis 
(Lanfear et al., 1994).
Cell cycle effects of Se Compounds
Both drugs inhibited all phases of the cell cycle with an associated increase in the sub-
G1 (apoptotic) fraction and induced caspase dependent apoptosis. In terms of the effect 
of MSA upon cell cycle, Zhao et al found a similar effect to that described in this 
Chapter, where all phases of the cell cycle were retarded. Zhao et al went on to show 
that cell cycle promoters were inhibited and cell cycle inhibitors were enhanced in all 
phase of the cell cycle by MSA (Zhao et al., 2004). Similarly, in the human prostate 
cancer cell-line PC3, MSA retarded cell cycle progression at multiple transition points 
without changing the proportion of cells in different phases of the cell cycle (Dong et 
al., 2003). In contrast, in the premalignant human breast epithelial cell-lines 
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MCF10AT1 and MCF10AT3B MSA blocked cell cycle progression at the G0/G1 phase 
of the cell cycle (Dong et al., 2002).
There are no other reports beyond that presented here of the effect of SDG on the cell 
cycle progression/arrest. A single paper describes sodium selenite inducing an S-phase 
block in the human prostate cancer cell-line DU145 (Jiang et al., 2001).
ROS generation by SDG and MSA
ROS generation was critical to the cytotoxic activity of SDG in two out of the four cell-
lines examined but not for the activity of MSA. The ROS and NAC data detailed above 
also demonstrated that the cytotoxicity of SDG can be independent of ROS as the 
compound was active in DoHH2 cells in the absence ROS generation, and in the 
presence of NAC and in CRL, which generated ROS on exposure to SDG yet was still 
killed by SDG in the presence of NAC. The report in this Chapter of the antioxidant 
NAC, a precursor of glutathione, preventing the cytotoxic activity of SDG in DHL4 and 
SUD4 supports the results of Fleming et al, who found NAC blocked the activity of 
SDG and p-XSC in human oral cancer cells (Fleming et al., 2001). Similarly, the 
actions of p-XSC were blocked by NAC and the putative hydroxyl scavengers mannitol 
and pyrrolidine, confirming that the activity of p-XSC is mediated, in part at least, 
through the generation of superoxide (Fleming et al., 2001). In keeping with these 
results, others have shown ROS are produced by selenite and selenocystine treatment of 
breast cancer or hepatoma cells in vitro upon glutathione reduction (Yan and Spallholz, 
1993, Shen et al., 2002).
The production of ROS by SDG but not the positive control (H2O2) in DHL4 cells 
suggests the primary ROS generated in DHL4 by SDG is superoxide rather than 
hydrogen peroxide. Fleming et al found p-XSC generated superoxide; whilst SDG 
generated hydrogen peroxide in the oral cancers they studied (Fleming et al., 2001). 
Similarly, Jiang et al found that superoxide rather than hydrogen peroxide generation 
was critical for the cytostatic and cytotoxic actions of selenite in the DU145 prostate 
cancer cell-line (Jiang et al., 2001).
The findings detailed in this Chapter indicate that SDG exerts its antiproliferative and 
cytotoxic activity by ROS dependent and independent pathways. SDG can therefore act 
through both ROS dependent and independent mechanisms.
From the results given in this Chapter it is clear that the actions of MSA do not require 
the build up of ROS to induce cell death and that addition of NAC to MSA had no 
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effect on the cytotoxicity of MSA. In contrast, in the human hepatoma cell-line 
HepG(2) augmentation of intracellular glutathione by addition of NAC resulted in a 
significant increase in MSA induced apoptosis (Shen et al., 2002). Further investigation 
showed that intracellular glutathione was rapidly depleted by exposure of HepG(2) to 
MSA. In contrast, depletion of intracellular glutathione by addition of buthionine 
sufoximine caused a marked reduction in MSA-related cell death. It is clear that 
glutathione is involved in the metabolism of many methylated forms of Se to 
methylselenol as well as being of importance to the efficacy of hydrogen selenide pool 
members (Shen et al., 2002). These data, generated from a methylselenol pool member, 
also support the hypothesis that higher intracellular glutathione level present in many 
tumours compared to their equivalent normal tissues could account for part of the 
evident therapeutic index for Se compounds in animal studies (Shen et al., 2002).
Primary cell culture activity of SDG and MSA
The cytotoxic activity of SDG and MSA was also studied in primary lymphoma 
samples from patients who had received multiple previous lines of chemotherapy and in 
a pooled normal B-cell sample. All primary samples showed a concentration dependent 
loss of viability after a 2-day exposure to SDG or MSA, with the potentially genotoxic 
compound SDG showing slightly greater potency than MSA (EC50 values 15–28 µM 
compared to 39–300 µM respectively). Although only one pooled normal B-cell sample 
was studied, by virtue of it having come from multiple donors it provided a population 
estimate of the effect of the Se compounds on normal B-cells. It is noteworthy that the 
EC50 concentrations for both SDG and MSA were higher in this pooled normal B-cell 
sample than for the lymphoma samples (EC50 viability SDG 110 µM and MSA 1070 
µM). The primary cell culture results presented in this Chapter therefore raise the 
possibility of a therapeutic index existing for SDG and MSA in vivo by virtue of the 
relative resistance of pooled normal B-cell sample to both agents. This finding is 
supported by the primary cell cultures results of Fleming et al, who studied human 
normal oral mucosa and oral carcinomas (Ghose et al., 2001). This group found that 
SDG-induced apoptosis more readily in the malignant cells than their normal 
counterparts (Ghose et al., 2001). Wan et al also found a therapeutic index for p-XSC 
between normal and cancerous prostate cells in vitro (Wan et al., 2003). Taken together 
these results demonstrate the differential sensitivity of tumour cells and normal cells to 
SDG and p-XSC from the hydrogen selenide pool and MSA from the methylselenol 
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precursor pool, suggesting that these agents may be useful as cytotoxics in their own 
right or as chemotherapy adjuncts, potentiating the activity of established cytotoxics 
against malignant cells whilst protecting normal cells against cytotoxic damage.
Apoptotic Cell Death Induction by SDG and MSA
Contrary to the statements by Ip et al that SDG causes necrotic rather than apoptotic 
cell death(Ip, 1998), this Chapter details the occurrence of caspase-mediated apoptosis, 
confirmed by FACS analysis of PI/annexin V stained cells. Lanfear et al were also able 
to demonstrate apoptosis induction by SDG (Lanfear et al., 1994). In keeping with the 
findings stated in this Chapter, Jiang et al found that 5 M MSA caused caspase-3, -7, -
8, and -9 activation and PARP cleavage (Jiang et al., 2001). This group also failed to 
demonstrate selenite-induced caspase-dependent apoptosis but rather found DNA 
fragmentation associated with phosphorylation of JNK1/2 and p38/MAPK (Jiang et al., 
2001).
Cell Proliferation Promotion by SDG and MSA
One concern raised by some of the data detailed in this Chapter is that low 
concentration Se supplementation could in fact stimulate rather than inhibit malignant 
cell proliferation particularly in resistant cells. In DHL4, low concentration SDG 
increased the cell count compared to no treatment controls and in the primary tumour 
experiments, the 2-day cell count EC50s for SDG were paradoxically higher than the 2-
day viability EC50s in three of the four NHL primary tumours tested and the pooled 
normal B-cell sample and MSA increased the cell count of two of the four NHL 
primary tumours, although the 2-day cell count EC50s for MSA were all lower than the 
2-day viability EC50s. These results are not unique. In the gastric adenocarcinoma cell-
line SNU-1, cells responded to selenomethionine with a biphasic proliferative curve: 
enhanced incorporation of 3H-thymidine into DNA within a very narrow range of 
selenomethionine concentrations followed by decreased 3H-thymidine uptake at higher 
levels (Verma et al., 2004). The findings of Verma et al suggest that, at certain 
concentrations, selenomethionine induces mild oxidative stress that, in turn, stimulates 
DNA synthesis. From the 24-hour investigation of selenite, campthotecin and their 
combination upon the cervical carcinoma cell-line Hep-2 HeLa by Rudolf et al, it is 
clear that selenite at the lowest concentrations actually stimulated cell growth and 
slightly reduced cytotoxicity and proapoptotic effects of campthotecin (Rudolf et al., 
2004). Selenomethionine in the culture medium of three hepatoma cell-lines promoted 
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cell growth at subcytotoxic levels (1-20 M), but the growth of malignant lymphoid and 
myeloid cells was not stimulated (Kajander et al., 1990). MSA was found to mildly 
stimulate proliferation at 2.5 M before inhibiting proliferation at 5 M (Zu and Ip, 
2003). Therefore subtoxic concentrations of hydrogen selenide and methylselenol pool 
members can stimulate cell growth.
The repercussions of these observations as regards animal and human in vivo studies 
could be as follows:-
1) They may not hold true in vivo.
2) They could be true and beneficial, as any increased tumour cell cycling and 
proliferation could increase the tumour’s sensitivity to other cytotoxics and 
prevent chemoresistance – one of the hypotheses put forward in Chapter 3 to 
account for the discovered associations between serum Se and response and 
overall survival.
3) A serum threshold concentration of Se supplementation may need to be passed to 
guarantee cytotoxic single-agent activity in vitro.
4.5.2 Literature Review of the Gene Expression Changes Induced by Selenium 
Compounds
The Pre-Microarray Data
Beyond ROS generation, protein thiol oxidation appears to be an important means of 
hydrogen selenide pool members’ activity in vitro. Bjørnstedt et al showed that SDG is 
a highly efficient oxidant of NADPH and a substrate for mammalian TR, with the 
consequence of dramatic inhibition of Trx-dependent reduction of CDP (cytidine 5 -
diphosphate) to dCDP (deoxycytidine 5-diphosphate) by ribonucleotide reductase 
(Bjornstedt et al., 1992), and Kim et al demonstrated protein oxidised thiol cross-
linking capable of inducing apoptosis (Kim et al., 2003b). Therefore the ability of Se 
compounds to induce apoptosis is likely to be due, in part, to their oxidation of thiols, 
such as cysteine residues of proteins and enzymes in addition to the generation of 
superoxide in the presence of glutathione.
Selenite induced apoptosis in DU145 prostate cancer cells was associated with 
decreased expression of p27kip1 and p21WAF1 and increased phosphorylation of AKT, 
JNK-1, JNK-2 and p38 MAP kinase (Jiang et al., 2001). In keeping with these findings, 
Ghose et al found marked induction of Fas-ligand with both SDG and p-XSC, which in 
turn, correlated closely with the level of apoptosis seen and was associated with 
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activation of the JNK and MAPK stress kinase pathways (Ghose et al., 2001). Ghose et 
al speculate that the upstream regulator of JNK/p38 MAP kinases, apoptosis signal-
regulating kinase-1 is released from inhibition by reduced levels of Trx and glutathione 
due to their oxidation by SDG (Ghose et al., 2001). Phosphorylation of MAPK-1 and -3 
is also seen in a concentration-dependent manner with selenomethionine-induced 
growth arrest, and is associated with the consequent phosphorylation of histone H3 and 
p90RSK (Goulet et al., 2005). These results suggest that activation of the MAPK 
pathway is an important means of expression of activity for both hydrogen selenide and 
methylselenol pool members. An interesting discovery in the light of the SC-236 data 
described in Chapter 6 is that selenomethionine regulates COX-2 (cyclo-oxygenase-2) 
at the transcriptional level by modulating the activity of NFB (Cherukuri et al., 2005).
Recently redox modification of thiol/disulphide interchange in proteins by MSA was 
shown to produce protein unfolding in the endoplasmic reticulum (Zu et al., 2006). This 
process, known as the unfolded protein response, blocks general protein synthesis in 
order to reduce the burden of more unfolded proteins forming within the cell. 
Persistence of the unfolded protein response forces the endoplasmic reticulum to switch 
from attempting to keep the cell alive to triggering apoptotic cell death. In PC3 cells the 
unfolded protein response was rapidly initiated on exposure to MSA, resulting in 
increased expression of p21WAF1 in a p53-independent manner (PC3 cells are p53 null). 
Zu et al concluded that their findings support the hypothesis that the endoplasmic 
reticulum’s unfolded protein response is an important mechanism in mediating the 
anticancer activity of selenium (Zu et al., 2006).
Microarray Derived Effects of Se Compounds
Evidence of widespread effects of selenocompounds upon RNA synthesis first came to 
light nearly 30 years ago when selenite was found to cause a widespread reduction in 
RNA synthesis (Gruenwedel and Cruikshank, 1979). Since the advent of micro-array 
technology and genome-wide gene expression profiling six papers have investigated the 
effects of Se compounds using microarray technology: three papers describing in vitro
experiments using MSA, one paper detailing in vivo studies with p-XSC, one paper 
which compared in silico gene expression data generated from normal and malignant 
human prostate tissue, in vitro prostate cancer cell-line experiments with Se compounds 
and androgen stimulation, and one paper from a human intervention study where 
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normal oesophageal tissue pre- and post- 10-month supplementation with 
selenomethionine was gene expression profiled. Each paper will be reviewed in turn.
Investigation of the mRNA changes over the 48-hours of exposure induced by the 2-day 
cell count EC50 of MSA in the human prostate cancer cell-line PC3 revealed transcript 
variance of >2 and <0.5 in 2650 genes (20% of those present on the U95A Affymetrix 
chip) (Dong et al., 2003). Clustering analysis using the SOM algorithm produced 12 
clusters, defined by their different kinetic patterns of modulation by MSA. There were 
three early response clusters (at 12 hours), five intermediate response clusters (between 
24 and 32 hours) and four late clusters (after 36 hours). Only the analysis of the early 
response clusters was given. Multiple targets were affected by MSA in PC3 cells 
including induction of inhibitors of cell cycle progression (p19INK4d, p21WAF1, RB 
binding protein 1, GADD45, RAD9 and CHK2) and repression of promoters of cell 
cycling (cyclins A & E2, cdk-1, -2 & -4, MCM (minichromosome maintenance) -3, -5, -
6 & -7, thymidylate synthase, dihydrofolate reductase and PCNA). Few apoptosis-
related genes were affected at the 12-hour time point (caspase-9 and toll-like receptor-2 
were induced, and survivin was repressed). The gene expression of a host of 
transcription factors and signal transduction genes was affected (e.g. PKC (induced) 
and PI3-kinase (repressed) and several members of the MAPK cascade). There was a 
70% correlation between the array findings and western blotting results for the 
corresponding protein expression.
In the human breast cell-line MCF10AT1 exposure to 5 M MSA caused significant 
transcript changes at 6 and/or 12 hours in 30 genes out of around 200 on the membrane 
based array of cell cycle and apoptosis related genes (Dong et al., 2002). Expression of 
CDK-1, -2 & -4, cyclin A was decreased, whilst the expression of GADD153, MAPK-3
and c-JUN genes was increased.
The exposure of LNCaP, an androgen-sensitive human prostate cancer cell-line, to 3-30 
M MSA over the time course of 48 hours, induced significant concentration- and time-
dependent changes in the expression of 951 genes (Zhao et al., 2004). Transcript levels 
of many cell cycle-regulated genes changed in response to MSA, suggesting that MSA 
inhibited proliferation via multiple proteins (e.g. DNA replication initiation (CDC6, 
MCM2, and MCM6), DNA repair (PCNA), and cell cycle control (CDC25A and E2F1 -
expressed in G1/S phase), DNA replication (RRM1, RRM2, and TYMS - expressed in 
S phase), chromosome condensation and organisation (TOP2A and CENPA), mitotic 
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spindle checkpoint (CDC20 and BUB1B), and centrosome duplication (PLK and 
STK15 - expressed in G2 and M phase)). Consistent with these gene expression 
changes, cells accumulated at the G0/G1 phase of the cell cycle (as detected by flow 
cytometry). MSA also modulated expression of many androgen-regulated genes, 
suppressed androgen receptor expression at both mRNA and protein level, and 
decreased levels of prostate specific antigen secreted into the medium. Low 
concentrations of MSA also induced significant increases in transcript levels of phase II 
detoxification enzymes (Zhao et al., 2004). These results suggest that MSA may protect 
against prostate cancer by inhibiting cell proliferation, by modulating the expression of 
the androgen receptor and androgen receptor-regulated genes and by inducing 
carcinogen defences (Zhao et al., 2004).
Microarray analysis of the mammary adenocarcinomas formed in rats fed DMBA 
receiving a standard diet or one supplemented with 10 ppm pXSC revealed induction of 
specific phase II detoxifying enzymes including selenoprotein P and several glutathione 
S transferase forms (El-Bayoumy et al., 2003). Phase I P450 enzymes were 
significantly inhibited and the cell cycle genes cyclin-D1 and -D2 were downregulated 
(El-Bayoumy et al., 2003). One concern with these results is that the genes 
overexpressed in the adenocarcinomas that developed on a diet of 10 ppm p-XSC were 
not those that were critical to the significantly fewer tumours that formed in the 
supplemented rats compared to controls but rather were the genes whose expression led 
to resistance and development on p-XSC.
Using a custom-built ‘dot-blot’ array, the Roswell Park group studied the effect of MSA 
on genes transcripts in the LNCaP human prostate cancer cell-line (Zhang et al., 2005a). 
Zhang et al then compared the gene expression profiles obtained in silico with their own 
from experiments with MSA and the PC3 prostate cancer cell-line detailed above 
((Dong et al., 2003)) and those of others of gene signatures considered important to 
human prostate carcinogenesis and gene transcripts affected by androgen stimulation of 
prostate cancer cell-lines. They found that Se reverses the expression of genes
implicated in prostate carcinogenesis and counteracted the effect of androgen on the 
expression of androgen-regulated genes (Zhang et al., 2005a).
In the Limburg study the chemopreventive activity of selenomethionine was studied in 
asymptomatic adults with squamous dysplasia of the oesophagus in Linxian province, 
China (Limburg et al., 2005). As well as taking biopsies of the areas of dysplasia, 
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biopsies of adjacent normal tissue were taken pre- and post- the 10-month intervention 
with selenomethionine and/or placebo and celecoxib and/or placebo. From the 117 
subjects in the selenomethionine and placebo arms suitable paired samples of 
histologically confirmed normal mucosa taken from 29 individuals (11 individuals 
whose dysplasia regressed, 13 who had stable dysplasia, and five subjects whose 
dysplasia progressed) (Joshi et al., 2006). Microarray analysis was performed using 
Affymetrix HU 133A chips to search for genes associated with regression and 
progression of squamous dysplasia. Joshi et al discovered that the higher expression of 
20 genes in the normal oesophageal mucosa was associated with regression and the 
higher expression of 129 genes in the normal oesophageal mucosa was associated with 
progression in neighbouring squamous dysplasia samples. These 149 differentially 
expressed genes were categorised into known or probable functional categories using 
the Gene Ontology database. The top five categories included immune response (15 
genes), cell cycle (15 genes), metabolism (15 genes), calcium transport or calcium ion 
activity (10 genes) and regulation of transcription (9 genes). Using the EASE software 
package, which aids discovery of biological themes within gene lists, only the 15 genes 
associated with the immune response pathway were overrepresented compared to the 
total number of immune response genes on the microarray chip (P < 0.01). Of these 15 
genes, those associated with dysplasia regression had functions associated with 
upregulation of the immune response, including antigen presentation (HLA-DPA1, 
HLA-DRA, and HLA-DQB1), protection of T cells from cell death (CD58), and T-cell 
activation (FCERA1). In contrast, the genes associated with progression of oesophageal 
squamous dysplasia were involved in immunosuppression (CNR2) and NFATC4), acute 
phase response and inflammation (CRP, ORMS, SERPINA7 and SERPINA1), or a 
decrease in the level of B- and T-cells (NFRKB) (Joshi et al., 2006).
4.5.3 Should Se Compounds be used as Adjuvant or Maintenance Treatment?
In vitro Data
A recurrent and critical question and concern in research is whether in vitro effects will 
be reproduced in vivo. Where in vitro and in vivo effects appear comparable the issue is 
whether the results will be the same in humans. The potential for additive or synergistic 
interactions between Se compounds and cytotoxics, through preferential increase in 
oxidative cell stress in tumours, is supported by work of Frenkel and Caffrey. They 
discovered the potential for Se compounds to prevent chemoresistance to low-level 
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continuous cytotoxic agent exposure, the principal reason for treatment failure in 
DLBCL (Caffrey and Frenkel, 2000). Additionally, moderate and higher concentrations 
of selenite enhanced the cytotoxic and proapoptotic effects of campthotecin, changing 
cell death from apoptosis into more necrosis-like cell death (Rudolf et al., 2004).
In vivo Studies
In athymic nude mice MSC and selenomethionine reduced the toxicity and improved 
the anti-tumour activity of several anticancer drugs against human carcinoma xenografts 
(Cao et al., 2004). By starting the Se compounds for a month seven days before 
chemotherapy, the maximum tolerated dose of irinotecan, a topoisomerase I poison, 
could be quadrupled and resistant cell-line xenografts rendered chemosensitive with a 
high cure rate. The Se compounds therefore selectively protected normal tissues from 
irinotecan toxicity, whilst sensitising the malignant cells to cytotoxics.
Human Trials
The same group has gone on to conduct several human phase I studies of high-dose oral 
selenomethionine supplementation prior to irinotecan treatment in a patients with 
chemoresistant/refractory cancer (Fakih et al., 2006, Fakih et al., 2008). The results are 
contrary to those of the nude mouse model experiments summarised above. No 
selective protective effect of Se supplementation for normal tissues against the side-
effects of irinotecan were observed, even at 7.2 mg of selenomethionine twice daily for 
a week followed by once daily dosing, which lead to Se plasma concentrations >150 
mol/l. However, three PRs and nine stable disease cases were seen out of 41 patients 
investigated (disease control rate of 30%). The authors concluded that 
selenomethionine, at the dose and schedule used, may induce irinotecan sensitivity in a 
minority of patients and on this basis plan further clinical studies to verify this 
proposition (Fakih et al., 2006, Fakih et al., 2008).
These results are disappointing and encouraging. The failure of high-dose 
selenomethionine to protect normal tissues from irinotecan poisoning may be due to any 
of the following:
1 Selenomethionine is ineffective and its mechanisms of protection in athymic 
nude mice do not hold true in humans with end-stage cancer.
2 The dose of selenomethionine was too high, so as to be toxic to normal tissues 
i.e. not only was the putative chemosensitising serum concentration passed but 
also the possible cytoprotective concentration for normal cells exceeded.
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3 The wrong Se compound was used.
4 The wrong cytotoxic agent was used.
In the light of the above and the finding detailed in this Chapter that low concentration 
Se exposure can stimulate proliferation, the concerns are that Se supplement 
interactions may be no more than neutral and possibly antagonistic. Alternatively, 
stimulation of proliferation via oxidative stress may be the very mechanism by which 
Se compounds can prevent chemoresistance and potentiate the activity of established 
cytotoxics, as exemplified in the work of Cao (Cao et al., 2004). From the data 
described in Chapter 3 it is clear that the majority of DLBCL patients are Se deficient at 
presentation. Therefore, it is likely that Se supplementation will need to go beyond 
restoration of physiological function to achieve chemosensitising levels. The potential 
effect of ‘supraphysiological but low-dose chemosensitising’ Se supplementation on 
cell cycling and proliferation will need investigation as to whether it occurs 
preferentially in malignant cells vs. normal and whether this effect augments (e.g. by 
depleting intracellular glutathione leading to increased sensitivity to cytotoxic drugs that 
are inactivated by conjugation with glutathione, such as cisplatin or doxorubicin.) or 
antagonises the efficacy of conventional cytotoxics. Other potential roles for Se 
supplementation are as a maintenance treatment to reduce the risk of lymphoma 
recurrence and to prevent the development of treatment-related malignancy.
4.5.4 Choice of Se compound for Human Investigation
The metabolism and bioavailability of Se compounds are influenced by absorption in 
the gastrointestinal tract, transport in the blood, metabolism and storage in tissues, and 
rate of excretion in the urine and faeces (Daniels, 1996). The organic forms of Se such 
as selenomethionine are more bioavailable than are inorganic forms such as sodium 
selenite (Daniels, 1996). In terms of which methylselenol-pool precursor would be 
suitable for clinical trials, selenomethionine has already been used and proved effective 
(Clark et al., 1996). However excess selenomethionine accumulates in tissues through 
competition with methionine during protein transcription and the results from the 
Roswell Park group’s phase I clinical studies failed to show protection of normal tissues 
from chemotherapy toxicity. Beyond selenomethionine, MSC looks to be a promising in 
vivo methylselenol precursor with equivalent efficacy to MSA as a chemopreventive 
agent in animal studies, with the tumour reducing effect of 2 ppm/day Se being the 
same for MSA and MSC i.e. 10-fold more than the 0.2 ppm needed to restore the 
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function of seleno-enzymes in deplete animals (Ip et al., 2000). In terms of production, 
MSC generation is simpler than MSA, as it is the principal Se compound of selenium-
enriched vegetables such as garlic and broccoli. Both MSC and MSA are stable for at 
least 7-10 days in the prepared feed of rats (Ip et al., 2000). From the hydrogen selenide 
pool selenite and p-XSC are the two candidate Se compounds. The latter was 
specifically developed as a potential Se supplement in humans, due to its superior 
therapeutic index in vivo compared to selenite (Ip et al., 1994).
In summary, the results presented in this Chapter demonstrated that both a hydrogen 
selenide Se compound (SDG) and a methylselenol pool member (MSA) are cytostatic 
and cytotoxic towards human DLBCL cell-lines and ex vivo cultured human primary 
lymphoma samples and induced caspase-8 and -9 dependent apoptosis. The next stage 
of investigation suggested by these results would be the investigation of SDG and MSA 
in combination with established cytotoxics to search for any chemosensitising ability in 
human DLBCL cell-lines and primary lymphomas.
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CHAPTER 5: DISCOVERY OF OUTCOME PREDICTIVE GENE 
EXPRESSION SIGNATURES IN DLBCL USING MICROARRAY PROFILING
5.1 Chapter Summary
This Chapter describes the rational approach of gene expression profiling used to 
search for predictors of outcome to anthracycline-based treatment in previously 
untreated DLBCL. RNA was extracted and converted into labelled cDNA from 
cryopreserved, presentation lymph node material from 58 DLBCL patients and 19 FL 
patients. The labelled cDNA was hybridised onto Affymetrix Hu6800 gene expression 
chips and the resultant intensities of ‘probe-target’ hybridisations measured using a 
laser scanner. The raw array data was pre-processed as detailed in Chapter 2 to allow 
comparison of sample data. The supervised learning classification algorithm ‘weighted 
voting’ was used in an attempt to delineate DLBCL from the closely related GC 
(germinal centre) B-cell-lineage malignancy, FL. Following the successful delineation 
of DLBCL from FL, the weighted voting algorithm and two other prediction methods 
were used to try and predict the post-treatment alive and cured DLBCL patients from 
the dead/with refractory disease DLBCL patients using their respective microarray 
expression data. Within the 58 DLBCL group, application of each of the three different 
prediction methods, supported by ‘leave-one-out’ cross-validation, could significantly 
stratify the patients into ‘alive and cured’ and ‘fatal/refractory disease’ groups. 
Furthermore, a model of just 13 out of the 6,800 genes arrayed could define ‘alive and 
cured’ and ‘fatal/refractory disease’ groups alone and within the different IPI risk 
groups. The molecular gene expression model was therefore extracting additional 
prognostic information to that of the clinical IPI. In silico and immunohistochemical 
validations were performed and supported the legitimacy of the findings. When the 
SBH cohort of 19 patient samples was investigated alone, a separate 19-gene model 
proved highly effective at outcome prediction within this cohort.
5.2 Introduction
The paucity of precision in the description of the molecular events and players in 
DLBCL suggests that many if not most of the critical participant genes and proteins 
underlying and explaining the clinical heterogeneity of DLBCL are unknown and 
unlinked to the illness. To date, investigation of potential molecular prognostic factors 
has been labour intensive, due to each target requiring individual scrutiny. The 
discovery and validation of individual prognostic factors in DLBCL has thus been slow. 
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Furthermore, the factors investigated were already established as having a role in the 
pathogenesis of tumours in general (e.g. TP53) or DLBCL in particular (BCL-6). The 
advent of microarray technology broke the restraints of individual gene scrutiny by 
allowing thousands of genes to be interrogated in parallel. In the research described 
below 6,800 different gene transcripts from across the human genome were investigated 
simultaneously using the HU6800 Affymetrix chip. This obviated the need for 
empirical hypotheses justifying individual or multiple target investigation. The aims of 
the project were guided by the reproduction and extension of traditional acute 
leukaemia classification using Affymetrix array technology and supervised learning 
analyses. In addition to the acute leukaemia specimens arrayed being correctly 
classified as ALL and AML based upon their expression signatures further, novel gene 
expression signature generated subclasses were suggested (Golub et al., 1999). The 
lymphoma project set out to answer the following rational as opposed to empirical
questions: 
 Could gene expression profiling allow DLBCL to be distinguished from the 
related B-cell NHL FL using supervised learning analyses?  As the histological 
distinction between DLBCL and FL is considerable this question was 
anticipated to be easily addressed by analyses of gene expression profiling.
 Could supervised learning methods distinguish ‘alive and cured’ patients from 
‘fatal/refractory disease’ patients based solely on the gene expression profiles of 
their respectively diagnostic lymphoma material?  To date such a distinction has 
not been possible by any method. This was therefore expected to be a 
considerably more difficult question to address.
 Could a treatment outcome predictor for DLBCL be developed from expression 
signature differences?  If this was possible, then the potential application of such 
a predictor to other DLBCL series could have far reaching and positive benefits 
for patients, clinicians and trialists.
5.3 Methods
The research relating to the use of gene expression profiling was conjoint work. My role 
in this research was limited. I identified and collected over 30 frozen diagnostic samples 
of diffuse large B-cell lymphoma (DLBCL) from the tissue archives at St 
Bartholomew’s Hospital. For each sample I extracted key clinical data from the 
lymphoma database and the original case notes, retrospectively assigning a performance 
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status to the patient at presentation based on recorded clinical details.  Where no 
presentation serum LDH was available I identified archived frozen serum samples from 
presentation and obtained an LDH level. I identified the corresponding formalin fixed 
paraffin embedded diagnostic tissue blocks and slides to the frozen specimens in the St 
Bartholomew’s Hospital histopathology department archive. I then transported the 
samples to the Whitehead Institute microarray facility and Dana Farber Cancer Institute. 
Jon Aster, the project’s principal histopathologist, examined the corresponding 
histopathology blocks and slides to confirm the diagnosis of DLBCL. At the Whitehead 
Institute microarray facility I helped prepare the samples I had transported for 
expression profiling. Only nineteen of the more than 30 specimens processed were of 
sufficient quality and of standard DLBCL rather than several variants excluded which 
were excluded from the study. The initial expression profiling of the samples was 
performed by Michelle Gaasenbeek in my presence. Michelle conducted the repeat 
profiling after my return to the UK. The subsequent data analyses were performed by 
the team at the Whitehead Institute and repeated on only the St Bartholomew’s Hospital 
samples by Spouros Sgouros in the UK.
In brief, total RNA was extracted from each frozen tumour specimen and converted to 
double-stranded cDNA before in vitro transcription of biotinylated cRNA. Ten g of 
fragmented, biotinylated cRNA was hybridised to HU6800 oligonucleotide Affymetrix 
arrays at 45 C for 16 hours (see Chapter 2 for more details). The arrays were then 
washed and stained twice with SAPE prior to scanning on an Affymetrix scanner. The 
expression value for each gene was then calculated using Affymetrix GeneChip 
software. The raw data was cleaned and processed as detailed in Chapter 2 to allow 
application of supervised learning methodologies as detailed in Chapter 2. The 
algorithms used to classify according to phenotype distinction were weighted voting, -
nearest neighbours and support vector machines. Hierarchical clustering was used to 
reassess the Alizadeh et al dataset reduced to just the 90 genes common to the 
‘Lymphochip’ and the Affymetrix HU6800. A classifier was built through cross-
validation using the ‘leave-one-out’ technique. Several models were built using 
different numbers of marker genes, allowing the final model to be chosen with the 
lowest error rate in cross-validation. The Kaplan-Meier method was used to calculate 
predicted OS curves and the log rank test was used to calculate the respective P values 
(Kaplan and Meier, 1958).
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5.4 Results
The 5-year OS of the 58 DLBCL patients was 54%, a result better than expected from 
larger series treated with the same therapy (Figure 5.1). The most likely explanation for 
this difference is the higher number of good-risk and low-intermediate risk IPI patients 
in this series compared to others. At time of data censuring (April 2000) 32 of 58 
patients were alive and disease-free and 26 had died of DLBCL (23) or had refractory 
disease (3).
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Figure 5.1 Kaplan-Meier Plot 
of 5-year overall survival for 
the 58 DLBCL Patients The 5-
year OS was 54%, which is slightly 
better than expected for DLBCL but in 
keeping with the favourable IPI score 
of the majority of patients (see 
Chapter 2).
5.4.1 Distinguishing DLBCL from FL
The 6,817 genes were sorted by the degree of their expression correlation with the 
DLBCL vs. FL distinction using their mean signal-to-noise ratios. The 100 best gene 
markers for the DLBCL versus FL distinction are illustrated in Figure 5.2. Using the 
weighted voting algorithm and the leave-one-out cross-validation method a model 
containing 30 of the most discriminating genes predicted the correct class of 71 of the 
77 (91%) samples (p < 1.4 x 10–9). The 30-gene predictor incorrectly classified six 
DFCI DLBCL as FL (Table 5.1).
Weighted Voting Assigned Class
DLBCL FL Total
True DLBCL 52 6 58
Class Follicular 0 19 19
Total 52 25 77
Table 5.1: confusion matrix for the prediction of the DLBCL versus FL distinction 
using the 30-gene weighted voting algorithm generated model. None of the FL cases 
were incorrectly assigned to the DLBCL subclass but six DLBCL were incorrectly assigned to the FL 
subclass of NHL by the weighted voting algorithm.
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Figure 5.2 Pinkogram of 
the 100 most 
discriminating genes 
between DLBCL and FL
The 50 genes most differentially 
expressed at h igher  levels in 
DLBCL compared to FL are 
shown at the top of the 
‘pinkogram’ while the 50 genes 
that were most highly expressed in 
FL compared to DLBCL are 
shown at the bottom. Red indicates 
a high relative expression while 
blue represents a low relative 
expression. Each column 
represents a sample and each row a 
gene (with the first rows of the 
DLBCL and FL sections showing 
an idealised expression profile). 
Expression profiles for the 58 
DLBCL samples are on the left 
while the profiles for the 19 FL 
samples are on the right.
 = standard deviation
from mean
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5.4.2 Distinguishing DLBCL ‘Alive and cured’ from DLBCL ‘Fatal/refractory 
disease’
The 6,817 genes were sorted according to the degree of expression correlation with the 
‘alive and cured’ vs. ‘fatal/refractory disease’ distinction using the mean signal-to-
noise ratios for each gene. The 100 most discriminating genes, 50 for each class (‘alive 
and cured’ and ‘fatal/refractory disease’), are illustrated in Figures 5.3.
It is clear from Figure 5.3 that this class distinction was less clear-cut than that 
achieved for DLBCL vs. FL. Indeed, taken individually, the top marker genes for 
treatment outcome prediction did not show statistical significance - unlike the top 
marker genes for morphological distinction of FL from DLBCL. Nevertheless, from the 
approximately 700 genes that demonstrated differential expression in relation to the 
supervised learning class divider ‘alive and cured’ vs. ‘fatal/refractory disease’, a pool 
of genes could be extracted that, when combined, effectively predicted for the ‘alive 
and cured’ vs. ‘fatal/refractory disease’. Application of the weighted voting algorithm 
and leave-one-out cross validation testing revealed that predictors containing a 
minimum of eight and maximum of 16 genes produced statistically significant class 
distinctions. Of these models, the 13-gene model was the most accurate. For each 
patient’s sample, the leave-one-out cross-validation method created a slightly different 
set of 13 genes as the treatment outcome predictor. Seven genes were common to all 58 
cross-validation 13-gene models; four genes were included in 54 or more models, three 
genes were included in 20-34 models, and five additional genes were used in 3-8 of the 
58 cross-validation models. The top 13 of these 19 genes were used to create the final 
13-gene outcome prediction model. Details of these 19 genes are given in Table 5.2 and 
the expression values of the 13-gene model are illustrated in Figure 5.4.
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Dystrophin related protein 2 (U43519)
3'UTR of unknown protein (Y09836)
Uncharacterized (HG2314-HT2410)
Protein kinase C (Z15114)
Mitogen induced nuclear orphan receptor (U12767)
5-hydroxytryptamine 2B receptor (X77307)
Nuclear antigen H731 (U83908)
Transducin-like enhancer protein 1 (M99435)
PDE4B (L20971)
Uncharacterized (AC002450)
Protein kinase C--1 (M18255)
Oviductal glycoprotein (U09550)
Zinc-finger protein C2H2-150 (U38864)
Figure 5.3 100 most discriminating genes for DLBCL samples from patients with 
‘Alive and cured’ vs. from patients ‘dead/with refractory disease’. The genes that were 
expressed at higher levels in samples from ‘alive and cured’ patients are shown at the top while the genes 
that were more highly expressed in the tumours of those with ‘fatal/refractory disease’ are shown at the 
bottom. Red indicates a high relative expression whilst blue represents a low relative expression and each 
column represents a sample and each row a gene (with the first rows of the two sections showing an 
idealised expression profile). Expression profiles for the 32 samples from the ‘alive and cured’ patients 
are on the left while the profiles for the samples from the 26 patients with ‘fatal/refractory disease’ are on 
the right.  = standard deviation from mean
13-gene model genes Samples from Alive and Cured Fatal/Refractory 
-3 -2 -1 0 +1 +2 +3
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Application of the 13-gene model created using the top 13 genes detailed in Table 5.2 
created an ‘alive and cured’ group with a 5-year OS of 70% and a ‘fatal/refractory 
disease’ group with a 5-year OS of 12% (p = 0.00004) (Figure 5.5). Use of two further 
analysis tools, -nearest neighbours and support vector machines, produced ‘alive and 
cured’ and ‘fatal/refractory disease’ groups from the 58 patients with similar 5-year OS 
to that produced by the weighted voting algorithm 13-gene model. For -near neighbour 
the 5-year OS were 72% and 12% respectively (log rank P = 0.00002) and for support 
vector machine the 5-year OS were 68% and 23% (log rank P = 0.002) respectively for 
the ‘alive and cured’ and ‘fatal/refractory disease’ groups.
Unigene
Identifier
Number of Cross Validation 
Models Using Gene Description
U43519 Hs.159291 58 Dystrophin related protein 2 (DRP2)
M18255_cds2 Hs.77202 58 Protein kinase C 1 (PKC)
U83908 Hs.100407 58 Nuclear antigen H731
Y09836 Hs.82503 58 3'UTR of unknown protein
M99435 Hs.28935 58 Transducin-like enhancer protein 1
AC002450 58 Uncharacterised
L20971 Hs.188 58 Phosphodiesterase 4B (PDE4B)
HG2314-HT2410 57 Uncharacterised
Z15114 Hs.2890 57 Protein kinase C   (PKC)
U09550 Hs.1154 55 Oviductal glycoprotein
U12767 Hs.80561 54 MINOR (Mitogen induced nuclear orphan receptor)
U38864 Hs.108139 34 Zinc-finger protein C2H2-150
X77307 Hs.2507 23 5-Hydroxytryptamine 2B Receptor
L40377 Hs.41726 20 Cytoplasmic antiproteinase 2 (CAP2)
U65093 Hs.82071 8 Msg1-related gene 1 (mrg1)
Z30644 Hs.123059 7 Chloride channel (putative) 2163bp
U02609 Hs.114416 5 Transducin-like protein
Z83802 4 Axonemal dynein heavy chain (partial, ID hdhc3)
M55531 Hs.33084 3 SLC2A5 Solute carrier family 2
Table 5.2 Details of the 19 genes included in the 58 individually generated 13-gene 
models using the weighted voting algorithm and leave-one-out cross-validation 
testing for predicting outcome in the 58 DLBCL patients. The upper 13 genes highlighted 
in bold type constitute the final 13-gene model applied to all 58 samples to generate the OS curves 
illustrated in Figure 5.5.
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Affymetrix
Identifier
Description No. ofModels
Using Gene
U43519 Dystrophin related protein 2 (DRP2) 58
Y09836 3'UTR of unknown protein 58
HG2314- Uncharacterised 57
Z15114 Protein kinase C  (PKC) 57
U12767 MINOR (Mitogen induced nuclear orphan receptor) 54
X77307 5-Hydroxytryptamine 2B Receptor 23
U83908 Nuclear antigen H731 58
M99435 Transducin-like enhancer protein 1 58
L20971 Phosphodiesterase 4B (PDE4B) 58
AC002450 Uncharacterised 58
M18255 Protein kinase C 1 (PKC) 58
U09550 Oviductal glycoprotein 55
U38864 Zinc-finger protein C2H2-150 34
Alive and cured Fatal/refractory disease
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Figure 5.4 13-gene outcome prediction model for DLBCL ‘alive and cured’ vs. ‘fatal/refractory disease’.
The six genes that were expressed at higher levels in samples from ‘alive and cured’ patients are shown at the top while the seven genes that were more highly 
expressed in the tumours of those with ‘fatal/refractory disease’ are shown at the bottom. Red indicates a high relative expression whilst blue represents a low relative 
expression. Each column represents a sample and each row a gene (with the first rows of the two sections showing an idealised expression profile). The vertical black 
line separates the expression profiles for the 32 samples from the ‘alive and cured’ patients to the left from the profiles for the samples from the 26 patients with
‘fatal/refractory disease’ to the right
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Figure 5.5 Overall Survival 
for the Predicted ‘Alive and 
cured’ and ‘Fatal/refractory 
disease’ Groups
Kaplan-Meier plot for the 5-year 
OS for the predicted ‘alive and 
cured’ and ‘fatal/refractory 
disease’ risk groups where the 
predicted groups were defined by 
the 13-gene model described 
above. The patients in the array 
model-predicted ‘alive and cured’
group had 70% survival at five 
years compared to only 12% 5-
year OS for the patients in the 
model-predicted ‘fatal/refractory 
disease’ group (log-rank P = 
0.00004).
The confusion matrix summarising the leave-one-out cross-validation of the 13-gene 
predictor is shown in Table 5.3. It can be seen that the principle failing of the 13-gene 
predictor was the incorrect classification of 11 ‘fatal/refractory disease’ cases as cured. 
This gives a false-positive rate of 42% and constitutes 27.5% of the cured cases 
predicted by the model. This figure in turn explains why the 5-year OS of the predicted 
cured cases was 70% and not 100%. Only three cured patients were predicted to have 
‘fatal/refractory disease’ by the 13-gene model, a false negative rate of 9%. In turn, this 
error explains why the 5-year OS for the 13-gene model generated ‘fatal/refractory 
disease’ group was 12% and not 0%.
Predicted Class
Alive and cured Fatal/Refractory disease Total
True 
Class
Alive and cured 29 3 32
Fatal/Refractory 
disease
11 15 26
Total 40 18 58
Table 5.3 Confusion Matrix Summarising the Leave-One-Out Cross-Validation 
Prediction Results Generated by Application of the 13-Gene Model for ‘Alive and 
cured’ vs. ‘Fatal/refractory disease’.
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5.4.3 Application of the 13-gene predictor within the IPI categories
Application of the 13-gene model to the patients within the low/low-intermediate and 
high-intermediate IPI categories resulted in further stratification. This suggests that the 
clinical and molecular prediction models captured distinct information. Within the 
combined low/low intermediate IPI patients, the 13-gene model produced ‘alive and 
cured’ and ‘fatal/refractory disease’ groups with 5-year OS of 75% and 32% 
respectively (log rank P = 0.02) and within the high intermediate patients the 13-gene 
model produced ‘alive and cured’ and ‘fatal/refractory disease’ groups with 5-year OS 
of 57% and 0% respectively (log rank P = 0.02). Figures 5.6 through 5.8 illustrate the 
Kaplan-Meier plots of 5-year OS for the 58 patients stratified according to the IPI alone, 
and the low/low-intermediate and high-intermediate IPI patients stratified by the 13-
gene model respectively.
5.4.4 In silico and Immunohistochemical Validation of the 13-gene Model
Two approaches were used in an attempt to validate and provide biological plausibility 
to the 13-gene outcome predictor model. Firstly, in silico validation was explored using 
the NCI (national cancer institute, USA) group’s microarray results generated using the 
‘lymphochip’ from 40 pretreatment DLBCL samples (Alizadeh et al., 2000). 
Hierarchical clustering was performed using just the 90 Unigene clusters from the 
‘lymphochip’ class-defining ‘cell-of-origin’ set that were also present on the Affymetrix 
HU6800. These 90 Unigene clusters were represented by 139 clones on the 
Lymphochip and by 100 ‘probes’ on the oligonucleotide arrays. This hierarchical 
clustering analysis confirmed the delineation of two groups, a GCB-like class and an 
ABC-like class within both the original Alizadeh et al series of 40 DLBCL and also 
within the 58 DFCI/SBH cases. However, only in the NCI series did the GCB-like 
group have a more favourable 5-year OS than the ABC-like class (2= 0.2 for one 
degree of freedom, P = 0.631). In the DFCI/SBH series the ‘cell-of-origin’ class divider 
created using the common 90 genes did not predict for outcome (Figure 5.9). However 
for the 19 SBH cases the ‘cell-of-origin’ classifier proved moderately effective: for the 
GCB-like subgroup the 5-year OS was 77% compared to 50% for the ABC-like 
subgroup.
Chapter 5
192
Figure 5.6 OS Curves for the 
Patients within each IPI group
Kaplan-Meier OS curves for the 56 patients 
with an IPI score, subdivided into the four 
risk groups of the IPI. OS data has been 
censured at five years follow-up.
IPI Groups
Low risk n = 26
Low-intermediate n = 11
High-intermediate n = 17
High-risk n = 2
Total n = 56
Figure 5.7 OS curves for the 
low/low-intermediate IPI group 
stratified according to the 13-gene 
model.
Kaplan-Meier 5-year OS plots following 
application of the 13-gene model to the 37 of 
the 58 DLBCL patients that were classified as 
low/low-intermediate risk according to the 
IPI. The upper curve represents the 13-gene 
model generated ‘alive and cured’ group with 
5-year OS of 75% and the lower curve 
represents the significantly different 13-gene 
model generated ‘fatal/refractory disease’
group with 5-year OS of 32%; nominal log-
rank P = 0.02. OS data has been censured at 
five years follow-up.
Figure 5.8 OS curves for the high-
intermediate IPI group stratified 
according to the 13-gene model.
Kaplan-Meier 5-year OS plots following 
application of the 13-gene model to the 17 of 
the 58 DLBCL patients that were classified as 
high-intermediate risk according to the IPI. 
The upper curve represents the 13-gene 
model generated ‘alive and cured’ group with 
5-year OS of 57% and the lower curve 
represents the significantly different 13-gene 
model generated ‘fatal/refractory disease’ 
group with 5-year OS of 0%; nominal log-
rank P = 0.02. OS data has been censured at 5 
years follow-up.
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Only three of the thirteen genes from the 13-gene model, namely PKC, PDE4B and 
MINOR, were also represented on the ‘Lymphochip’. Taken individually, each of these 
three genes was found to predict for OS in the NCI dataset, with P values of 0.04, 0.07 
and 0.05 respectively for PKC, PDE4B and MINOR.
Immunohistochemical staining for PKC protein was performed using a tissue array for 
19 of the DFCI patients. A significant correlation between outcome and OS for these 19 
cases was found using a t test (p = 0.03) and the PKC protein level showed a trend 
towards a correlation with the Affymetrix PKC probe M18255_cds2 expression using 
Fisher’s exact test (p = 0.08).
Figure 5.9 OS curves for the 90 Unigene cluster defined germinal centre-like and 
activated B-cell-like subgroups. Kaplan-Meier 5-year OS plots following application of the 
subset of 90 common Unigene clusters from the cell-of-origin signature used to predict OS in the 
LLMPP/NCI series. OS data has been censored at five years follow-up.
A = OS curves for the 40 DLBCL from the LLMPP/NCI series
B = OS curves for the 58 DLBCL from the DFCI/SBH series
GC = germinal centre-like Act. PB = Activated peripheral blood B-cell-
like
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5.4.5 Independent Analysis of the St Bartholomew’s Hospital Cohort
Evidence suggesting that a different set of genes may also serve as predictors of OS in 
only the SBH subset of patients was first suggested by the earliest representations of the 
50 most discriminating and highly expressed genes in the ‘alive and cured’ vs. 
‘fatal/refractory disease’ where the SBH cases were placed together as illustrated in 
Figure 5.10. It can be seen that these 50 genes could be clustered into six groups with 
the second group being highly expressed in the SBH ‘alive and cured’. The six genes in 
this cluster were zinc finger protein 91, transporter protein G17, retinoic acid receptor 
related orphan receptor A, a (1,2) fucosyltransferase 5’ untranslated region (UTR) 
partial sequence, GATA-1 transcription factor and 3’ UTR of an unknown protein 
(Figure 5.10).
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Figure 5.10 Pinkogram of the 50 most discriminating and highly expressed genes 
in ‘Alive and cured’ compared to ‘Fatal/refractory disease’ patients. Expression profiles 
for the samples from the 32 alive and cured patients are to the left of the vertical black line, while the 
profiles for the samples from the 26 patients with fatal/refractory disease are on the right. Each column 
represents a sample and each row a gene. Red indicates a high relative expression while blue represents a 
low relative expression. The genes have been grouped into six clusters according to similarity of co-
expression. The six genes belonging to cluster 2 were more highly expressed in the SBH rather than the 
DFCI alive and cured patient samples and have been named.
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In order to test for an SBH-specific outcome predictor model based on expression data, 
a supervised analysis using hierarchical clustering was performed using the microarray 
data from just the 19 SBH patients. The supervised class distinction of ‘alive and cured’
and ‘dead from disease’ was applied. A model consisting of the 19 most discriminating 
genes correctly predicted the class of 92% of the ‘alive and cured’ cases and 100% of 
the dead-from-disease (Table 5.4, Figures 5.11 and 5.13). The genes in the model are 
named in Figure 5.16. Eight of the genes were more highly expressed in the ‘alive and 
cured’ patients compared to the ‘dead from disease’ cases and 11 were expressed more 
highly in the ‘dead from disease’ patients compared to the ‘alive and cured’. Only one 
of the 19 genes was shared in common with the 100 most discriminating genes for 
‘alive and cured’ and ‘fatal/refractory disease’: retinoic acid receptor related orphan 
receptor A. This gene is expressed in mesenchymal stem cells derived from bone 
marrow, where cells undergoing osteogenic differentiation show increased expression. 
Frustratingly, application of the SBH generated 19-gene model to the whole cohort of 
58 patients failed to accurately predict the outcome class, as illustrated in Figure 5.12.
Predicted Class
Alive and 
cured
Dead from 
disease Total
Observed Class
Alive and cured 11 1 12
Dead from disease 0 7 7
Total 11 8 19
Table 5.4: Confusion matrix summarising the leave-one-out cross-validation 
prediction results.
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Figure 5.11 Hierarchical 
Cluster Dendrogram 
Produced by the 19 most 
discriminating Genes for 
‘Alive and cured’ vs. 
‘Dead From Disease’ in 
the SBH Patients.
ND = Not Dead = Sample from 
an Alive and cured Patient
D = Dead = Sample from a 
patient dead-from-disease/ with 
refractory DLBCL.
Figure 5.12 Hierarchical 
Cluster Dendrogram for 
the 58 Patients 
according to the 19-gene 
Outcome Predictor for 
the SBH Patients.
ND = Not Dead = Sample from 
an Alive and cured Patient
D = Dead = Sample from a 
patient dead-from-disease/ with 
refractory DLBCL.
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Figure 5.13 Dendrogram Produced by the 19 most discriminating Genes for ‘Alive and Cured’ vs. ‘Dead From Disease’ in the 
SBH Patients Illustrating the 19 Genes Identifiers. Each column represents a patient sample and each row a gene. The eight samples classified as 
‘dead-from-disease’ are to the left of the black line and the 11 samples classified as ‘alive and cured’ are to the right of the line. To the right of the Figure, the 
Affymetrix identifiers and names of the 19 genes are displayed. Green represents high relative expression and orange represents low relative expression. To the 
left of the Figure the threefold variance in expression is colour quantified.
A =  ‘alive and cured’. D =  ‘dead-from-disease’
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5.5 Discussion
5.5.1 Review of Experimental Findings in Comparison with Published Data
Chapter Results Summary
The research detailed in this Chapter achieved the ambitious aims of creating a 
molecular classifier capable of distinguishing DLBCL from the closely related FL; of 
identifying genes that were differentially expressed in pre-treatment DLBCL samples 
according to the post-treatment survival outcome of the corresponding patients; and 
producing a highly effective 13-gene outcome predictor model that was at least as 
effective as the best clinical tool, the IPI. The 13-gene model captured aspects of 
DLBCL biology independent of the IPI and, in conjunction with the IPI, produced the 
most accurate predictor of outcome to treatment in DLBCL yet described. In silico and 
IHC validation of the 13-gene model confirmed components of it to have prognostic 
significance. Finally, a separate analysis of the SBH cohort resulted in the creation of a 
tailored SBH specific 19-gene outcome prediction model. Because all the patients from 
whom the DLBCL material came received chemotherapy, it was not possible to clarify 
if the 13- and 19-gene models were also predictive of outcomes to treatment or simply 
prognostic models.
Summary of the Preceding NCI Microarray Paper
The preceding 2000 paper from the NCI-led consortium, which became the LLMPP, 
took a different approach to array profiling in DLBCL to that of the DFCI-led group’s 
results described in this Chapter. Alizadeh et al also sought to realise a very different 
goal, namely discovery of molecular subtypes of DLBCL defined by ‘cell-of-origin’. As 
well as using the alternative type of array, a ‘dot-blot’ cDNA array, Alizadeh et al
analysed different types of malignant and non-malignant lymphoid samples and 
employed hierarchical clustering to segregate the samples. Specifically, a custom-made 
cDNA array, the Lymphochip, was created, which comprised 17,856 cDNA clones 
from a GC B-cell library, B-cell lymphoid malignancies and from genes of importance 
to tumour biology (Alizadeh et al., 2000). Forty-two presentation DLBCL cases were 
arrayed alongside 56 other samples derived from benign T- and B-cells, tonsil and 
lymph node, malignant B-cell-lines and primary FL and CLL samples. A reference 
cDNA probe was prepared from a pool of mRNAs isolated from nine different 
lymphoma cell-lines. After preprocessing, a dataset containing 4,026 array elements 
remained. Hierarchical clustering segregated the samples from the three different 
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lymphoid malignancies correctly in all but two cases (Figure 5.14). The following gene 
expression ‘signatures’ were then created: ‘T-cell’, ‘Activated B-cells (ABC)’, ‘lymph 
node’, ‘resting B-cell’, ‘germinal centre B-cell (GCB)’, ‘proliferation’ and ‘major 
histocompatibility complex’ (‘MHC’ signature). The DLBCL samples were found to 
express the ‘lymph node’ signature, the  ‘proliferation’ signature (silent in the FL and 
CLL samples) and to variably express the ‘T-cell’ and ‘GCB’ signatures. In the belief 
that ‘GCB’ defined clustering would reveal subtypes of DLBCL arising from different 
stages of normal B-cell differentiation, Alizadeh et al reclustered the DLBCL samples 
using only the expression pattern of the genes that defined their ‘GCB’ signature. A two 
branch Dendrogram resulted, with one subgroup being named GCB-DLBCL and the 
other being named ABC-DLBCL.
Alizadeh et al went on to create Kaplan-Meier OS curves for the 40 patients whose 
clinical data was available, and found the 5-year OS of the patients with DLBCL 
subclassified as GCB was 76% compared to only 26% for the patients with array-
defined ABC DLBCL. This difference in OS led the group to make this statement: “the 
molecular differences between these two kinds of lymphoma were accompanied by a 
remarkable divergence in clinical behaviour, suggesting that GC B-like DLBCL and 
activated B-cell DLBCL should be regarded as distinct diseases”. The GCB vs. ABC 
distinction added to the outcome predictive ability of the IPI in the low-risk but not the 
high-risk IPI subgroupings.
Figure 5.14 Dendrogram of hierarchical clustering of the Lymphochip derived 
gene expression data. The dendrogram illustrates the hierarchical clustering of gene expression 
data, depicting the relationships between the 96 samples of normal and malignant lymphocytes analysed. 
The closer a sample is to another in the dendrogram the greater the relatedness of gene expression 
between the samples. The dendrogram is colour-coded according to the category of mRNA sample 
studied as per the right-hand key. It can be seen that all the FL and all the CLL samples are clustered 
together and that the germinal centreB-cells and lymph node and tonsil samples sit within the DLBCL 
samples, which are bordered by the activated B-cell samples (adapted from (Alizadeh et al., 2000)).
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Critique of the Preceding NCI Microarray Paper
I consider that the Alizadeh et al paper was a milestone in DLBCL translational 
research. The limitations of the paper have come to light as this research field has 
matured. Firstly, too few samples were used to define the pivotal signatures of ‘T-cell’, 
‘ABC’, ‘GCB’, ‘proliferation’ and ‘lymph node’. Additionally, the process of signature 
assignment and selection was informal and subjective, using no criteria or algorithm. 
The definition of the non-GCB subgroup as ABC was imposed from amongst the 
hundreds of genes differentially expressed between the GCB and non-GCB DLBCL. It 
is likely that a mixture of other genes, particularly those from the ‘proliferation’
signature, could have better defined the non-GCB group.
A potential weakness of both the Lymphochip and the Affymetrix Hu6800 is their lack 
of comprehensive representation of the entire genome, an issue addressed by the latest 
Affymetrix chips. The limited gene repertoire of the two arrays has hindered 
comparative studies of the rival group’s strategies and assertions due to only a minority 
of genes that were differentially displayed on each array being present on the other. The 
unanswered question for both arrays is just how many genes critical to DLBCL biology 
were excluded or absent.
In terms of providing an efficient predictor of outcome to empirical chemotherapy, the 
differential post-treatment outcome of GCB vs. ABC DLBCL was a beguiling finding. 
Nevertheless, I suspect that more effective outcome prediction clusterings were missed 
due to the application of the ‘cell-of-origin’ supervised classifier rather than 
performance of a separate, supervised search specifically addressing this critical clinical 
issue and I concur with others that this secondary assessment of the ‘cell-of-origin’ 
classifier is inferior to the use of direct supervised methods (Smyth et al., 2003).
When compared to the 13-gene model’s results, the GCB vs. ABC classifier proved less 
efficient within its own series and proved ineffective at predicting OS post-treatment 
within the series described in this Chapter. Part of this discrepancy will come from the 
fact that the 13-gene model was the optimal for the 58 samples/patients studied by 
ourselves, whilst the GCB vs. ABC classifier was created for another purpose and found 
to have a secondary ability to predict OS. For both series the issue of overfitting and 
transferability is raised, due to the absence of validation series.
In conclusion, the Alizadeh et al paper, established a benchmark in terms of gene 
expression-defined subclassification of lymphoma and that the majority of the 
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reservations relating to it have been addressed by subsequent research, as will be 
described below.
Summary of the Subsequent LLMPP DLBCL Microarray Paper
The follow-on 2002 LLMPP paper confirmed and extended the findings of Alizadeh et 
al and validated the strategy of outcome prediction pursued in this Chapter (Rosenwald
et al., 2002). On this occasion, 240 presentation DLBCL samples were arrayed using 
the Lymphochip, so by overcoming the common weakness of the DFCI/SBH paper 
described in this Chapter and the 2000 NCI paper, namely small series size. For each 
sample, corresponding patient’s clinical data was available and all patients had received 
anthracycline-based chemotherapy, with an average follow-up of 4.4 years and 138 
deaths in the cohort. As in their preceding paper (Alizadeh et al., 2000), the group 
sought to impose a ‘cell-of-origin’ expression based classifier on the series using 
hierarchical clustering, and to search for an expression-based predictor of outcome (OS) 
independent of the ‘cell-of-origin’ classifier using supervised learning. The dendrogram 
produced by application of hierarchical clustering according to the top 100 from the 
nearly 400 genes used in the Alizadeh et al series for the GCB vs. ABC division yielded 
three not two subgroups. Two of the three corresponded to the GCB (48%) and ABC 
(22%) subtypes of the first paper, along with a third robustly distinct subgroup named 
‘Type 3’ DLBCL (30%), which expressed neither set of genes at a high level. OS after 
anthracycline-based chemotherapy differed significantly among the subgroups, as in the 
Alizadeh et al series (P <0.001). Patients with GCB-DLBCL had a significantly better 
5-year OS rate of 60%, compared to 39% for patients with Type 3 DLBCL and 35% for 
those with ABC-DLBCL, in keeping with the previous study (P < 0.01). However, it is 
clear from these percentages that the ‘cell-of-origin’ molecular classifier was less 
effective at outcome prediction than in the first series of 40 patients and failed to 
capture a significant proportion of the determinants of OS.
The remarkable ability of gene expression profiling to extract critical innate molecular 
properties from presentation DLBCL that heavily influence treatment outcome, as first 
demonstrated in the research detailed in this Chapter, was then confirmed by the 
LLMPP. Application of a Cox proportional-hazards model by Rosenwald et al
identified 670 significantly associated with a good or bad outcome in the training group 
of 180 samples (P <0.01). Just over half of the genes associated with OS could be 
classified into four of their signatures: ‘GCB’=15 (all genes associated with a 
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favourable outcome), ‘MHC’=35 (all genes associated with a favourable outcome), 
‘lymph node’=32 (30 genes associated with a favourable outcome), ‘proliferation’=293 
(287 associated with a poor outcome), leaving 44% (295) OS-associated genes as 
unclassified. Rosenwald et al chose 16 out of 17 genes from amongst their signatures to 
create an outcome predictor (3 GCB genes, four MHC class II genes, six lymph node 
genes, and three proliferation genes). After ranking the patients according to their 17-
gene model score and dividing them into quartiles, a significant difference in 5-year OS 
was produced in both the training and validation sets of patients/samples. For the whole 
group the 5-year OS rates were 73 %, 71 %, 34 %, and 15 % in quartiles -1 to -4 
respectively. Although the 17-gene model captured different prognostic information 
from the IPI in this cohort of patients and samples, the upper two and the lower two 
quartiles needed to be combined to produce differences in OS within the 
low/intermediate risk IPI and within the few high-risk IPI patients. The 17-gene 
outcome predictor score could also be used to subdivide the patients within each of the 
‘cell-of-origin’ subgroups into distinct survival risk groups, confirming the 17-gene 
model’s greater prognostic power compared to the ‘cell-of-origin’ classifier.
Critique of the Subsequent LLMPP DLBCL Microarray Paper
The creation of a third, unclassified, subgroup by the GCB/ABC classifier, which 
constitutes a third of cases and is in fact larger than the ABC subgroup, confirms that 
the ‘cell-of-origin’ classifier is far from comprehensive. ‘Type 3’ DLBCL may truly 
represent a hidden stage (or stages) of B-cell development or it could indicate that this 
classifier is inappropriately named, reflecting instead dominant molecular pathways 
disrupted in DLBCL. The imposition of the ‘cell-of-origin’ order on the gene 
expression data may in fact have merely imposed constraints and as such risk having 
missed important associations and findings. Louis Staudt, head of the LLMPP, has 
speculated that the cell of origin for the ABC subclass is the plasmablastic B-cell on the 
brink of exiting the germinal centre and that GCB-DLBCL are derived from normal 
germinal centre B-cells and retain much of their biology (Staudt and Dave, 2005). The 
extrapolation from the LLMPP array data by Staudt et al to the unproven is illustrated 
well by this statement “These three DLBCL subgroups [ABC, GCB and PMBCL 
[primary mediastinal B-cell lymphoma]] should be considered separate disease entities 
since they arise from B-cells at different stages of differentiation, utilise different 
oncogenic pathways, and have distinct clinical behaviours.”(Staudt and Dave, 2005). 
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Gone is the ‘Type 3’ DLBCL subclass conveniently swept under the array bench and in 
comes the long recognised clinical subtype of DLBCL, PMBCL, demonstrated, not 
surprisingly by both the DFCI and LLMPP consortia to display a reproducibly distinct
expression signature from DLBCL (Feuerhake et al., 2005, Rosenwald et al., 2003).
Nevertheless, the different approach taken by the LLMPP, compared to the DFCI 
consortium, has opened up a tantalising area of research: the division of the 
heterogeneous DLBCL subtype of NHL into distinct, molecularly defined subtypes 
according to the stage in normal B-cell development that malignant transformation 
arose. 
As with the 100-gene ‘cell-of-origin’ classifier, imposition of 16 genes in the 17-gene 
model for post treatment outcome prediction from amongst the LLMPP’s signatures is 
likely to have imposed constraints and forfeited inclusion of important genes of 
unknown function. Frustratingly, no gene present in the 13-gene model is present in the 
17-gene model for outcome prediction and vice versa. Certainly, the lack of genes in 
common between the two different arrays used will partly explain this. The concern 
remains that for both series, the outcome prediction models were curated for their 
datasets to the extent that they demonstrated maximal intrinsic predictive power but lost 
the critical ability to be universally applicable to patients and their samples treated with 
anthracycline-based chemotherapy.
The Rosenwald et al paper successfully confirmed and extended the results of the 2000 
NCI paper (Alizadeh et al., 2000). Consequent IHC, CGH and molecular studies have 
supported GCB-DLBCL and ABC-DLBCL being distinct subtypes of DLBCL with 
different aetiologies. The ‘cell-of-origin’ classifier retained prognostic significance, 
whilst a 17-gene model predicted outcome to CHOP-like chemotherapy and captured 
distinct prognostic information compared to the ‘cell-of-origin’ classifier and the IPI.
Non-array validation of distinct pathways in DLBCL Lymphomagenesis
In terms of the ABC vs. GCB as an aetiological classifier, supporting evidence has been 
provided by cytogenetic and CGH studies. BCL-2 translocations are seen in 45% of 
GCB-DLBCL and are absent in ABC-DLBCL cases (Rosenwald et al., 2002, Huang et 
al., 2002). Similarly, amplification of the REL locus on chromosome 2p appears 
restricted to a minority of GCB-DLBCL and is absent in ABC-DLBCL (Bea et al., 
2005, Rosenwald et al., 2002). Another distinction between ABC- and GCB- DLBCL is 
the presence of ongoing somatic hypermutation only in the GCB subgroup (Lossos et 
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al., 2004). Lastly, certain CGH detected gains and losses were seen more frequently in 
the different subtypes: ABC-DLBCL (trisomy 3, gains of 3q and 18q21-q22, and losses 
of 6q21-q22), GCB-DLBCL (gains of 12q12) and PMBCL (gains of 9p21-pter and 
2p14-p16) (Bea et al., 2005). However only gain of 3p11-p12 was an independent 
adverse prognostic factor, an abnormality not unique to the ABC subset.
Summary of the Subsequent DFCI DLBCL Microarray Paper
In 2005 the DFCI consortium published their second paper reporting the results of 
expression profiling of presentation DLBCL material – the follow-on paper to that 
described in this Chapter (Monti et al., 2005). In this research two weaknesses of the 
experiments described in this Chapter and the first paper from the LLMPP were 
overcome, namely small cohort size and a restricted gene set on the microarray. A large 
cohort of 176 presentation DLBCL samples were arrayed and the most comprehensive 
array developed, the Affymetrix HG-U133 A and B series (39,000 transcripts, 
representing 33,000 genes) was used (Monti et al., 2005). For 130 samples, 
corresponding patient clinical data was available and all had received CHOP-based 
treatment. Monti et al set out to molecularly subdivided DLBCL into robust subtypes. 
Instead of using supervised hierarchical clustering and the 100-gene ‘cell-of-origin’
classifier of the LLMPP, the DFCI consortium followed the example of Todd Golub 
(the DFCI microarray project leader) in his seminal report on the molecular 
classification of acute leukaemia using self-organising maps in an unsupervised 
analysis, as described in Chapter 1.4.14 (Golub et al., 1999). To ensure the 
reproducibility of any classifier created by the self-organising maps method, two other 
analysis tools were used to verify the findings: model-based probabilistic clustering and 
hierarchical clustering. Monti et al discovered that the DLBCL cohort could be divided 
into subgroups of between two and nine in number. After testing for stability by 
consensus clustering, a consensus matrix was constructed based upon sample 
assignment agreement. The result was the same using the three analysis tools: three 
distinct clusters, with 80% of the samples being assigned to the same cluster by the 
three algorithms. Again a different strategy to that of the LLMPP was used in order to 
bring meaning to the three clusters/subgroups produced. Rather than impose ‘cell-of-
origin’ signatures upon the three clusters, gene set enrichment analysis was performed 
to identify groups of genes differentially expressed in the three clusters from within 281 
recognised gene sets. The first cluster (termed ‘OxPhos’) was found to be significantly 
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enriched for oxidative phosphorylation, mitochondrial function and electron transport 
chain genes. The second cluster (termed ‘BCR/Proliferation’) had greater expression of 
cell cycle regulatory genes, DNA repair genes, and components of the BCR-signalling 
cascade. The third cluster (termed ‘Host Response’) appeared to be largely defined by 
the host response rather than the tumour itself, due to increased expression of T-cell 
receptor components, molecules associated with T/NK (natural killer) -cell activation 
and the complement cascade and markers of ongoing inflammation/immune response.
Using all three analysis techniques, 28% of samples were assigned to the ‘OxPhos’
cluster, 28% to the ‘BCR/Proliferation’ cluster, 24% to the ‘Host Response’ cluster and 
16% were inconsistently classified. The 5-year OS for the patients assigned to each of 
the three clusters were similar. Importantly, thanks to the comprehensive array used, 
sufficient genes were found in common with the Lymphochip for the three consensus 
clusters to be successfully reproduced from within the LLMPP series of 240 DLBCL. 
The DFCI molecular classifier of DLBCL was therefore reproducible in the other large 
DLBCL gene expression dataset created using a different array. Importantly, no 
correlation between ‘cell-of-origin’ subgrouping and the ‘OxPhos, BCR/Proliferation,
Host Response’ consensus clustering was discovered, indicating that the two 
classification systems were capturing largely different aspects of DLBCL biology.
Critique of the Subsequent DFCI DLBCL Microarray Paper
The major disappointment with the paper of Monti et al is in what it didn’t say rather 
than what it did. There is no mention of any attempt to investigate the ability of the 13-
gene or the 17-gene models, or the ‘cell-of-origin’ classifier at outcome prediction in 
the 130 samples with allied clinical data.  This constitutes a surprising omission, given 
that this was the major achievement of the group’s first paper - the subject of this 
Chapter. No independent analysis of this dataset has been published addressing this 
issue.
In conclusion, Monti et al successfully used a different approach to gene expression 
profiling to that of the LLMPP, so by creating a novel molecular classifier of DLBCL 
and revealed new insights into the molecular aetiology of DLBCL. In particular, this 
paper gives credence as much to the non-malignant milieu as to the malignant 
characteristics of DLBCL in terms of influencing tumour biology and response to 
treatment.
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DLBCL Microarray Data from Tumour Samples of Patients Treated with CHOP-
R-like Treatment
IN 2007 an ASH meeting oral presentation by the LLMPP described the results of gene 
expression profiling of 156 DLBCL samples from previously untreated patients using 
the Affymetrix U133 plus chips (Lenz et al., 2007). All patients received rituximab and 
CHOP-like chemotherapy. Seventy one DLBCL samples were classified as GCB-
DLBCL, 63 as ABC-DLBCL, and 22 as Type 3. After a median follow-up of 2.3 years, 
addition of rituximab to CHOP-like chemotherapy GCB-DLBCL had a superior OS 
compared to ABC-DLBCL, with 3-year OS rates of 86% for GCB-DLBCL vs. 68% for 
ABC-DLBCL (P = 0.014). The 3-year OS rate of unclassified DLBCLs was 69%. The 
‘lymph node’ signature was associated with favourable OS (p = 0.023) and the 
‘proliferation’ signature with inferior OS (p = 0.009). Therefore the previously 
described findings of the LLMPP (detailed above) have held true on addition of 
rituximab to chemotherapy.
Quantitative Real-Time Polymerase-Chain-Reaction Analyses: an Alternative to 
Microarray Gene Expression Profiling?
Lossos et al sought to make the findings described in this Chapter and those of the 
LLMPP simpler to replicate and of prognostic significance in both of these, and 
hopefully future, series by restricting the genes investigated to 36 and using RQ-PCR to 
quantify gene expression (Lossos et al., 2004). The 36 genes were investigated for 
correlation with OS in 66 newly diagnosed DLBCL patients using univariate Cox 
proportional models. The six most significant genes were included in a multivariate 
proportional hazards model, coefficients derived and the cases stratified into three 
prognostic groups – low-, intermediate- and high-risk. Lossos et al then validated their 
6-gene model in both the DFCI/SBH 58 DLBCL series and the LLMPP 240 DLBCL 
series, demonstrating that the model could stratify into three groups with different OS in 
the Rosenwald et al series and two groups in the Shipp et al series with the intermediate 
and high risk having similar OS in the latter series.
Last year the same 6-gene model was proven to still be predictive of outcome following 
R-CHOP therapy for DLBCL (Malumbres et al., 2007). Using RNA extracted from 100 
patient’s paraffin-embedded specimens (up to six years old) the expression of the six 
genes comprising the model was measured in these samples and the mortality-
prediction score was calculated for each patient. The 3-year OS was 80% in the low risk 
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and 50% in the high risk groups, respectively. The predictive power of the 6-gene 
model was independent of the IPI prognostic factors for prediction of OS (P = 0.06) and 
PFS (P = 0.01) in these patients. If validated in an independent patient series, the 6-gene 
model could be easily added to routine clinical investigation in major treatment centres.
In Silico Reanalyses of DLBCL Microarray Datasets
At least five papers have reanalysed the DFCI/SBH dataset described in this Chapter 
and/or the LLMPP dataset of 240 DLBCL to produce models predictive of OS. Matsui 
used his group’s novel prediction models to create an 85-gene model to predict OS for 
the LLMPP patients (Matsui, 2006). Bair and Tibshirani arrived at a 23-gene model 
predictive of OS using semi-supervised methods and est statistics (Bair and Tibshirani, 
2004).
Because the ‘cell-of-origin’ classifier failed to predict for survival in the DFCI/SBH 
series described in this Chapter, Wright et al reanalysed the later LLMPP dataset of 240 
DLBCL in an attempt to reconcile the disparate findings of the two groups in regard to 
the outcome predictive ability of the ‘cell-of-origin’ classifier (Wright et al., 2003). 
Using Bayes rule and ‘compound covariates/linear predictor scores’ to distinguish 
between the subtypes of GCB- and ABC-DLBCL, a 27-gene model was derived from 
those genes differentially expressed between the ‘cell-of-origin’ subgroups in the 
Rosenwald et al series. Using this model, Wright et al were able to reproduce GCB and 
ABC subgroups with significantly different 5-year OS in the LLMPP series and also in 
the DFCI/SBH series of samples and patients (using the 14 out of the 27 genes form the 
model present on the Hu6800). For the DFCI/SBH dataset, the 5-year OS rates for the 
GCB and ABC DLBCL patients were 62% and 26%, respectively (P = 0.005) (Wright
et al., 2003). Significant results but still considerably less predictive than the 5-year OS 
of 70% and 12% for the ‘alive and cured’ and ‘fatal/refractory disease’ groups defined 
by the 13-gene model (p = 0.00004) (Shipp et al., 2002).
In a further paper, two of the principal concerns with the data analysis methods of 
Rosenberg et al, namely the subjective and informal means of signature assignment and 
selection, led Segal et al to reanalyse the LLMPP 240 series data using a range of 
techniques (Senftleben et al., 2001). Segal et al concentrated on searching for gene 
expressions associated with outcome. They found that an L1 penalised proportional 
hazards method (Gui and Li, 2005) produced the best predictor of outcome followed by 
the original 17-gene model of Rosenberg et al. Using area under time dependent ROC 
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curves, Segal et al found that the predictive powers were 67% and 65% for the L1
penalised proportional hazards method and 17-gene model respectively. Segal et al also 
sought evidence that the outcome predictive models from the LLMPP and the 
DFCI/SBH series were transferable to the competitor’s dataset. After restriction to the 
genes from the Lymphochip common to the Hu6800 Affymetrix array, use of the L1
penalised proportional hazards method resulted in a 3-gene model, which had a 65% 
predictive power in the LLMPP series it was derived from, but a lower 60% predictive 
power in the DFCI/SBH series. Conversely, the 6-gene model, produced from the 
DFCI/SBH dataset, when subjected to the L1 penalised proportional hazards method 
resulted in a 78% predictive power for post-treatment outcome in the DFCI/SBH series 
it was derived from but only a 53% predictive power for OS estimation in the rival 
LLMPP series i.e. little better than by chance alone. The 6-gene model of Lossos et al, 
described above (Lossos et al., 2004), fared badly in both series, with OS predictive 
power of 59% and 61% in the LLMPP series and the DFCI/SBH series respectively.
Are the Results of this Chapter still of Importance?
Distinguishing FL from DLBCL by Gene Expression Profiling
This was a major achievement. The utility of the 30-gene discriminator in other datasets 
and the development of a successor created from the more recent and comprehensive 
Affymetrix arrays are awaited. It is expected that investigation of differential expressed 
genes between FL and DLBCL will help unravel their respective pathogeneses and 
suggest potential treatment targets for investigation.
Distinguishing ‘alive and cured’ from ‘dead-from-disease/refractory’ Patients with 
DLBCL
This was an attention grabbing achievement and remains so as an exercise in proof of 
principle: namely supervised analysis of gene expression data can produce a post-
treatment outcome predictor from pre-treatment malignant tissue. That such a predictor 
can be distilled into a small number of genes from the many differentially expressed 
between the two outcome groups is remarkable. The independence of the molecular 
predictor from the clinical IPI gives the promise of long-term utility of such models and 
strengthened the predictive power of a combined molecular and clinical score.
SBH Cohort Specific Results
The finding that a completely different 19-gene set to the 13-gene model proved more 
effective at outcome prediction within the 19 SBH but not the 37 DFCI patients and 
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samples is initially alarming but on reflection not surprising. There is a massive 
imbalance between data points and samples in microarray experiments, with a multitude 
of varying genes exhibiting differential expression. The top genes for such 
discriminations vary depending firstly on the genes present on the arrays, next 
according to the thresholding used and lastly according to the analysis techniques 
employed. Thus for the DFCI/SBH dataset three outcome predictors are effective in the 
SBH cohort (the original 13-gene model, the Wright et al ‘cell-of-origin’ 14 of 27-gene 
model and the SBH specific 19-gene model), whilst in the LLMPP 240 DLBCL series 
five different models have been published that are capable of outcome prediction (as 
detailed above), none of which contain anything but a few overlapping genes with the 
original 17-gene model. The disappointment of this revelation is that the holy grail of a 
universally applicable molecular outcome predictor is no longer readily in sight. I 
anticipate that many hundreds to several thousands of similarly treated patients will 
need presentation material to be arrayed using the same array for the core of universally 
applicable outcome predictive genes to be truly identified. Furthermore, the change of 
empirical treatment from chemotherapy to immunochemotherapy necessitates repeat 
microarray investigation to ascertain the relevance of the described outcome predictive 
expression models and to search for new prognostic expression signatures.
Shipp vs. Staudt: which strategy will triumph?
Microarray Platform
Realistically the lymphochip, as used in the LLMPP papers will not become standard 
clinical kit nor will a version with a greatly reduced number of features. It simply 
cannot be manufactured with adequate provision of identical control cDNA for 
worldwide research or clinical utility. The Affymetrix system is more quantitative and 
allows results to be interpreted and combined between series and institutions, as no 
control cDNA is required. Equally the Affymetrix chips used to date will not be widely 
used at the clinical level: the Hu6800 has already been withdrawn due to larger, more 
comprehensive chips succeeding it (e.g. the HG-U133 PLUS chip featuring 47,000 
transcripts, which represent 38,000 genes). Indeed the most recent LLMPP DLBCL 
microarray study used the HG-U133 PLUS chip (Lenz et al., 2007). Even the most 
recent chips are not useful to molecular pathology laboratories long-term due to the 
gross redundancy of features. Quite simply there are too many genes of no relevance 
present, making the complexity of analysis and the cost prohibitive. The development of 
Chapter 5
211
custom-made chips with a much reduced number of DLBCL relevant features capable 
of translating outcome predictive molecular insights from DLBCL into sufficiently 
robust, affordable and practical tests to allow them to be used clinically. The fashion for 
Bcl-6 and CD-10 IHC may be a complementary response by pathologists to the ABC 
vs. GCB distinction but it remains of little clinical relevance, as there are no ABC vs. 
GCB defined treatment decisions to be made as yet. The treatment of DLBCL remains 
empirical and still largely generic despite the introduction of rituximab and dose-dense 
therapy as described in Chapter 1. Until more treatment choices are available, the 
molecular prediction of which treatment to use remains impossible and all outcome 
predictive gene expression models remain solely prognostic and not predictive.
Aetiological Molecular Classification
In terms of aetiological molecular classifications I think Staudt’s ‘cell-of-origin’
classifier will be (and needs) refinement due to the ‘Type 3’ subgroup comprising more 
than the ‘ABC’ subgroup and the latter subgroup being arbitrarily if apparently 
successfully defined. The DFCI consortium approach of consensus clustering followed 
by gene set enrichment analysis looks more promising in terms of identifying the 
multiple pathways and processes critical to lymphomagenesis and potentially allowing 
complex mapping of serially acquired abnormalities along the lines of Horsman et al 
with CGH abnormalities in FL (Hoglund et al., 2004). One potential unifier of the 
LLMPP and DFCI hypotheses is that the malignant cell signatures are divisible by a 
‘cell-of-origin’ classifier and that consensus clustering dissects the non-malignant 
cellular component of the malignant phenotype. It will be important to perform analyses 
on the non-malignant and malignant cell populations individually and assess their 
contributions to the ‘GCB’, ‘ABC’ and ‘Type 3’ division and ‘OxPhos, 
BCR/Proliferation and Host Response’ subgrouping.
Gene Expression Outcome Prediction
In terms of gene expression models for outcome prediction, I consider Staudt et al to be 
ahead. Their 17-gene model, despite its subjective and informal construction, produced 
impressive results within the three risk groups defined by the IPI. If this model 
continues to stratify within the IPI subgroups following CHOP-R treatment it could well 
become established as an aid to risk estimation for patients and therefore treatment 
stratification within and outside of clinical trials. The hurdle of rapid and affordable 
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results production for such a labour intensive and costly test may limit such a molecular 
predictive tool’s accessibility.
Although the 13-gene model was created in a more rational way to the rival 17-gene 
model (and proved highly effective in the 58 DLBCL cases and samples investigated) I 
feel it is unlikely to be used, due to it remaining of unproven utility beyond its original 
dataset. I anticipate that Shipp et al will create a successor to the 13-gene model for 
outcome prediction following rituximab-polychemotherapy using the vastly more 
comprehensive modern Affymetrix chips.
My concerns with gene expression models are that the choice of genes predictive of OS 
can clearly be influenced by the methods and dataset used to create it; that the variation 
in genes between models suggests that the number of genes with predictive power is 
likely to be considerably larger than at first thought and can be expected to grow, rather 
than shrink, as more genes and DLBCL samples are surveyed; and that application of a 
particular model to a new sample or series may not produce the individualised risk 
stratifying predictions so hoped for from gene expression profiling. The potential 
clinical application of upfront gene expression profiling to stratify patients and 
determine treatment is therefore likely to be further off than hoped. Ultimately I believe 
that expression profiling of pretreatment DLBCL will only ever provide part of the 
answer to treatment outcome, even in combination with the IPI or equivalent clinical 
variables. Potential closure of this area of uncertainty in prediction may come through 
pharmacogenomic analyses to create a tripartite predictor, which quantifies risk due to 
the patient’s clinical condition, their lymphoma’s biology and their drug handling 
characteristics.
Subsequent Research for this Thesis - Validation of the 13-gene Model
Through rational investigation using gene expression profiling a molecular predictor of 
OS was produced. To further investigate the 13-gene model constituents as molecular 
targets in DLBCL I went on to study inhibitors of PKC and PDE4B, two of the 13 
gene-model’s poor prognostic genes common to all of the 58 DLBCL individual 
predictor models on ‘leave-one-out’ cross-validation. Furthermore, both PKC and 
PDE4B were predictive of OS in the Alizadeh et al dataset and have recognised 
functions in haematological cells. If the overexpression of these two genes indeed has a 
direct influence upon DLBCL response and resistance to chemotherapy, inhibitors of 
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PKC and PDE4B used alone or in conjunction with established cytotoxics in vitro
should induce cytostasis or cytotoxicity.
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CHAPTER 6: IN VITRO INVESTIGATION OF THE RATIONAL TARGETS 
PDE4B AND PKC
6.1 Chapter Summary
Two of the seven poor-risk genes (PDE4B and PKC  from the 13-gene outcome to 
treatment prediction model described in Chapter 5 were selected for in vitro inhibition 
to ascertain if either could be a novel rational target for therapy. In vitro studies were 
performed using the panel of DLBCL cell-lines and primary lymphoma cultures 
employed in Chapter 4.
PDE4B inhibition using the PDE4 inhibitors rolipram and the more potent and PDE4B 
selective piclamilast proved incapable of diminishing cell count, proliferation or 
viability, either alone or with the established chemotherapy drugs doxorubicin and 
cytosine arabinoside. This inactivity was despite evidence of PDE4 inhibition producing 
c-AMP elevation. When the c-AMP augmenter forskolin was used, cell count inhibition 
was seen in all four DLBCL cell-lines and the primary CLL/SLL sample 02. Forskolin 
produced a meaningful decrease in viability only in the most chemo-sensitive cell-line 
DoHH2. Combined exposure to a PDE4 inhibitor and forskolin proved no more 
effective than forskolin use alone. Isolated PDE4B inhibition therefore does not offer a 
rational, novel treatment strategy in DLBCL.
In contrast, the PKC inhibitor SC-236 was found to inhibit cell count and viability in 
all four DLBCL cell-lines and the four primary lymphoma samples cultured.  PKC
inhibition may therefore be a potential novel and rational means of increasing treatment 
efficacy in DLBCL.
6.2 Introduction
6.2.1 PDE4B as a Rational Target in DLBCL
The PDEs play a decisive role in cyclic nucleotide-mediated intracellular signalling 
through destruction, by hydrolysis of the 3’-5’-phosphodiester bond, of the ubiquitous 
second messengers cyclic guanosine 3’-, 5’- monophosphate (c-GMP) and cyclic 
adenosine 3’-, 5-’ monophosphate (c-AMP). Intracellular c-AMP levels are also 
controlled by the rate of synthesis of c-AMP by adenylate cyclase, an enzyme activated 
by extracellular signals, so by allowing diverse extracellular signals to mediate 
intracellular responses via c-AMP and c-GMP. PKA, a serine-threonine type of protein, 
and EPAC (Exchange Protein directly Activated by c-AMP) are the best-described 
effectors of c-AMP mediated signals (Figure 6.1).
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Figure 6.1 Basic c-AMP Regulation and Function. The diagram depicts the basic 
intracellular synthetic and regulatory pathways for c-AMP. CNG channels = Cyclic Nucleotide Gated 
channels; GEFs = Guanine-nucleotide Exchange Factors; EPAC = Exchange Protein directly Activated 
by c-AMP; PKA = Protein Kinase A; PDEs = Phosphodiesterases; 5’-AMP = 5’ adenosine 
monophosphate; Gs= guanine nucleotide-binding stimulatory protein/adenylate cyclase 
stimulatory protein, alpha beta and gamma subunits; ATP = adenosine triphosphate; c-AMP = cyclic 
adenosine monophosphate. Adapted from (Beavo and Brunton, 2002)
Eleven PDE families have been described containing 50 different proteins and splice 
variants encoded by more than 20 genes, as summarised in Table 6.1 (Beavo, 1995, 
Soderling and Beavo, 2000). PDE iso-enzymes differ from each other in molecular 
structure, catalytic properties, intracellular regulation and location, and sensitivity to 
selective inhibitors. The common catalytic core of each PDE has 25-40% homology 
between PDE families and >80% homology within each PDE class.
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PDE 
Isoenzyme
No of 
Genes
No. of 
Isoforms Substrate
Km 
(M)
c-
AMP
Km 
(M)
c-
GMP
Tissue Expression Specific/Selective 
inhibitors * References
PDE 1 3 8 Ca
2+/calmodulin-
stimulated 1–30 3 Heart, brain, lung, smooth muscle
KS-505a (0.17-13)
Vinopocetine (5-25)
(Han et al., 1999, Ichimura et 
al., 1996)
PDE 2 1 c-GMP-stimulated 50 50 Adrenal gland, heart, lung, liver, platelets
EHNA (1)
8-MM-IBMX (0 4) (Mery et al., 1995)
PDE 3 2 4 c-GMP-inhibited, c-AMP-selective 0.2 0.3
Heart, lung, liver, platelets, 
adipose tissue, inflammatory cells
Cilostamide (0.005)
Milrinone (0.3)
Siguazodan (3)
(Nicholson and Shahid, 1994, 
Manganiello et al., 1995, Sudo et 
al., 2000)
PDE 4 4 20 c-AMP-specific 4 Sertoli cells, kidney, brain, liver, lung, inflammatory cells
Rolipram (1)
Roflumilast  
Piclamilast (0.001)
(Hatzelmann and Schudt, 2001, 
Ashton et al., 1994, Reeves et 
al., 1987)
PDE 5 1 3 c-GMP-specific 150 1 Lung, platelets, vascular smooth muscle
Sildenafil (0.003)
Zaprinast (0.3)
Dipyridamole (0.9)
(Stacey et al., 1998, Turko et al., 
1999)
PDE 6 4 4 c-GMP-specific 60 Photoreceptor Zaprinast (0.15)Dipyridamole (0.4)
(Zhang et al., 2005b, Gillespie 
and Beavo, 1989)
PDE 7 2 3 c-AMP-specific, high-affinity 0.2
Skeletal muscle, heart, kidney, 
brain, pancreas, T lymphocytes BRL-50481 (0.2) (Smith et al., 2004)
PDE 8 2 c-AMP-selective, 0.06
Testes, eye, liver, skeletal muscle, 
heart, kidney, ovary, brain, T 
lymphocytes
Dipyridamole (4-9) (Soderling et al., 1998)
PDE 9 1 4 c-GMP-specific, 0.17 Kidney, liver,lung, brain BAY 73-6691 (0.06) (Wunder et al., 2005)
PDE 10 1 2 c-GMP-sensitive, c-AMP-selective 0.05 3.0 Testes, brain SCH 51866 (1) (Soderling et al., 1999)
PDE 11 1 4 c-GMP-sensitive, dual specificity 0.7 0.6
Skeletal muscle, prostate, kidney, 
liver, pituitary and salivary glands, 
testes
Tadalafil (0.07)
Zaprinast (11–33) 
Dipyridamole (1.8)
(Bischoff, 2004)
Table 6.1 The PDE Family. The PDE enzyme’s ability to metabolise c-AMP and c-GMP, their tissue expression and best pharmacological inhibitors 
are displayed. * The numbers in brackets are the Ki or IC50 values, in mM, for the inhibitor against the PDE family in question. Table adapted from 
(Boswell-Smith et al., 2006, Feil et al., 2003). Chapter 6
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The PDEs are differentially expressed in various cell types by virtue of different 
transcription initiation sites or by alternative mRNA splicing (Beavo, 1995, Soderling 
and Beavo, 2000). Three PDE families are c-AMP specific: PDE4, PDE7 and PDE8 
(Conti et al., 2003, Bloom and Beavo, 1996, Kobayashi et al., 2003). PDE1 and PDE3 
hydrolyse both c-AMP and c-GMP, whilst PDE2, PDE5 and PDE9 hydrolyse c-GMP 
preferentially (Degerman et al., 1997, Meyer et al., 2000, Rybalkin et al., 2003, Huai et 
al., 2004). PDE6 (rod PDE) is the key effector enzyme of vertebrate visual transduction 
and is specific to the retina (He et al., 2000). PDE11A is the most recently cloned PDE 
belonging to a new family of unknown physiological significance (Fawcett et al., 2000).
PDE4 was selected as a rational target for inhibition in DLBCL because the gene 
appeared to be actively contributing to the chemoresistant phenotype rather than merely 
being a bystander gene for the following reasons: -
i. PDE4B was overexpressed in poor prognosis DLBCL patients in three independent 
microarray series.
ii. PDE4 is the principle phosphodiesterase in B- and T- lymphocytes.
iii. PDE inhibition has been proven to be cytotoxic in two other lymphoproliferative 
malignancies in vitro.
iv. PDE inhibitors are being actively developed for clinical use and a whole class of 
orally administered PDE4 selective inhibitors are approaching licensing.
i. PDE4B was overexpressed in poor prognosis DLBCL patients in three 
independent microarray series.
In the DLBCL microarray series described in Chapter 5, PDE4B was a component of 
the 13-gene model of all 58 cases, being overexpressed in the ‘fatal/refractory disease’
patients (Table 5.2). Furthermore PDE4B was overexpressed in the poorer prognosis 
ABC-like patients in the LLMPP consortium series (Rosenwald et al., 2002, Alizadeh et 
al., 2000) and was overexpressed in the transformed FL biopsy series microarrayed by 
Davies et al (personal communication).
ii. PDE4 is the principle phosphodiesterase in B- and T- lymphocytes.
In B- and T- lymphocytes PDE4 is the major PDE family expressed followed by PDE7, 
with marginal PDE3 activity (Gantner et al., 1998). The PDE4 family consists of 
PDE4A, B, C and D, with isoforms of each existing. PDE4B isoforms are the principal 
subtype seen in lymphocytes, where they exert differing effects depending on the type 
and physiological state of the lymphocytes. PDE4 isoforms, by virtue of their unique 
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intracellular targeting, play a pivotal role in controlling functionally and spatially 
distinct pools of c-AMP. Targeting occurs through association with proteins, such as 
arrestins, SRC family tyrosyl kinases, A-Kinase Anchoring Proteins (AKAPs) and 
Receptor for Activated C kinase-1 (RACK1) – reviewed in (Houslay and Adams, 2003). 
In T-cells, the c-AMP pathway promotes apoptosis and has an inhibitory action on T-
cell proliferation (Kizaki et al., 1990, Averill et al., 1988). Specific inhibition of PDE4 
preferentially blocks the production of Th1 versus Th2 effector cytokines in vitro
(Claveau et al., 2004). Similarly in GC B-cells and resting human peripheral blood B-
cells, elevation of c-AMP levels promotes apoptosis (Knox et al., 1993). For example 
the c-AMP-inducing agent forskolin caused a significant, concentration-dependent 
increase in cell death (relative to spontaneous death in medium alone) in resting human 
peripheral blood B-cells, an effect reversed by B-cell activation using IL-4 and TPA (O-
tetradecanoylphorbol-13-acetate) (Lomo et al., 1995). On the contrary, peripheral B-cell 
proliferation (in response to a mitogenic stimulus) can be further enhanced by 
pharmacological elevation of c-AMP (Gantner et al., 1998). On stimulation of CD19+ 
peripheral blood lymphocytes with lipopolysaccharide and IL-4, c-AMP levels rose and 
increased further on addition of the PDE4 inhibitors rolipram and piclamilast, with 
further augmentation of their proliferative response. The effect of the PDE4 inhibitors 
could be partly replicated by using c-AMP analogues, whilst addition of an inhibitor of 
PKA, the major c-AMP effector, led to a decreased proliferative response in control 
cells and reversed the proliferative response induced by rolipram (Gantner et al., 1998). 
These data suggest that the c-AMP-dependent second messenger system plays 
dramatically different roles in resting and activated peripheral B-cells and germinal 
centre B-cells, promoting apoptosis in resting B-cells and survival and proliferation in 
activated B-cells. These data indicate the potential importance of PDE4 inhibition in 
DLBCL but also raise the possibility of stimulation not inhibition of ABC-like DLBCL, 
if the findings of Gantner et al are valid and applicable to malignant B-cells.
iii. PDE inhibition has been proven to be cytotoxic in two other 
lymphoproliferative malignancies in vitro.
Data indicating cytostatic and cytotoxic activity of PDE4 inhibition in 
lymphoproliferative malignancies comes from in vitro work in ALL and CLL. In a 
glucocorticoid-resistant subclone of the human T-cell ALL cell-line CEM (CEM-GH), 
non-specific PDE inhibition by methylxanthines, PDE4 inhibition by rolipram and c-
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AMP augmentation by forskolin-induced adenylate cyclase stimulation, all led to 
decreased CEM-GH cell proliferation in a concentration-dependent manner (Ogawa et 
al., 2002). Forskolin proved the most potent of these drugs at inducing dexamethasone 
sensitivity in this glucocorticoid-resistant cell-line, increasing the sensitivity to 
dexamethasone 1,000-fold compared to just 5-fold for the PDE inhibitors (Ogawa et al., 
2002). In primary CLL cells ex vivo cell death was induced by PDE4 inhibition in 
conjunction with c-AMP level elevation by the adenylate cyclase potentiator forskolin, 
an effect further augmented by simultaneous PDE3 inhibition (Moon et al., 2002, Moon 
and Lerner, 2003). Beyond Lerner and Moon’s laboratory research a randomised 
clinical trial of chlorambucil ± theophylline in CLL found that the CR rate and the EFS 
were significantly better in the combination therapy arm (Mabed et al., 2004). These 
results suggest the potential for efficacy of PDE4B inhibition in DLBCL.
iv. PDE inhibitors are being actively developed for clinical use and a whole class of 
orally administered PDE4 selective inhibitors are approaching licensing.
The clinical use of PDE inhibitors goes back more than 30 years to the introduction of 
the non-selective PDE inhibitors theophylline and aminophylline for the treatment of 
reactive airways diseases, due to their anti-inflammatory properties. The interaction of 
theophylline and aminophylline with other drugs and their narrow therapeutic indices 
has limited their use. Rolipram was the first selective PDE4 inhibitor to enter clinical 
practice, as an antidepressant, in the 1980’s, leading to the second-messenger 
dysbalance hypothesis of affective disorders (Zeller et al., 1984, Wachtel, 1990). 
However, the efficacy of rolipram proved to be no better than that of the tricyclic 
antidepressants with production of the troublesome side-effect of nausea (Scott et al., 
1991). In neurons, elevation of c-AMP promotes cell survival not cell death, in contrast 
to resting thymocytes and lymphocytes (Li et al., 2000). Resurgent medical interest in 
rolipram and PDE4 inhibition has followed reports of its ability to promote functional 
recovery, axon growth, and attenuation of glial scarring after spinal cord injury, when 
combined with embryonic spinal or Schwann cell grafts in rodents (Nikulina et al., 
2004, Pearse et al., 2004).
The development of more selective PDE4 inhibitors than rolipram has been actively 
pursued for the treatment of asthma and chronic obstructive pulmonary disease 
(COPD). Such inhibitors have demonstrated immunosuppressive and anti-inflammatory 
effects (Souness et al., 2000). PDE4B inhibition appears to result in anti-inflammatory 
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effects whilst PDE4D inhibition leads to the undesirable side-effect of nausea through 
stimulation of neurons in the vomiting centre of the area postrema (Manning et al., 
1999). The two most advanced PDE4 inhibitors in clinical development are roflumilast 
and cilomilast, the latter being ten times more selective for PDE4D than PDE4B with 
more nausea associated with its use (Lipworth, 2005). Roflumilast is in late phase III 
studies for use in both asthma and COPD, whilst cilomilast is in late phase III studies 
for COPD only, due to lack of efficacy in asthma. In mild to moderate persistent 
asthma, roflumilast has proven as effective as the gold standard treatment, low-dose 
inhaled corticosteroids (Izquierdo et al., 2003). The commonest side-effects of 
roflumilast are higher in the first weeks of therapy and then settle to the following 
incidences: headache (6%), diarrhoea (3%), nausea (1%) and abdominal pains (1%) 
(Izquierdo et al., 2003). Such a side-effect profile would be readily accepted in the field 
of oncology and indicates the feasibility of combining PDE4 inhibition with 
conventional polychemotherapy.
Choice of PDE4 Inhibitors for in vitro Experiments
Taken together these data support the investigation of PDE4B inhibition in DLBCL and 
suggest that PDE4 inhibition may contribute to the reversal of the chemoresistant 
phenotype present in half of DLBCL. In addition to rolipram, a selective PDE inhibitor, 
piclamilast, was obtained for in vitro cell-line and primary culture experiments in 
DLBCL. The Ki (the dissociation constant for the enzyme-inhibitor complex) for 
rolipram against human PDE4 and PDE3 are 2.4 M and >25 M respectively (Reeves
et al., 1987). In contrast, the Ki for piclamilast against PDE4 has consistently been 
shown to be only 1nM (Ashton et al., 1994).
6.2.2 PKC as a Rational Target in DLBCL
The protein kinase C (PKC) family of serine-threonine kinases consists of at least ten 
members classified as conventional (PKC , 1, 2, and ), novel (,   and ) or 
atypical (PKC and PKC) according to their activation by the lipid second messenger 
diacylglycerol, calcium or phosphatidylserine – reviewed in (Mellor and Parker, 1998). 
A related enzyme, PKC (alternative name protein kinase D) displays multiple unique 
features that make it a distant relative of the PKC enzymes (Johannes et al., 1994). With 
the exception of PKC1 and 2, which are alternative spliced variants, each PKC 
enzyme is the product of a separate gene. Evidence indicates that the , ,  and the 
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atypical isoforms are anti-apoptotic in their action, whereas the  and  isoforms are 
usually involved in the promotion of apoptosis – reviewed in (Gutcher et al., 2003).
In vitro exploration of PKC inhibition as a novel and rational means of DLBCL 
control and eradication was undertaken for the following reasons: -
i. The microarray data described in Chapter 5 and in the LLMPP series.
ii. The importance of PKC for effective BCR signalling.
iii. In vitro and animal data demonstrating a causal link between PKC and the 
malignant phenotype of cell-lines and the development of gastrointestinal tumours.
i. The microarray data described in Chapter 5 and in the LLMPP series.
In the DLBCL microarray series described in Chapter 5, PKC2, like PDE4B, was a 
component of the 13-gene model of all 58 cases, being overexpressed in the 
‘fatal/refractory disease’ patients. PKC was also overexpressed in the poorer 
prognosis ABC-DLBCL patients in the LLMPP consortium series, indicative of a 
potentially causal role of PKC in poor prognosis/chemoresistant DLBCL (Rosenwald
et al., 2002, Alizadeh et al., 2000).
ii. The importance of PKC for effective BCR signalling.
PKC1 and –2 have been shown to play a critical role in BCR dependent NFB 
survival signalling. PKC1 and PKC2 (and PKC deficient mice exhibit severe 
immunodeficiencies because B-cell and T-cell receptor engagement cause cell death 
rather than proliferation (Sun et al., 2000, Leitges et al., 1996). In contrast, PKC
deficiency in mice causes B-cell hyperactivity with the development of autoimmune 
disease (Miyamoto et al., 2002). Subsequent investigation has shown that PKC is 
required for the correct formation of the lipid rafts of the BCR signalosome, which 
allow the recruitment of IB kinase (Su et al., 2002).
iii. In vitro and animal data demonstrating a causal link between PKC and the 
malignant phenotype of cell-lines and the development of gastrointestinal tumours.
PKC2 has been linked to carcinogenesis in animal models of gastrointestinal tumours. 
PKC2 overexpression in the colon of transgenic mice produces hyperproliferation and 
an increased incidence of colon carcinoma (Murray et al., 1999). This activity is 
achieved through induction of COX-2, suppression of TGF- signalling, and 
establishment of a TGF--resistant, hyperproliferative state in the colonic epithelium 
(Yu et al., 2003). When PKC2 is overexpressed in rat intestinal epithelial cells, an 
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invasive phenotype develops, which is blocked by use of the PKC1 and -2 inhibitor 
Ly379196. Invasion is produced through PKC activating K-Ras, which in turn 
activates Rac1 leading to Mek activation (Zhang et al., 2004a).
Choice of PKC Inhibitor for in vitro Experiments
The choice of SC-236 as the PKC inhibitor to investigate in vitro was made on the 
basis of its ability to induce apoptosis in the human gastric cancer cell-line AGS (Jiang
et al., 2002). In this cell-line PKC proved to be a survival mediator, with 
overexpression of PKC protecting the cells against SC-236. Importantly, the ability of 
SC-236 to decrease PKC protein expression and kinase activity was found to be 
independent of the COX-2 inhibitory properties of SC-236 (Jiang et al., 2002).
6.3 Methods
All work described in this Chapter was performed by myself. Three-day cell culture 
experiments were conducted using DLBCL cell-lines in exponential growth. Two-day 
cell culture experiments were undertaken with primary lymphoid malignant material 
(see Chapter 2). Different concentrations of PDE4 inhibitor or SC-236 alone or in 
combination with the established cytotoxics cytosine arabinoside and doxorubicin or the 
adenylate cyclase potentiator forskolin were added on day-0. Day-3 cell proliferation 
was measured by the MTS assay; day-3 cell count and viability were assessed by trypan 
blue exclusion assay. Each experiment was performed on at least three separate 
occasions, unless stated otherwise. The data analysis package, GraphPad prism 
software, was used to analyse results. One-way ANOVAs were performed to identify
statistically significant (P <0.05) differences in outcome variable (proliferation, cell 
count, viability) of the different concentrations and combinations of drugs used. To 
minimise the risk of false-positive differences being identified due to the multiple 
comparisons undertaken, Bonferoni’s multiple comparison test was applied to each set 
of one-way ANOVAs.
6.4 Results
6.4.1 Effect of Piclamilast on Cell Proliferation of DLBCL Cell-lines
Cell proliferation (assessed by MTS assay) of the DLBCL cell-lines SUD4, DoHH2 and 
CRL following 3-day exposure to piclamilast and DMSO is illustrated in Figure 6.2 and 
Appendix Table A6.1. For each cell-line no difference was observed between 
piclamilast 300 nM (DMSO = 0.03%), piclamilast 1000 nM (DMSO = 0.1%) and 
vehicle-only controls (P >0.05). DMSO, the initial solvent for piclamilast, had no effect 
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on cell proliferation until a 1% solution was used (present in 10,000 nM piclamilast 
solution) (P <0.001). Thus, although piclamilast 10,000 nM appeared to inhibit cell 
proliferation (64.9%, 49.7% and 63.3% cf. no treatment controls for SUD4, CRL and 
DoHH2 respectively), this effect was due to the 1% DMSO content of the 10,000 nM 
piclamilast solution (cell proliferation for 1% DMSO controls cf. no treatment controls 
being 58.6%, 40.1% and 65.1% for SUD4, CRL and DoHH2 respectively). In summary, 
the proliferation of SUD4, DoHH2 and CRL was not altered after 3-day exposure to 
piclamilast, despite use of concentrations up to 10,000-fold higher than the Ki for PDE4 
inhibition.
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Figure 6.2 Cell Proliferation after 3-day Exposure to Piclamilast assessed by MTS 
Assay After 3 days of exposure to piclamilast, media alone or DMSO controls, cell proliferation was 
assessed by MTS assay. Cell proliferation is displayed relative to no treatment controls. The results 
displayed are the mean of at least four independent experiments. The error bars represent the standard 
deviation.
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6.4.2 DLBCL Cell-line Proliferation after 3-day Exposure to Piclamilast, 
Cytosine Arabinoside and Doxorubicin 
The effects of 3-day exposure to piclamilast, cytosine arabinoside, doxorubicin and 
DMSO (as a control) upon cell proliferation in SUD4, DoHH2 and CRL are illustrated 
in Figures 6.3 and 6.4. For all three cell-lines a concentration-response effect to cytosine 
arabinoside alone was confirmed (P <0.001). For SUD4, CRL and DoHH2 no 
differences between the 0.25 and 0.5 x EC50 concentrations of cytosine arabinoside with 
or without piclamilast 300 nM (DMSO = 0.03%) and 1000 nM (DMSO = 0.1%) 
respectively were seen (P >0.05) (Appendix Table A6.2).  In each cell-line piclamilast 
10,000 nM (DMSO 1%) added to the 1- and 2- x EC50 concentrations of cytosine 
arabinoside appeared to inhibit cell proliferation compared to the 1- and 2- x EC50 
concentrations of cytosine arabinoside alone (P <0.001). However, in all three cell-lines 
this effect was due to the DMSO content of the piclamilast solution, as the one-way 
ANOVA of piclamilast 10,000 nM and the 1- x EC50 concentration of cytosine 
arabinoside compared to DMSO 1% and the 1- x EC50 concentration of cytosine 
arabinoside was not significant (P >0.05), whilst the combination of DMSO 1% and the 
1- x EC50 concentration of cytosine arabinoside compared to the 1- x EC50 concentration 
of cytosine arabinoside alone was significant, confirming that the antiproliferative effect 
was due to the solvent DMSO and not the PDE4 inhibitor (P <0.001) (Appendix Table 
A6.2).
For SUD4, CRL and DoHH2 3-day exposure experiments revealed the expected 
concentration-response effect to doxorubicin alone (P <0.001). For each of the cell-lines 
no differences between the 0.25- and 0.5- x EC50 concentrations of doxorubicin with or 
without piclamilast 300 nM (DMSO = 0.03%) and 1000 nM (DMSO = 0.1%) 
respectively were seen (P >0.05), with the exception of CRL and doxorubicin 20 nM 
with and without piclamilast 300 nM (DMSO = 0.03%), where the addition of 
piclamilast increased cell proliferation (P >0.05) (Appendix Table A6.3). Piclamilast 
10,000 nM (DMSO 1%) added to the 1- and 2- x EC50 concentrations of doxorubicin 
appeared to inhibit cell proliferation compared to the 1- and 2- x EC50 concentration of 
doxorubicin alone (P <0.001). However, as seen in the above-described experiments, 
the effect was due to the 1% DMSO content of the piclamilast solution and not 
piclamilast itself.
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In summary, both cytosine arabinoside and doxorubicin inhibited proliferation of the 
three cell-lines, whilst piclamilast in combination with the chemotherapy drugs cytosine 
arabinoside or doxorubicin had no effect on cell proliferation independent of the DMSO 
content remaining from the initial piclamilast stock solution. Piclamilast was therefore 
ineffective against the DLBCL cell-lines examined as a single agent and in combination 
with standard chemotherapy agents.
Figure 6.3 Cell Proliferation after 3-day Exposure to Piclamilast &/or Cytosine 
Arabinoside assessed by MTS Assay After a 3-day exposure to piclamilast, ara-c, DMSO 
control or neither the proliferation of the cell-lines was assessed by MTS assay. The mean proliferation is 
shown as a percentage relative to that of the no treatment control cells. A minimum of three independent 
experiments was conducted. Error bars represent the standard deviation.
Pic = piclamilast Ara-c = cytosine arabinoside A = SUD4; B = CRL; C = DoHH2
* Piclamilast 1000 nM +Ara-c vs. Ara-c with equivalent DMSO concentration = non-significant
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Figure 6.4 Cell Proliferation after 3-day Exposure to Piclamilast &/or Doxorubicin 
assessed by MTS Assay After a 3-day exposure to piclamilast, doxorubicin, DMSO control or 
neither the proliferation of the cell-lines was assessed by MTS assay. The mean proliferation is shown as 
a percentage relative to that of the no treatment control cells. A minimum of three independent 
experiments was conducted. Error bars represent the standard deviation.
Pic = piclamilast Dox = doxorubicin A = SUD4; B = CRL; C = DoHH2
* Piclamilast 1000 nM +Dox EC50 vs. Dox EC50 with equivalent DMSO concentration = non-
significant
6.4.3 Cell Count and Viability Results after 3-day Exposure to Piclamilast, 
Rolipram and Forskolin in DLBCL Cell-lines
The cell count results following 3-day exposure of SUD4, CRL, DoHH2 and DHL4 to 
piclamilast, rolipram and forskolin alone and in combination are displayed in Figure 6.5 
and Appendix Table A6.4. In CRL piclamilast 1 M and rolipram 100 M alone 
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reduced cell count to a mean of 74% (P <0.05) and 72% (P <0.01) respectively. DHL4 
cells were also affected by piclamilast 1 M and rolipram 100 M, as cell count 
reduced to a mean of 81% (P <0.05) and 76% (P <0.05) respectively. For DoHH2 cells, 
no cytostatic activity was seen for piclamilast 1 M (81% P >0.05), whilst rolipram 100 
M reduced cell count to a mean of 68% (P <0.01). In contrast, SUD4 was oblivious to 
3-day exposure to piclamilast 1 M and rolipram 100 M alone, retaining cell counts of 
97 and 89% respectively (P >0.05).
In contrast, single agent forskolin demonstrated cytostatic activity in all four cell-lines. 
This effect was most marked in DoHH2 where forskolin 40 M reduced cell count to a 
mean of 10% (P <0.001). SUD4 exhibited a concentration-response effect to forskolin, 
as cell count fell to 60% with 20 M and a further significant reduction when incubated 
with forskolin 40 M to 40% (P <0.05). For CRL, Forskolin 20 and 40 M also 
significantly decreased 3-day cell count compared to no treatment controls to 60% (P
<0.001), with no concentration-response effect being evident. Lastly DHL4 proved the 
least sensitive cell-line to forskolin 20 and 40 M, as cell count decreased only 
moderately to 75 and 57% respectively (P <0.001). The activity of forskolin was not 
accountable for by the DMSO content of the different concentrations. Only in SUD4 did 
the maximum concentration of DMSO used in the forskolin and PDE4 inhibitor 
combinations – 0.4% - have a minor effect on cell count. In none of the four cell-lines 
tested did the addition of rolipram or piclamilast to forskolin add to the cytostatic 
activity of forskolin alone (P >0.05).
The viability results following 3-day exposure of SUD4, CRL, DoHH2 and DHL4 to 
piclamilast, rolipram and forskolin alone and in combination are displayed in Figure 6.6 
and Appendix Table A6.4. Viability was unaffected in the four cell-lines by either the 
0.2 and 0.4% DMSO controls, piclamilast 1 M or rolipram 100 M – in keeping with 
the 3-day cell proliferation results described above (P >0.05). The viability of CRL and 
DHL4 cells was unaffected by forskolin alone or in combination (P >0.05). In SUD4 
forskolin caused a minor but significant fall in viability to 87% compared to no 
treatment controls with 40 M (P <0.05). Addition of rolipram and piclamilast to 
forskolin did not enhance the cytotoxic activity of forskolin alone (P >0.05). Only in 
DoHH2 did single agent forskolin 40 M produce a marked decrease in viability 
compared to no treatment controls (50%; P <0.001). The addition of piclamilast 1 M 
or rolipram 100 M to forskolin 20 M further and significantly increasing the 
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cytotoxic activity compared to single agent forskolin 20 M (37% P <0.05; 26% P
<0.001 respectively vs. 58% for forskolin 20 M compared to no treatment controls).
In summary, the PDE4 inhibitors failed to impact meaningfully on DLBCL cell-line 
viability after 3-day exposure when used alone or in combination with the c-AMP 
potentiator forskolin in all but the most sensitive cell-line, DoHH2. In contrast, single-
agent forskolin demonstrated cytostatic activity in all four cell-lines (cell count reduced 
to 10-57% relative to no treatment controls), minor cytotoxic activity against SUD4 and 
appreciable cytotoxicity against DoHH2 (viability decreased to 87% and 50% 
respectively compared to no treatment controls) further enhanced by addition of a high 
concentration of PDE4 inhibitor.
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Figure 6.5 DLBCL Cell-line Cell Count after 3-day Exposure to a PDE4 Inhibitor 
and/or Adenylate Cyclase Potentiator Forskolin. After a 3-day exposure to piclamilast, 
forskolin, rolipram, DMSO control or neither the cell count of the cell-lines was assessed by trypan blue 
exclusion assay. The mean cell count (n = 2) is shown as a percentage relative to the no treatment control 
cells for each experiment. Error bars represent the standard deviation. Pic = piclamilast; Fors = forskolin; 
Rol = rolipram The final DMSO content was  = 0.1% DMSO;  = 0.2% DMSO; = 0.3% DMSO; = 
0.4% DMSO. A = SUD4; B = CRL; C DoHH2; D = DHL4
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Figure 6.6 DLBCL Cell-line Viability after 3-day Exposure to a PDE4 Inhibitor 
and/or Adenylate Cyclase Potentiator Forskolin. After a 3-day exposure to piclamilast, 
forskolin, rolipram, DMSO control or neither the viability of the cell-lines was assessed by trypan blue 
exclusion assay. The mean viability (n = 2) is shown as a percentage relative to the no treatment control 
cells for each experiment. Error bars represent the standard deviation. Pic = piclamilast; Fors = forskolin; 
Rol = rolipram The final DMSO content was  = 0.1% DMSO;  = 0.2% DMSO; = 0.3% DMSO; = 
0.4% DMSO. A = SUD4; B = CRL; C DOHH2; D = DHL4
A
C
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6.4.4 Primary CLL 48-hour Ex Vivo Culture With PDE4 Inhibitors And 
Forskolin
The results for the 48-hour primary culture exposure experiments with the CLL/SLL 
sample 02 are illustrated in Figures 6.7 and 6.8. Single agent piclamilast produced a 
minor, non-significant reduction in cell count (89.5% for 1 M piclamilast), no 
reduction in viability and no evidence of a concentration-response effect (P >0.05). 
Rolipram 60 M induced a concentration-dependent reduction in cell count (73% P
<0.001) but only a minor reduction in viability (93% P <0.01). Similarly, forskolin 20 
M alone produced a non-significant decrease in cell count to 76.3% and viability to 
95.8% (P >0.05). When piclamilast was combined with forskolin, a significant 
reduction in cell count and viability was seen (e.g. 51.7% and 72.6% respectively for 1 
M piclamilast and 20 M forskolin (p <0.001)). The combination of forskolin and 
rolipram also produced a significant reduction in cell count and viability (e.g. 62% and 
66.5% respectively for 100 M rolipram and 20 M forskolin (P <0.001)). Rolipram 
combined with forskolin produced a greater effect than either agent used alone (P
<0.01). The combination results for a PDE4 inhibitor and the adenylate cyclase 
potentiator forskolin were not due to the DMSO content of the solutions, as the 
maximum DMSO concentration (0.4%) had no effect on cell count or viability 
compared to no treatment controls (P >0.05).
In summary, single agent PDE4 inhibitor or forskolin had no or little activity compared 
to significant activity for a combination of high concentration PDE4 inhibitor and 
forskolin in the ex vivo culture primary CLL/SLL sample 02.
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Figure 6.7 CLL Sample 02 Primary Culture Cell Count (A) and Viability (B) after 
2-day exposure to Piclamilast and Rolipram. After 48-hour exposure to piclamilast, rolipram 
or vehicle alone, the cell count and viability of sample 02 was assessed by trypan blue exclusion assay. 
The mean cell counts (n = 6) and viabilities (n = 6) are shown as a percentage relative to that of the no 
treatment control cells. Error bars represent the standard deviation. The maximum DMSO content was 
0.12%. In the subsequent experiment with sample 02, 0.4% DMSO controls had no effect on cell count 
and viability (see Figure 6.8) Pic = piclamilast; Rol = rolipram
Figure 6.8 CLL Sample 02 Primary Culture Cell Count (A) and Viability (B) after 
2-day Exposure to PDE4 Inhibitors and Forskolin. After a 2-day exposure to piclamilast, 
forskolin, rolipram, DMSO control or neither the cell count and viability of sample 02 was assessed by 
trypan blue exclusion assay. The mean cell counts (n = 6) and viabilities (n = 6) are shown as a 
percentage relative to that of the no treatment control cells. Error bars represent the standard deviation. 
The final DMSO content was  = 0.1% DMSO;  = 0.2% DMSO; = 0.3% DMSO;  = 0.4% DMSO, 
= 0.04% DMSO
Pic = piclamilast; Fors = forskolin; Rol = rolipram
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6.4.5 c-AMP Assay with cell-lines after Exposure to Piclamilast and Rolipram
The c-AMP assay was undertaken qualitatively on four separate occasions and 
quantitatively once.  Further repeats were not possible due to time constraints. The 
results from the quantitative assay are illustrated in Figure 6.9 and followed the trend of 
the preceding qualitative experiments. Piclamilast and rolipram alone and in 
combination produced a significant rise in c-AMP levels compared to no treatment 
controls in CRL and SUD4 but not in DoHH2 or DHL4. No concentration-response 
effect was seen for either agent. The elevation of c-AMP did not correlate with either 
the effect of piclamilast or rolipram upon cell count, as rolipram reduced cell count to 
approximately 70% of no treatment controls in CRL, DHL4 and DoHH2 yet had no 
effect on cell count in SUD4 (Figure 6.5).
Figure 6.9 DLBCL Cell-line c-AMP levels after 4 hours exposure to PDE4 
Inhibitors. c-AMP was measured in fmol.  The magnitude of c-AMP augmentation was different in 
each cell-line. Thus, for DoHH2 and DHL4 there was less than a fold rise in c-AMP with piclamilast &/or 
rolipram compared to a 7 to 17-fold rise for SUD4 and 5 to 9-fold rise from a much higher baseline for 
CRL. Pic = piclamilast; Rol = rolipram
SUD4
Concentration in M
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6.4.6 Effect of the PKC Inhibitor SC-236 on Cell Count and Viability of 
DLBCL cell-lines
In 3-day exposure experiments, the cell count and viability of SUD4, DHL4, CRL and 
DoHH2 were significantly inhibited in a concentration-dependent manner by SC-236 
(Figures 6.10 and 6.11). The EC50 and 95% CI for cell count and viability are given in 
Table 6.2 and the raw data in Appendix Tables A6.5 through A6.12. DoHH2 and SUD4 
were more sensitive than CRL or DHL4. Unfortunately it was not possible to pursue the 
mechanism of action of SC-236 due to time constraints.
SC-236 Cell Count Viability
Cell-lines EC50 M 95% CI M EC50 M 95% CI M
SUD4 15 13 to 17 28 24 to 31
CRL 26 21 to 32 41 38 to 44
DoHH2 14 12 to 16 22 20 to 25
DHL4 25 22 to 27 68 64 to 71
SC-236 Cell Count Viability
Primary Cultures EC50 M 95% CI M EC50 M 95% CI M
O3 131 115 to 149 141 134 to 149
O4 103 64 to 166 78 67 to 92
Table 6.2 DLBCL Cell-line and Primary Culture Cell Count and Viability EC50s 
following 3-day and 2-day exposure to SC-236 respectively
CI = Confidence Interval
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Figure 6.10 DLBCL Cell-line Cell Count after 3-day exposure to SC-236
After a 3-day exposure to SC-236 or media alone the cell count of the cell-lines was assessed by trypan 
blue exclusion assay. The mean cell count (n = 4) is shown as a percentage relative to that of the no 
treatment control cells. Error bars represent the standard deviation.
Figure 6.11 DLBCL Cell-line Viability after 3-day exposure to SC-236
After a 3-day exposure to SC-236 or media alone the viability of the cell-lines was assessed by trypan 
blue exclusion assay. The mean viability (n = 4) is shown as a percentage relative to that of the no 
treatment control cells. Error bars represent the standard deviation.
n = 4
n = 4
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6.4.7 Effect of SC-236 on Cell Count and Viability of Primary NHL Cell 
Culture
In 2-day exposure experiments, the cell count and viability of the MCL samples 03 and 
04 was significantly inhibited in a concentration-dependent manner by SC-236 (Figure 
6.12). The EC50s for cell count and viability were significantly higher than in the cell-
lines examined (Table 6.2; raw data in Appendix Tables A6.13 through A6.16).
Figure 6.12 Primary Culture Cell Count (A) and Viability (B) after 2 days 
exposure to SC-236 for Samples 03 & 04 After a 2-day exposure to SC-236 or media alone the 
cell count and viability of samples 03 and 04 was assessed by trypan blue exclusion assay. The mean cell 
counts (n = 6) and viabilities (n = 6) are shown as a percentage relative to that of the no treatment control 
cells. Error bars represent the standard deviation.
6.5 Discussion
6.5.1 Review of Experimental Findings in Comparison with Published Data
PDE4 Inhibition and c-AMP Potentiation in DLBCL Cell-lines
From the 3-day cell count experiments it is clear that the PDE4 inhibitors rolipram and 
piclamilast have only modest cytostatic activity (68 – 89% for rolipram 100 M and 74 
– 96.5% for piclamilast 1 M relative to no treatment controls) and no cytotoxic or anti-
proliferative effects on the four DLBCL cell-lines (Tables A6.2, A6.3 and A6.4). This is 
despite using concentrations of both PDE4 inhibitors 50 to 1,000-fold higher than their 
Ki values for PDE4 inhibition of 2.4 M only 1nM for rolipram and piclamilast. Even 
A B
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when the PDE4 inhibitors were added to the chemotherapy drugs cytosine arabinoside 
and doxorubicin they produced no additional impact on cell proliferation.
At the outset of the PDE4 inhibitor experiments, the finding of Ogawa et al of reduced 
cell proliferation following exposure to rolipram and forskolin for four days in the 
dexamethasone resistant T-cell ALL cell-line CEM-GH was encouraging (Ogawa et al., 
2002). However, after discovering the PD4 inhibitors to be inactive, the CEM cell-line 
was tested and rolipram found to have no cytotoxic activity against it (data not shown). 
A subsequent personal communication from group head for Ogawa et al acknowledged 
his group’s  subsequent failure to reproduce Ogawa’s results.
One possible explanation for the lack of efficacy of the PDE4 inhibitors could be the 
subtype of cell-line used. All four were GCB-DLBCL rather than ABC-DLBCL, whilst 
PDE4 was overexpressed in ABC-DLBCL rather than GCB-DLBCL in the LLMPP 
series. Although logical, this argument doesn’t stand up, as rolipram has been found to 
be ineffective against ABC-like DLBCL cell-lines in subsequent experiments and 
produced a small but significant reduction in cell proliferation in the chemosensitive 
GCB-like DHL6 (to 80% compared to no treatment controls) (Smith et al., 2005). 
Furthermore, it is clear that the ‘cell-of-origin’ distinction captures only a part of the 
chemoresponsive/resistant phenotype of DLBCL (see Chapter 5 discussion).
In contrast to the PDE4 inhibitors, the c-AMP potentiator forskolin exhibited cytostatic 
activity, producing a significant fall in 3-day cell count in all four cell-lines, especially 
DoHH2, compared to no treatment controls (forskolin 40 M: SUD4 39.5%, CRL 61%, 
DoHH2 10% and DHL4 56.5% P values <0.001). Addition of piclamilast or rolipram to 
forskolin did not enhance the cell count reduction produced by single agent forskolin. 
Forskolin 40 M produced a noticeable fall in viability in DoHH2 to 50% (P <0.001) 
and a minor reduction in SUD4 to 87% compared to no treatment controls (P <0.05). In 
DoHH2 alone, addition of a PDE4 inhibitor (piclamilast 30-1000 nM or rolipram 100 
M) to forskolin 20 M reduced viability further from a mean of 58% to 35% (P
<0.01). Similarly, experiments by Margaret Shipp’s group found forskolin reduced 
proliferation to 25% compared to no treatment controls in the very chemosensitive 
DHL6 and modestly to 75% in the other three DLBCL cell-lines tested (Smith et al., 
2005). A possible explanation for the sensitivity of DoHH2 to forskolin and the relative 
insensitivity of the other three cell-lines tested in this Chapter could be their differential 
TP53 status - DoHH2 possessing functional p53 (heterozygous) whilst the other three 
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cell-lines are null for the p53 protein. In support of this hypothesis, Ogawa et al found 
CEM cell death induced by rolipram and forskolin was via the intrinsic apoptotic 
pathway associated with rapid induction of p53 and then p21WAF1 (Ogawa et al., 2002). 
In all four cell-lines studied in this Chapter the basal levels of c-AMP were found to be 
very low (70-100 fmol in SUD4, DoHH2 and DHL4 and was 350 fmol in CRL), as in 
normal peripheral blood B- and T-cells (Diamond et al., 1987). Margaret Shipp’s group 
also found c-AMP levels to be very low or undetectable in the seven DLBCL cell-lines 
they tested (Smith et al., 2005). c-AMP levels were unaffected by PDE4 inhibition in 
DoHH2 and DHL4, whilst they rose markedly on exposure to rolipram and piclamilast 
in SUD4 and CRL. Therefore, despite the PDE4 inhibitors elevating c-AMP in SUD4 
and CRL they were inactive agents in the DLBCL cell-lines studied. Three possible 
explanations of this lack of efficacy are:- (1) That PDE4 is not important for DLBCL 
survival. (2) That the inhibition of PDE4 is ineffective due to the presence or rapid 
induction of the other c-AMP PDEs PDE3 and PDE7. Against this hypothesis is the fact 
that the high concentrations of PDE4 inhibitor used by others and myself meant that 
PDE3 and PDE7 would have been effectively inhibited and yet the agents tested 
remained inactive. (3) That sustained high levels of c-AMP are needed to induce 
cytostasis, for which use of a c-AMP augmenter or analogue is required. Unfortunately, 
due to time constraints, it was not possible to measure the effect of forskolin ± PDE4 
inhibitor on c-AMP levels in the four DLBCL cell-lines.
More recently, inhibition of PDE4B in conjunction with c-AMP promotion by forskolin 
improved the activity of dexamethasone and rapamycin in the DLBCL cell-lines DHL6 
and OCI-Ly3 (Batra et al., 2007). This brings the PDE4 inhibition story full circle to the 
results of Ogawa et al – suggesting that glucocorticoid sensitivity could be promoted by 
the use of a PDE4 inhibitor and a c-AMP potentiator (Ogawa et al., 2002).
PDE4 Inhibition and c-AMP Potentiation ex vivo in Primary CLL/SLL Sample 02
The data generated from the 2-day primary culture experiments with the CLL/SLL 
sample 02 was interesting and different from those in the DLBCL cell-lines. Used 
alone, piclamilast, rolipram and forskolin were largely ineffective, whilst the use of 
either piclamilast or rolipram with forskolin produced significant falls in cell count and 
viability (e.g. cell count reduced to 51.7% and viability to 72.6% following exposure to 
1 M piclamilast and 20 M forskolin (p <0.001)).
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Moon and Lerner have previously demonstrated that CLL primary cells cultured simply 
in RPMI and 10% calf serum undergo apoptosis via the intrinsic apoptotic pathway 
when exposed to rolipram 10 M ± forskolin 40 M for 24 hours (Moon and Lerner, 
2003). Caspase-9 is activated following mitochondrial membrane depolarisation, 
resulting in caspase-3 activation and PARP cleavage (Moon and Lerner, 2003). 
However, by 48 hours 27% of the no treatment control cells were apoptotic. This 
suggests that their primitive culture conditions were acting as a significant primer to cell 
death. Moon and Lerner found that c-AMP analogues were capable of down-regulating 
Bcl-2 and Bcl-xL, up-regulating Bax and Bad and inducing apoptosis in primary CLL 
cells (Moon and Lerner, 2003).
In conclusion, the results presented in this Chapter indicate that targeting PDE4B alone 
is ineffective in DLBCL and certainly not a means of sensitising chemoresistant cell-
lines to established cytotoxics and by extrapolation PDE4 inhibition is unlikely to 
improve response and outcome to chemotherapy in poor prognostic DLBCL.. Although 
forskolin proved to be cytostatic it was cytotoxic in only the most chemosensitive cell-
line DoHH2. Combination therapy with a PDE4 inhibitor and a c-AMP potentiator was 
similarly disappointing in the cell-lines investigated and only modestly effective against 
the primary CLL sample, 02. In keeping with these results, Smith et al found some 
efficacy for the selective PDE4B inhibitor PLX563 combined with forskolin in the very 
chemosensitive DHL6, an effect mediated via PI3-kinase down-regulation. Therefore 
PDE4 inhibition in conjunction with c-AMP elevation is not worthy of further 
investigation as a rational target in DLBCL application as it is not likely to have 
efficacy in any but the most sensitive lymphomas, the very ones that don’t require a 
novel treatment strategy. At best such a strategy may still be a viable novel treatment 
strategy in CLL/SLL.
SC-236 Activity and PKC Inhibition
SC-236 demonstrated cytostatic and cytotoxic activity in all four cell-lines examined, 
with the chemotherapy insensitive cell-line DHL4 being relatively less sensitive to the 
cytotoxic actions of SC-236 (EC50 cell count 14-26 M; EC50 viability 22-68 M). In 
primary culture studies, the chemoresistant MCL samples 03 and 04 were less 
susceptible to SC-236, with considerably higher EC50s for cell count and viability (EC50
cell count 103-131 M; EC50 viability 78-141 M). The results presented in this 
Chapter were produced only in GCB-DLBCL cell-lines, as the two described ABC-
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DLBCL cell-lines OCI-Ly3 and OCI-Ly10 were not available for study. These results 
suggest that SC-236 and other PKC inhibitors merit further investigation as novel 
agents in DLBCL regardless of ‘cell of origin’, and support the hypothesis that PKC
overexpression may indeed by causally associated with chemoresistance and poor 
outcome in DLBCL as per PKC’s inclusion in the 13-gene model described in Chapter 
5. The potential for PKC inhibition in poor prognosis ABC-like DLBCL is suggested 
by the overexpression of PKC in such cases.
Use of the specific PKC inhibitor, Ly37919, in human DLBCL cell-lines inhibited 
BCR-dependent IB kinase activation, so by blocking the PKC-dependent NFB 
pathway and causing a concentration-dependent reduction in cell viability in seven of 
eight cell-lines examined (Su et al., 2002). As chemotherapy can induce NFB, this 
may be a mechanism to secondary chemoresistance and a means of novel therapeutic 
attack via NFB or PKC inhibition, with the potential that PKC could prove a more 
specific target than NFB.(Das and White, 1997, Cheng et al., 2000). 
Two other sets of data indicate that the down-regulation of PKC can have an anti-
tumour effect. Firstly, the omega-3 fatty acid eicosapentaenoic acid (present in fish 
oils), inhibits colon carcinogenesis by suppression of PKC2 activity, which in turn 
causes inhibition of COX-2 protein expression, re-expression of TGF-R2, and 
restoration of TGF-1-mediated transcription in rat intestinal epithelial cells (Yu et al., 
2003). Secondly, the total PKC activity was reduced in TM6 cells by the Se compound 
MSC (50 M) within 30 minutes of treatment for calcium-dependent and independent 
PKCs, both in cytosolic (55.4 and 77.6% respectively) and membrane (35.2 and 34.1% 
respectively) fractions. Whilst PMA significantly elevated the PKC activity in the 
membrane fraction (P < 0.01), addition of MSC inhibited this activation by more than 
57%. The effect of MSC was Se compound specific, as selenomethionine and 
sulphurmethyl-L-cysteine did not alter PKC activity either in the cytosolic or membrane 
fractions (Sinha et al., 1999). Therefore certain Se compounds may be able to inhibit the 
activity of PKC as one of their routes to cytotoxicity.
Could COX-2 Inhibition be an Alternative Mechanism of SC-236 Activity?
`the efficacy of SC-236 demonstrated here could have been due in part, or in its entirety, 
to the COX-2 inhibitory properties of SC-236, as the anti-cancer activity of NSAIDs has 
been observed in vitro and in vivo. In human studies a decreased incidence of 
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gastrointestinal cancers has been observed in those taking NSAIDs compared to 
controls and in people with familial polyposis coli the incidence and rate of colonic 
polyp formation was reduced by their use (Steinbach et al., 2000, Gupta and DuBois, 
1998). COX-2, but not COX-1, up-regulation occurs in adenomas and adenocarcinomas 
compared with adjacent normal colonic mucosa (Sano et al., 1995, Eberhart et al., 1994, 
Kargman et al., 1995). Furthermore the level of COX-2 overexpression correlates with 
angiogenesis (Cianchi et al., 2001). The anti-neoplastic activity of NSAIDs may not be 
solely derived from COX-2 inhibition as COX-deficient cell-lines are still inhibited by 
NSAIDs (Richter et al., 2001).
The worldwide withdrawal of COX-2 inhibitors from clinical use in 2004 due to the 
shock discovery of a clinically relevant increased risk of cardiac and cardiovascular 
events due to the prothrombotic side-effect of unopposed COX-2 inhibition has led to 
the abandonment of secondary prevention trials of COX-2 inhibitors in colorectal 
cancer patients. This makes the pursuit of agents such as SC-236 with COX-2 inhibitory 
properties less attractive in DLBCL.
Human Trials of PKC Inhibitors
The practicality of PKC inhibition is suggested by the entry of ruboxistaurin 
(Ly333531), a PKC inhibitor, into phase III trials for diabetic nephropathy and 
retinopathy and enzastaurin into phase II studies in combination with chemotherapy in 
patients with malignancies. Indeed the oral PKC inhibitor enzastaurin has rapidly 
passed from single-agent phase I to phase II studies in cancer and lymphoma patients. 
From phase I studies, fatigue and gastrointestinal toxicities were the most common seen 
and prolonged QTc interval on electrocardiogram monitoring was the dose-limiting 
toxicity. This led to the recommended dose for phase II trials of 525 mg once daily 
(Carducci et al., 2006). Margaret Shipp has led a phase II study of enzastaurin in 
patients with relapsed or refractory DLBCL (Robertson et al., 2007). No deaths or 
discontinuations due to toxicity were reported; only one grade 4 toxicity 
(hypomagnesaemia) occurred and six grade 3 toxicities included (fatigue, oedema, 
headache, motor neuropathy, and thrombocytopenia). Of the 55 patients studied, 22% 
(12 of 55) experienced freedom from progression (FFP) for two cycles (56 days) and 
four patients (three with CR and one with stable disease) remained free from 
progression for more than 20-50 months. In a similar phase II study of enzastaurin in 
patients with relapsed or refractory MCL, no responses were seen but 27% (6 of 22) 
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were free from progression for more than 6 months. Fatigue was the most common 
toxicity and there were only six grade 3 toxicities (Morschhauser et al., 2008). Phase I 
studies of enzastaurin in combination with gemcitabine and cisplatin or capecitabine 
have shown the PKC inhibitor to be safe and to produce prolonged FFP in a minority 
of patients (Rademaker-Lakhai et al., 2007, Camidge et al., 2008). As SC-236 proved 
efficacious in GCB-DLBCL lines, the question of efficacy of PKC inhibition in PKC
protein expressing NHLs, rather than solely ABC-like DLBCL, will be of interest.
Summary of PKC Inhibitor Results
In conclusion, SC-236 demonstrated cystostatic and cytotoxic activity as a single agent 
in DLBCL cell-lines and MCL primary cultures. More recent clinical research has 
shown PKC inhibition can stabilise and induce responses in a minority of 
chemoresistant/refractory lymphoma patients. This suggests that PKC inhibition is 
indeed a valid rational target for intervention, as suggested by the 13-gene model results 
of Chapter 5. Further investigation of PKC inhibition as a single agent and in 
combination with chemotherapeutics is therefore warranted.
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CHAPTER 7: DISCUSSION
Summary of Introductory Chapter and Thesis Aims
DLBCL is the commonest subtype of NHL and is increasing in incidence. At the time 
of the initiation of the research described in this thesis the treatment of DLBCL was 
almost universally with CHOP-21 chemotherapy, which produced long-term remission 
in a minority of patients (Fisher et al., 1994). Subsequently the boundaries of successful 
treatment have pushed further through the addition of rituximab, the humanised 
monoclonal antibody against CD20, to chemotherapy and dose intensification of 
therapy (Tilly et al., 2003, Pfreundschuh et al., 2004b, Pfreundschuh et al., 2004a, 
Coiffier et al., 2002). As a consequence the 5-year OS for DLBCL now exceeds 50%. 
Nevertheless the treatment of DLBCL remains empirical and virtually the same for all 
new patients and combination therapies still fail to cure a significant minority, due to 
primary or secondary chemoresistance or complications of treatment. The stratification 
of patients into meaningful risk groups following their diagnosis of DLBCL has long 
been sought for several decades. As outlined in Chapter 1, numerous individual 
prognostic factors have been discovered in DLBCL through retrospective analyses. 
Despite these findings, the majority of putative prognostic factors have not been 
validated in independent series. In the early 1990’s a collaborative group investigated 
the existing prognostic factors and developed the IPI (The-International-Non-
Hodgkin's-Lymphoma-Prognostic-Factors-Project, 1993). The IPI has proven capable 
of stratifying patients into its four risk groups for estimated chances of response and/or 
outcome to first treatment and at relapse in numerous patient series. Although the IPI 
provides a general estimate of risk of treatment success it is unable to provide a 
sufficiently accurate risk to allow individualised risk estimation. This is particularly true 
for a patient whose IPI score places them in one of the intermediate risk categories. No 
successor to the IPI had been described at the time the research for this thesis was 
started. 
This thesis was undertaken to discover and validate novel prognostic and predictive 
factors in DLBCL through the rational strategy of gene expression profiling and the 
empirical investigation of presentation serum Se for correlations with dose-delivery, 
response to treatment and OS. Critical to the research was the hypothesis that the 
clinical and biochemical factors comprising the IPI represent only a part of the patient 
and tumour biology that go on to determine the success or failure of CHOP-based 
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treatment. As described in detail in Chapter 1 the genetic and molecular basis for cancer 
and DLBCL in particular is complex, heterogeneous and still poorly understood. If new 
prognostic and possibly predictive factors could be discovered in DLBCL then this 
heterogeneous illness may indeed become divisible into more tangible subtypes. This in 
turn would bring the promise of novel, rational, treatment adjuncts and regimens to at 
last afford more individualised treatment strategies based on the biology of a patient and 
their DLBCL.
Investigation of Presentation Serum Selenium as a Prognostic Factor in DLBCL
The empirical research into Se concentration in presentation serum as a prognostic 
factor in DLBCL produced positive results. Serum Se was measured using inductively 
coupled plasma mass spectrometry in archived presentation sera from 100 patients with 
high-grade NHL (78% DLBCL). Ninety-three of the 100 patients were treated with 
CHOP-like chemotherapy, six with radiotherapy and one received no treatment. The 
presentation serum Se concentration was normally distributed for the 100 patients with 
a mean of 0.92 mol/l (standard deviation = 0.25) and range of 0.33 to 1.51 mol/l. 
Seventy-three patients had a Se level below the UK adult reference range of 1.07-1.88 
mol/l (Matthews et al., 1990). Four outcome measures were studied for an association 
with presentation serum selenium: chemotherapy dose-delivery, response to treatment, 
first remission duration and OS. Serum Se closely correlated with performance status 
but no other clinical variable.
An area-under-the-curve summary measure, AUCratio was created especially for the 
project to allow more accurate assessment of chemotherapy dose-delivery. The AUCratio
of cumulative dose vs. time revealed not only variation in time taken and dose 
administered, but also distinguished between dose reductions and delays incurred at the 
beginning from those incurred at the end of treatment. Comprehensive dose-delivery 
data was available for 87 of the 93 patients given chemotherapy. Multivariate analysis 
revealed that a significantly better dose-delivery (as summarised by AUCratio) was 
associated with younger age, advanced stage, and higher serum Se.
In terms of response to treatment, fitting a logistic regression model produced an odds 
ratio of 0.62 for every 0.2 mol/l increase in serum Se (P = 0.01; 95% CI 0.43, 0.90). A 
higher Se level was therefore associated with a lower probability of having a poor 
outcome to treatment. When serum Se was considered in quartiles response was 
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significantly better in the highest quartile compared to the lower three (88.0% vs. 56% 
of patients achieved a CR or GPR (2=9.52; P = 0.023)).
When associations between OS and the variables collected were analysed using a Cox 
model, Se was the most significant factor, with a hazard ratio of 0.76 for every increase 
of 0.2 mol/l in serum Se level (Table 3.2). Thus, a lower serum Se concentration was 
associated with shorter survival. For example, a patient with a serum Se concentration 
of 1.0 mol/l had a 24% lower risk of death than a patient with a concentration of 0.8 
mol/l, over the duration of the study.
In conclusion, presentation serum Se predicted for dose-delivery of chemotherapy, 
response to first treatment and OS. Significant inverse associations were found for 
serum Se and all four of the outcome measures investigated (dose-delivery, response to 
treatment, first remission duration and OS). Reproduction of these results in a patient 
series treated with CHOP-R like chemotherapy is awaited, as is the exploration of a 
possible threshold effect for serum Se to promote dose-delivery, response to treatment 
and OS.
In Vitro Investigation of SDG and MSA
In vitro exploration of this discovery was undertaking using two Se compounds, SDG 
and MSA. Both agents were highly active in the DLBCL cell-lines, inducing caspase-
dependent apoptosis. The 3-day viability EC50s ranged from 4 to 9 M for SDG and 2 
to 10 M for MSA with the exception of DHL4 which was relatively resistant to MSA 
(3-day viability EC50 of 166 M). In the primary tumour cultures, SDG was also 
cytotoxic (2-day viability EC50 of 18 to 28 M), whilst the pooled normal B-cell sample 
was less sensitive (2-day viability EC50 of 109 M). For MSA, the results were less 
impressive as two of the four primary tumours were resistant (2-day viability EC50s of 
102 and 300 M for 01 and 03 respectively) and two were relatively sensitive (2-day 
viability EC50s of 38 and 68 M for 04 and 02 respectively). More encouraging was the 
observation of the marked resistance of the pooled normal B-cell sample to MSA (2-day 
viability EC50 of 1071 M) indicating the presence of a potentially clinically relevant 
therapeutic index between normal and malignant cells. In terms of the type of cell death 
induced by SDG and MSA, both agents were found to induce apoptotic cell death via 
caspase-8 and/or –9 activation and PARP cleavage. The generation of ROS by SDG and 
MSA and the importance of ROS generation for effect cell death by the two Se 
compounds were investigated in the DLBCL cell-line panel. In terms of mechanisms of 
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action, exposure to SDG led to ROS generation within 30 minutes in three of the four 
cell-lines and was critical to the cytotoxicity of SDG in two of the three cell-lines tested. 
In contrast, cell-line incubation with MSA failed to generate ROS, confirming the 
cytotoxic activity of MSA to be independent of ROS production.
This in vitro data generated using SDG and MSA was the first generated in human 
DLBCL cell-lines and primary NHL tumours and adds to the growing literature 
demonstrating the cytotoxic properties of Se compounds. Subsequent in vitro research 
combining MSA with established cytotoxic drugs used to treated NHLs found a 
surprising finding; that minimally toxic concentrations of MSA increased the efficacy of 
the chemotherapy drugs by up to 2.5-fold via the down-regulation of NFB (Juliger et 
al., 2007). Elsewhere, clinical research has taken place into the role of very high dose 
selenomethionine as an adjunct to irinotecan chemotherapy, with the goal of side-effect 
reduction and increased cytotoxicity. Unlike their animal model data, the Roswell Park 
group found no clinically meaningful reduction in side-effects was apparent, which 
prevented the anticipated dose-escalation of irinotecan (Fakih et al., 2008, Fakih et al., 
2006, Cao et al., 2004). Nevertheless, unexpected responses to treatment and cases of 
disease stabilisation were seen in the end-stage patients studied.
In conclusion, the empirical research undertaken proved fruitful, by not only finding a 
new serum prognostic factor in DLBCL but also by demonstrating the cytotoxic effects 
of two Se compounds against DLBCL cell-lines and primary lymphoid malignancies. 
The clinical potential for Se supplementation in DLBCL is now being actively pursued. 
Outstanding questions are the form of Se to use, the dose, which, if any, 
chemotherapeutics to use it in combination with. And whether Se compounds could be 
used alone as priming or maintenance therapy.
Discovery of Outcome Predictive Gene Expression Signatures in DLBCL using 
Microarray Profiling
The gene expression profiling research described in Chapter 5 used labelled cDNA 
created from the RNA from cryopreserved, presentation lymph node material from 58 
patients with DLBCL and 19 patients with FL. This was subject to gene expression 
profiling using the Hu6800 Affymetrix microarray. The results proved remarkable; 
firstly, the supervised learning classification algorithm ‘weighted voting’ correctly 
delineated DLBCL from FL, the closely related GC B-cell lineage malignancy. More 
importantly, class distinction proved possible within the group of 58 DLBCL samples. 
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Substantial gene expression differences were revealed between those that came from the 
32 patients that were ‘alive and cured’ and those DLBCL samples that came from the 
patients who died from DLBCL or had refractory disease. From the 100 genes that 
exhibited the clearest distinction between the ‘alive and cured’ and ‘fatal/refractory 
disease’ groups, application of the weighted voting algorithm analysis tool and ‘leave-
one-out’ cross-validation revealed that predictors of outcome to treatment containing a 
minimum of eight and a maximum of 16 genes out of the 6,800 genes arrayed could 
accurately separate the 58 sample profiles into ‘alive and cured’ and ‘fatal/refractory 
disease’ groups (P <0.05) (Shipp et al., 2002). The 13-gene model proved the most 
accurate, creating an ‘alive and cured’ group with 70% 5-year OS and a 
‘fatal/refractory disease’ group with only a 12% 5-year OS (P = 0.00004). Importantly, 
the 13-gene model predicted outcome both independently of the IPI and within the 
subgroups of the IPI. This discovery strongly suggests that the gene expression model 
was capturing different, additional prognostic information to that of the clinically based 
IPI outcome prediction model. In silico and immunohistochemical validations of 
components of the 13-gene model were performed and supported the legitimacy of the 
findings. Separate investigation of the SBH cohort of 19 DLBCL patient samples 
discovered that a distinct 19-gene model proved highly effective at outcome prediction 
within this cohort.
‘Shipp vs. Staudt’: Which Strategy is Best?
The subsequent expression profiling research in DLBCL from the DFCI collaboration 
and the LLMPP have followed different paths. The DFCI group has delved into what I 
term the ‘social geography’ of DLBCL whilst the LLMPP has continued to explore the 
‘history’ of DLBCL. The DFCI group asked the simple question “what’s different 
between DLBCL samples?” which to me constitutes an investigation into the ‘social 
milieu’ present in DLBCL bound by the anatomy of the host material – it’s ‘geography’. 
Using this approach resulted in the subclassification by gene expression profiling of 170 
presentation DLBCL samples into three groups termed ‘OxPhos, BCR/Proliferation and 
Host Response’ (Monti et al., 2005).  Thanks to the gene expression data having been 
generated on the very comprehensive Affymetrix HG-U133 A and B series (39,000 
transcripts, representing 33,000 genes), interrogation of the LLMPP’s 2002 DLBCL 
dataset created using the Lymphochip ‘dot-blot’ slide was possible. This found that the 
‘OxPhos, BCR/Proliferation and Host Response’ classifier was successfully reproduced 
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in the LLMPP series of 240 DLBCL samples. Importantly, no correlation between ‘cell-
of-origin’ subgrouping and the ‘OxPhos, BCR/Proliferation, Host Response’ consensus 
clustering was discovered, indicating that the two classification systems were capturing 
largely different aspects of DLBCL biology. The 5-year OS for the patients assigned to 
each of the three clusters were similar and no attempt was made to develop a prognostic 
model as in Chapter 5. This paper gives credence as much to the non-malignant milieu 
as to the malignant characteristics of DLBCL i.e. the tumour’s ‘social geography’ in 
terms of influencing tumour biology and response to treatment.
The original findings of the LLMPP research for the putative ‘cells of origin’ of 
DLBCL were extended in their microarray examination of a second, large series of 240 
biopsies from cases of DLBCL. Staudt’s group revealed that DLBCL could be 
subclassified based upon molecular profiling into GCB-like, ABC-like, and Type 3 
DLBCL with different OS following CHOP-like treatment (Rosenwald et al., 2002). 
Staudt et al also developed a 17-gene model, which predicted outcome to CHOP-like 
chemotherapy more accurately than the ‘cell of origin’ classifier and the IPI. Staudt’s 
research into the origins, the ‘history’ of DLBCL has yielded satisfy and tangible results 
borne out by the findings of others.
The in silico analyses by others of the DFCI results detailed in Chapter 5 and the 2002 
LLMPP series make it clear that multiple models with prognostic power can be created 
capable of outcome prediction, but that they remain most effective within the dataset 
they were created and validated in. In view of the thousands of gene transcripts 
examined there is the risk that apparently robust gene-expression models may have 
arisen by chance. Hence the need for dedicated bioinformatics and statisticians to 
interpret and mine gene expression data will not diminish.
In summary both the LLMPP and the DFCI groups have successfully used different 
approaches to gene expression profiling to create novel molecular classifiers of DLBCL 
and revealed new insights into the molecular aetiology of DLBCL. Neither has created 
an outcome prediction model that has reached the clinic nor has either yet reproduced 
their experiments in a cohort of samples from patients treated with CHOP-R like 
therapy. As the two groups have used different microarray platforms, this has hampered 
comparison but may have helped their diverging lines of research to develop. 
Fortunately, the public accessibility of their datasets allows ongoing reinterpretation. 
My expectation is that their respective strategies will continue to reveal new insights 
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into the biology and heterogeneity of DLBCL and the interaction of the patients’ 
tumours with their immune systems and other normal tissues. Ultimately I cannot see 
individualised treatment decisions coming from microarray data in isolation of 
intelligent integration of clinical factors. A further hurdle to be passed is the need to 
develop alternative treatments to CHOP-R. If nothing betters CHOP-R than profiling to 
know it won’t work in a particular individual isn’t going to be helpful without an idea of
what to try in it stead. This of course brings out the other deficit of the DFCI and 
LLMPP models to date – they are at best prognostic for an historical treatment and have 
no predictive power, as they were developed from patient series treated identically. 
Much work therefore remains to be done.
In Vitro Investigation of the Rational Targets PDE4B and PKC
In an attempt to build upon and explore the 13-gene model described in Chapter 5, in 
vitro studies were undertaken of PDE4 and PKC inhibitors in a panel of DLBCL cell-
lines and primary NHL with the ultimate goal of discovering a novel treatment for poor
prognosis, chemoresistant DLBCL. PDE4 inhibition was undertaken with piclamilast 
and rolipram and proved unsuccessful in the four DLBCL cell-lines studied. With the 
exception of the highly chemosensitive DoHH2, the PDE4 inhibitors remained 
ineffective when combined with the c-AMP potentiator forskolin or the established 
cytotoxics doxorubicin and cytosine arabinoside. This lack of activity of the PDE4 
inhibitors was despite their ability to raise c-AMP levels dramatically in two of the four 
cell-lines. For DoHH2 cell viability was unaffected by DMSO, piclamilast 1 M or 
rolipram 100 M alone (P >0.05), whilst forskolin 40 M alone significantly decreased 
viability to 50% compared to no treatment controls (P <0.001). Addition of piclamilast 
1 M or rolipram 100 M to forskolin 20 M significantly increasing cytotoxic activity 
compared to forskolin alone 20 M (37% P <0.05, 26% P <0.001 and 58% 
respectively).
In contrast to the findings in DLBCL cell-lines, the primary CLL/SLL tumour 02 was 
sensitive to PDE4 inhibition at high concentrations. Rolipram induced a dose-dependent 
reduction in cell count (73% P <0.001) but only a minor reduction in viability (93% P
<0.01), whilst piclamilast or forskolin alone had no cytostatic or cytotoxic effect. When 
the PDE4 inhibitors were combined with forskolin they produced a greater effect than 
either agent used alone in terms of cytostasis (cell counts relative to no treatment 
controls for 20 M forskolin with 100 M rolipram = 62% and with 1 M piclamilast = 
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51.7%; P <0.01) and cell kill (viability relative to no treatment controls for 20 M 
forskolin with 100 M rolipram = 66.5% and with 1 M piclamilast = 72.6%; P <0.01).
In summary, PDE4 inhibition was effective only in combination with the c-AMP 
potentiator forskolin in the most sensitive DLBCL cell-line, DoHH2, and the CLL/SLL 
primary tumour 02. The pursuit of PDE4 inhibition as a novel treatment strategy in 
high-risk DLBCL does not appear promising based upon these results but may still 
warrant further attention in CLL.
All four DLBCL cell-lines proved sensitive to SC-236, the PKC inhibitor investigated. 
The 3-day EC50 cell count ranged from 15 to 26 M and the 3-day EC50 viability ranged 
from 22 to 68 M. In the two chemoresistant primary MCL tumours examined, SC-236 
also inhibited cell growth and induced cell death but at higher concentrations. Since this 
research was conducted the PKC inhibitor enzastaurin has entered clinical trials in 
patients DLBCL and other cancers. Encouragingly three of the 55 relapsed/refractory 
DLBCL patients achieved a CR and ongoing remissions of >20 months at the time of 
publication (Robertson et al., 2007). From the results in relapsed/refractory MCL 
enzastaurin holds the promise of PKC inhibition proving to be an effective 
maintenance treatment or a useful adjunct to standard cytotoxic therapy in a minority of 
patients. Molecular clarification of which patients will benefit from this novel treatment 
would be a welcome proof of principle for this rational therapy.
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Thesis Summary and Predictions
In summary, the aims and objectives of this thesis were achieved. Novel empirical and 
rational predictors of response and outcome were discovered and validated in vitro. 
Further work has been suggested by the results generated. The long-term goal of 
accurate risk-stratification and treatment selection for individual DLBCL patients 
requires greater understanding of the molecular pathogenesis of DLBCL and the 
mechanisms governing response and resistance to treatment. It is my expectation that a 
combined clinical, molecular and pharmacogenomic prognostic model will be capable 
of more accurately risk stratifying DLBCL patients than each model in isolation or in 
dual combinations and will ultimately allow individualised treatment strategies to be 
studied. The research described in this thesis suggests that such knowledge is now 
within reach of investigators and will lead to additional rational therapies for DLBCL.
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APPENDIX
Data Tables for Chapter 4
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 1.00 1.00 1.00 1.00
3.00 0.48 0.74 0.82 0.85 0.72
6.00 0.78 0.01 0.01 0.02 0.01
10.00 1.00 0.00 0.00 0.00 0.00
12.00 1.08 0.00 0.00 0.00 0.00
20.00 1.30 0.00 0.00 0.01 0.00
Table A4.1 SDG 3-day cell count relative to no treatment controls for SUD4
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 1.00 1.00 1.00 1.00
3.00 0.48 0.92 0.98 0.94 0.99
6.00 0.78 0.08 0.08 0.06 0.05
10.00 1.00 0.01 0.01 0.01 0.01
12.00 1.08 0.00 0.00 0.01 0.01
20.00 1.30 0.00 0.00 0.02 0.00
Table A4.2 SDG 3-day viability relative to no treatment controls for SUD4
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 0.96 1.07 0.91 1.11
1.00 0.00 0.81 1.09 0.83 0.85
3.00 0.48 0.98 1.00 0.97 0.79
6.00 0.78 0.75 0.55 0.71 0.59
10.00 1.00 0.12 0.15 0.19 0.18
20.00 1.30 0.04 0.04 0.01 0.02
Table A4.3 SDG 3-day cell count relative to no treatment controls for CRL
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 1.00 0.98 0.99 1.00
1.00 0.00 0.99 0.99 0.95 0.98
3.00 0.48 0.96 0.91 0.95 0.93
6.00 0.78 0.97 0.84 0.87 0.84
10.00 1.00 0.26 0.38 0.46 0.50
20.00 1.30 0.10 0.13 0.05 0.08
Table A4.4 SDG 3-day viability relative to no treatment controls for CRL
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Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 1.00 1.00 1.00 1.00
2.00 0.30 0.99 1.08 0.91 1.11
3.00 0.48 1.08 1.21 0.84 0.83
5.00 0.70 0.05 0.02 0.05 0.05
7.00 0.85 0.01 0.02 0.03 0.02
12.00 1.08 0.01 0.01 0.02 0.02
Table A4.5 SDG 3-day cell count relative to no treatment controls for DoHH2
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 1.00 1.00 1.00 1.00
2.00 0.30 1.01 0.96 0.98 1.00
3.00 0.48 0.96 0.92 1.00 0.93
5.00 0.70 0.18 0.08 0.22 0.18
7.00 0.85 0.05 0.09 0.15 0.07
12.00 1.08 0.05 0.03 0.10 0.08
Table A4.6 SDG 3-day viability relative to no treatment controls for DoHH2
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 0.95 1.06 1.03 1.07
1.00 0.00 1.20 1.19 1.03 1.40
3.00 0.48 1.17 1.02 1.34 1.78
6.00 0.78 0.07 0.08 0.25 0.31
10.00 1.00 0.00 0.02 0.04 0.03
20.00 1.30 0.00 0.00 0.02 0.02
Table A4.7 SDG 3-day cell count relative to no treatment controls for DHL4
Values in italics were censored as outliers
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 1.00 1.01 0.99 1.00
1.00 0.00 0.99 1.00 0.98 1.00
3.00 0.48 0.93 1.00 1.00 0.98
6.00 0.78 0.53 0.46 0.80 0.70
10.00 1.00 0.02 0.13 0.25 0.21
20.00 1.30 0.03 0.04 0.12 0.10
Table A4.8 SDG 3-day viability relative to no treatment controls for DHL4
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[  ]
Log
[  ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1 1 1 1 1 1 1 1
0.10 -1.00 0.72 1.05 0.84 1.14
0.30 -0.52 0.72 0.74 0.84 1.19
1.00 0.00 0.68 0.85 0.96 1.13
3.00 0.48 0.82 0.64 1 0.8 0.56 0.86 0.72 1.41
6.00 0.78 0.85 0.42 0.94 0.51
8.00 0.90 0.43 0.2 0.37 0.21
10.00 1.00 0.18 0.08 0.2 0.12 0.09 0.13 0.1 0.11
15.00 1.18 0.18 0.09 0.12 0.09
Table A4.9 MSA 3-day cell count relative to no treatment controls for SUD4
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1 1 1 1 1 1 1 1
0.10 -1.00 1.02 0.98 1.08 0.95
0.30 -0.52 1.02 0.97 1.01 0.96
1.00 0.00 1.01 0.99 1.02 0.98
3.00 0.48 1 0.97 0.98 0.98 1.04 1 0.99 1.06
6.00 0.78 0.94 0.95 0.88 1
8.00 0.90 0.86 0.76 0.73 0.81
10.00 1.00 0.41 0.48 0.37 0.34 0.49 0.49 0.43 0.38
15.00 1.18 0.37 0.3 0.29 0.37
Table A4.10 MSA 3-day viability relative to no treatment controls for SUD4
[   ] = concentration M; values in italics were censored as outliers.
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[   ] Log [   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.00 0.00 1.43 0.85 1.30 0.65
3.00 0.48 0.98 1.02 1.20 0.90 0.86 0.66 0.85 0.79
4.50 0.65 0.63 0.43 0.56 0.68
6.00 0.78 0.28 0.17 0.24 0.22 0.26 0.23 0.39 0.38
10.00 1.00 0.15 0.12 0.11 0.12 0.12 0.12 0.12 0.11
20.00 1.30 0.02 0.04 0.04 0.06
30.00 1.48 0.01 0.01 0.03 0.03
Table A4.11 MSA 3-day cell count relative to no treatment controls for CRL
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.00 0.00 1.00 1.07 1.01 0.94
3.00 0.48 1.00 1.04 1.04 1.01 0.94 0.90 0.93 0.96
4.50 0.65 0.88 0.90 0.97 0.96
6.00 0.78 0.61 0.64 0.66 0.64 0.72 0.77 0.91 0.79
10.00 1.00 0.37 0.44 0.45 0.48 0.42 0.48 0.41 0.43
20.00 1.30 0.08 0.17 0.15 0.23
30.00 1.48 0.01 0.03 0.12 0.10
Table A4.12 MSA 3-day viability relative to no treatment controls for CRL
[   ] = concentration M; values in italics were censored as outliers.
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[   ] Log [   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
0.10 -1.00 1.03 1.20 1.31 0.95
0.30 -0.52 0.85 1.22 1.06 0.84 1.05 0.69 0.76 0.82
1.00 0.00 0.51 0.46 0.88 0.48 0.45 0.43 0.44 0.68
3.00 0.48 0.02 0.00 0.07 0.02 0.11 0.07 0.12 0.12
6.00 0.78 0.06 0.05 0.04 0.07
10.00 1.00 0.00 0.00 0.01 0.00 0.03 0.03 0.03 0.03
Table A4.13 MSA 3-day cell count relative to no treatment controls for DoHH2
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1 1 1 1 1 1 1 1
0.10 -1.00 1 0.94 1.07 1.02
0.30 -0.52 0.97 0.97 1.04 0.92 1 0.88 1.03 1.04
1.00 0.00 0.83 0.71 0.84 0.82 0.7 0.72 0.88 0.95
3.00 0.48 0.1 0.01 0.18 0.11 0.33 0.26 0.39 0.33
6.00 0.78 0.17 0.2 0.18 0.21
10.00 1.00 0.03 0.01 0.05 0.01 0.14 0.15 0.16 0.13
Table A4.14 MSA 3-day viability relative to no treatment controls for DoHH2
[   ] = concentration M; values in italics were censored as outliers.
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[   ]
Log [   
]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.00 0.00 1.16 0.60 0.79 0.87 0.87 1.00 0.84
2.00 0.30 0.48 0.32 0.37 0.43
3.00 0.48 0.29 0.28 0.28 0.35 0.52 0.33 0.28 0.48
6.00 0.78 0.31 0.26 0.24 0.22
8.00 0.90 0.24 0.23 0.24 0.24
10.00 1.00 0.23 0.24 0.27 0.20 0.21 0.08 0.12 0.18
20.00 1.30 0.18 0.19 0.22 0.23 0.16 0.15 0.10 0.17
30.00 1.48 0.18 0.18 0.17 0.17 0.11 0.06 0.10 0.13
60.00 1.78 0.19 0.16 0.18 0.15
100.00 2.00 0.09 0.09 0.12 0.12
Table A4.15 MSA 3-day cell count relative to no treatment controls for DHL4
[   ] = concentration M; values in italics were censored as outliers.
[   ]
Log [   
]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.00 0.00 1.01 0.99 0.99 1.01 1.02 1.03 1.02 1.02
2.00 0.30 1.01 1.01 0.99 1.00
3.00 0.48 1.02 1.00 1.00 0.99 1.05 1.02 1.00 1.02
6.00 0.78 0.98 0.98 0.91 0.98
8.00 0.90 0.96 0.95 0.95 0.94
10.00 1.00 1.02 1.00 0.96 0.97 0.96 0.93 1.03 0.97
20.00 1.30 0.92 0.95 0.90 0.93 0.93 0.95 0.91 0.94
30.00 1.48 0.93 0.90 0.92 0.94 0.81 0.91 0.97 0.92
60.00 1.78 0.88 0.78 0.83 0.77
100.00 2.00 0.68 0.54 0.69 0.68
Table A4.16 MSA 3-day viability relative to no treatment controls for DHL4
[   ] = concentration M; values in italics were censored as outliers.
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[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.09 0.95 0.90 0.75 1.59 0.72
3.00 0.48 1.06 0.44 0.92 0.78 0.69 0.87
10.00 1.00 1.25 0.96 0.91 0.81 0.62 0.57
30.00 1.48 0.75 0.73 0.72 0.80 0.00 0.00
100.00 2.00 0.87 0.68 0.55 0.53 0.51 0.27
300.00 2.48 0.44 0.51 0.34 0.44 0.29 0.40
Table A4.17 SDG 2-day cell count relative to no treatment controls for 01
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.04 0.98 1.03 0.97 1.00 0.98
3.00 0.48 0.79 0.97 0.92 0.92 0.79 0.60
10.00 1.00 0.74 0.69 0.55 0.50 0.42 0.32
30.00 1.48 0.47 0.43 0.44 0.47 0.00 0.00
100.00 2.00 0.52 0.39 0.31 0.28 0.31 0.19
300.00 2.48 0.28 0.33 0.24 0.26 0.18 0.22
Table A4.18 SDG 2-day viability relative to no treatment controls for 01
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.05 1.00 1.09 1.12 0.84 0.91
3.00 0.48 0.93 0.90 0.95 1.01 1.11 1.23
10.00 1.00 0.89 0.68 0.84 0.79 0.83 0.72
30.00 1.48 0.79 0.65 0.32 0.66 0.60 0.24
100.00 2.00 0.57 0.54 0.33 0.31 0.39 0.22
300.00 2.48 0.26 0.06 0.23 0.15 0.17 0.13
Table A4.19 SDG 2-day cell count relative to no treatment controls for 02
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.00 0.98 0.97 0.98 1.04 1.04
3.00 0.48 0.89 0.88 0.84 0.84 0.88 0.89
10.00 1.00 0.74 0.60 0.62 0.58 0.55 0.53
30.00 1.48 0.65 0.52 0.34 0.48 0.43 0.36
100.00 2.00 0.46 0.46 0.35 0.31 0.31 0.22
300.00 2.48 0.21 0.08 0.24 0.18 0.20 0.12
Table A4.20 SDG 2-day viability relative to no treatment controls for 02
[   ] = concentration M; values in italics were censored as outliers
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[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Replicate 7 Replicate 8 Replicate 9 Replicate 10 Replicate 11 Replicate 12
0.00 -3.00 0.87 1.03 0.77 1.26 1.03 1.05 1.17 0.98 1.03 0.89 0.97 0.97
1.00 0.00 0.91 0.87 0.82 0.95 1.21 0.94
3.00 0.48 1.31 1.19 1.04 1.25 1.17 0.79 1.23 1.08 0.95 0.89 0.87 1.05
4.00 0.60 1.08 0.79 0.69 0.93 0.91 0.93
6.00 0.78 0.73 0.82 0.87 1.15 0.90 1.10
8.00 0.90 0.90 0.84 0.70 0.87 0.93
10.00 1.00 0.73 0.66 0.58 0.91 0.87 0.89 0.62 0.78 0.89 0.70 0.55 0.75
12.00 1.08 0.74 0.79 0.81 0.77 0.66 0.52
14.00 1.15 0.47 0.46 0.58 0.62 0.63 0.40
30.00 1.48 1.00 1.30 1.06 1.03 0.74 0.30 0.27 0.25 0.42 0.47 0.33 0.21
100.00 2.00 0.78 0.78 0.47 0.47 0.16 0.22 0.21 0.21 0.37 0.18 0.21 0.17
Table A4.21 SDG 2-day cell count relative to no treatment controls for 03
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6 Replicate 7 Replicate 8 Replicate 9 Replicate 10 Replicate 11 Replicate 12
0.00 -1.00 0.95 0.99 1.01 1.02 1.03 1.01 1.00 1.05 0.99 1.09 0.93 0.93
3.00 0.48 1.00 0.98 1.01 0.92 1.02 0.94 0.67 0.71 0.69 0.64 0.67 0.42
10.00 1.00 0.65 0.56 0.72 0.50 0.50 0.49 0.49 0.43 0.42 0.52 0.36 0.29
30.00 1.48 0.30 0.37 0.50 0.50 0.33 0.23 0.56 0.60 0.59 0.43 0.36 0.18
100.00 2.00 0.23 0.21 0.30 0.17 0.19 0.15 0.37 0.42 0.28 0.22 0.10 0.13
Table A4.22 SDG 2-day viability relative to no treatment controls for 03
[   ] = concentration M; values in italics were censored as outliers.
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[   ] Log [   ] Replicate 1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
Replicate 
9
Replicate 
10
Replicate 
11
0.00 -3.00 1.07 0.89 1.02 1.06 0.96 0.99 1.08 0.87 1.05 0.98 1.02
1.00 0.00 1.25 0.90 1.18 1.26 1.44
3.00 0.48 0.81 1.03 0.66 0.78
4.00 0.60 1.47 1.48 1.00 0.86 1.48 1.30
6.00 0.78 1.30 1.05 1.05 0.95 0.83 0.79
10.00 1.00 1.19 0.77 1.20 0.47 1.02 0.68 0.87 0.77 0.71 0.66 0.66
12.00 1.08 1.15 0.60 0.53 0.64 1.09
15.00 1.18 0.92 1.00 0.86 0.65 0.63 0.51
20.00 1.30 0.79 0.79 0.63
30.00 1.48 0.52 0.47 0.37 0.77 0.50 0.52 0.50 0.46 0.45 0.33
100.00 2.00 0.50 0.49 0.30 0.25 0.29 0.25
300.00 2.48 0.18 0.13 0.16 0.10 0.12 0.10
Table A4.23 SDG 2-day cell count relative to no treatment controls for 04
[   ] = concentration M; values in italics were censored as outliers.
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[   ] Log [   ] Replicate 1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
Replicate 
9
Replicate 
10
Replicate 
11
Replicate 
12
0.00 -3.00 1.06 1.04 0.93 1.00 0.98 1.00 0.98 0.98 1.01 1.02 1.04 0.98
1.00 0.00 1.05 1.01 1.08 1.08 1.00 0.95
3.00 0.48 0.99 0.81 0.76 0.24 0.17
4.00 0.60 1.09 1.09 1.05 0.97 1.00 0.84
6.00 0.78 0.90 0.88 0.80 0.72 0.76 0.76
10.00 1.00 0.78 0.83 0.78 0.69 0.91 0.95 0.90 0.81 0.69 0.18
12.00 1.08 0.84 0.86 0.68 0.60 0.70 0.69
15.00 1.18 0.68 0.83 0.70 0.65 0.68 0.57
20.00 1.30 0.63 0.75 0.57 0.75 0.65
30.00 1.48 0.74 0.67 0.39 0.39 0.37 0.41 0.51 0.68 0.55 0.56 0.42 0.24
100.00 2.00 0.40 0.40 0.33 0.31 0.29 0.29
300.00 2.48 0.14 0.11 0.13 0.08 0.09 0.07
Table A4.24 SDG 2-day viability relative to no treatment controls for 04
[   ] = concentration M; values in italics were censored as outliers.
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[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.25 1.03 0.90 0.96 0.99 0.87
3.00 0.48 0.83 0.69 0.91 0.84 0.64 0.63
10.00 1.00 0.60 0.60 0.65 0.53 0.54 0.70
30.00 1.48 0.83 0.76 0.43 0.38 0.38 0.69
100.00 2.00 0.93 0.68 0.68 0.65 0.81 0.88
300.00 2.48 0.38 0.49 0.49 0.69 0.45 0.37
Table A4.25 SDG 2-day cell count relative to no treatment controls for pooled 
normal B-cells
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 0.99 0.99 1.03 1.02 1.00 0.97
3.00 0.48 0.80 0.82 0.85 1.01 0.86 0.69
10.00 1.00 0.60 0.71 0.63 0.59 0.51 0.55
30.00 1.48 0.57 0.62 0.46 0.38 0.45 0.60
100.00 2.00 0.62 0.62 0.61 0.49 0.61 0.62
300.00 2.48 0.49 0.45 0.47 0.48 0.38 0.32
Table A4.26 SDG 2-day viability relative to no treatment controls for pooled 
normal B-cells
[   ] = concentration M; values in italics were censored as outliers.
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[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.09 0.95 0.90 0.75 1.59 0.72
10.00 1.00 1.34 1.72 1.31 1.48 1.30 1.42
30.00 1.48 1.23 1.09 1.28 1.25 1.47 0.90
100.00 2.00 0.62 0.69 0.62 0.60 0.69 0.74
300.00 2.48 0.44 0.70 0.51 0.44 0.32 0.28
Table A4.27 MSA 2-day cell count relative to no treatment controls for 01
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.04 0.98 1.03 0.97 1.00 0.98
10.00 1.00 0.89 1.01 0.90 0.91 0.91 0.93
30.00 1.48 0.78 0.77 0.76 0.75 0.82 0.71
100.00 2.00 0.45 0.51 0.35 0.46 0.48 0.49
300.00 2.48 0.34 0.41 0.37 0.27 0.23 0.20
Table A4.28 MSA 2-day viability relative to no treatment controls for 01
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [  ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.05 1.00 1.09 1.12 0.84 0.91
10.00 1.00 1.06 0.88 0.86 0.85 0.61 0.68
30.00 1.48 0.66 0.73 0.49 0.68 0.45 0.67
100.00 2.00 0.77 0.56 0.54 0.36 0.38 0.54
300.00 2.48 0.32 0.37 0.42 0.33 0.24 0.46
Table A4.29 MSA 2-day cell count relative to no treatment controls for 02
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 1.00 0.98 0.97 0.98 1.04 1.04
10.00 1.00 0.79 0.69 0.70 0.71 0.65 0.68
30.00 1.48 0.61 0.57 0.60 0.59 0.59 0.54
100.00 2.00 0.57 0.48 0.46 0.36 0.43 0.47
300.00 2.48 0.29 0.39 0.41 0.29 0.32 0.35
Table A4.30 MSA 2-day viability relative to no treatment controls for 02
[   ] = concentration M; values in italics were censored as outliers.
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[   ] Log [   ] Replicate 1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
0.00 -3.00 1.17 0.98 1.03 0.89 0.97 0.97
3.00 0.48 1.39 1.19 2.36 1.44 1.22 1.52
10.00 1.00 2.06 1.41 1.41 2.11 1.63 1.36
30.00 1.48 1.58 1.68 1.65 1.14 1.61 1.08
100.00 2.00 1.08 0.85 1.01 0.87 1.03 1.09
Table A4.31 MSA 2-day cell count relative to no treatment controls for 03
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
0.00 -3.00 1.00 1.05 0.99 1.09 0.93 0.93
3.00 0.48 0.92 0.96 0.89 0.93 0.91 0.90
10.00 1.00 0.81 0.88 0.79 0.86 0.87 0.78
30.00 1.48 0.77 0.76 0.78 0.83 0.72 0.65
100.00 2.00 0.63 0.64 0.60 0.51 0.65 0.73
Table A4.32 MSA 2-day viability relative to no treatment controls for 03
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
0.00 -3.00 0.89 0.86 1.09 1.06 1.12 0.99
10.00 1.00 0.43 0.69 0.74 0.49 0.46 0.75
30.00 1.48 0.68 0.54 0.47 0.53 0.28 0.43
100.00 2.00 0.64 0.49 0.33 0.48 0.55 0.4
300.00 2.48 0.42 0.39 0.52 0.28 0.28 0.39
Table A4.33 MSA 2-day cell count relative to no treatment controls for 04
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
0.00 -1.00 0.98 1.00 0.99 1.00 1.02 1.00
10.00 1.00 0.63 0.59 0.68 0.50 0.49 0.62
30.00 1.48 0.63 0.54 0.50 0.45 0.35 0.51
100.00 2.00 0.53 0.49 0.36 0.44 0.40 0.39
300.00 2.48 0.42 0.38 0.44 0.31 0.36 0.39
Table A4.34 MSA 2-day viability relative to no treatment controls for 04
[   ] = concentration M; values in italics were censored as outliers.
Appendix
266
[   ] Log [   ] Replicate 1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
0.00 -3.00 0.99 0.99 1.03 1.02 1.00 0.97
10.00 1.00 1.29 1.05 0.82 0.94 1.08 0.99
30.00 1.48 0.74 0.55 0.90 0.73 1.02 0.73
100.00 2.00 0.96 0.74 0.96 0.82 0.60 0.71
300.00 2.48 0.67 0.63 0.67 0.74 0.63 0.60
Table A4.35 MSA 2-day cell count relative to no treatment controls for pooled 
normal B-cells
[   ] = concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
0.00 -3.00 0.99 0.99 1.03 1.02 1.00 0.97
10.00 1.00 0.94 0.92 0.99 0.84 0.90 0.96
30.00 1.48 0.79 0.80 0.91 0.77 0.94 0.93
100.00 2.00 0.92 0.88 0.90 0.93 0.69 0.74
300.00 2.48 0.65 0.65 0.65 0.77 0.62 0.58
Table A4.36 MSA 2-day viability relative to no treatment controls for pooled 
normal B-cells
[   ] = concentration M; values in italics were censored as outliers.
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Cell-line and SDG
Concentration M
CRL
0
CRL
0
CRL
0
CRL
1
CRL
2
CRL
4
CRL
7
CRL
10
CRL
10
A % 9 9 7 9 8 11 22 40 40
G1 % 57 57 62 55 56 46 13 16 16
S % 20 18 17 19 18 21 41 28 26
G2 % 14 16 14 17 18 22 24 16 18
Total 99 100 100 100 100 100 100 100 100
Cell-line and SDG
Concentration M
DHL4
0
DHL4
0
DHL4
0
DHL4
6
DHL4
8
DHL4
10
DHL4
12
DHL4
14
A % 2 1 1 24 11 18 25 28
G1 % 54 51 52 36 40 34 35 39
S % 29 29 28 20 26 23 22 17
G2 % 16 18 18 19 23 23 18 16
Total 100 100 100 100 100 98 100 100
Cell-line and SDG
Concentration M
SUD4
0
SUD4
0
SUD4
0
SUD4
2
SUD4
4
SUD4
7.5
SUD4
12
SUD4
15
A % 6 5 5 6 9 19 10 13
G1 % 48 51 56 53 48 34 45 41
S % 27 28 25 23 27 24 31 29
G2 % 17 14 13 16 14 23 14 17
Total 98 98 99 99 98 100 99 100
Table A4.37 Cell Cycle Distribution for the four cell-lines following 3-day exposure to increasing concentrations of SDG. A % = percentage
cells in Apoptosis i.e. sub-G1; G1 = percentage cells in Growth phase 1, S = percentage cells in Synthesis phase and G2 = percentage cells in Growth phase 2.
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Cell-line and MSA 
Concentration M
CRL
0
CRL
1
CRL
3
CRL
3
CRL
3
CRL
6
CRL
6
CRL
10
CRL
10
CRL
30
CRL
30
A % 11 11 11 11 14 23 24 41 43 57 51
G1 % 46 46 40 44 42 45 41 37 38 16 22
S % 24 23 25 23 23 15 19 15 12 23 19
G2 % 18 19 23 21 21 15 16 7 7 4 8
Cell-line and MSA 
Concentration M
DHL4
0
DHL4
1
DHL4
1
DHL4
3
DHL4
3
DHL4
10
DHL4
10
DHL4
20
DHL4
20
DHL4
30
DHL4
30
DHL4
30
A % 2 2 1 2 3 3 4 11 7 16 15 14
G1 % 43 49 49 44 50 67 67 67 53 44 48 45
S % 34 27 31 33 27 17 8 7 10 14 15 28
G2 % 20 22 19 22 20 12 21 15 29 26 22 13
Cell-line and MSA 
Concentration M
DoHH2
0
DoHH2
0
DoHH2
0.1
DoHH2
0.1
DoHH2
0.3
DoHH2
0.3
DoHH2
1
DoHH2
3
DoHH2
10
A % 8 7 8 10 7 16 51 78 72
G1 % 44 42 47 48 46 44 22 5 5
S % 32 32 28 24 27 23 20 16 21
G2 % 16 19 16 18 20 17 6 1 2
Cell-line and MSA 
Concentration M
SUD4
0
SUD4
0
SUD4
0.1
SUD4
0.1
SUD4
0.3
SUD4
0.3
SUD4
1
SUD4
1
SUD4
3
SUD4
3
SUD4
10
SUD4
10
A % 3 3 2 3 5 3 3 4 3 5 52 65
G1 % 49 52 47 49 44 51 47 49 45 49 19 10
S % 30 25 31 27 29 26 31 31 32 30 25 22
G2 % 17 18 19 20 22 20 18 16 19 16 4 3
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Table A4.38 Cell Cycle Distribution for all four cell-lines following 3-day exposure to increasing concentrations of 
MSA. A % = percentage cells in Apoptosis i.e. sub-G1; G1 = percentage cells in Growth phase 1, S = percentage cells in Synthesis phase and G2 
= percentage cells in Growth phase 2.
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Cell-line and SDG Concentration M B-cells0
B-cells
0
B-cells
3
B-cells
3
B-cells
10
B-cells
10
B-cells
30
B-cells
30
B-cells
100
B-cells
100
B-cells
300
B-cells
300
A % 22 22 16 21 15 13 16 15 17 16 50 46
G1 % 69 66 78 74 78 81 75 78 73 73 45 49
S % 6 9 3 3 4 3 4 3 4 4 6 3
G2 % 3 2 3 3 4 3 5 4 6 6 1 1
Cell-line and MSA Concentration M B-cells0
B-cells
0
B-cells
10
B-cells
10
B-cells
30
B-cells
30
B-cells
100
B-cells
100
B-cells
300
B-cells
300
A % 22 22 22 23 34 35 31 34 31 32
G1 % 69 66 66 62 53 50 54 47 58 45
S % 6 9 11 12 10 12 12 17 9 19
G2 % 3 2 1 2 2 2 2 2 2 2
Cell-line and SDG Concentration M (04)0
(04)
1
(04)
1
(04)
4
(04)
4
(04)
6
(04)
6
(04)
10
(04)
10
A % 26 21 17 24 23 60 61 51 52
G1 % 53 60 65 53 54 27 27 38 38
S % 16 11 11 16 17 8 8 8 6
G2 % 4 7 6 7 5 4 3 2 2
Cell-line and SDG Concentration M (04)12
(04)
12
(04)
15
(04)
15
(04)
20
(04)
20
(04)
30
(04)
30
A % 54 53 53 53 49 49 49 50
G1 % 35 37 37 38 42 42 43 42
S % 7 7 6 6 6 6 5 5
G2 % 3 3 2 2 2 2 1 1
Table A4.39 Cell Cycle Distribution for the Pooled Normal B-cells and MCL sample (04) following 3-day exposure to increasing 
concentrations of MSA and SDG and SDG Respectively. A % = percentage cells in Apoptosis i.e. sub-G1; G1 = percentage cells in Growth phase 1, S = percentage 
cells in Synthesis phase and G2 = percentage cells in Growth phase 2.
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Cell-line SUD4 SUD4 SUD4 Cell-line CRL CRL CRL
Replicate 1 2 3 Replicate 1 2 3
Luminescence % cf Control % cf Control % cf Control Luminescence % cf Control % cf Control % cf Control
Control 100 100 100 Control 100 100 100
Control (DMSO) 93 104 97 Control (DMSO) 93 103 105
Control (H2O2) 191 208 195 Control (H2O2) 228 231 237
SDG 2M 375 341 402 5M SDG 264 305 323
SDG 5M 424 413 494 10M SDG 290 309 329
SDG 10M 415 418 521 25M SDG 283 302 326
MSA 5M 146 170 192 5M MSA 114 134 145
MSA 10M 157 186 210 10M MSA 102 113 125
MSA 25M 155 186 211 25M MSA 100 107 111
Cell-line DoHH2 DoHH2 DoHH2 Cell-line DHL4 DHL4 DHL4
Replicate 1 2 3 Replicate 1 2 3
Luminescence % cf Control % cf Control % cf Control Luminescence % cf Control % cf Control % cf Control
Control 100 100 100 Control 100 100 100
Control (DMSO) 94 102 103 Control (DMSO) 98 105 108
Control (H2O2) 118 107 153 Control (H2O2) 78 90 149
SDG 2M 149 121 238 SDG 4M 220 218 243
SDG 4M 153 131 239 SDG 7M 206 208 236
SDG 10M 153 134 228 SDG 20M 172 186 217
MSA 1M 136 153 137 MSA 100M 119 108 121
MSA 2M 155 177 150 MSA 200M 106 99 110
MSA 5M 175 200 146 MSA 500M 97 91 107
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Table A4.40 ROS Generation after 30-minute Exposures to the cytotoxic EC50 Concentrations of SDG or MSA The generation 
of ROS in lymphoma cells relative to control (0.75% DMSO) after exposure for 30 minutes to SDG and MSA at concentrations around the 3-day cytotoxic 
EC50 concentrations. 25 M H2O2 was used as the positive control.
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SUD4 Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
Control 100 100 101 101 97 100
NAC 83 100 103 104 102 101
SDG 61 55 69 62 46 33
SDG+NAC 77 71 98 103 88 94 *
MSA 47 61 70 76 46 46
MSA+NAC 53 51 74 73 38 41
CRL Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
Control 99 99 103 99 0 0
NAC 88 78 101 103 0 0
SDG 15 50 40 37 0 0
SDG+NAC 43 43 46 47 0 0
MSA 16 33 43 60 0 0
MSA+NAC 23 28 36 53 0 0
DoHH2 Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
Control 105 102 97 94 100 99
NAC 108 104 80 81 101 101
SDG 66 62 39 35 88 89
SDG+NAC 67 78 54 62 82 85
MSA 63 68 43 46 82 72
MSA+NAC 65 72 33 33 80 77
DHL4 Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
Control 104 101 96 96 102 103
NAC 104 104 93 94 101 100
SDG 52 34 32 46 57 71
SDG+NAC 63 70 70 78 80 80 *
MSA 47 40 30 40 59 58
MSA+NAC 34 34 46 42 34 41
Table A4.41 Effect of N-acetyl cysteine on the Cytotoxicity of SDG and MSA after 
3-day Exposures to the cytotoxic EC50 Concentrations of SDG or MSA Cells were 
continuously co-exposed to EC50 viability concentrations of SDG or MSA ± N-acetyl cysteine (NAC) or 
N-acetyl cysteine alone. SDG concentration: SUD4, CRL, DoHH2, DHL4 and cells = 4.0, 9.0, 4.2 and 
7.0 µM, respectively; MSA concentration SUD4, CRL DoHH2 and DHL4 cells 10.0, 9.0, 1.9 and 166  
µM, respectively, N-acetyl cysteine 2.5 µM throughout. * P = 0.0008 and 0.0053 respectively for SUD4 
and DHL4 SDG vs. SDG + NAC. SDG = selenodiglutathione, MSA = methylseleninic acid and NAC = 
N-acetyl cysteine
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Data Tables for Chapter 6
SUD4 Mean ± Standard Deviation Number of Replicates
Pic 0 nM DMSO 0% 100 ± 12 18
Pic 300 nM DMSO 0.03% 103 ± 17 24
Pic 1000 nM DMSO 0.1% 89 ± 14 24
Pic 10000 nM DMSO 1% 65 ± 16 24 *
DMSO 0.5% 92 ± 10 6
DMSO 1% 59 ± 12 15 *
CRL Mean ± Standard Deviation Number of Replicates
Pic 0 nM DMSO 0% 100 ± 8 13
Pic 300 nM DMSO 0.03% 97 ± 22 21
Pic 1000 nM DMSO 0.1% 88 ± 17 21
Pic 10000 nM DMSO 1% 50 ± 15 21 *
DMSO 0.5% 95 ± 17 3
DMSO 1% 40 ± 9 18 *
DoHH2 Mean ± Standard Deviation Number of Replicates
Pic 0 nM DMSO 0% 100 ± 5 13
Pic 300 nM DMSO 0.03% 104 ± 18 24
Pic 1000 nM DMSO 0.1% 95 ± 17 24
Pic 10000 nM DMSO 1% 63 ± 12 24 *
DMSO 0.5% 82 ± 8 6
DMSO 1% 65 ± 14 18 *
Table A6.1 Effect of 3-day Exposure to Piclamilast on DLBCL Cell-line 
Proliferation
After a 3-day exposure to piclamilast, DMSO control or neither the proliferation of the cell-lines was 
assessed by MTS assay. The mean proliferation is shown as a percentage relative to that of the no 
treatment control cells. A minimum of three independent experiments was conducted with the total 
number of wells assayed being indicated in the Number column.
Pic = piclamilast
Piclamilast 10000 nM vs. DMSO 1% = non-significant*
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SUD4 Mean Standard Deviation Number of Replicates
Pic 0 nM (DMSO 0%) Ara-c 0 nM 100 ± 12 9
Pic 300 nM (DMSO 0.03%) Ara-c 313 nM 76 ± 17 12
Pic 1000 nM (DMSO 0.1%) Ara-c 625 nM 55 ± 12 12 *
Pic 10000 nM (DMSO 1%) Ara-c 1250 nM 26 ± 6 12
Pic 10000 nM (DMSO 1%) Ara-c 2500 nM 20 ± 5 9
Ara-c 0 nM 100 ± 12 9
Ara-c 313 nM 65 ± 12 12
Ara-c 625 nM 56 ± 11 12 *
Ara-c 1250 nM 43 ± 7 12
Ara-c 2500 nM 42 ± 7 12
DMSO 1% Ara-c 1250 nM 19 ± 7 9
CRL Mean Standard Deviation Number of Replicates
Pic 0 nM (DMSO 0%) Ara-c 0 nM 100 ± 3 12
Pic 300 nM (DMSO 0.03%) Ara-c 158 nM 59 ± 11 12
Pic 1000 nM (DMSO 0.1%) Ara-c 315 nM 54 ± 17 12 *
Pic 10000 nM (DMSO 1%) Ara-c 630 nM 37 ± 8 12
Pic 10000 nM (DMSO 1%) Ara-c 1260 nM 31 ± 6 12
Ara-c 0 nM 100 ± 4 12
Ara-c 158 nM 63 ± 12 12
Ara-c 315 nM 48 ± 11 12 *
Ara-c 630 nM 45 ± 13 12
Ara-c 1260 nM 47 ± 10 12
DMSO 1% Ara-c 630nM 26 ± 4 12
DoHH2 Mean Standard Deviation Number of Replicates
Pic 0 nM (DMSO 0%) Ara-c 0 nM 99 ± 4 12
Pic 300 nM (DMSO 0.03%) Ara-c 15 nM 91 ± 11 9
Pic 1000 nM (DMSO 0.1%) Ara-c 29 nM 76 ± 12 12 *
Pic 10000 nM (DMSO 1%) Ara-c 58 nM 32 ± 6 12
Pic 10000 nM (DMSO 1%) Ara-c 116 nM 20 ± 7 12
Ara-c 0 nM 100 ± 3 12
Ara-c 15 nM 86 ± 17 6
Ara-c 29 nM 69 ± 15 6 *
Ara-c 58 nM 47 ± 9 12
Ara-c 116 nM 25 ± 8 12
DMSO 1% Ara-c 58 nM 30 ± 8 12
Table A6.2 Cell Proliferation After a 3-day Exposure to Piclamilast and Cytosine 
Arabinoside
After a 3-day exposure to piclamilast, ara-c, DMSO control or neither the proliferation of the cell-lines 
was assessed by MTS assay. The mean proliferation is shown as a percentage relative to that of the no 
treatment control cells. A minimum of three independent experiments was conducted with the total 
number of wells assayed being indicated in the Number column.
Pic = piclamilast; Ara-c = cytosine arabinoside
Piclamilast 1000 nM +Ara-c vs. Ara-c with equivalent DMSO concentration = non-significant*
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SUD4 Mean ±Standard Deviation Number of Replicates
Pic 0 nM (DMSO 0%) Dox 0 nM 100 ±13 9
Pic 300 nM (DMSO 0.03%) Dox 45 nM 100 ±11 12
Pic 1000 nM (DMSO 0.1%) Dox 90 nM 72 ±12 12 *
Pic 10000 nM (DMSO 1%) Dox 180 nM 9 ±4 12
Pic 10000 nM (DMSO 1%) Dox 360 nM 3 ±4 12
Dox 0 nM 100 ±13 9
Dox 45 nM 90 ±8 12
Dox 90 nM 76 ±11 12 *
Dox 180 nM 53 ±7 12
Dox 360 nM 26 ±7 12
DMSO 0.5% Dox 180 nM 41 ±8 6
DMSO 1% Dox 180 nM 9 ±3 6
CRL Mean ± Standard Deviation Number of Replicates
Pic 0 nM (DMSO 0%) Dox 0 nM 100 ±9 9
Pic 300 nM (DMSO 0.03%) Dox 20 nM 82 ±11 12
Pic 1000 nM (DMSO 0.1%) Dox 40 nM 70 ±10 12 *
Pic 10000 nM (DMSO 1%) Dox 80 nM 31 ±4 11
Pic 10000 nM (DMSO 1%) Dox 160 nM 18 ±3 11
Dox 0 nM 100 ±9 9
Dox 20 nM 66 ±10 9
Dox 40 nM 64 ±8 9 *
Dox 80 nM 52 ±5 9
Dox160 nM 43 ±5 9
DMSO 0.5% Dox 80 nM 56 ±4 3
DMSO 1% Dox 80 nM 26 ±3 6
DoHH2 Mean ±Standard Deviation Number of Replicates
Pic 0 nM (DMSO 0%) Dox 0 nM 100 ±6 9
Pic 300 nM (DMSO 0.03%) Dox 3 nM 97 ±15 12
Pic 1000 nM (DMSO 0.1%) Dox 5 nM 93 ±10 12 *
Pic 10000 nM (DMSO 1%) Dox 10 nM 37 ±12 12
Pic 10000 nM (DMSO 1%) Dox 20 nM 14 ±7 12
Dox 0 nM 100 ±6 9
Dox 3 nM 93 ±8 12
Dox 5 nM 83 ±10 12 *
Dox10 nM 59 ±13 12
Dox 20 nM 35 ±16 12
DMSO 0.5% Dox 10 nM 64 ±11 6
DMSO 1% Dox 10 nM 37 ±4 6
Table A6.3 Cell Proliferation After a 3-day Exposure to Piclamilast and 
Doxorubicin
After a 3-day exposure to piclamilast, doxorubicin, DMSO control or neither the proliferation of the cell-
lines was assessed by MTS assay. The mean proliferation is shown as a percentage relative to that of the 
no treatment control cells incubated for the same time period with vehicle alone. A minimum of three 
independent experiments was conducted with the total number of wells assayed being indicated in the 
Number column. Pic = piclamilast; Dox = doxorubicin
* Piclamilast 1000 nM +Dox EC50 vs. Dox EC50 with equivalent DMSO concentration = non-significant
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Cell Count SUD4 SUD4 SUD4 CRL CRL CRL DoHH2 DoHH2 DoHH2 DHL4 DHL4 DHL4
Mean SD n Mean SD n Mean SD n Mean SD n SD =
0 Control 100 7 2 100 0 2 100 7 2 100 7 2 Standard deviation
Pic 30 nM Fors 20  M 48 6 2 57 2 2 13 1 2 81 4 2
Pic 100 nM Fors 20  M  55 4 2 47 3 2 8 3 2 59 7 2 n = number
Pic 300 nM Fors 20  M  53 0 2 57 7 2 11 0 2 68 5 2
Pic 1000 nM Fors 20  M  46 1 2 57 7 2 10 2 2 57 8 2  = 0.1% DMSO
Piclamilast 1000 nM  96 1 2 74 7 2 81 0 2 81 27 3  = 0.2% DMSO
Forskolin 20  M  59 3 2 59 3 2 13 3 2 75 13 2  = 0.3% DMSO
Forskolin 40  M  39 6 2 61 6 2 10 1 2 56 6 2 = 0.4% DMSO
Rolipram 100  M 89 3 2 71 3 2 68 4 2 76 3 2
Rol 100 mM Fors 20  M  55 6 2 55 3 2 7 2 2 53 4 2 Pic = piclamilast
DMSO 0.2% 87 1 2 94 12 2 95 13 2 97 5 2 Rol = rolipram
DMSO 0.4% 77 3 2 93 2 2 90 0 2 100 4 2 Fors = forskolin
Viability SUD4 SUD4 SUD4 CRL CRL CRL DoHH2 DoHH2 DoHH2 DHL4 DHL4 DHL4
Mean SD n Mean SD n Mean SD n Mean SD n SD =
0 Control 100 1 2 100 3 2 100 0 2 100 0 2 Standard deviation
Pic 30 nM Fors 20  M  84 3 2 98 3 2 46 2 2 99 0 2
Pic 100 nM Fors 20  M 88 1 2 99 2 2 37 7 2 99 3 2 n = number
Pic 300 nM Fors 20  M  87 6 2 95 3 2 40 6 2 100 0 2
Pic 1000 nM Fors 20  M  85 2 2 95 1 2 37 6 2 100 1 2  = 0.1% DMSO
Piclamilast 1000 nM  92 2 2 101 2 2 97 2 2 99 1 2  = 0.2% DMSO
Forskolin 20  M  93 3 2 98 4 2 57 3 2 99 1 2  = 0.3% DMSO
Forskolin 40  M  86 2 2 99 4 2 49 8 2 99 1 2 = 0.4% DMSO
Rolipram 100  M  97 1 2 99 1 2 96 1 2 100 1 2
Rol 100 mM Fors 20  M  82 2 2 92 0 2 26 5 2 98 1 2 Pic = piclamilast
DMSO 0.2% 96 1 2 100 2 2 103 0 2 98 0 2 Rol = rolipram
DMSO 0.4% 100 3 2 100 1 2 102 1 2 101 1 2 Fors = forskolin
Table A6.4 Viability and Cell Count After a 3-day Exposure to PDE4 Inhibitor &/or Forskolin After a 3-day exposure to piclamilast, forskolin, rolipram, 
DMSO control or neither the cell count and viability of the cell-lines was assessed by trypan blue exclusion assay. The mean cell counts and viabilities (n = 2) are shown relative to 
the control cells for each experiment. The standard deviation is given. Pic = piclamilast; Fors = forskolin; Rol = rolipram
The final DMSO content was:  = 0.1% DMSO;  = 0.2% DMSO; = 0.3% DMSO; = 0.4% DMSO
275
A
ppendix
Ara
Appendix
276
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 1.00 1.00 1.00 1.00
1.00 0.00 1.11 0.71 0.69 0.85
3.00 0.48 0.83 0.70 0.80 0.81
10.00 1.00 1.08 0.70 0.79 0.72
30.00 1.48 0.22 0.18 0.06 0.07
100.00 2.00 0.00 0.00 0.00 0.00
Table A6.5 SC-236 3-day cell count relative to no treatment controls for SUD4
Concentration M; values in italics were censored as outliers.
Concentration Log Concentration Replicate 1 Replicate 2 Replicate 3 Replicate 4
0.00 -3.00 1.00 1.00 1.00 1.00
1.00 0.00 0.94 0.96 1.07 0.95
3.00 0.48 0.93 1.00 1.04 0.96
10.00 1.00 0.92 0.99 0.97 0.97
30.00 1.48 0.61 0.57 0.24 0.29
100.00 2.00 0.00 0.00 0.00 0.01
Table A6.6 SC-236 3-day viability relative to no treatment controls for SUD4
Concentration M; values in italics were censored as outliers.
[   ]
Log
[   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 0.88 0.73
1.00 0.00 1.00 1.11 0.79 1.22 0.90 1.02 0.93
3.00 0.48 1.07 0.98 0.69 0.81 1.17 0.80 1.16 0.93
10.00 1.00 0.75 0.85 0.54 0.77 1.12 0.70 0.81 0.62
30.00 1.48 0.42 0.54 0.49 0.57 0.68 0.52 0.48 0.44
60.00 1.78 0.02 0.01
100.00 2.00 0.01 0.00 0.00 0.00
Table A6.7 SC-236 3-day cell count relative to no treatment controls for CRL
[   ] = Concentration M; values in italics were censored as outliers.
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[   ] Log[   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.98
1.00 0.00 0.97 0.97 1.00 0.99 1.02 1.04 0.99 0.98
3.00 0.48 0.94 1.02 0.94 1.00 1.01 1.01 0.98 1.02
10.00 1.00 0.95 0.94 0.99 0.97 1.01 0.95 0.94 0.95
30.00 1.48 0.66 0.75 0.82 0.86 0.85 0.93 0.98 0.97
60.00 1.78 0.09 0.10
100.00 2.00 0.02 0.00 0.02 0.01 0.04 0.01
Table A6.8 SC-236 3-day viability relative to no treatment controls for CRL
[   ] = Concentration M; values in italics were censored as outliers.
[   ] Log[   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.00 0.00 0.85 0.91 0.68 0.84 0.84 1.11 0.95 1.21
3.00 0.48 0.90 0.97 0.88 1.04 1.04 1.16 0.85 1.16
10.00 1.00 0.61 0.76 0.65 0.80 0.65 0.74 0.85 0.91
30.00 1.48 0.03 0.02 0.03 0.03 0.12 0.17 0.08 0.14
60.00 1.78 0.01 0.01
100.00 2.00 0.01 0.00 0.00 0.00 0.00 0.02
Table A6.9 SC-236 3-day cell count relative to no treatment controls for DoHH2
[   ] = Concentration M; values in italics were censored as outliers.
[   ] Log[   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.00 0.00 0.98 0.96 1.02 0.96 0.94 1.02 0.98 0.96
3.00 0.48 0.95 0.94 1.00 1.00 0.97 1.00 0.99 1.00
10.00 1.00 0.88 0.86 0.89 0.92 1.00 0.93 0.98 0.93
30.00 1.48 0.12 0.06 0.17 0.10 0.45 0.53 0.32 0.52
60.00 1.78 0.04 0.02
100.00 2.00 0.04 0.01 0.00 0.00 0.00 0.07
Table A6.10 SC-236 3-day viability relative to no treatment controls for DoHH2
[   ] = Concentration M; values in italics were censored as outliers.
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[   ]
Log
[   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
Replicate 
9
Replicate 
10
Replicate 
11
Replicate 
12
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.09 0.94
1.00 0.00 0.92 0.92 0.95 0.81 1.06 1.15 0.96 1.31 0.98 1.08 0.82 1.07
3.00 0.48 0.81 0.97 0.91 0.96 0.82 1.17 0.88 1.15 0.97 1.01 1.01 1.01
10.00 1.00 0.84 0.69 1.11 0.85 0.72 1.08 0.82 1.05 1.19 0.98 0.89
15.00 1.18 0.83 0.89 0.71 0.81
20.00 1.30 0.53 0.50 0.67 0.83
30.00 1.48 0.11 0.12 0.16 0.14 0.48 0.42 0.48 0.51 0.31 0.36 0.20 0.34
45.00 1.65 0.45 0.33 0.34 0.40
60.00 1.78 0.25 0.24 0.21 0.19 0.03 0.04
100.00 2.00 0.00 0.00 0.00 0.00 0.03 0.02 0.02 0.03 0.02 0.02
Table A6.11 SC-236 3-day cell count relative to no treatment controls for DHL4
[   ] = Concentration M; values in italics were censored as outliers.
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[   ]
Log
[   ]
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
Replicate 
9
Replicate 
10
Replicate 
11
Replicate 
12
0.00 -3.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.03 1.00
1.00 0.00 1.00 0.99 1.00 0.98 0.98 1.01 0.99 1.04 1.03 1.02 1.03 0.96
3.00 0.48 0.98 1.00 0.98 1.01 0.99 1.00 0.99 1.02 1.03 1.01 1.00 1.01
10.00 1.00 1.00 0.97 0.98 0.98 0.99 1.01 1.00 1.03 1.02 1.01 1.01 1.02
15.00 1.18 1.00 1.00 0.97 0.99
20.00 1.30 0.96 1.00 0.95 0.98
30.00 1.48 0.94 0.97 0.92 1.01 0.87 0.90 0.93 0.89
45.00 1.65 0.58 0.62 0.64 0.56
60.00 1.78 0.28 0.23
100.00 2.00 0.00 0.03 0.00 0.00 0.17 0.17 0.15 0.20 0.12 0.10
Table A6.12 SC-236 3-day viability relative to no treatment controls for DHL4
[   ] = Concentration M; values in italics were censored as outliers.
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Concentration Log Concentration
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
Replicate 
9
Replicate 
10
Replicate 
11
Replicate 
12
0.00 -3.00 1.00 1.00 1.35 0.98 0.91 0.76 1.05 0.95 1.03 1.03 0.94 1.00
3.00 0.48 1.25 1.26 1.09 1.21 0.94
10.00 1.00 0.93 0.84 1.30 0.92 1.13 1.14
30.00 1.48 1.22 1.12 0.81 1.21 1.21 0.84 0.98 0.44 0.62 0.66 0.75 0.87
100.00 2.00 0.81 0.74 0.63 0.96 0.74 0.81
200.00 2.30 0.19 0.21 0.07 0.18 0.12 0.04
250.00 2.40 0.08 0.06 0.07 0.08 0.04 0.06
Table A6.13 SC-236 2-day cell count relative to no treatment controls for primary MCL (03)
[   ] = Concentration M; values in italics were censored as outliers.
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Concentration Log Concentration
Replicate 
1
Replicate 
2
Replicate 
3
Replicate 
4
Replicate 
5
Replicate 
6
Replicate 
7
Replicate 
8
Replicate 
9
Replicate 
10
Replicate 
11
Replicate 
12
0.00 -3.00 1.00 0.98 1.03 1.02 0.98 0.98 1.03 0.96 1.00 0.99 1.03 1.00
3.00 0.48 0.96 1.00 0.99 0.96 0.99
10.00 1.00 0.99 0.91 0.93 0.89 0.98 0.94
30.00 1.48 0.97 0.95 0.98 0.92 1.00 0.96 0.97 0.71 0.80 0.84 0.83 0.80
100.00 2.00 0.98 0.93 0.89 0.96 0.93 0.88 0.70 0.78 0.65 0.78 0.74 0.70
200.00 2.30 0.16 0.22 0.11 0.20 0.15 0.05
250.00 2.40 0.10 0.09 0.10 0.09 0.04 0.05
Table A6.14 SC-236 2-day viability relative to no treatment controls for primary MCL (03)
[   ] = Concentration M; values in italics were censored as outliers.
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[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 0.89 0.86 1.09 1.06 1.12 0.99
2.40 0.38 0.85 0.99 0.80 1.08 1.07 1.06
8.00 0.90 0.86 0.68 0.81 0.95 0.88 0.81
24.00 1.38 0.88 0.74 0.89 0.68 0.88 0.89
80.00 1.90 0.61 0.51 0.43 0.57 0.68 0.42
Table A6.15 SC-236 2-day cell count relative to no treatment controls for primary 
MCL (04)
[   ] = Concentration M; values in italics were censored as outliers.
[   ] Log [   ] Replicate 1 Replicate 2 Replicate 3 Replicate 4 Replicate 5 Replicate 6
0.00 -3.00 0.98 1.00 0.99 1.00 1.02 1.00
2.40 0.38 0.85 0.89 0.89 0.97 0.98 0.98
8.00 0.90 0.82 0.88 0.90 0.96 0.94 0.86
24.00 1.38 0.81 0.82 0.82 0.82 0.83 0.86
80.00 1.90 0.47 0.55 0.43 0.48 0.55 0.40
Table A6.16 SC-236 2-day viability relative to no treatment controls for primary 
MCL (04)
[   ] = Concentration M; values in italics were censored as outliers.
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